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Lung cancer: the patient journey
P001 DELAY IN LUNG CANCER CLINIC APPOINTMENT:
AUDIT OF GP REFERRALS
N. Surange, F. Zaman. Burnley General Hospital, UK
The NICE (National Institute for Health and Clinical Excellence)
guidelines for the diagnosis and treatment of lung cancer1 advise that
patients with a chest x ray (CXR) suggestive of lung cancer should be
referred urgently to a respiratory physician (1.1.5). They advise that a
copy of the CXR report be sent to the lung cancer multidisciplinary team
(MDT) for an appropriate action (1.2.1). The referral pathways of these
patients differ between hospitals. In Burnley the report of an abnormal
CXR is sent to the patient’s GP who then refers the patient to the fast-track
lung cancer clinic.
We audited retrospectively the GP referral letters marked ‘‘2 week
rule’’ in 2005 (n = 80) and the patients’ case notes with an aim of
assessing the potential delay in the lung cancer clinic appointment
caused by the practice of receiving referrals from GPs. We did this by
calculating the number of days between (1) date of first CXR and date of
GP referral to the lung cancer clinic; (2) date of GP referral and date of
first appointment for the two week lung cancer clinic.
Discussion: In Burnley General Hospital the outpatient CXRs are reported
on the same day and the report faxed to the GP by the next working day.
The lung cancer specialist nurse receives a copy of the CXR report and
reminds the GP if a referral is not received within the next 7 days, but the
MDT does not intervene in any other way. Our audit showed that there
was a median delay of 10 days from the date of chest x ray (that is,
9 days from receiving CXR report) to the date of sending a referral to
lung cancer clinic.
Conclusion: This audit reveals that direct action by the lung cancer MDT
on the abnormal x ray reports would potentially cut considerable time
(median 9 days) to the date of lung cancer clinic appointment. The
results of our audit support the recommendation 1.2.1 in NICE
guidelines
1. NICE. Clinical Guideline 24. The diagnosis and treatment of lung
cancer. February 2005. Available at http://www.nice.org.uk/
page.aspx?o = cg024niceguideline (accessed September 2006).
P002 IMPACT OF A TWO-STOP CLINIC ON DIAGNOSTIC
TIMES, TREATMENT DELAYS, AND TREATMENT INTENT
IN PATIENTS REFERRED WITH SUSPECTED LUNG
CANCER
S. C. Madathi, S. Phillips, C. Russell, I. Woolhouse. Department of
Respiratory Medicine, University Hospital Birmingham Foundation Trust,
Birmingham, UK
Background: The NICE (National Institute for Health and Clinical
Excellence) guidelines for the diagnosis and treatment of lung cancer
(2005) recommend early diagnosis clinics for patients with suspected
lung cancer on the basis that resection rates, and hence survival, may be
improved. As yet this is unproven therefore we assessed the impact of a
two-stop lung cancer clinic on diagnostic times, treatment delay, and
treatment intent at our trust.
Methods: Diagnostic and treatment data were collected on patients
referred to clinic with suspected lung cancer over a six month period in
2004 and then over a similar period in 2005 following the introduction
of a two-stop clinic, in which the computed tomography scan of the
thorax was the primary investigation.
Results: The results for two groups of patients are shown in the table.
Conclusions: The introduction of the two-stop lung cancer clinic was
associated with a significant reduction in the time from referral to
definitive treatment planning at the MDT meeting and a significant
increase in the proportion of patients receiving specific anti-cancer
treatment. There was a trend towards a greater proportion of patients
undergoing radical treatment with a reduction in the time to receive this
treatment, however this did not reach statistical significance. Further
study is required to determine whether these improvements are
associated with increased survival.
P003 CHEST PHYSICIANS AND LUNG CANCER NURSE
SPECIALISTS: WHO PREDICTS THE
MULTIDISCIPLINARY TEAM DISCUSSION OUTCOME
BEST?
S. Bari, L. Sundararajan, A. McIver, C. Smyth, M. J. Walshaw, M. J. Ledson.
Liverpool Lung Cancer Unit, The Cardiothoracic Centre, Liverpool, UK
Introduction: The role of the lung cancer multidisciplinary team (MDT) is
to enhance the management of lung cancer by facilitating the diagnostic
process and speeding the treatment plan, in the hope that this will
improve the outcome. However, such MDTs are resource intensive and
costly both in terms of the number of, and time spent by, specialist
personnel. We wanted to find out whether the resource of the MDT could
be better targeted towards difficult cases if ‘‘straightforward’’ patients
could be could be managed separately. To do this, we assessed whether
a chest physician (CP) or lung cancer nurse specialist (NS) alone would
come to the same conclusion as the full MDT discussion in organising the
management decision.
Method: We asked our CP and NS separately to go through all the
information available for each patient, and then document the projected
outcome from the MDT discussion. We then compared their opinions with
each other, and finally to the ultimate outcome of the subsequent MDT
discussion. Other core members of our MDT are radiologists, a pathologist,
oncologists, palliative care specialists and thoracic surgeons.
Abstract P001 Delay for the 2 week rule lung cancer clinic
appointment.
n = 80
Time from CXR
to referral by GP
(days)
Time from GP
referral to clinic
date (days)
Time from CXR
to clinic date
(days)
Mean 16.34 12.26 28.46
Median 10 11 20
Abstract P002
2004 2005
Audit period May–Oct June–Nov
No of patients seen 165 171
Final diagnosis of lung cancer 52 (32%) 49 (29%)
Time from referral to MDT meeting 34 (11–80) 26 (6–56) p,0.001
Specific anti-cancer treatment given 33 (63%) 42 (86%) p = 0.009
Radical treatment intent 10 (19%) 13 (27%) p = 0.262
Time from referral to radical treatment 95 (34–128) 73 (30–106) p = 0.376
Data for diagnostic and treatment times are shown as median (range) days. MDT, multidisciplinary team.
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Results: The outcome of 153 consecutive patient discussions (mean
patient age 71 years (range 36–95), 80 male) were studied. We
categorised the outcome in these discussions as: Oncology (radiotherapy
and/or chemotherapy) (O), Surgical resection (S), Surgical biopsy
(mediastinoscopy/thoracoscopy) (SBx), staging PET scan (PET), interval
CT scan (IS), discharge (DIS), referral to other cancer service (breast,
colon, etc) (ROS), CT guided biopsy (CTBx), and others (see table). The
MDT outcome matched that of the CP in 121 cases (79%) and that of the
NS in 119 cases (78%), and both in 114 cases (75%). The outcome
projection of CP matched that of the NS in 133 cases (87%).
Conclusion: This study shows that in the majority of cases, key members
of the respiratory team can independently deduce the correct pathway
steps in the management plan of lung cancer patients, indicating that
those resource intensive MDT discussions may not be necessary for most
patients. Such discussions may be best targeted towards more difficult
cases, and we are now assessing protocols to enable this precious
resource to be used more effectively.
P004 BODY COMPOSITION ASSESSMENT IN PATIENTS
ATTENDING A RAPID ACCESS LUNG CANCER CLINIC
J. Duckers1, C. E. Bolton1,2, P. Thomas3, I. A. Campbell1, D. J. Shale2,
S. J. Linnane1. 1Respiratory Medicine, Llandough Hospital, Penarth, S Wales,
UK; 2Department of Respiratory Medicine, Llandough Hospital, Cardiff
University, Penarth, S Wales, UK; 3On behalf of the Lung Function
Department, Llandough Hospital, Penarth, S Wales, UK
Background: Cachexia is generally considered a late manifestation of lung
cancer and associated with poor prognosis. Less extreme body composition
abnormalities may go undetected. We explored the utility of routine
bioelectrical impedance analysis (BIA) to determine body composition at the
time of referral to a rapid access lung cancer clinic (RALC).
Method: All patients referred to RALC Clinic between 01/05–01/06 had
BIA (Tanita 310). A height squared fat free (FFMI) and body mass index
(BMI) were calculated and their effect on a variety of outcome measures
determined.
Results: 216 (127 male) patients were assessed. 34 had a low BMI
(,20 kg/m2); 33 had a low FFMI (,15 kg/m2 male,,16 kg/m2 female);
18 of the 33 with low FFMI also had a low BMI and 15 a normal BMI
(hidden loss of FFM). Overall 49 (22%) had altered body composition. 69
(34 male) patients were diagnosed with lung cancer (NSCLC n = 48, SCLC
n = 5, non-histological clinical diagnosis n = 11, other n = 5). Of these, 8
had a low BMI-low FFMI, 7 normal BMI-low FFMI, and 8 low BMI-normal
FFMI at presentation. A low FFMI was not more prevalent in those with a
diagnosis of cancer than those where it was excluded, p = 0.07. A low FFMI
was not more prevalent in (a) one histology group or (b) more advanced
disease or (c) worse performance score (PS). The median (95% CI) survival
of this outpatient referred group with diagnosed lung carcinoma was 61 (40
to 83) weeks. Body composition did not delineate a separate survival group,
though survival was less in those with a worse PS or staging, p,0.05. Two
of the 9 patients with intended curative surgery had a low FFMI. Two of the
15 patients with low FFMI received chemotherapy compared to 12 of the 54
with a normal FFMI.
Conclusions: BIA is easily incorporated into RALC assessment and allows
the early detection of altered body composition which may affect survival
though extended follow up period is required to assess this.
Determination of body composition is not a surrogate for other
recognised prognostic markers such as PS/histology/staging.
However, altered body composition may have had a potentially
unwarranted effect on management decisions taken.
P005 EFFECT OF RAPID ACCESS CLINICS ON STAFF:
COMPARISON WITH OTHER DUTIES
L. Sundararajan, S. Bari, A. Youzguin, C. Smyth, M. J. Walshaw, M. J. Ledson.
Liverpool Lung Cancer Unit, The Cardiothoracic Centre, Liverpool, UK
Introduction: Rapid access clinics are designed to compress and
streamline the diagnostic process, for the ultimate benefit of patient
care. However, little work has been done to look at the effect this
pressure has on the staff of the multidisciplinary team (MDT), who have
to work to tight deadlines in order to meet tough government targets. We
therefore surveyed the staff working in our large and busy rapid access
lung cancer clinic, which deals with up to 600 patients per year.
Method: We conducted an anonymous prospective survey of doctors
(D), nurses (N) and technical and clerical staff (TC) working in our MDT.
We used a questionnaire adapted from the NHS staff survey 2003 which
contained questions on role enjoyment/satisfaction/awareness, feed-
back, emotional challenges and worry, rapport and patient contact,
training/support, deadlines, and interference with other work activities
(1 to 5 scale, 5 = strong agreement). We also asked them to compare the
MDT work with their other duties.
Results: Thirty four members were surveyed (11 D, 15 N, and 8 TC), and
all returned the questionnaire. Overall, staff spent an average of 26% of
their time in the MDT role. The results (mean scores) are given in the
table.
In the subgroup analysis, nurses were more satisfied, supported, and
enjoyed colleague rapport, whereas doctors complained about lack of
training and clerical and technical staff felt less supported.
Conclusion: Although the rapid access clinic work is challenging, staff
seemed to enjoy it more than their normal work. Team spirit and
colleague support play a part in this, and the absence of formal training
and the need to meet deadlines did not affect the outcome. Creating a
well supported environment is the key to establishing an effective MDT
with good staff morale.
P006 THE LUNG CANCER MDT: WHO CONTRIBUTES TO
DECISION MAKING?
S. Bari, L. Sundararajan, J. Hughes, C. Smyth, M. J. Walshaw, M. J. Ledson.
Liverpool Lung Cancer Unit, The Cardiothoracic Centre, Liverpool, UK
Introduction: The UK Cancer Plan states that the multidisciplinary team
(MDT) is a mandatory part of every cancer unit, and in lung cancer the
core team must consist of a Respiratory Physician (RP), Radiologist (R),
Pathologist (P), Nurse Specialist (LCNS), Oncologist (O), Palliative Care
Specialist (PCS) and Thoracic Surgeon (TS). Active participation and
coordination between the team members should enhance patient care.
We investigated the contribution of these members in our MDT meeting,
where only patients with suspected lung cancer are discussed.
Method: We prospectively audited individual member’s contribution to
the MDT meetings, including their comments or questions, which patients
they commented on, and the outcome of consecutive cases over an 13
week period. We did not include the presentation of a case or report as
comment.
Results: 207 cases (mean age 70 years (range 36–95), 114 male) were
audited. Of these, 203 (98.5%) were presented by a RP. There were a
mean of 2.8 comments per case (0 to 8). Contribution by members: RP
Abstract P003
O S SBx PET IS DIS ROS CTBx Other
MDT result 58 16 9 13 18 6 10 8 7
CP prediction 51 12 8 10 17 0 7 7 5
NS prediction 51 12 7 9 17 0 7 7 5
Abstract P005
Parameter Usual role MDT role p Value
Role enjoyment 4.0 4.6 ,0.002
Support 3.9 4.4 ,0.05
Feedback 3.5 3.9 NS
Satisfaction 3.7 4.1 NS
Worry about the role 2.4 2.3 NS
Rapport 4.4 4.6 NS
Emotional challenge 3.4 3.1 NS
Patient contact 4.6 4.5 NS
Formal training 4.3 3.8 0.04
Working to deadlines 3.9 4.1 NS
Interference with other work 2.1 2.1 NS
Role awareness 4.3 4.3 NS
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136 (mean 0.65 per patient), TS 140 (0.85), R 176 (0.85), O 99 (0.47),
P 11 (0.05), LCNS 16 (0.08), and PCS 7 (0.03). More comments were
made where the outcome was resection (3.4 per patient) or thoraco-
scopy/mediastinoscopy (3.4) compared to CT guided biopsy (3.0),
palliative care (2.7), oncological treatment (2.45), or simply radiological
follow up (2.16). Respiratory physicians made more comments on
patients with an outcome of palliative care (0.77 per patient) and those
who were referred onward to another team (0.78). Input from TS was
more in cases with outcome of surgery (1.26), CT guided biopsy (1.21),
and PET scan (1.16). As expected, radiologists commented mainly on the
outcome of CT guided biopsy (1.14) and those who required
radiological follow up (1.08). PCS made the least comments overall
but on patients with an outcome leading to palliative treatment. Although
the LCNS knew more about most of the patients, they commented less
(0.08). The pathologist made the least comments (0.05), but this
normally had the greatest effect on treatment.
Conclusion: This study has identified active and passive participants in
our MDT meetings. We intend to feedback the results to encourage
members to participate more. We aim to use this to avoid herd
behaviour and collective team thinking for groups of patient, ensuring
that each patient has an individual discussion. We believe this model of
feedback is important and refreshes the MDT members’ outlook and
attitude to the care of this unfortunate patient group.
P007 COMPARING CANCER REGISTRY DATA WITH LOCAL
LUCADA DATA
P. Beckett1, Carly. Jones2. 1Queens Hospital, Burton-on-Trent, UK; 2West
Midlands Cancer Intelligence Unit, University of Birmingham, UK
Introduction: The Cancer Peer Review utilises cancer registry data in two
measures. Data from the cancer registry for our hospital appeared to be
incorrect. We sought to compare data in the registry to our own local
data, collected for the national LUCADA project.
Methods: The two databases were searched for all patients with a date
of diagnosis in 2005. Results were collated onto spreadsheets. The data
were then evaluated and the two datasets were compared. Mismatches
between the data were investigated more thoroughly to ascertain any
common factors.
Results: The cancer registry contained 76 patients, 70 of which were full
details, 6 were death certificate details only. Of these latter 6, 2 received
palliative care, 2 received active monitoring, 1 received chemotherapy,
and 1 received radiotherapy. Only 1 patient was not on the local
database—this patient was seen in 2004 and a diagnosis of lung
abscess was made. The local database contained 94 patients and 18 of
these were not on the registry list. One was probably a recurrence rather
than a new patient, but had been included in the local database as new.
10 were outside of the WMCIU region (and presumably were picked up
by another registry). Two were labelled as unknown primary by the
registry and so did not appear as lung cancer, although they were
dignosed as having lung cancer (one liver biopsy adenocarcinoma, one
lymph node small cell carcinoma). This left 5 patients with a secure
diagnosis of lung cancer who did not appear on the registry database: 1
FNA ‘‘highly suspicious of small cell carcinoma’’, 1 not biopsied—for
active monitoring only, 1 FNA showing small cell carcinoma carried out
at another hospital, 1 diagnosis made at end of 2005, but positive
biopsy not until early 2006, 1 several biopsies, all negative, working
diagnosis still lung cancer.
Conclusions: The local database appears to be the more comprehensive.
There are numerous reasons why some patients do not get picked up by
the registry. The registry data are only as good as the information given
to them. More communication and data sharing is crucial if the data are
to be accurate and trustworthy. Comparison of local databases and
registry data is a useful way of auditing data collection.
P008 ESTABLISHMENT AND EXPERIENCE OF A NURSE-LED
HAEMOPTYSIS CLINIC
A. Conway, A. Richardson, J. Entwisle, J. A. Bennett, M. D. Peake.
Department of Respiratory Medicine, Glenfield Hospital, Groby Road,
Leicester LE3 9QP, UK
Background: At a time when we were having difficulty in meeting the
target of seeing all urgent cancer referrals within two weeks, we noticed
a significant number of patients being referred with haemoptysis and a
normal chest x ray (CXR). An audit of such referrals over a year failed to
reveal any cases of lung cancer, but a wide variety of other respiratory
problems. We therefore decided to establish a nurse-led clinic for these
patients. A literature review identified very little relevant or recent
published data on this group of patients.
Pilot phase: Two experienced specialist respiratory nurses initially ran a
clinic parallel to the rapid access lung cancer clinic with 44 patients
being seen during this pilot phase. The initial consultation was with one
of the nurses and included a full medical history and clinical
examination. The results of any initial investigations were reviewed,
including the CXR, spirometry, and the results of any relevant blood tests.
The patients were then presented to the lead clinician and a differential
diagnosis agreed which determined further investigation and manage-
ment. None of these 44 patients had a final diagnosis of malignancy.
Establishment of clinic: As a result of this experience a management
algorithm was developed after which an independent nurse-led clinic
began with the nurses having the authority to discharge patients at first
visit, but having immediate access to a consultant in the parallel clinic if
required. As experience developed and the nurses were appraised, they
were authorised to prescribe a range of antibiotics, to order CT scans,
and request bronchoscopy.
Results: Between July 2003 and May 2006 202 patients (excluding the
initial 44) have been seen in this independent nurse-led clinic. The mean
age was 62 (range 19–90). The commonest final diagnoses included:
infection (30%), idiopathic (16%), and bronchiectasis (15%). There was 1
case of tuberculosis and 12 cases of lung cancer (6%). In only 3 of these
12 were the CXRs, on review, entirely normal; so the incidence of lung
cancer in patients with haemoptysis and truly normal CXR was only
1.5%. 62 patients (31%) were discharged at the first visit by the nurse
alone, but all patients were seen by a consultant respiratory physician if
they were called back for a second visit. 113/202 (56%) of the patients
went on to have a CT scan. Only 17 patients had a bronchoscopy.
Within the management algorithm, haemoptysis was split into ‘‘major’’
and ‘‘minor’’, based on the amount of blood expectorated and its
duration. We found that higher volume haemoptyses were not
associated with lung cancer, but more persistent haemoptysis (7 days
or more) were. This observation would have to be tested in a larger
population. In summary we have demonstrated the feasibility, safety,
and effectiveness of a nurse-led haemoptysis service and consideration
should be given to extending the role of specialist nurses into other
areas.
P009 NATIONAL LUNG CANCER AUDIT: DATA
COMPLETENESS
N. Chanarin1, R. Stanley2, M. D. Peake1. 1Royal College Physicians, London,
UK; 2Health and Social Care Information Centre, UK
LUCADA (LUng CAncer DAta) is a long term audit of lung cancer care in
England. The audit is now commissioned by the Healthcare Commission
and managed within the information centre for Health and Social Care
by the National Clinical Audit Support Programme (NCASP) in
partnership with the Royal College of Physicians. LUCADA began
collecting data in 2004 and as at 30.6.06 had 23 539 patient records in
total. The first annual report will be published in autumn 2006 and will
present data on all cases of lung cancer with an initial date of referral in
2005. Data relating to this cohort of patients continued to be entered
onto the database up until June 2006. This abstract describes the data
completeness of this data set. A high level of data completeness is vital if
we are to be in a position to carry out proper risk adjusted analyses in an
attempt to explain wide regional variations in lung cancer treatment and
outcomes.
For subsequent risk adjusted analysis LUCADA collects data on the
following case mix variables: age, gender, postcode (and thereby
deprivation index), cell type, cancer stage, performance status, and the
presence of a comorbidity which would preclude a curative procedure.
The first three variables are automatically populated from the ‘‘Open
Exeter’’ database on entering the NHS number. Completeness for these
variables is thus 100%. The table sets out completeness for the remaining
key data fields.
Abstract P009
Data item Completed Completed excluding unknown
Histology/clin diagnosis 78% Not applicable
Cancer stage 52% 48%
Performance status 65% 53%
Comorbidity 66% 46%
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For ideal risk adjusted analysis to be carried out, all of the above key
variables need to be available. In this 2005 data set only 36% of the
cases have complete data for all case mix factors with no missing or
unknown values.
Data completeness is a huge challenge and there are multiple factors
which have an influence including time, organisation, and resources. The
challenge for LUCADA is to achieve continuing high levels both of
participation and data completeness in a difficult service environment.
Autumn 2006 will see the first annual report but will not contain any risk
adjusted analysis. The aim for 2006 is to ensure that the data for the next
annual report will be of sufficient quality to make it possible for these
analyses to be done. By 2007 we aim to be able to publish comparative
performance and outcome data that will have the potential to influence
the service improvement agenda.
P010 ARE WE GOING TO BE ABLE TO MEET THE ‘‘31 DAYS
TO TREAT FROM REFERRAL’’ TARGET FOR LUNG
CANCER PATIENTS?
C. M. Ohri, C. Baines, J. Lemon, P. Haldar, J. A. Bennett, M. D. Peake.
Thoracic Oncology Unit, Institute For Lung Health, Glenfield Hospital,
Leicester LE3 9QP, UK
Introduction: In 2008 guidelines recommended by the National Health
Service Cancer Plan will be implemented, recommending that all patients
with lung cancer (LC) referred via the two week wait (2ww) process,
should be diagnosed and have started treatment within 31 days of the
initial referral date, except for good clinical reasons. We are a regional
centre for LC serving a population of around 1 000 000.
Aim: To assess how close our centre is to achieving this target.
Method: We looked at our patients diagnosed with LC referred via the
2ww process, in the same six-month periods (January to June) over four
consecutive years from 2003–06. This was a retrospective analysis of all
patients referred as a 2ww for suspected LC as defined from our LC
tracker database.
Results: During these six-month periods we received 334 2ww referrals
in 2003, 305 in 2004, 362 in 2005, and 328 in 2006. The number of
LC diagnoses made via the 2ww process for these periods was 115
(34.4% of the 2ww referrals) in 2003, 101 (33.1%) in 2004, 95 (26.2%)
in 2005, and 83 (25.3%) in 2006. The mean number of days that our
patients have waited from initial referral to treatment is 51.3 days in
2003, 49.3 days in 2004, 39.9 days in 2005, and 36.3 days in 2006.
The median number of days from referral to first visit was 14 days in
2006.
Discussion: It is proving to be a challenge to initiate treatment for LC
patients within 31 days of referral. However, our data support an
improvement in the mean time to treat 2ww LC patients from referral, by
15 days (p,0.001), over the last four years. This improvement has
arisen despite access to positron emission tomography (PET) scanning
being limited and at a distant centre, which has added further complexity
to the diagnostic pathway. We feel that the reason for this improvement
is due to changes in our service as follows:
N A new clinic structure with a mini multidisciplinary team (MDT)
meeting on Tuesday involving a radiologist, chest physician, MDT
tracker, and specialist nurse, prior to the Tuesday clinic with new
referrals.
N The implementation of an ultrasound neck and fine needle aspiration
diagnostic service being offered on the day of the first clinic visit.
N Continuation of the main weekly MDT meeting on a Friday.
Conclusion: We have identified that at present we would not meet the
‘‘31 days to treat from referral’’ target. There are two potential areas for
improvement. If the time between referral and first visit were shortened,
many more of our 2ww patients would commence treatment within
31 days of referral. Secondly, local implementation of PET scanning will
improve our diagnostic pathway duration.
P011 INCIDENCE OF LUNG CANCER IN PATIENTS RE-
PRESENTING TO THE RAPID ACCESS LUNG CANCER
CLINIC
A. Youzguin, S. Bari, L. Sundararajan, M. J. Ledson, M. J. Walshaw,
C. Smyth. Liverpool Lung Cancer Unit, The Cardiothoracic Centre, Liverpool, UK
Introduction: Patients with features suggestive of lung cancer are now
referred to rapid access clinics, where less than half will be diagnosed
with the disease. However, the remainder is still at risk and may re-
present at a later date, raising questions as to whether the tumour was
apparent at the initial presentation and whether the clinical features
prompting further referral have changed. Also, the incidence of cancer
in these ‘‘representers’’ is unknown. To look at this further, we reviewed
all cases who presented for the second time to our large rapid access
clinic, which processes up to 600 cases per year, 45% of which have
lung cancer.
Method: We interrogated our comprehensive database which records
the method of referral, presenting features, demographics, and outcome
of all referrals, looking for patients who presented more than once to the
rapid access clinic. In the representers, we compared the data of those
subsequently diagnosed with cancer with the remainder. All patients
underwent a CT scan, and bronchoscopy when appropriate.
Results: Of 4839 patients processed over six years, 46 (1%) who did not
have cancer at the initial referral were referred again with suspicious
features (mean time to re-referral 27 months (range 5–59)). 18 (39%)
were subsequently diagnosed with lung cancer (8 non-small cell, 2
adenocarcinoma, 3 small cell, 1 mesothelioma, 1 carcinoid, 3 clinical
diagnosis). Although 25 patients represented with new symptoms, there
was no difference between those with cancer and the remainder. There
was no difference in clinical features between the two groups (see table,
(mean + range)), but patients were less likely to be referred from primary
care the second time (GP 1st referral 40/46 v 2nd referral 25/46,
x2 = 11.80, p,0.001), although these cases were more likely to have
cancer (GP 1st referral 18/18 v 2nd referral 8/18, x2 = 13.9,
p,0.001).
Review of CT scans showed that the tumours in the representers were
not visible at the first presentation, but 22% had contralateral changes,
17% had normal scans, and 61% had ipsilateral changes not indicative
of the ultimate cancer.
Conclusion: In this small but important group of patients, the incidence of
lung cancer was similar to that expected for new referrals. We were
reassured that the lung cancer had not been missed at first presentation
even though the average time to representation was just over two years:
this illustrates the difficulties in screening high risk individuals for lung
cancer. It is of note that primary care colleagues were less likely to re-
refer patients, even when they had new symptoms indicative of lung
cancer.
P012 MANAGEMENT OF LUNG CANCER IN THE ELDERLY
A. M. Higton1, J. S. Monach1, K. Steele1. 1Worthing Hospital, West Sussex,
Worthing General Hospital, Lyndhurst Road, Worthing, West Sussex BN11
2DH, UK
Background: Lung cancer is common and has a poor prognosis.1 Peak
incidence is between 75 and 80 years.2 Worthing has the largest
percentage of over 85 year olds in Europe. This study was designed to
review the management of patients with lung cancer at Worthing
Hospital, comparing the elderly (over 75 years) population with the
younger (under 75 years) patients, and assessing factors which influence
survival.
Methods: Patients with a new diagnosis of lung cancer between January
02 and December 04 were identified from the lung cancer database and
their medical records were reviewed.
Results: 367 patients were identified, 221 were aged under 75, 146
were 75 or older (range 31–95). Histological confirmation was achieved
Abstract P011
Parameter Age Male Smokers
Re-presentation time
(months) FEV1%
Cancer 68 (52–82) 50 18 27 (9–59) 57 (22–102)
Non-cancer 67 (41–81) 50 29 27 (5–56) 67 (27–104)
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in 79% of patients overall but only in 66% of patients over 75 years. 225
patients had non-small cell (NSCLC), 41 patients had small cell (SCLC)
and 26 had mesothelioma. Most patients had good performance status
(PS 0–2) 73%, but PS was not recorded in 16%. 96% of patients were
formally staged. Of the patients with NSCLC 21% were early stage (1a–
2b), 17% were stage 3a, 37% were stage 3b, and 47% were stage 4. Of
the SCLC patients only 27% had limited stage disease at diagnosis.
Younger patients were more likely to receive active treatment (surgery,
chemotherapy or radical or palliative radiotherapy) 62% v 33%. Mean
survival was 197 days in the under 75 years group and 172 days in the
over 75 year olds, with no significant difference. Comparing active
treatment (AT) against best supportive care (BSC) for under 75 year olds:
the AT patients had a longer survival; a mean survival of 238 days
compared with 145 days for those who received BSC (p = 0.01). This
pattern was also seen in the over 75 year olds whose mean survival was
221 days if actively treated v 137 days (p = 0.013). The strongest
predictor of improved survival was PS, followed by treatment type
(active/BSC).
Conclusion: This study shows that elderly patients at Worthing are less
likely to have histological confirmation and are less likely to receive
active treatment despite having a good performance status. It is not clear
whether this is due to clinicians’ more conservative approach to
management in the elderly, patient choice, or comorbidities. This study
suggests regardless of age, patients with a good performance status
have a survival advantage if they receive active treatment compared to
best supportive care. We were unable to differentiate between outcomes
of those treated with curative or palliative intent.
1. British Thoracic Society. Burden of lung disease, Second edition.
2. Brown JS, Eraut D, Trask C, et al. Age and the treatment of lung
cancer. Thorax 1996;51:564–8.
P013 SURVIVAL FOLLOWING SURGICAL RESECTION OF
LUNG CANCER: A DISTRICT EXPERIENCE
J. Quint1, D. Eraut1, S. Ansari1, A. Davison1, G. Lingam1, P. Leonard1,
C. Trask1, R. Uppal2. 1Southend University Hospital, UK; 2London Chest
Hospital, UK
Background: Surgical survival figures for lung cancer vary worldwide. In
the UK results of surgery for lung cancer are not usually as good as those
quoted internationally. Mountain quoted 1 year survival (5 year survival)
for 1A 91% (67%), 1B 94% (57%), 2A 88% (55%), 2B 77% (39%), 3A
64% (23%).1 NICE weighted average 5 year survival for 1A 69%, 1B
52%, 2A 45%, 2B 33%, 3A (T3) 33%, and 3A (N2) 25%.2 We looked at
survival in the district of Southend over a 15 year period.
Methods: We reviewed the notes from our database of patients who
underwent surgery for lung cancer from the beginning of 1990 to the
end of 2004, before the introduction of routine PET scans.
Results: 181 individuals had surgery in London: mean age 63.1 years
(SD 8.8), FEV1 2.18 L (0.62), FEV1 % predicted 83% (30). 12 patients
(0.6%) had a diagnosis of non-small cell lung cancer, 101 (56%)
squamous cell, 49 (27%) adenocarcinoma, 1 (0.6%) bronchoalveolar
carcinoma, 15 (8%) large cell, and 2 (1%) small cell. 56 patients (31%)
had a pneumonectomy (P), 103 (57%) a lobectomy (L), and 22 (12%)
had a thoracotomy but no curative surgery. 68 patients (38%) had
stage I disease, 37 (20%) stage II, 53 (29%) stage III, 4 (2%) stage IV
and 19 (11%) stage unrecorded. Chemotherapy was given preopera-
tively in 2 patients, and within 3 months in 3 L and 3 P patients,
radiotherapy within 3 months in 7 L and 13 P. Mean survival from
diagnosis to death for those undergoing L was 41.4 months (range 0–
167), for P 36.1 months (range 1–177) and open and close
17.2 months (range 1–126). Mortality at 30 days was 5.4% for P,
2.2% for L. Mean survival for those with Stage I disease was
51.6 months, (range 1–170), stage II 36.4 months (range 8–162),
stage III 28.1 months (range 0–158), and stage IV 11.7 months (range
6–19). Cerebral seconadaries developed in 7 P and 8 L in the first year
post op (9.4% in total). Survival following L at 1 year was 80%, 2 years
60%, and 3 years 42%. Following P was 68%, 32% and 29% at 1, 2,
and 3 years respectively. Overall survival at 1, 2, and 3 years for
stage I disease was 88%, 66%, and 49%, stage II disease 70%, 46%,
32%, stage III disease 60%, 26%, 17%, and stage IV 25%, 0%, and
0%. Patients who underwent accelerated radical radiotherapy instead
of surgery had survival figures as follows: 1 year 66%, 2 years 38%,
and 3 years 27%.
Discussion: Survival following resection for lung cancer in our district
appears to be shorter compared to international figures. We do not
know the reason for the poorer survival figures in the UK, but our figures
correlate with other UK reports.
1. Mountain CF. Chest 1997;111:1710–17.
2. NICE National Collaborating Centre for Acute Care. Diagnosis and
treatment of lung cancer, February 2005.
Pulmonary vascular disease:
clinical aspects
P014 PRIMARY THROMBOPROPHYLAXIS IN MEDICAL
INPATIENTS: AN AUDIT OF OUR CURRENT PRACTICE
WITHIN THE DIVISION OF MEDICINE OF A LARGE
TEACHING HOSPITAL AND A POSSIBLE SOLUTION
FOR CHANGE OF PRACTICE
B. Sethugavalar, H. M. Khor, A. R. Guhan. Department of Respiratory
Medicine, Division of Medicine, The James Cook University Hospital, South
Tees Hospitals NHS Trust, Middlesbrough, UK
Introduction: 75% of inpatient mortality from venous thromboembolism
(VTE) occurs among medical patients even though post-surgical VTE
receives higher profile. Incidence of VTE among medical inpatients could
be reduced by almost 50% with primary thromboprophylaxis (pTP).
Despite the SIGN guidelines for pTP for medical inpatients being
available on http://www.sign.ac.uk/guidelines, compliance with these
is thought not to be optimal. We audited our compliance with these
guidelines within the Division of Medicine of our 1000-bedded teaching
hospital.
Methods: Case notes and drug cards of every inpatient on 11 medical
wards during the four-day period of study (20/3/2006 to 23/3/2006)
were scrutinised for the following data: demographic profile, length of
stay up to day of study, primary diagnosis, secondary diagnosis,
prescription (or not) of prophylactic low molecular weight heparin
(LMWH) and where LMWH is contraindicated (c/i), the use (or not) of
alternative methods (eg, TED stockings) of pTP. Patients were categorised
into: Group A: Guideline recommended LMWH pTP given; Group B:
Recommended pTP LMWH c/i, as the patient was on warfarin already
for another indication; Group C: Recommended pTP LMWH c/i due to
internal haemorrhage risk, so alternative pTP used; Group D: Guideline
recommended pTP (LMWH or alternative) not followed; Group E: pTP
not recommended; and Group F: Guideline recommendation not clear.
Percentage of patients for whom the SIGN guidelines recommended pTP
was calculated as: n(Groups A+B+C+D) 4 n(all patients) 6 100 and
Compliance (%) = n(Group A+B+C) 4 n(Groups A+B+C+D) 6100.
Results: 289 patients on 11 medical wards (including oncology) were
studied in the four-day period. Following the SIGN guideline-
recommendations, 240 (83.7%) should have received pTP though only
26 (Group A) actually received this (as LMWH) with a further 17 (Group
B) receiving warfarin for another indication. Compliance within our
Division of Medicine with the SIGN pTP guidelines therefore calculates to
be 17.9%.
Conclusions: Our practice of pTP among medical inpatients could be
optimised. Simple awareness of the SIGN pTP guidelines might not
automatically mean it is applied. As per the SIGN guidelines, more than
80% of patients should have received pTP. A possible solution could be
to consider pTP in every medical admission unless specifically contra-
indicated.
Abstract P014
Group A Group B Group C Group D Group E Group F Total
n = 26 n = 17 n = 0 n = 197 n = 27 n = 22 n = 289
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P015 SEATED IMMOBILITY AT WORK IS A COMMON RISK
FACTOR FOR VENOUS THROMBOEMBOLISM
S. Aldington1, K. Perrin2, R. Beasley1. 1Medical Research Institute of New
Zealand, Wellington, New Zealand; 2Wellington Hospital, Wellington, New
Zealand
Background: The role of seated immobility in the pathogenesis of venous
thromboembolism (VTE) associated with long distance travel is well
recognised. However, whether seated immobility at work is also an
important risk factor for VTE is uncertain. The aim of this case series was
to determine the frequency of seated immobility at work as a clinical risk
factor in patients admitted to hospital with a deep vein thrombosis (DVT)
or pulmonary embolism (PE).
Methods: Patients aged ,65 years attending an outpatient VTE clinic
following a recent admission for DVT and/or PE were interviewed to
obtain information regarding clinical risk factors. Seated immobility at
work was identified as a risk factor if in the four week period prior to the
onset of symptoms, the subject had been seated a maximum of>8 hours
per day and>3 hours at a time without getting up, or had been seated a
maximum of >12 hours per day and >1 hour at a time without getting
up.
Results: There were 62 subjects studied in whom 49 had a DVT, 33 had
a PE, and 20 had both DVT and PE. Prolonged seated immobility at work
occurred in 21/62 (34%) of cases, representing one the most common
risk factors together with family history (35%) and thrombophilic state
(32%). Seated immobility secondary to prolonged air travel (.8 hours)
was identified in 13/62 (21%) of cases Although other risk factors
commonly occurred in subjects with seated immobility at work, in 4
subjects no other risk factors were identified. Of the 21 subjects with
seated immobility at work 6 (29%) worked in the IT industry, 4 (19%)
worked in management, and 2 (9.5%) were taxi drivers. Seated
immobility, as a result of either work or travel, accounted for nearly half
(48%) of all cases.
Conclusions: Seated immobility at work may represent an important
independent risk factor for VTE. Further research is required to better
understand its role, identify the high risk occupations and the efficacy of
preventive measures. Overall seated immobility in different situation,
included work and air travel, represented the most common risk factors
for VTE, the term seated immobility thromboembolism (SIT syndrome), is
proposed to include all cases of VTE which have occurred following
seated immobility.
P016 PULMONARY EMBOLI AND DEEP VENOUS
THROMBOSES: PRECIPITATING FACTORS AND RISKS
IN PATIENTS WITH HEREDITARY HAEMORRHAGIC
TELANGIECTASIA AND PULMONARY
ARTERIOVENOUS MALFORMATIONS
M. E. Begbie, N. L. Sulaiman, C. L. Shovlin. Respiratory Medicine,
Hammersmith Hospital, and Imperial College Faculty of Medicine (National
Heart and Lung Institute), London, UK
Introduction: Pulmonary emboli (PE) carry significant hazards in all
patient groups. Authoritative guidelines including those from the British
Thoracic Society, advise on appropriate prophylaxis to reduce the
incidence of venous thromboemboli (VTE) in at-risk patients. In some
groups of patients, risk-benefit considerations regarding prophylactic
and therapeutic anticoagulation are complex. For example, patients with
pulmonary arteriovenous malformations (PAVMs) are often hypoxaemic
and polycythaemic, and, due to the presence of their right-to-left shunts,
may be at risk of paradoxical embolic stroke from PEs. Many PAVM
patients do not receive prophylaxis or full treatment for VTE however,
because of underlying hereditary haemorrhagic telangiectasia (HHT,
Osler-Weber-Rendu syndrome). HHT which causes epistaxis, chronic
gastrointestinal haemorrhage and anaemia, is considered a relative
contraindication to anticoagulation.
Methods: In order to determine the incidence of PE and DVT in patients
with HHT and PAVMs, and to identify risk factors to improve prevention
and management, we studied 311 consecutive patients with definite HHT
reviewed in our specialised clinic between May 1999 and May 2005.
207/311 (66.6%) of patients had PAVMs, though these were diagnosed
due to respiratory symptoms in only 44/207 (21.3%).
Results: (1) 22 out of 311 patients had confirmed DVT and/or PE (7.1%)
at median age 61 (range 32–82) years. Univariate and binary logistic
regression indicated that patients with thromboses did not have an
excess of PAVMs, hypoxaemia, or polycythaemia. (2) Factor V Leiden
heterozygosity was more common in DVT/PE patients (p = 0.0137,
Fisher’s exact test). All VTEs in patients with Factor V Leiden followed a
recognised precipitating clinical event, particularly a PAVM-induced
brain abscess. (3) In a subgroup of 38 healthy HHT/PAVM patients,
mean plasma Factor VIII:Ag (ELISA, Diagnostica Stago) was significantly
higher than in 38 age and sex matched controls at 137.8 (119.1,
156.5)%, compared to 100 (89.3, 110.6)%. In a validation study in 125
healthy HHT clinic patients, service laboratory FVIII:Ag exceeded the
normal laboratory range of 0.45–1.58 m/ml (mean 1.94 (1.80, 2.07)m/
ml. (4) In the 125 clinic patients, FVIII:Ag was significantly higher in
patients with thromboses than without thromboses, and in binary logistic
regression, independently contributed to thrombotic risk (p = 0.012,
Wald test).
Conclusion: There is a significant incidence of venous thromboembolism
in PAVM/HHT patients. Elevated FVIII:Ag may be an HHT-specific factor
that contributes with known clinical and genetic risk factors, to overall
thrombotic risk.
Funding support: Hammersmith Hospitals Trustees Research
Committee.
P017 THE USE OF IMAGING IN THE DIAGNOSIS AND
EXCLUSION OF PULMONARY EMBOLISM: DO THE BTS
GUIDELINES REDUCE THE NEED FOR IMAGING?
T. M. French1, J. P. Finnerty1, I. M. Keeping1, R. J. Etherington2. 1Respiratory
Department, 2Radiology Department, Countess of Chester Hospital NHS
Foundation Trust, Chester, UK
Introduction: We studied the use of radiological imaging for suspected
pulmonary embolism (PE) over a four month period at the Countess of
Chester NHS Foundation Trust. The diagnostic work up was compared
with that suggested by the British Thoracic Society (BTS) guidelines
(2003). Our aim was to test whether application of the guidelines could
have prevented the need for imaging in a proportion of patients, and/or
whether adherence to the guidelines would have resulted in missed
diagnoses.
Methods: 173 patients were investigated for suspected PE. 65 computed
tomography pulmonary angiograms and 108 perfusion scans were used
as initial imaging. 13% were found to have pulmonary embolism on
imaging. 46% had a respiratory diagnosis (infection, COPD, interstitial
lung disease), while 18% had cardiovascular disease.
Clinical probability was poorly recorded in the notes. Retrospective
calculation revealed that the positive predictive value for patients with
high probability scores was only 38%. The negative predictive value of a
low probability risk score was 96%.
D-dimer was often inappropriately used and poorly interpreted. The
level set by the haematology department (255 units (u)) had 100%
sensitivity but only 8% specificity for PE. We calculated that an optimum
level of 400 u would have 100% sensitivity and 78% specificity.
Results: 114 patients with PE ruled out by imaging had low or
intermediate clinical probabilities (76%). Of these, 28 had not had a d-
dimer. Nine had a d-dimer of less than 255 u, and 20 had a d-dimer
less than 400 u. Therefore with appropriate use of clinical probability
and d-dimer testing, between 20 and 48 scans could have been
avoided. 12 patients with proven DVT had unnecessary imaging studies.
Using the BTS guidelines, between 32 and 60 scans could have been
avoided; a reduction of 18% to 35%. Application of the guidelines would
not have resulted in any missed diagnoses.
P018 THE PATH AFTER V/Q SCANNING IN A SUSPECTED
PULMONARY EMBOLISM
J. Nanjappa, A. Graham. Huddersfield Royal Infirmary, UK
Introduction: Although CT pulmonary angiography (CTPA) is being used
increasingly in the investigation of pulmonary embolism (PE), ventila-
tion/perfusion (V/Q) scanning is still widely used. In our hospital both
investigations are available. We wished to establish whether V/Q scans
were being appropriately requested and whether patients with
indeterminate V/Q scans were being appropriately managed after-
wards to ensure PE was not missed or unnecessary anticoagulation
given. We also wished to assess the extent to which both imaging
modalities were used to help define whether there is still a role for the V/
Q scanning service. We compared management with that recommended
in our local guidelines. These state that patients with an abnormal chest x
ray (CXR) or existing respiratory disease should have a CTPA rather than
a V/Q scan, that patients with a low probability V/Q scan but high
clinical probability of PE should have a CTPA and that patients with an
intermediate V/Q scan should have a CTPA. The audit focused on these
points.
Methodology: Forty two consecutive patients with a suspected PE and
who underwent V/Q scanning between 01/11/2003 to 31/10/2004
at Huddersfield Royal Infirmary were identified and their case notes
analysed. The presence/absence of existing lung disease, clinical
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probability of PE (Well’s score) and V/Q scan result were noted. The
subsequent clinical management was noted in terms of further
radiological investigation and anticoagulant therapy.
Results: Eight of the patients (19%) were known to have existing lung
disease but had a V/Q scan. 29 patients (69%) had a low probability V/
Q scan. 13 of these had a high clinical probability of PE but only 2 of
them (15%) were followed with further imaging, CTPA. Seven patients
had an intermediate probability V/Q scan of which 3 (42%) went on to
have CTPA. Six patients had a high probability V/Q scans and were
treated as PE.
Conclusion: These findings indicate that the guidelines are not been
strictly followed, as a result of which PE could be missed or unnecessary
anticoagulation given. If our guidelines had been strictly followed, then 8
patients would have had CTPA rather than V/Q scanning initially and a
further 15 patients would have had CTPA as a second imaging
investigation. V/Q scanning led to a clear management decision in 22
(55%) of the 40 patients indicating that it still has a useful role when
pressures on CT scanning services are increasing.
P019 V/Q OR CTPA AS INVESTIGATION FOR PULMONARY
EMBOLUS: AN AUDIT
M. Masoli, L. Dobson, D. Sinclair, J. Goldman. Depatment of Respiratory
Medicine, Torbay Hospital, Devon, UK
Introduction: The BTS advocates imaging ideally within 24 hours for
non-massive PE and within 1 hour for massive pulmonary embolus (PE).
CT pulmonary angiogram (CTPA) and ventilation-perfusion (V/Q) scan
are available at our hospital although currently CTPA is generally
recommended only for those with an abnormal chest x ray or massive
PE. We performed an audit to examine the adherence to local protocol
(based on BTS guidelines) in the assessment of suspected PE and to
assess the time taken for appropriate imaging.
Methods: We identified all patients who had CTPA or V/Q scan for the
investigation of acute PE between April and July 2005. The notes were
reviewed to assess evidence of documentation of pre-test probability
(PTP) of PE, D-Dimer and the number of hospital days taken for the result
of either V/Q scan or CTPA. If PTP was not recorded it was calculated
retrospectively using information from the notes.
Results: Eighty six patients had a V/Q or CTPA performed. 16 patients
were diagnosed with PE (19%) (9 CTPA, 7 V/Q scans). 56 had V/Q
scans, 37 had a CTPA and 7 required V/Q followed by CTPA. One
patient had a CTPA to exclude PE at a later date after a low probability
V/Q scan. Five patients with non-diagnostic V/Q scans did not have
any further imaging. Two were diagnosed and treated as PE. Only 12%
had PTP documented and 28% had risk factors documented.
Retrospective scoring showed 52% with a low probability, 44% with
mod/high probability and 4% in whom a score could not be calculated.
The time from request to result was 3.0 days (range 0–11) for V/Q scan
and 1.6 days (range 0–11) for CTPA. 28/56 (50%) patients waited over
2 days for a V/Q scan compared with 6/37(16%) for a CTPA. An
alternative diagnosis was forthcoming from CTPA in 22 patients. CTPA
either diagnosed PE or provided significant alternative information with
which to make a diagnosis in 31/37 (84%).
Conclusion: Clinicians remain poor at documenting clinical probability
and risk factors in the assessment of PE. CTPA was performed
significantly more quickly than V/Q scan which is likely to result in a
shorter hospital stay. CTPA also provided information with which to
make an alternative diagnosis in 59%. 13/56 (23%) of patients required
further CTPA after non-diagnostic V/Q scans. However this did not
occur in 5 cases. We propose that primary investigation of PE with CTPA
instead of V/Q scan would result in less hospital days, fewer
requirements for further imaging, and would provide an alternative
diagnosis in a significant number of patients.
P020 AUDIT: THE OUTPATIENT MANGEMENT OF CTPA
CONFIRMED PULMONARY EMBOLIC DISEASE
J. W. Dodd, R. Nadama. Department of Respiratory Medicine, Royal Devon
& Exeter Hospital, Devon, UK
Introduction: British Thoracic Society (BTS) guidelines support the out-
patient treatment of low risk patients with computerised tomographic
pulmonary angiography (CTPA) confirmed pulmonary thromboembolism
(PTE).1 This approach does not lead to significant adverse events, may save
up to 5.5 days inpatient stay and is highly acceptable to patients.2
Aim: The primary aim of our audit was to find out if we are following the
BTS guidelines on management of PTE. We also collected clinical data
on each patient to help answer why some patients may not have been
managed as outpatients. Finally we asked whether or not there may be a
role for the outpatient management of low risk patients with suspected
PTE to be investigated and treated entirely as outpatients (including
outpatient CTPA).
Methods: CTPAs done at the Royal Devon & Exeter Jan–March’06. We
randomly selected case notes of 64 patients. 30 day mortality score was
then retrospectively calculated using simple 11 point patient character-
istics.3 We also collected data on patient clinical symptoms, signs,
investigations and duration of inpatient stay.
Results: Forty four patients were included; Average age 66. 29% (12) of
the CTPAs were positive. The average inpatient stay was 8.8 days the
average wait for CTPA was 3.3 days (report 0.5 days) and the average
duration of anticoagulation was 9.2 days. No low risk confirmed PTE
were managed as outpatients but 57% (7) could have been according to
BTS guidelines. 16% (7) of suspected VTE were managed entirely as
outpatients but some of these were ‘‘high risk’’ on mortality scoring.
On review of ‘‘low risk’’ patient characteristics it appears they were
more likely to have chest pain (64% v 60%) and higher clinical
probability of PTE (wells score and d dimmer) than the inpatient group as
a whole. This may be influencing the decision for outpatient treatment.
Conclusion: We are NOT following the BTS guidelines for the
management of CTPA confirmed PTE. We propose the introduction of
mortality scoring and expansion of existing outpatient DVT clinics.
1. Thorax 2003;58:470–84.
2. Thorax 2005;60(Suppl II):S155.
3. Am J Respir Crit Care Med 2005;172:1041–6.
P021 MICROTHROMBI IN A SEVERE CHRONIC
OBSTRUCTIVE PULMONARY DISEASE PATIENT
COHORT: A PILOT HISTOLOGICAL STUDY
I. J. Clamp1, G. C. Booth2, M. L. Foster1. 1Department of Pathology,
AstraZeneca R&D Charnwood, Leicestershire, UK; 2Respiratory/
Inflammation Research Area, AstraZeneca R&D, Alderley Park, UK
Introduction: Although there is evidence for a hypercoagulative state in
chronic obstructive pulmonary disease (COPD), there appears to be little
morphological data published on the presence of microthrombi in the
small vessels of COPD patients. During histopathological studies on lung
specimens from severe COPD patients undergoing lung volume
reduction surgery (LVRS), we have noted a significant incidence of
vascular congestion and thrombosis in the alveolar capillary bed that
prompted a formal pilot study of distribution. We have used both H&E
staining and thrombomodulin immunohistochemistry to assess thrombo-
tic potential in these vessels.
Method: Ten peripheral lung tissue blocks were selected at random from
archival tissues originally obtained from patients undergoing LVRS at the
Glenfield Hospital, Leicester. All tissues were obtained with full ethical
consent. Samples were stained with H&E and graded according to overall
lung pathology, the presence and distribution of vascular congestion and
apparent microthrombi and then subject to thrombomodulin IHC to assess
endothelial cell integrity as a putative marker of ‘‘pre-thrombotic’’ potential.
Results: Morphological assessment of lung samples showed a range of
pathologies in the airways, blood vessel walls, and parenchyma consistent
with inflammatory damage and post-inflammatory remodelling seen in
severe COPD. With regards to the microvasculature, there was a
widespread congestion of vessels, often associated with hyalinisation of
the vessel wall and loss of capillary integrity, particularly in areas of
emphysema. Many examples showed microthrombi disrupting the normal
anatomy of the capillary wall. There was no apparent increase in the
incidence of lesions in areas surrounding remodelled large vessels or within
alveolar walls adjacent to active bronchiolitis. Thrombomodulin staining
was very widely distributed throughout the sections with many examples of
staining without overt association with microthrombi. Interestingly, there
seemed to be a spectrum of thrombomodulin staining from marked in many
‘‘normal’’ capillaries through to a loss of staining in areas of active
pneumonitis and then a ‘‘reappearance’’ of marked staining with overt
microthrombosis.
Abstract P020
30 day mortality Total inpatients Total outpatients
0.8% (low risk) 24% (9) 29% (2)
2.5% (low risk) 32% (12) 29% (2)
4.3% 23% (8) 42% (3)
9.9% 13% (5) 0% (0)
27.1% 8% (3) 0% (0)
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Conclusion: This pilot study supports the idea that microvascular
endothelial injury and microthrombosis are features of the natural
history of severe COPD. Histological studies are underway in order to
understand whether this is a primary lesion reflecting a hypercoagulative
state or whether this is a secondary response to the loss of capillary
integrity leading to microvascular stasis.
P022 ISCHAEMIC STROKE AND BRAIN ABSCESS DUE TO
PULMONARY ARTERIOVENOUS MALFORMATIONS
C. L. Shovlin1,4, A. R. Benjamin1, H. Ramadan1, I. H. Jenkins2,4,
J. E. Jackson3,4. 1Respiratory Medicine, 2Neurology, 3Imaging,
Hammersmith Hospital, 4Imperial College Faculty of Medicine, London, UK
Introduction: Pulmonary arteriovenous malformations (PAVMs) are a
recognised cause of hypoxaemia and haemoptysis. In the absence of
symptoms or cyanosis however, many patients are not referred for
treatment. Possible reasons include poor recognition of PAVM-induced
ischaemic stroke and brain abscess risk, and the lack of published
evidence that PAVM treatment by embolisation reduces these risks.
Methods: In order to determine risk factors for PAVM-induced ischaemic
stroke and brain abscess, and risk reduction following embolisation, 219
consecutive PAVM patients reviewed between May 1999 and May 2005
were studied. 139 were referred for treatment of PAVMs, and 80 for
investigation of known or suspected hereditary haemorrhagic telangiec-
tasia (HHT). Presentation pattern, severity of any HHT, neurovascular risk
factors and focal cerebral deficit of rapid onset lasting .24 hours were
recorded, and if ischaemic (diagnosed by neurologists), brain abscess
(by neurosurgical reports) or of other aetiologies. Pre embolisation,
arterial oxygen saturation (SaO2), and right-to-left shunt (
99mTc scans)
were measured. 192 patients were placed on a waiting list for
embolisation (never .6 months), when PAVM features and the presence
of untreatable PAVMs (feeding arteries (2–3 mm) were recorded.1
Confirmation of complete PAVM obliteration was by chest x ray, SaO2
and R-L shunt performed at intervals for a mean of 3.7 (95% CI 2.6 to
4.8) years.
Results: In a predominantly asymptomatic population, excluding
ascertainment bias, 40/203 (19.7%) individuals experienced ischaemic
stroke or brain abscess. Overall, 31 patients experienced at least one
ischaemic stroke, 28 a brain abscess, and one patient experienced both
events. 39/60 (65%) had no pre-existing diagnosis of PAVM. Of the 21
patients with a pre-existing PAVM diagnosis, only 10 (48%) had been
treated, and median PAVM diagnosis to stroke interval was 7.0 (Q1 1.5;
Q3 11.5) years. The median age at stroke was 45 (Q1 38; Q3 53) years.
Significant persistent neurological defects were present in 30/49 (62%)
of abscess/stroke patients at a median interval of 8.0 (Q1 1.5;Q3 11.5)
years, and 12/15 (80%) of brain abscess patients were unable to return
to their former occupation. In univariate analyses, and Cox proportional
hazards models with embolisation as a time-dependent covariate, none
of six quantitative markers of PAVM severity or structure was associated
with ischaemic stroke or brain abscess. PAVM embolisation significantly
reduced ischaemic stroke and brain abscess rates. However, for patients
diagnosed after 1985, the mean delay to treatment was significantly
longer when the risk of stroke/abscess was not recognised (incidental
diagnosis 6.6 (95% CI 3.4 to 9.8) years; respiratory symptom diagnosis
4.0 (2.6 to 5.4) years; diagnosis by HHT screening programme 1.5 (0.4
to 2.7) years; diagnosis after stroke/abscess 1.1 (0.7 to 1.6) years.
Conclusions: Ischaemic stroke and brain abscess occur commonly in
patients with PAVMs. Opportunities for preventative treatment are being
missed.
Funding support: HHT patient donations
1. Gupta, et al. Am J Roent 2002;179:347–55.
P023 PULMONARY ARTERIAL PRESSURE, PULMONARY
ARTERIOVENOUS MALFORMATIONS (PAVMS), AND
PAVM EMBOLISATION
C. L. Shovlin, R. J. Davies, J. S. R. Gibbs, J. E. Jackson. Hammersmith
Hospital and Imperial College, London, UK
Introduction: Pulmonary arteriovenous malformations (PAVMs) are
abnormal dilated vessels that provide a direct capillary-free commu-
nication between pulmonary arteries and veins. The majority of PAVM
patients have underlying hereditary haemorrhagic telangiectasia (HHT,
Osler-Weber-Rendu syndrome). PAVMs lead to hypoxaemia, haemor-
rhage, and paradoxical embolic stroke. Increasing evidence is support-
ing the use of embolisation to treat PAVMs. PAVMs provide low
resistance pathways for pulmonary blood flow, and patients with PAVMs
would be predicted to have low pulmonary vascular resistance (PVR) and
pulmonary arterial pressure (PAP), as demonstrated in a series of 7
patients.1 However, pulmonary hypertension has been recognised in a
small number of PAVM patients, as a result of diverse aetiologies
including HHT-associated pulmonary hypertension.2 The presence of
pulmonary hypertension is considered a relative contra-indication to
embolisation of PAVMs.
Aims: (1) To examine the distribution of PAP in patients with PAVMs. (2)
To establish whether embolisation increases the PAP, in particular in
patients with pre-existing pulmonary hypertension.
Methods: A prospective study of contributory factors and PAP
measurements was performed in 143 PAVM patients undergoing
embolisation. 131/143 patients (92%) had underlying HHT.
Pulmonary artery pressure measurements were made prior to contrast
injection, and, where clinically indicated, following embolisation.
Results: The mean PAP mean was 14.00 (SD 5.01) mmHg (range 6–
40 mmHg). PAP was significantly correlated with age (p,0.0001,
Spearman rank), with the most significant increase occurring in the
upper quartile (age .58 years). Of the 5 individuals with mean PAP
.25 mmHg, 3 had severe left ventricular disease and/or mitral valve
pathology, and 2 had idiopathic pulmonary hypertension. Overall, there
was no significant increase in PAP mean as a result of embolisation, even
in patients with initial PAP mean in the upper quartile (.16 mmHg). In half
of this group, embolisation led to a fall in PAP mean; the maximum rise was
4 mmHg in the same session, and 8 mmHg in sequential angiography
sessions 3–80 (mean 26.7) months apart.
Conclusion: PAVM patients have higher PAP than previously predicted,
increasing with age. PAVM embolisation does not lead to a consistent
increase and may be undertaken with caution in the presence of pre-
existing pulmonary hypertension.
Funding support: HHT patient donations
1. Whyte, et al. J Appl Physiol 1993;75:321–8.
2. Trembath, et al. New Engl J Med 2001;345:325–34.
P024 LONG TERM ADMINISTRATION OF INTRAVENOUS (IV)
ILOPROST FOR PULMONARY ARTERIAL
HYPERTENSION
L. S. Mackay, J. DeSoyza, R. Cracket, T. Small, J. Lordan, A. J. Fisher,
P. A. Corris. Northern Pulmonary Vascular Unit, Freeman Hospital,
Newcastle upon Tyne, UK
Introduction: IV Epoprostenol is considered gold standard therapy for
pulmonary arterial hypertension (PAH), but is unstable and has a short
half-life. In our centre, intravenous Iloprost, a synthetic PGI2 analogue
with a longer half-life and better stability, is used in these patients.
Methods: A retrospective review of patients with PAH treated with IV
Iloprost (Schering Health). The primary end point was survival as
compared with that predicted by the D’Alonzo equation.1 Secondary
end points were change in six-minute walk distance and WHO class. All
data expressed as mean (SD) unless stated. Changes in walk test and
WHO class were analysed using t test for paired data (significance
p,0.05).
Results: Thirty five patients (25 females), age 43 (SD 14) years, were
treated with IV Iloprost between Nov 99 and May 06 for a median
242 days (range 2–1862). Treatment was generally well tolerated by 17
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patients with idiopathic PAH, 7 CTEPH, 6 connective tissue disease
associated PAH, 3 congenital heart disease associated PAH, 1 PAH
secondary to pulmonary vasculitis, and 1 post-pneumonectomy.
Haemodynamics prior to treatment: mean RA pressure 12 (7) mmHg,
mean PAP 59 (17) mmHg, PCWP 12 (6) mmHg, CI 2.1 (0.7), and PVR
14 (5) Wood units. Treatment dose was 2.8 (1.2) ng/kg/min. Eleven
patients died on treatment, 3 received lung transplantation, and 15
patients remain stable on treatment. Seven patients were transitioned to
other therapies. Walk test improved from 254 (116) m to 317 (127) m,
p = 0.001. WHO class improved 3.5 (0.5) to 2.9 (0.8), p = 0.0002.
Conclusion: Iloprost improves both survival and function in patients with
PAH and can be used as an alternative to Epoprostenol in this patient
population.
1. Ann Intern Med 1991;115:343–9.
P025 PHOSPHODIESTERASE TYPE 5 INHIBITOR AND THE
SPECTRUM OF PULMONARY HYPERTENSION
D. K. C. Lee. Pulmonary Vascular Diseases Unit, Papworth Hospital,
Papworth Everard, Cambridge CB3 8RE, UK
Background: The precise therapeutic role of phosphodiesterase type 5
inhibitor in the management of pulmonary hypertension remains to be
fully elucidated.
Methods: An analysis was conducted in 353 patients from six studies
evaluating the clinical efficacy of oral sildenafil therapy in pulmonary
hypertension. Outcome measures of efficacy were the change in exercise
capacity as measured by the total distance walked in six minutes and the
change in cardiopulmonary haemodynamics as measured by the mean
pulmonary artery pressure.
Results: Sildenafil significantly improved (p,0.05) the mean (standard
error of mean) six minute walk distance and pulmonary artery pressure
by 81 (16) m and 10 (2) mmHg respectively in patients with idiopathic
pulmonary arterial hypertension and pulmonary hypertension asso-
ciated with congenital heart disease, connective tissue disease,
haemoglobinopathy, and high altitude.
Conclusion: Sildenafil improved exercise capacity and cardiopulmonary
haemodynamics throughout the spectrum of pulmonary hypertension.
Further studies are now required to evaluate whether survival is
prolonged with the inhibition of phosphodiesterase type 5 in patients
with pulmonary hypertension.
P026 A POTENTIAL ROLE FOR SILDENAFIL IN THE
MANAGEMENT OF PULMONARY HYPERTENSION IN
PATIENTS WITH PARENCHYMAL LUNG DISEASE
B. P. Madden, M. Allenby, T-K. Loke, A. Sheth. Department of
Cardiothoracic Medicine, St George’s Hospital, London, UK
Background: Sildenafil offers potential to treat patients with pulmonary
hypertension by selectively inhibiting phosphodiesterase type five
pathways in the lung. It is recommended for selected patients with
pulmonary arterial hypertension but its role in the management of
pulmonary hypertension associated with parenchymal lung disease is
unclear.
Patients and Methods: Seven patients (68–86 years) with end stage
chronic obstructive pulmonary disease (COPD, 4) and idiopathic
pulmonary fibrosis (IPF, 3) were referred to our unit. All patients had
a long term history of chronic lung disease and were on maximal
appropriate therapy prescribed by their referring pulmonologist.
Thromboembolic disease was excluded by pulmonary angiography
and all patients had had high resolution thoracic CT scan. At assessment
right heart catheterisation, 2D echocardiography and 6-minute walk test
were performed prior to commencement of Sildenafil 50 mg tds. Their
medication was otherwise unchanged. After eight weeks treatment right
heart catheterisation, 2D echocardiography and 6-minute walk test were
repeated.
Results: The pulmonary vascular resistance was reduced in six patients
(from 13, 3, 3, 6.5, 3.5, and 10.5 wood units to 9.7, 2.5, 2.8, 4.4, 2.5,
and 5.4 wood units respectively). Six minute walk test increased in six
patients (from 110 m, 210 m, 80 m, 30 m, 210 m, and 80 m to 130 m,
312 m, 120 m, 82 m, 244 m, and 100 m respectively). One patient
with COPD did not demonstrate a favourable response although their
cardiac output increased on sildenafil therapy. 2D echocardiography
showed a reduction in estimated PA pressure in six patients with an
improvement in right ventricular systolic function in two COPD patients.
Conclusion: Our results suggest that Sildenafil may have a role for
selected patients with COPD and IPF who have pulmonary hypertension.
P027 ACUTE HAEMODYNAMIC RESPONSES TO INHALED
NITRIC OXIDE AND INTRAVENOUS SILDENAFIL IN
DISTAL CHRONIC THROMBOEMBOLIC PULMONARY
HYPERTENSION
J. Suntharalingam, P. George, R. Hughes, K. Goldsmith, M. Toshner,
K. Sheares, J. Pepke-Zaba. Pulmonary Vascular Diseases Unit, Papworth
Hospital, Cambridge, UK
Introduction: Although surgery is the treatment of choice for chronic
thromboembolic pulmonary hypertension (CTEPH), it is not appropriate
for patients with inaccessible distal disease. These patients are
traditionally managed supportively but may benefit from newer, more
specific vasoactive therapies. This study examines the acute haemody-
namic responses to inhaled nitric oxide (iNO) and intravenous sildenafil
in this patient population.
Methods: Patients with de novo distal CTEPH or with persistent
pulmonary hypertension post pulmonary endarterectomy were enrolled.
At standard right heart catheterisation baseline measures of mean
pulmonary artery pressure (mPAP), cardiac output (CO), pulmonary
vascular resistance (PVR), blood pressure, and systemic vascular
resistance (SVR) were recorded. iNO was then administered at
20 ppm for 10 minutes. After repeat measurements, iNO was
discontinued with a subsequent washout period of at least 5 minutes.
Sildenafil was then administered intravenously at two incremental doses
(‘‘sild1’’ and ‘‘sild2’’, which have equivalent plasma levels to 25 mg and
50 mg orally) with further haemodynamic measurements during each
infusion.
Results: Fourteen subjects (5/14 female, mean age 54.6 years (SD 15.1)
were enrolled, with mean baseline measurements mPAP 45.9 mmHg
(SD 9.3), CO 3.9 l/min (SD1.0), and PVR 10.2WU (SD4.6). Significant
improvements in mPAP and PVR were demonstrated following iNO
(24.1 mmHg or 29.8% (p,0.001) and 21.4WU or 216.2%
(p = 0.001)), sild1 (27.3 mmHg or 216.3% (p,0.001) and 22.6WU
or 223.7% (p,0.001)), and sild2 (28.6 mmHg or218.9% (p,0.001)
and 22.9WU or 227.1% (p,0.001)). The reduction in mPAP following
sild2 was significantly greater than that following sild1 (p = 0.04).
Individual mPAP and CO responses to iNO correlated well with
responses to sild1 (r = 0.86 p,0.001 and r = 0.82 p,0.001) and sild2
(r = 0.67 p = 0.009 and r = 0.61 p = 0.02). The PVR/SVR ratio, a
measure of pulmonary selectivity, remained unchanged between
administration of iNO, sild1, and sild2 (0.37 v 0.36 v 0.35 p = 0.289).
Discussion: Although failing to meet formal positive haemodynamic
response criteria, subjects displayed significant acute responses to both
iNO and sildenafil, suggesting that increased vascular tone forms an
important component of distal CTEPH. Individual responses to iNO and
sildenafil correlated well, as would be expected given their common
mechanism of action. Both iNO and sildenafil shared pulmonary
selectivity, although sildenafil was associated with greater haemody-
namic improvements than iNO. Incremental doses of sildenafil were
associated with a dose dependent effect on mPAP.
Conclusions: Both nitric oxide and sildenafil lead to selective pulmonary
vasodilatation in distal CTEPH.
P028 PULMONARY ARTERIAL PULSE PRESSURE AND
MORTALITY IN PULMONARY ARTERIAL
HYPERTENSION
K. G. Blyth1, R. Syyed1, J. E. Foster1, J. Chalmers1, T. Saba2, R. Naeije3,
C. Melot3, A. J. Peacock1. 1Scottish Pulmonary Vascular Unit, Western
Infirmary, Glasgow, UK; 2Sheffield Pulmonary Vascular Unit, Sheffield, UK;
3University Libre de Bruxelles, Brussels, Belgium
Objectives: Mean pulmonary artery pressure is an inconsistent predictor
of mortality in pulmonary arterial hypertension (PAH) (Sitbon et al, J Am
Coll Cardiol 2002). Systemic arterial pulse pressure is a powerful
prognostic tool in conditions affecting the left ventricle (Franklin et al,
Circulation 1999). We investigated the prognostic influence of
pulmonary arterial pulse pressure (PAPP) in PAH.
Methods: Data for 67 patients with PAH (diagnosed January 1996–
March 2004) were reviewed retrospectively. PAPP was correlated
against cardiac index (CI) and a (a measure of pulmonary circulation
distensibility) (Reeves et al, Am J Physiol Lung Cell Mol Physiol 2005).
Linear Cox regression and Kaplan-Meier analyses were used to identify
predictors of mortality.
Results: PAPP and a correlated powerfully (r =20.838, p,0.001). PAPP
and CI did not correlate suggesting a more complicated relationship
between these two variables. CI, mixed venous O2 (MVO2) saturation
and 6-minute walk test distance were the best predictors of mortality in a
linear model. PAPP related to mortality in a bell-shaped fashion; 5-year
mortality was 40%, 91% and 54% in patients with low, intermediate and
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high PAPP, respectively. There was a trend towards lower CI and MVO2
saturation in patients with intermediate PAPP and the highest mortality,
although these differences did not reach statistical significance.
Conclusion: The bell-shaped relation between PAPP and survival that we
found is compatible with the notion that disease progression in PAH is
characterised by simultaneous, but perhaps staggered, reductions in
pulmonary circulation distensibility and CI. In advanced disease, low
distensibility and low CI may coexist, resulting in intermediate PAPP. To
improve their predictive value, PAPP and CI should be reported
simultaneously.
Pulmonary rehabilitation
P029 A ROLLING PROGRAMME FOR PULMONARY
REHABILITATION: VIABLE OR NOT?
K. Ford, M. R. Hetzel, A. Kendrick. Departments of Physiotherapy &
Respiratory Medicine, Bristol Royal Infirmary, Bristol BS2 8HW, UK
We report a pilot audit to compare the efficacy of intermittent versus
rolling pulmonary rehabilitation programmes (PRP).
We previously ran a fixed 7 week hospital based PRP course 4–5
times a year. 15 patients were initially assessed per course with an
average of 5–6 patients completing it. Because of apparently high ‘‘did
not attend’’ (DNA) rates, during 2005, we sent a questionnaire to 20
patients who failed to complete more than 50% of the course. Of the 75%
who replied, the commonest reason (50%) for withdrawal was being
unwell due to their chest condition. Since previous studies1, 2 have shown
that 21% of patients relapse within two weeks of an exacerbation, and
early pulmonary rehabilitation after admission for an acute exacerbation
of COPD is safe, from February 2006 we started a rolling programme to
see if this would decrease waiting time for rehabilitation following an
acute exacerbation and whether it might affect withdrawal rates during
the course.
Conclusion: Although new patients enter a rolling program at different
points, continuity has not been a problem. While the proportion of
patients completing the programme and the mean number of sessions
attended was the same, the rolling programme achieved a substantially
reduced waiting time after exacerbations of COPD and may therefore be
more effective in reducing readmission rates for subsequent exacerba-
tions.
1. Kim S, et al. Chest 2004;125:473–81.
2. Mann DC, et al. BMJ 2004;329:1209–14.
P030 EDUCATION IN PULMONARY REHABILITATION: THE
PATIENTS’ PERSPECTIVE
J. S. Wilson1, B. O’Neill2, J. Reilly3, J. MacMahon1, M. Hall2,
J. M. Bradley1,2. 1Department of Respiratory Medicine, Belfast City
Hospital Trust, N Ireland; 2Health and Rehabilitation Sciences Research
Institute, University of Ulster, N Ireland; 3UNESCO Centre, University of
Ulster, N Ireland
Introduction: There is limited research to direct the content and delivery
of the educational component of pulmonary rehabilitation. Current
guidelines (BTS, 2001) give no indication about which topics are
essential for inclusion, nor the specific content and method of delivery.
Importantly these proposed topics are not based on the patients’
perspective.
Aims: To ascertain from the patients’ perspective what should be
included in the educational component of pulmonary rehabilitation (PR)
and how this should be delivered.
Methods: A purposive sample of 32 patients with COPD were recruited
from the regional respiratory centre at the Belfast City Hospital (8 mild,
20 moderate, 4 severe). Six focus groups were conducted (2 groups had
attended PR, 2 non-PR groups, and 2 mixed groups). A structured
schedule of topics was used to guide the discussion facilitated by an
experienced moderator.
Data analysis: Focus groups were videotaped and analysed using a
grounded approach. Results were verified by means of a follow up
report which elicited participants’ comments on the findings.
Results: The physical and psychosocial impact of COPD was described
extensively. Patients reported considerable lifestyle adjustments and
frustration as a result of their symptoms. Key topics identified by
participants were: disease education (what is COPD and causes);
management of breathlessness (practical strategies for activities of daily
living and walking, pacing, and panic reduction); medication (how,
when, and why to use medications); welfare and benefits system
(disability entitlements, access to home aids, and appliances); exacer-
bation management (recognition of worsening of symptoms, when and
where to seek help). There was ambivalence concerning the importance
of disease progression and end of life issues. The majority of patients felt
these along with a range of other topics should be included in
supplementary information, which they could choose to access.
Patients preferred a group format as practical demonstrations and peer
support were considered important aspects of learning. The location
could be hospital based or otherwise, as long as the sessions were
delivered by a knowledgeable/credible individual.
Conclusion: This study has identified deficits in patients’ knowledge,
understanding, and management of their COPD. Health professionals
should ensure that educational components are included in PR
programmes which meet these needs, in a format that is acceptable to
patients.
P031 BRISTOL COPD KNOWLEDGE QUESTIONNAIRE:
EXPERIENCE WITH 100 PATIENTS ATTENDING AN
OUTPATIENT PULMONARY REHABILITATION
PROGRAM
J. James, V. Sandrey, S. Barr, E. Nash, R. White, D. Smith. North Bristol Lung
Centre, Frenchay Hospital, Bristol BS16 1LE, UK
Introduction: The Bristol COPD Knowledge Questionnaire (BCKQ) is a
new tool developed to measure knowledge of COPD in patients. It
consists of 13 questions with 5 items offering a true/false/don’t know
choice. The 13 topic areas are epidemiology, aetiology, symptoms,
breathlessness, phlegm, infections, exercise, smoking, vaccination,
inhaled bronchodilators, antibiotics, oral steroids, and inhaled steroids.
It has been shown to be valid and consistent with good test re-test
reliability and responsiveness (Chronic Respiratory Disease 2006;3:1–
7).
Methods: We have now administered the BCKQ to 100 patients before
and after pulmonary rehabilitation to measure change in knowledge
imparted by our program. 100 patients with COPD (mean (SD, range) %
predicted FEV1 45.2 (17.7, 17–118)), mean age 67.9 (8.5, 49–85), 68
male, took part in an 8 week outpatient based PR program and
completed the BCKQ before and after. The mean total score prior to PR
was 51.4 (14.2, 8–85) % improving to 66.5 (12.6, 31–86) % following
PR. Prior knowledge for the group was strongest in the areas of
aetiology, exercise, and smoking. Specifically the effects of stopping
smoking on risk of heart disease and decline of lung function together
with the recommendation for yearly flu vaccination were the highest
scoring items (all .95% correct). Prior knowledge was weakest
concerning the topics of oral and inhaled steroids. Over 95% of patients
believed that lung function improved following smoking cessation and
with inhaled steroids.
Results: The greatest improvements in knowledge were seen in the topic
areas of phlegm (mean improvement 25%), exercise and oral and
inhaled steroids (all .20%). Least was learned regarding antibiotics
(mean improvement 8%). Specifically the effects of dehydration on
sputum clearance and the efficacy of spacer devices in reducing oral
Abstract P029
Program type/dates
Waiting
times (weeks)
Started
PRP (n)
Completed
PRP (n)
Failed to
complete (n)
Mean classes
completed
Fixed program March–May
2005
9–36 11 5 6 12.4
May–July 2005 11–20 11 6 5 12
Rolling Program
February–June 2006
3–6 11 6 5 12.8
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thrush both showed at least 40% improvement in correct responses.
Uncertainty was reduced as a result of education with the proportion of
don’t know responses reduced from 29 (16) % to 11 (9) %.
Conclusions: In this large group of patients there was no significant
correlation found between improvements in knowledge and improve-
ments in exercise performance or changes in health status measured with
HAD, SEQ, and CRDQ. There was, however a significant (p,0.001)
negative correlation between age and post education score suggesting
there may be some truth in the contention that you can’t teach an old dog
new tricks.
The BCKQ has proved a useful tool in measuring the effects of the
education component of our PR program and highlighting areas within
the program that need revision or further emphasis.
P032 A PILOT STUDY TO COMPARE QIGONG EXERCISES
WITH CONVENTIONAL EXERCISES IN PULMONARY
REHABILITATION
A. Price1, M. Meah2, T. O’Shaughnessy3. 1Newham Primary Care Trust;
2University Of East London; 3Newham University Hospitals NHS Trust, UK
Background: Qigong (Tai Chi) is a low impact Chinese exercise known
for its benefits in improving strength and flexibility in chronic conditions.1
Qigong requires no specialist equipment, can be performed anywhere
and is available in the community. Previous studies of Qigong have
demonstrated improvements in cardiopulmonary function.2 Pulmonary
rehabilitation (PR) is a gold standard for patients with chronic obstructive
pulmonary disease (COPD). There is no evidence of the use of Qigong as
an exercise for PR and therefore investigated whether Qigong would
benefit COPD patients as part of a PR programme.
Method: Twenty two patients were recruited for the eight week study
(M = 13, F = 9), median age 66 years (range 55–81), Forced expiratory
volume in 1 sec (FEV1) (% of predicted) median 39 (range 18–72) and
were randomised to conventional PR or Qigong PR groups. Patients were
stratified for disease severity using the Medical Research Council
Dyspnoea (MRC) scale and FEV1%. Outcome measures used were
incremental shuttle walk test (ISWT), BORG breathlessness score, chronic
respiratory disease questionnaire-self reported (CRQ-SR), Hospital
Anxiety and Depression Scale (HADS), endurance shuttle walking
(ESW), and a patient satisfaction survey. Differences in mean data
between and within groups were analysed using SPSS and significance
was set at 95% (p,0.05)
Results: Fourteen patients completed the study. Both groups showed
improvement from baseline with the biggest improvement in ESW
(p,0.036 PR, p,0.002 Qigong PR). No significant differences were
shown between the two groups (table).
Conclusion: Qigong exercises improve exercise tolerance and quality of
life in most COPD patients on a PR programme.
1. Thornton, et al. Health benefits of tai chi exercise: improved balance
and blood pressure in middle aged women. Health Promot Int
2004;19:33–8.
2. Chao, et al. The cardiorespiratory response and energy expenditure
of tai-chi qui-gong. Am J Chin Med 2002;30:451–61.
P033 IS A PRACTICE INCREMENTAL SHUTTLE WALK TEST
REALLY NECESSARY?
F. Gray1, A. Smith2, M. Britton2, P. Murray2, J. Bott1. 1Respiratory Care
Team, North Surrey Primary Care Trust, Chertsey, Surrey, UK; 2Department
of Respiratory Medicine, Ashford and St Peter’s NHS Trust, Chertsey, Surrey,
UK
Introduction: The incremental shuttle walk test (ISWT) is a commonly
used outcome measure for pulmonary rehabilitation (PR). The distance
walked in the ISWT can be used to calculate the speed of the endurance
shuttle walk test (ESWT). The ESWT consists of 16 levels (1 = 1.5 kph,
16 = 6.0 kph). Singh et al (1992) advocate a practice walk (PISWT) but
few centres do one. We set out to find out the following: (1) is a PISWT
really necessary and (2) does a PISWT affect the level of ESWT?
Method: All patients attending PR perform a PISWT and an ISWT before
the ESWT level is calculated. We present our data on the differences.
Results: 205 patients were assessed for PR between October 2002 and
December 2005. We have PISWT and ISWT data on 184 patients. Table
1 shows the difference in distance walked between PISWT and ISWT.
Table 2 shows the effect of PISWT on ESWT level.
Discussion: We have shown that there is a wide range in difference
between PISWT and ISWT and the effect this has on ESWT can be very
significant for an individual patient although not when taken as a whole.
Conclusion: A PISWT is necessary to gain an accurate ESWT level. An
inaccurate ISWT at baseline could impact on apparent post PR outcome
whether using the ISWT or ESWT as the outcome measure.
P034 COMPARING THE INCREMENTAL SHUTTLE WALK TEST
AND ENDURANCE SHUTTLE WALK TEST AS AN
OUTCOME MEASURE FOR PULMONARY
REHABILITATION
F. Gray, A. Smith, J. Bott. Physiotherapy, North Surrey Primary Care Trust &
Ashford and St Peter’s NHS Trust, Surrey, UK
Introduction: The incremental shuttle walk test (ISWT) is a progressive
walking test at an externally paced speed using a 10 m course. The
endurance shuttle walk test (ESWT) is an endurance walk along the same
course, at 85% VO2 peak calculated from the ISWT (2nd walk). Since an
ISWT needs to be performed to obtain the ESWT speed, more walks are
required, making it more time consuming, and few centres therefore use
it as an outcome measure. However, it has been reported as more
sensitive to change than ISWT (Revill, 1999). The minimally clinically
important change (MCIC) for the ISWT is 50 m but none is available for
ESWT. We present data on the change in both walks following
pulmonary rehabilitation (PR).
Method: Sixty three patients were assessed for PR between July 2005
and April 2006. ISWT & ESWT data were available for 41 patients. The
change in both ISWT and ESWT was calculated post PR.
Results: Nineteen patients (45%) met the minimally clinically important
change (MCIC) for ISWT.
Discussion: Most patients increased distance walked post PR, although
less than half met the MCIC for the ISWT. The actual distances walked
and the change in ESWT are much larger, giving participants greater
evidence of their ability and their improvement, which we feel aids
motivation. Even though it takes longer to perform we therefore believe
Abstract P032 Comparison between group means (SD) scores
Outcome measure Qigong pre Qigong post Control pre Control post p Value
CRQ-SR 12.79 (4.33) 14.46 (4.93) 14.41 (5.34) 15.70 (4.12) 0.85
ISWT (m) 229 (45) 275 (51) 203 (149) 242 (136) 0.79
ESW (m) 180 (47) 448 (59) 201 (209) 426 (266) 0.67
HAD anxiety 9.8 (4.2) 11.1 (5.4) 9.1 (4.7) 9.5 (6.1) 0.71
HAD dep 9.6 (4.5) 7.7 (3.3) 7.2 (4,.8) 5.9 (3.3) 0.66
Abstract P033 Table 1 Comparison of PISWT
and ISWT
Difference (m) % Difference
Mean 20 22
Median 20 10
Range 255 to 340 2110 to 170
Abstract P033 Table 2 Effect of PISWT on ESWT
level
Median change in level 0
Mean change in level 1
Range 24 to 6
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the ESWT is a better outcome measure than the ISWT for PR, and find it a
useful clinical tool.
Conclusion: In our DGH and community hospital based three site PR
programme, we have confirmed the ESWT to be more sensitive to
change than the ISWT. Moreover, greater walking distances and larger
changes achieved potentially improves motivation.
P035 USE OF THE MODIFIED CANADIAN OCCUPATIONAL
PERFORMANCE MEASURE IN PULMONARY
REHABILITATION
J. Callaghan, F. Gray, J. Bott. Respiratory Care Team, North Surrey Therapy
Primary Care Trust, UK
Introduction: The Canadian Occupational Performance Measure
(COPM) is a tool for recording self-perception of function and has been
used in COPD. A modified version of this tool was used for pragmatic
reasons due to a period of restricted Occupational Therapy input to our
pulmonary rehabilitation (PR) programme. We are interested in
evaluating its validity and sensitivity. The Self Report Chronic
Respiratory Questionnaire (CRQ-SR), a quality of life measure, is widely
used within this client group. The CRQ-SR dyspnoea (D) component is
very similar to the COPM Performance (P) component and the CRQ-SR
mastery (M) component has some similarities to the COPM satisfaction
(S) component. We present our audit data, having evaluated the change
in both following PR.
Method: Fifty two patients enrolled in one of our PR programmes across
three sites in North Surrey, completed the CRQ-SR and COPM pre and
post PR. For the COPM, patients were asked to rate (0–10) performance
(P) and satisfaction (S), for three chosen tasks important to them. The
Minimal Clinically Important Change (MCIC) for both the dyspnoea and
mastery components of the CRQ is 0.5 and for the COPM is 2.
Results: See table (n = 52).
Discussion: Our data suggest that COPM P may be more sensitive than
CRQ-SR D, or that for some patients performance and dyspnoea are not
as closely linked as we may assume. More patients achieve MCIC for
both Satisfaction (COPM) and Mastery (CRQ-SR) than for either
Performance (COPM) or Dyspnoea (CRQ-SR).
Conclusion: We need to further explore validity and sensitivity of the
modified version of the COPM.
P036 INFLUENCE OF PULMONARY REHABILITATION IN
PATIENTS WITH CHRONIC OBSTRUCTIVE
PULMONARY DISEASE ON USE OF SECONDARY CARE
RESOURCES
J. P. Finnerty, S. Roberts. Countess of Chester Hospital, Chester, UK
We set out to assess the effect of our outpatient program of pulmonary
rehabilitation on the subsequent use of healthcare resources in both
primary and secondary care. A series of 6 week outpatient based
programs of pulmonary rehabilitation were performed. The program
has been described elsewhere (Finnerty JP et al. Chest 2001;119:1705–
10). Data were analysed for patients taking part in six successive
programs undertaken between February 2003 and March 2005,
looking at all visits to GPs, number of hospital admissions with
respiratory problems, and total days spent in hospital with respiratory
problems in the 12 months before the 6 week program and the
12 months afterwards. The source of the data was the hospital
information system (Meditech). Three patients died in the year after the
program of CCF and were excluded from the analysis, and 41 patients
had their data analysed. The mean number of GP visits before the
program was 1.76 (SE 0.38) and after the program was 2.02 (0.6)
(NS). Before the program, the mean number of hospital admissions was
0.90 (0.23), and after the program it was 0.68 (0.21) (NS). Before the
program, the mean number of inpatient days with respiratory problems
per patient was 8.78 (2.56), and after the program it was 3.44 (1.04)
(NS). The number of visits to the physiotherapist was 1.39 (0.26) before,
and 1.63 (0.58) after the program. The number of visits to our chest
clinic was 2.20 (0.21) before and 2.07 (0.28) after the program (NS).
The total number of hospital bed days with respiratory complaints in the
year before the program was 360, and in the year after the program it
was 141 (x2, p,0.001). We conclude that the number of inpatient days
with respiratory complaints was significantly less after the program. This
analysis cannot determine whether this was due to regression to the
mean, or a true effect of the program.
P037 POST-TRAUMATIC STRESS DISORDER AND CHRONIC
LUNG DISEASE: PREVALENCE AND CHANGES
FOLLOWING PULMONARY REHABILITATION
R. C. M. Jones, S. A. Harding, J. L. Campbell. Respiratory Research Unit,
Peninsula Medical School, Plymouth, UK
Background: Post-traumatic stress disorder (PTSD) is a common serious
condition, but is often undetected. Main features include hyperarousal,
avoidance behaviour and re-experiencing after a traumatic experience.
It is treatable. Little is known about the prevalence in chronic diseases
such as COPD and about the impact of PTSD on the symptoms and
disability associated with COPD. It is possible that attacks of breath-
lessness or being given the diagnosis of a life threatening condition may
cause PTSD in COPD patients and this may have a negative impact on
their symptoms and behaviour.
Research Questions: (1) What is the prevalence of PTSD in patients with
COPD referred to pulmonary rehabilitation (PR)? (2) Do PTSD symptom
scores fall following PR? (3) What is the relation between PTSD symptom
scores and changes in exercise tolerance and health status measures in
patients with COPD?
Design: Cross sectional and longitudinal survey.
Participants: Patients with chronic lung disease attending PR pro-
grammes in Plymouth, Exeter, and East Devon.
Outcome Measures: The Posttraumatic Diagnostic Scale (PDS), Impact of
Events scale (IES), the incremental shuttle walking test, Hospital Anxiety
and Depression scale (HADS), and Chronic Respiratory Questionnaire
(CRQ).
Methods: Questionnaires were completed at face to face interviews in
the subject’s home one week before commencing PR and at the end of
the PR programme.
Results: 100 subjects took part, mean age 68 years (8.2); 65 male.
Seventy per cent completed the PR programme. 192 traumatic
experiences were reported by 74 subjects, 37 related to their lung
disease. Their most traumatic experience was recorded, of which 24/74
(32%) were lung related. The prevalence of PTSD was 8% according to
the PDS criteria. Those with PTSD reported worse health status than those
without PTSD: mean CRQ total scores: 76 v 60, p = 0.02; mean HADS
anxiety: 11.8 v 7.2, p = 0.01. After PR, exercise capacity and all CRDQ
and HAD scales improved significantly in this cohort of patients, but
PTSD symptom severity measured by PDS or IES did not change. Those
with PTSD showed significantly greater improvements in CRQ mastery
(median 6.5 v 3.0, p = 0.048); total CRQ (27.5 v 15, p = 0.033) and
Abstract P034 Change in ISWT and ESWT post PR
n = 41
Metres %
Mean (SD) Median (range) Mean (SD) Median (range)
ESWT 404 (459) 275 (2830 to 1490 282 (548) 92.5 (281 to 3233)
ISWT 52 (53) 40 (250 to 180) 40 (60) 25 (220 to 260)
Abstract P035
% Achieving MCIC for COPM P 46
% Achieving MCIC for CRQ-SR D 38
% Achieving MCIC in both 25
% Not achieving MCIC in both 40
% Achieving MCIC for COPM S 54
% Achieving MCIC for CRQ-SR M 58
% Achieving MCIC in both 33
% Not achieving MCIC in both 15
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HADS anxiety (24.5 v 22, p = 0.023), but not in other CRQ scales,
HADS depression scale or shuttle test.
Conclusion: PTSD was present in a small minority of COPD patients
referred for PR and was associated with poor health status. Those with
PTSD improved more in anxiety and disease specific health status than
those without PTSD. There is no evidence that PTSD symptoms are
improved by rehabilitation, despite its positive effects on HAD scores,
exercise and health status in this cohort.
P038 WHY DO PATIENTS DECLINE TO TAKE PART IN A
RESEARCH PROJECT INVOLVING PULMONARY
REHABILITATION?
R. Taylor, S. Dawson, M. Sridhar*, M. R. Partridge. Imperial College London,
NHLI Division at Charing Cross Hospital, UK
Background: 303 patients with chronic obstructive pulmonary disease
(COPD) who had had a previous hospital admission for an exacerbation
were thought to be suitable to take part in a randomised controlled trial
of the effect of a comprehensive intermediate care package in preventing
admission to hospital of elderly patients with the disease. 122 of these
suitable patients consented to take part in the study but an identical
number declined (40.3%) and there was no response from 59 (19.5%)
Following the sending of an ethics committee approved recruitment
letter, 39 of the 122 patients (32%) who had declined to take part in the
study agreed to either a telephone or face-to-face interview which was
recorded in all but one case. The interviews lasted a mean of
20.1 minutes. Following transcription, analysis was undertaken using
the framework method (Ritchie and Spencer 1994).
Results: There was 86% congruence between two clinicians in identifying
six framework themes from 10 transcripts. Subsequent analysis of all 39
transcripts confirmed the six initial themes with one additional minor
theme. 19/39 (48.7%) patients reported location of the pulmonary
rehabilitation class and travel to and from the class as a major obstacle,
and 19/39 (48.7%) reported a perception that they would not benefit
either because they perceived their condition to be too severe or felt they
were on maximal therapy already. 15 of the 39 patients (38.5%) had
competing commitments or demands and in 12/39 (30.8%) there was
poor or negative understanding of the research study. In 11/39 cases
(28.2%) past negative experiences either with exercise, previous
research or healthcare staff led to decline to take part. In 10/39
(25.6%) of the cases the reason for declining to take part was influenced
by the patients’ perception that exercise would make them worse, and
that they would not be able to commit to the intervention. A minor theme
in a handful of cases concerned group work.
Conclusions: Non-participation in studies can lead to bias. Little is known
about the decision making progress patients engage in when consider-
ing participation in a research trial that involves physical activity. In
studies amongst those with COPD it appears that ease of access to the
study venue, transport issues and other commitments interact with
patients’ perception of risk, benefit and cost. These factors are of equal
or greater importance than items specifically related to taking part in a
research project.
This study was funded by The Health Foundation.
*Dr Sridhar died on the 29 June 2006.
P039 BENCH-MARKING PULMONARY REHABILITATION:
SHOULD THERE BE SOME STANDARDISATION?
J. C. Waterhouse1, J. Walsh2, S. Revill3, S. Singh4, on behalf of the TPRC.
1Royal Hallamshire Hospital; 2Derby Hospitals NHS Trust; 3Sherwood Forest
NHS Trust; 4University Hospitals of Leicester, UK
Introduction: The Trent Pulmonary Rehabilitation Consortium (TPRC) is a
long standing special interest group, based within a largely industrial/
former coalfield region of North/Central England. The total population
of the area is 4 million and has a high proportion of COPD. We believe
that the majority of pulmonary rehabilitation (PR) provided within the
region is represented by the group.
Methods: A questionnaire regarding service provision across the region
was piloted by a small number of group members to cover both hospital
and community provision of PR. Questions were reformatted to assist
clarity after this initial pilot. Subsequently all the group were invited to
complete the questionnaire. Seventeen members completed the ques-
tionnaire. Responses came from 3 NHS Foundation Trusts, 8 Hospital
Acute Trusts, and 9 Primary Care Trusts. Rehab leads were mostly
physiotherapists, with 1 clinical scientist, 1 practice nurse and one with a
nurse plus an audit lead. Sessions were usually twice weekly for a range
of 5 to 8 weeks in duration. Venues ranged from Acute Hospital to
Church Hall.
Results: Waiting lists varied from zero to more than six months.
Outcome measures used by more than half of the centres were, in order
of frequency, the incremental shuttle walking test, MRC breathlessness
grade, Heart rate and SpO2, BORG score, endurance shuttle walking
test, and the Hospital Anxiety and Depression questionnaire. Many
others were used by less than half of the respondees. Low levels of
funding and wide variation in staffing level were evident. Five centres
had access to a maintenance programme but only one thought it met the
needs of PR graduates.
Discussion: The NICE clinical guideline on chronic obstructive pulmonary
disease (COPD) recommends that PR should be available to all
appropriate people with COPD. This will surely be reflected in the new
national service framework (NSF) for COPD. Our region includes many
areas of deprivation and high incidence of respiratory disease. Provision
of PR is currently poor.
Conclusions: We recommend establishment of a national register and a
core set of outcome measures. This will facilitate comparison between
regions which will not only improve the quality of programmes but also
provide data to underpin fair distribution of finite funding.
P040 BEST BUY FOR PULMONARY REHABILITATION:
COMPARISON OF COMMUNITY AND HOSPITAL
PROVISION. A REPORT OF THE COHORT STUDY OF
PULMONARY REHABILITATION
Y. Oluboyede1, J. C. Waterhouse2, S. Walters1, R. Lawson2. 1School of
Health and Related Research, University of Sheffield; 2Royal Hallamshire
Hospital, UK
Introduction: This UK Health Technology Assessment Board funded study
is a randomised controlled clinical trial comparing community versus
hospital pulmonary rehabilitation sessions for patients suffering from
chronic obstructive pulmonary disease (COPD). Individuals were
randomly allocated into a 6-week programme taking place either in
the community (intervention) or hospital (control) setting. We have
reported clinical outcome elsewhere, here we report the interim cost
effectiveness analysis of the two rehabilitation programmes.
Methods: Cost and effectiveness data were collected on 72 and 85
individuals in the community and hospital rehabilitation arms respec-
tively. The cost of running each rehabilitation programme consisted of
staff costs, hire of facilities and equipment. Approximately 8 individuals
attended each session at a time. In addition costs were estimated for
each individual by accounting for drug and heath service use (eg GP
consultation, district nurse visits, etc). Effectiveness data were measured
using the medical outcomes survey Short Form 36 item questionnaire
(SF-36). The SF-36 scores were converted into a single preference based
utility score (SF-6D) representing a Quality Adjusted Life Year (QALY).
The ratio of the cost difference and the QALY difference between the two
arms of the trial was calculated.
Results: For each session the community based rehabilitation pro-
gramme cost £34.15 while the hospital based rehabilitation program
costs £29.56 per patient. The mean incremental cost of a community
based rehabilitation program compared to hospital rehabilitation was
£45.45 (95% bootstrap CI 219.19 to 106.47) and the mean
incremental effectiveness was 20.0013 (95% bootstrap CI 20.004 to
0.001) QALYs per patient. The point estimate of the incremental cost
effectiveness ratio was thus negative (235610 95% bootstrap CI
2443221.2 to 394794.98). This indicates that the standard treatment
(hospital rehabilitation) dominates.
Discussion: It must be borne in mind that these results are based only on
the immediate effects after a programme of pulmonary rehabilitation has
taken place. Data on longevity of effect (18 months) are still being
collected. They do however question the prevalent assumption that all
new pulmonary rehabilitation provision should be based in a community
setting.
Respiratory physiology
P041 CAN PATIENT VERBAL RATINGS OF BREATHLESSNESS
FACILITATE RAPID CLINICAL ASSESSMENTS?
A. Saracino1,2, A. Dent1, T. Weiland1, B. Jolly2. 1St Vincent’s Health
Melbourne, Australia; 2Monash University, Melbourne, Australia
Background: Acute shortness of breath (SOB) is common and a
potentially significant marker of cardiorespiratory disease. As a
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subjective symptom that cannot be directly measured, rapid severity
assessments and accurate site of care decisions can be difficult. This
study investigated the validity of a verbal subjective rating scale for SOB
and tested its ability to predict emergency department (ED) departure
status for the acutely breathless patient.
Methods: This was a two-part prospective observational study conducted
at a tertiary hospital: (1) tool validation, (2) predicting ED departure
status. (1) A convenience sample of patients presenting for cardiac stress
tests was used (n = 48). Objective and subjective breathlessness
parameters were collected before, during, and after exercise and
included respiratory rate (RR), oxygen saturation (SaO2), heart rate (HR),
blood pressure (BP), and verbal dyspnoea scores (VDS) for present
dyspnoea; ‘‘On a scale from 0–10, how bad is your SOB, with zero
being no SOB and ten the worst SOB you can imagine?’’ (2) A random
sample of patients presenting to the ED with SOB was used (n = 253).
Subjective and objective breathlessness parameters were collected at
initial presentation and 30 minutes later and included those considered
for tool validation, plus VDS for the worst SOB during the current
episode and arterial blood gasses (if applicable). Primary endpoints
were ED departure status (home, emergency observation unit, inpatient
ward) and inpatient length of stay (LOS).
Results: (1) Within-subjects, VDS were significantly correlated with RR
(mean r = 0.95), HR (mean r = 0.90), and systolic-BP (mean r = 0.95).
Between-subjects, correlations were significant at all time points for RR
only (r = 0.45 to 0.65, p,0.04), indicating high individual variability in
symptom perception. (2) Age and VDS at initial presentation were
significant predictors of ED departure status (78.3% correct classifica-
tion, p,0.001). VDS at initial presentation for present and worst
dyspnoea were strong and significant correlates with inpatient LOS.
Conclusion: A verbal numerical SOB rating scale is a valid measure of
breathlessness and in the acute care setting, may provide a useful
strategy for streamlining initial assessments, patient prioritisation and
site of care decisions.
P042 RESPIRATORY FUNCTION IN THE ARCTIC:
INVESTIGATION OF RESPIRATORY ACCLIMATISATION
AND THE ROLE OF THE HPA AXIS
S. M. Sharma, T. Powell, N. A. Jarad. Department of Respiratory Medicine,
Bristol Royal Infirmary, Lower Maudlin Street, Bristol BS2 8HW, UK
Background: Previous studies of cold acclimatisation and the acute cold
response have all focused on small numbers of participants, the majority
of whom are in military training.
Aims: To investigate acute and acclimatisation responses to the cold in
young healthy civilians during a five week expedition to Svalbard in the
Arctic, 400 miles south of the North Pole. The changes in salivary
cortisol secretion were also studied during this time.
Methods: Sixty eight volunteers (39M: 29F) were assessed at baseline
and in the fourth week to provide adequate time for acclimatisation. 13
subjects were also assessed on day 11 to investigate the acute response.
Respiratory function was measured with a GP hand held portable
spirometer within 12 hours of landing in Svalbard. We also measured
urinary pH, glucose and protein, blood pressure, oxygen saturation, and
resting pulse rate. During the expedition, the group was exposed to
temperatures ranging from 5 C˚ to220 C˚ (including wind-chill factor).
Salivary cortisol level was measured at multiple time points over two
days baseline and day 14 and again after the expedition. There was
similar calorific intake (4000 kcal) across the group as well as activity—
for example, trekking with packs and other forms of physical exercise
such as ice climbing.
Results: Statistical analysis was performed using paired t tests.
Comparison of the baseline (n = 68) there was a small but statistically
significant rise in FEV1 (mean base line 3.85 l, mean four week FEV1
3.93 l) (p = 0.02) and systolic blood pressure (mean base line 117.7
mmHg, mean four week BP 113 mmHg (p = 0.042) For those who
underwent three measurements (n = 13) there was a rise in FEV1 to
4.14 l on day 11 (p = 0.002) followed by a fall in week four (p = 0.005).
Salivary cortisols were significantly elevated during the expedition
compared to pre and post expedition measurements (mean pre-
expedition 5.61 nmol/l mean during expedition 10.99 nmol/l, mean
post expedition 5.85 nmol/l, p = 0.005). No significant differences were
found in diastolic blood pressure or between final and base line
measurements for urinary pH, O2 saturation, and resting pulse.
Conclusion: This study did not demonstrate a decline in lung function
during exposure to extreme cold weather indicating that acclimatisation
in healthy young people from temperate regions exposed to arctic
temperatures readily occurs. The small increase in FEV1 at day 11 and
at the end of the expedition may be explained by due to increase plasma
cortisol leading to reduced vagal tone.
P043 IS THE USE OF EARLOBE CAPILLARY BLOOD SAMPLES
FOR ASSESSMENT OF BLOOD GAS TENSIONS
SUFFICIENTLY RELIABLE TO ALLOW ITS USE IN
ROUTINE CLINICAL PRACTICE?
A. Lamb, P. Khera, N. Evans, D. G. Sinclair, J. M. Goldman, L. Dobson.
Respiratory Department, Torbay Hospital, Torquay, Devon, UK
Background: Arterial blood gas (ABG) sampling is a routine investiga-
tion used to gain immediate information about a patient’s gas exchange
and metabolic status. There are potential risks and discomfort associated
with this technique and for those patients in respiratory failure who
require repeated sampling these factors increase. For many years there
has been an alternative method available, arterialised capillary blood
gas (CBG) sampling. This test is well tolerated and less invasive with
scientific literature supporting its value, however it still remains under-
used (Pitkin AD, et al. Arterialised earlobe blood gas analysis: an
underused technique. Thorax 1994;49:364–6).
Aims: To assess the accuracy and reliability of CBG v ABG sampling
within a busy clinical setting.
Methods: Patients requiring ABG sampling were consented to undergo
simultaneous CBG earlobe sampling. All capillary samples were
obtained by trained nursing staff according to rigorous standards, and
all blood gases were taken by doctors using the Smiths ABG system. In
addition a third sample (control) was derived by inserting blood
obtained from an arterial sample into a capillary sample tube to control
for any error introduced by this mode of delivery to the blood gas
analyser. All samples were tested in the same analyser (Radiometer
ABL77Sci).
Results: Fifty samples were obtained from 32 patients. There was a
strong correlation between the CBG and ABG techniques for pH
(r = 0.86, p,0.0001), pCO2 (r = 0.96, p,0.0001), and pO2 (r = 0.92,
p,0.0001). For all of these parameters similar levels of correlation were
also noted when comparing ABG and CBG with the control sample. The
mean absolute difference between ABG and CBG was 20.02 (standard
deviation 0.03), 0.23 (0.55) kPa and 0.94 (1.26) kPa for pH, pCO2 and
pO2 respectively. Analysis with Student’s t test revealed that there were
no significant differences between ABG and CBG for pH (p = 0.10),
pCO2 (p = 0.54) and pO2 (p = 0.06). The same was true when
comparisons were made with the control sample.
Conclusions: We have shown that for pH and pCO2 there is only a small
mean absolute difference between ABG and CBG measurements with a
strong correlation. For pO2 this difference is larger, however the
correlation remains strong, implying that it underestimates at a consistent
level when compared to the true value. These results suggest that CBG
sampling is a reliable and accurate technique and confirm its value in the
management of respiratory failure patients on a busy medical ward. It is
however important to remember the relative inaccuracy of the pO2 when
considering the absolute value.
P044 CARDIOPULMONARY EXERCISE TESTING IN THE
INVESTIGATION OF UNEXPLAINED BREATHLESSNESS
R. Thompson, C. O’Brien. Cardiorespiratory Unit, George Eliot Hospital NHS
Trust, Nuneaton CV10 7DJ, UK
Cardiopulmonary exercise testing (CPET) is used to evaluate dyspnoea
unexplained by or disproportionate to patients’ cardiorespiratory
function.1 We report on 37 tests performed over 2 years in a district
general hospital. Consultant respiratory or cardiac physicians referred
patients after doing a careful clinical evaluation and appropriate
investigations. 19 males and 18 females (mean (SD) age 63 (11) years,
BMI 32 (7), FEV1 94 (20) % predicted) completed a maximal, symptom
limited exercise test with a ramp protocol on a cycle ergometer. A
respiratory physician and a clinical physiologist interpreted the results
using Wasserman’s flow charts.2 Static lung volumes and gas transfer
were measured in 24 patients each, 13 patients had neither measure-
ment, 13 underwent echocardiography, and 7 had a VQ scan. Prior to
CPET the following conditions potentially contributed to breathlessness:
obesity (65%), airflow obstruction, or bronchial hyperreactivity (46%),
restrictive defect or decreased gas transfer (16%), and cardiac disease
(24%); more than one condition was present in 51%, one condition in
35% and none in 13.5%. Of 25 patients with cardiorespiratory disease,
18 (72%) had a normal peak oxygen uptake (VO2), 4 (16%) a low VO2
that was abnormal, and 3 (12%) a low VO2 that was due to poor effort.
Of 12 patients without apparent cardiorespiratory disease, 7 (58%) had
a normal VO2, and 5 (42%) a low VO2 that was abnormal. The
commonest reason for stopping was leg fatigue (55%) followed by
dyspnoea (28%). At peak exercise the median (IQR) Borg score for
leg fatigue was 5 (3–7) in those with cardiorespiratory disease and
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4 (3–5.8) in those without apparent cardiorespiratory disease. For
dyspnoea the scores were 4 (3.8–5) and 4 (3–7.3), respectively. In the
group with cardiorespiratory disease, a new cause of dyspnoea was
identified in 5 (20%) patients (3 had dysfunctional breathing, 2 a cardiac
arrhythmia) whereas 17 (68%) had a normal response to exercise and 3
(12%) completed a submaximal test. In 12 subjects without apparent
cardiorespiratory disease, a new cause of dyspnoea was found in 6 (5
had dysfunctional breathing, 1 had a chronic metabolic acidosis); 6 had
a normal response to exercise. Thus, CPET demonstrated a normal ability
to exercise in the majority of patients. This cannot be predicted from
resting pulmonary and cardiac tests.2 Those with dysfunctional breathing
were given an explanation. No further testing was done in either group.
Early use of CPET in the assessment of unexplained dyspnoea may
provide reassurance about exercise capacity and reduce the overall
number of investigations in these patients.
1. Martinez F, et al. Graded comprehensive cardiopulmonary exercise
testing in the evaluation of dyspnoea unexplained by routine
evaluation. Chest 1994;105:168–74.
2. Wasserman K, et al. Principles of interpretation: a flow chart
approach. In: Principles of exercise testing and interpretation. Third
edition. Lippincott Williams and Wilkins, 1999.
P045 CORRELATION OF THE TIMED WALK TEST WITH LUNG
FUNCTION IN IDIOPATHIC PULMONARY FIBROSIS
T. Buckman, L. G. Spencer, E. Barrett, A. Duck, C. T. Leonard. North West
Lung Centre, Wythenshawe Hospital, Manchester M23 9LT, UK
Introduction: Idiopathic pulmonary fibrosis (IPF) is a severe, often life-
limiting disease. Simple reproducible measures of disease and functional
status are needed. Exercise testing is increasingly used in IPF to assess
disease severity. Tests available are the 6-minute walk test (6MWT), the
shuttle walk test, and full cardiopulmonary exercise testing. However,
these tests have limitations, for example the 6-minute walk test does not
correlate with survival in IPF patients and the externally paced shuttle
walk is not applicable to real life and IPF patients often underperform as
they cannot keep up with external pacing. A recently reported test, the
timed walk test (TWT) is a real world self-paced test which can be
performed in any outpatient setting, and by patients with a wide range of
disease severity.
Objective: To assess the TWT in 24 consecutive patients with IPF and
whether it correlated with lung function parameters and baseline
oxygenation.
Methods: The results of the TWT (distance walked, time walked, walk
velocity (metres per second), degree of oxygen desaturation, oxygen
desaturation per metre and per second) for 24 patients with IPF were
correlated with lung function tests carried out at that time (diffusing
capacity for carbon monoxide (DLCO), FVC, PO2, TLC, FEV1/FVC). To
make the test applicable to patients with a range of disease severity, and
to reduce the effect of hypoxaemia on walk velocity, patients with oxygen
saturations .88% on room air were exercised on room air and patients
with resting oxygen saturations ,88% were exercised with supplemental
oxygen
Results: Using Spearman’s rank test strong correlations were seen
between the distance walked, walk velocity and the DLCO and PaO2 at
rest (p,0.05). Additional correlations were seen between the change in
oxygen saturation per second and per metre and the DLCO (p,0.05).
Discussion: The parameters of the TWT reflect disease activity in IPF and
this test is applicable to real-world situations, easily performed, even by
those patients with severe disease. In addition this is the first report of the
velocity of oxygen desaturation (per second and per metre) on the TWT
correlating with DLCO. This is very helpful as DLCO is frequently
impossible to measure in patients with severe IPF. We are proceeding to
investigate whether the velocity of desaturation on the TWT correlates
with survival in patients with IPF.
P046 CAN RESPIRATORY PATIENTS ACCURATELY ESTIMATE
THEIR EXERCISE TOLERANCE?
G. Tack1, S. M. Jones2, S. J. Scott1, P. Walker1, L. Davies2, P. M. A.
Calverley1. 1University of Liverpool; 2University Hospital Aintree, Liverpool,
UK
Introduction: Respiratory patients are frequently asked how far they can
walk and this is often used as a measure of performance status.
Anecdotally patients’ estimations of exercise tolerance (distance walked
to first stop) appears poor. We hypothesised that estimation of exercise
tolerance would improve when given a visual prompt.
Methods: Patients undergoing a 6-minute walk test (6MWT) were asked
to estimate a fixed distance (22 metres; a short corridor), as a measure
of their distance perception. An estimation of exercise tolerance was
made with and without a visual prompt (lengths of a 6MWT course). All
values were converted to metres (m).
Results: Thirty patients had 6MWT, 14 male; mean (SD) age 66 (6)
years, median (IQR) FEV1 1.10 (0.84 to 1.42) l. 23 had COPD and 7
had other respiratory conditions. Only 4 patients accurately estimated
the fixed distance (¡1 m), 18/30 were incorrect by .10 m. Median
(IQR) estimated exercise tolerance for the whole group was 48 (19 to 87)
m and with the visual prompt was 70 (40 to 200) m. 2/30 patients were
excluded from further analysis as they did not stop during their 6MWT
and had not reached their estimated distance within 6 minutes.
Observed distance to first stop during the 6MWT was 140 (76 to 309)
m. Only 1/28 accurately estimated their exercise tolerance (¡5 m),
median (IQR] error 55 (21 to 77) %. Five overestimated their exercise
tolerance, but the majority (23/28; 82%) greatly underestimated how far
they could walk. Inclusion of a visual prompt improved the estimation in
22/28 (x2 = 0.001) but did not significantly improve the accuracy; error
43 (25 to 63) %.
Discussion: A combination of poor distance perception and inability to
estimate exercise tolerance makes patients own estimation of exercise
tolerance unreliable, even when a visual prompt is used. Patients’ reports
of exercise tolerance, without objective measures, should not be used as
a reliable indicator of performance.
P047 RADIOLOGICAL AND CLINICAL FEATURES OF ALPHA-
1-ANTITRYPSIN DEFICIENCY PATIENTS WITH
DISCORDANT LUNG FUNCTION
J. Holme1, R. A. Stockley2. 1,2University Hospital Birmingham NHS Trust, UK
Introduction: Several distinct phenotypes of chronic obstructive pulmon-
ary disease (COPD) exist (Sciurba. Chest 126;117S) which may relate to
different underlying pathophysiological mechanisms, and be amenable
to different therapeutic strategies. Alpha-1-antitrypsin deficiency (AATD)
predisposes to COPD and the UK. AATD registry has collated
radiological, clinical, and physiological data for more than PiZ 700
patients.
Aim: To examine the radiological features, paO2, and quality of life in
subjects with discordant lung function, to establish features that define
these phenotypes.
Method: The database for the UK AATD registry was searched to find 10
patients with a normal (.80% predicted) forced expiratory volume in
1 second (FEV1) and an abnormal (,80% predicted) transfer factor
corrected for alveolar volume (KCO) (group 1). 10 subjects with a
normal KCO and abnormal FEV1 were identified (group 2). The voxel
index (VI) was calculated for the upper zone (UZ) and lower zone (LZ) for
each CT scan, using a threshold of 2910 Hounsfield Units. Relative
distribution of emphysema was determined by subtracting the LZ VI from
the UZ VI. A positive result favoured lower zone predominance. In
addition, St George’s Respiratory Questionnaire (SGRQ) scores and
paO2 were compared between the two groups.
Results: Results are summarised in the table as mean (SD). There was no
difference between the two groups for the extent of upper zone VI
(p = 0.386), although subjects from group 2 had a significantly greater
lower zone VI than those from group 1, demonstrating greater lower
zone emphysema (p = 0.021). Relative distribution was therefore
different between the two groups (p,0.001), with group 2 demonstrat-
ing lower zone predominance.
Conclusion: Subjects with abnormal FEV1 and normal KCO have
predominant lower zone emphysema, lower paO2, and worse SGRQ
scores than those with an abnormal KCO and a normal FEV1. However,
the latter group still have impaired SGRQ and paO2 despite the normal
FEV1.
Abstract P047
Group 1 (n = 10) Group 2 (n = 10) p Value
FEV1 % Predicted 97.76 (16.4) 31.28 (5.6) ,0.001
KCO % Predicted 57.56 (6.6) 89.0 (7.4) ,0.001
Upper zone VI 33.84 (16.47) 28.14 (11.81) 0.386
Lower zone VI 38.03 (16.43) 54.94 (13.30) 0.021
PaO2 (kPa) 9.93 (1.6) 8.45 (0.7) 0.020
SGRQ Total score 33.0 (16.6) 56.75 (15.3) 0.004
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Surgical interventions in lung
disease
P048 THE UTILITY OF OUTREACH LUNG BIOPSIES IN
PERIPHERAL INTENSIVE CARE UNITS BY THORACIC
SURGEONS FOR PATIENTS WITH RESPIRATORY
FAILURE: A PRELIMINARY REPORT
S. Rathinam, R. S. Steyn. Heart of England NHS Foundation Trust,
Birmingham Heartlands Hospital, Birmingham, UK
Objectives: Acute respiratory failure with rapid deterioration needing
ventilatory support is a challenging condition to manage which can be
caused by a variety of causes. Management is guided by microbiology,
radiology, and bronchial washing, however it is not uncommon to need
a histological or microbiological diagnosis from the lung tissue to guide
treatment. Traditionally this involves transport of the patient to a centre
with thoracic services for lung biopsy. We have recently avoided all the
difficulties encountered in transferring a ventilated patient with organ
support and the time delay by performing open lung biopsies in the
intensive care units (ITU) in peripheral hospital. Postoperatively the
patients were looked after by the intensivists and chest physicians with
the thoracic surgeons available for any support.
Aim: The aim of the study was to review our results with the outreach
lung biopsy practice for patients with acute respiratory failure in the ITU.
Methods: A prospective collected data from Jan 2004 to Dec 2005 was
reviewed and analysed. The procedure was performed with single lumen
endotracheal tube with two lung ventilation (two patients were on jet
ventilation). All patients had bilateral infiltrates hence a non-targeted left
lung biopsy was performed through a left antero medial minithoracot-
omy using versifier stapler. A single chest drain was placed in all cases.
The procedure was performed in the ITU in six of the eight patients
avoiding any shifts to the operating theatre.
Results: Eight patients who underwent open lung biopsy in that time
frame in three referring hospitals two in the city of Birmingham and third
one 50 miles away. There were five female patients and the age range
was 24–65. None of the patients had any procedure related
complications. The chest drains were removed within the first 48 hours.
The diagnosis was established in all the patients and aided further
decision making without the delay of the wait for an ITU bed in our
centre.
Conclusions: Open lung biopsy can be safely performed through a mini-
thoracotomy without single lung ventilation in the intensive care units in
referring hospitals. This can be achieved by a team of visiting thoracic
surgeon and the chest physician and intensivist at the local hospital. This
practice avoids the undue delays in diagnosis due to lack of ITU beds
and transports and benefits both the parent hospital and the tertiary
centre.
P049 ORTHODEOXIA HINTS TOWARDS DIAGNOSIS OF
ATRIAL SEPTAL DEFECTS AFTER PNEUMONECTOMY:
REPORT OF THREE CASES AND A PROSPECTIVE STUDY
S. Jay, A. Martin-Ucar, A. Gaunt, A. Alwitry, D. Beggs, L. Beggs,
R. Henderson, J. Duffy. Nottingham City Hospital, UK
Introduction: A rare cause of dyspnoea after pneumonectomy is right to
left interatrial shunting due to atrial septal defect (ASD) that becomes
significant only after surgery. These cases often provide a diagnostic
mystery, but platypnoea and orthodeoxia-dyspnoea and significant
oxygen desaturation on assuming an upright position are pathogno-
monic. We have encountered three cases of platypnoea and ortho-
deoxia secondary to interatrial shunting after pneumonectomy in our
practice. We also performed a prospective study of post pneumonect-
omy patients aimed at determining whether simple, non-invasive
methods can be used to identify the presence of a shunt.
Methods: Over a 21 month period (July 2004 to March 2006) we
prospectively collected data for 25 patients (14 male and 11 female
patients, median age of 64 (range 45 to 77) years) surviving a
pneumonectomy (16 left and 9 right) in our unit. Between days 7 and 10
post surgery patients had oxygen saturation measurements taken in the
lying (0 )˚, recumbent (45 )˚, and standing (90 )˚ positions; and a
transthoracic echocardiogram was performed to exclude significant
ASD.
Results: There was no evidence of orthodeoxia on the basis of oxygen
saturations and no echocardiographic evidence of patent foramen ovale
(PFO) or ASD. Using these methods of assessment, there was no
evidence of undiagnosed right to left shunting.
Discussion: There were no false negatives in our study. Postural
saturation measurement is an inexpensive, non-invasive, acceptable
investigation that can be used to exclude interatrial shunting. We
recommend it be performed in all patients with unexplained dyspnoea
after pneumonectomy as atrial septal defects are eminently treatable
conditions.
P050 SPREADING THE BENEFIT OF LUNG VOLUME
REDUCTION SURGERY: ONE STAGE BILATERAL
VERSUS A STAGED UNILATERAL APPROACH
DETERMINED BY THE PATIENT
I. F. Oey, P. Vaughan, M. D. L. Morgan, D. A. Waller. Department of
Respiratory Medicine and Thoracic Surgery, Leicester, UK
Objective: Having demonstrated the comparative benefits of unilateral
over bilateral video assisted thoracoscopic lung volume reduction
surgery (VAT LVRS) it is now our policy to perform two-stage bilateral
LVRS. The timing of the second operation is determined by the patients’
perception of their symptoms. We wished to determine whether this
policy would result in a more sustained improvement in postoperative
benefits.
Patients/Methods: Since 1997 we have performed one-stage bilateral
LVRS (group 1) in 26 patients: median age 58 (41–72) years and two-
stage LVRS (group 2) in 7 patients:median age 59 (46–63) years. The
median time between the two operations was 47 (14–71) months. Two
further patients were turned down for their second stage procedure as
their FEV1 and DLCO had fallen below selection criteria. The
perioperative effects on pulmonary function and health status
(Euroquol and SF 36) were recorded preoperatively and at 3, 6, and
12 months and thence annually for five years.
Results: In both groups FEV1 significantly improved (27% in group 1,
35% in Group 2) for 6 months but in group 2 a second significant
improvement (32% from preoperative values) was seen at 4 years. After
the initial improvement the subsequent decline was 227 (+/274) ml/
year in group 2 and 2119 (+/288) ml/year in group 1 (p,0.01). In
both groups TLC and RV were significantly improved for 2 years (TLC
215% in group 1, 213% in group 2; RV 222% in group 1, 221% in
group 2), but in group 2 further significant improvements (TLC 224%;
RV230% from preoperative values) were seen at 4 years. No significant
improvements in Euroquol were seen in group 1 whereas significant
changes were seen from 2–4 years post LVRS in group 2. There were
significant changes up to 3 years in SF 36 scores in group 1, up to 4
years in Group 2.
Conclusion: Early results suggest a more prolonged surgical strategy
determined by the patient can lead to a more sustained benefit. Patients
need to be warned not to defer the second stage for too long as their
physiology may have deteriorated to preclude further surgery.
P051 DO EXPANDABLE METALLIC AIRWAY STENTS HAVE A
ROLE IN THE MANAGEMENT OF PATIENTS WITH
BENIGN TRACHEOBRONCHIAL DISEASE?
B. P. Madden, T-K. Loke, A. Sheth. Department of Cardiothoracic Surgery, St
George’s Hospital, London, UK
Background: With increasing availability, many centers are deploying
expandable metallic stents to manage patients with diverse endobron-
chial pathologies. Although these devices have an important role in
malignant disease their usefulness in benign large airway disorders is
less defined.
Patients and Methods: Between 1997 and 2005, 31 patients aged (34–
83 years) with benign large airway compromise secondary to
tracheomalacia (7), post tracheostomy stricture (8), post tracheostomy
rupture (2), post pneumonectomy bronchopleural fistula (2) and stricture
post lung transplantation (3), lobectomy, tuberculosis, traumatic injury to
right main bronchus (1 patient each) and external compression of the
airway secondary to achalasia, multinodular goitre, aortic aneurysm,
right brachiocephalic artery aneurysm, right interrupted aortic arch, and
dissecting aneurysm (one patient each) who were medically unfit for
formal surgical intervention were treated by Ultraflex stent deployment.
The range of follow up was one week to 96 months. Stents were
deployed under anaesthesia using rigid bronchoscopy.
Results: Complications included granulation tissue formation (11) treated
with Nd Yag laser ablation; stent migration (1); stent removed, another
deployed) metal fatigue (1); stent removal (1)); mucus plugging (2);
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halitosis (6) difficult to treat despite antibiotics. 13 patients died from
unrelated causes between one week and 15 months after stent
deployment.
Conclusion: Endobronchial metallic stents should be considered only for
selected patients with large airway compromise secondary to benign
airway diseases for whom other medical comorbidities contraindicate
formal airway surgery. Once deployed, they are difficult to remove, are
associated with significant complications and require prospective
bronchoscopic surveillance and often further therapeutic intervention.
P052 MESOTHELIOMA AND RADICAL SURGERY: THE MARS
TRIAL
C. Tan1, N. Duffy2, T. Treasure1. 1Guy’s Hospital, London; 2Institute of
Cancer Research, Sutton, UK
Mesothelioma incidence continues to increase and will not fall again to
present levels for about 15 years. Death rates in the UK are already
higher than for malignant melanoma or cervical cancer. Over the last 30
years extrapleural pneumonectomy (EPP) has been offered by a limited
number of centers internationally and they attract patients in hope of
cure. EPP as sole therapy has generally been abandoned and is now
performed within trimodality therapy. There have been no randomised
clinical trials of EPP. The MARS feasibility pilot aims to recruit 50
patients. There are two stages to the trial. Patients who are eligible and
consent are registered into the first phase during which they all receive
three cycles of platinum based chemotherapy and are then restaged.
Eligibility for randomisation is confirmed by the MARS MDM. After the
second consent, patients are randomised to have or not have EPP. EPP is
followed by radical radiotherapy. Outcomes to test feasibility are
acceptability of the trial and tolerability of treatment. If feasibility is
proven we will proceed to the full trial for which outcomes are survival
and quality of life.
Eleven ‘‘local’’ centres are recruiting. There are two surgical centres
and eight centres giving radical radiotherapy. By 28 July 2006, 93
mesothelioma patients were screened for eligibility. Of these, 46 (49%)
were eligible and 37 (40%) have consented to the first phase. Eleven
have been randomised, five of them to EPP.
All participating centres who responded to a recent questionnaire
confirmed their continued support. The two phase consent has proved to
be helpful in that both patients and teams have a two month period as
fellow travelers on this difficult cancer journey before randomisation is
called for. If half of the registered patients are subsequently randomised
at the present rate the target should be met by September 2007.
On behalf of the MARS Trial Management Group.
P053 THE INTERRELATIONSHIP OF BODY MASS INDEX AND
LUNG VOLUME REDUCTION SURGERY
P. Vaughan, I. F. Oey, M. Steiner, M. D. L. Morgan, D. A. Waller. Glenfield
Hospital, Leicester, UK
Objectives: Lung volume reduction surgery (LVRS) is thought to result in
significant improvements in body mass index (BMI) in patients with
severe emphysema. Patients with a higher BMI at the time of diagnosis of
COPD are known to have better survival, and those with a low BMI prior
to LVRS have significantly worse perioperative morbidity. We aimed to
assess the influence of BMI on the outcome of LVRS in our own
experience.
Methods: Complete preoperative BMI data were available in 99 of 116
patients who have undergone LVRS since 1995. These patients were
placed in three categories: underweight (BMI (19 kg/m2), normal (BMI
20–25 kg/m2), and overweight (BMI .26 kg/m2). The in-hospital
course and perioperative change in BMI at 3, 6, 12, 24, and 36 months
were recorded for each category and compared.
Results: Expressed as median (range). There were no significant
differences in pre-op variables. There were significantly more post op
ITU admissions among the patients in the lowest two BMI groups (10/23,
17/53, and 3/23 respectively, p = 0.02), and significantly shorter
hospital stay in overweight patients (16 days (5–79) v 17 days (6–111)
v 13 days (6–25) respectively, p = 0.02). There was no difference in
survival between the three groups (p = 0.6). BMI increased significantly
in the underweight and decreased significantly in the overweight.
Conclusions: LVRS and BMI are interrelated. Future work is needed to
explore the roles of changing energy requirements and exercise capacity
in this relationship.
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P054 DOES THE WEIGHT OF LUNG RESECTED INFLUENCE
THE OUTCOME OF LUNG VOLUME REDUCTION
SURGERY?
M. W. Khalil, I. F. Oey, P. Vaughan, M. D. Morgan, D. A. Waller.
Department of Respiratory Medicine and Thoracic Surgery, Glenfield
Hospital, Groby Road, Leicester LE3 9QP, UK
Background: Lung volume reduction surgery (LVRS) has been shown to
be of benefit in improving the respiratory function, but it remains more of
an ‘‘art’’ than a ‘‘science’’. We wished to determine whether an
optimum resected weight of lung could be derived for this operation.
Methods: A retrospective review of prospectively collected data of 58
cases of LVRS of the upper lobes, performed in our centre by a single
surgeon between 1997 and 2005, was performed. Standard selection
criteria were applied. LVRS was performed using buttressed stapling.
Extent of resection was determined by estimating functionless target
areas. Median weight of resected lung was 90 g (range 39–170 g).
Patient were divided into four quartiles based on lung mass resected
(30–60, 60–90, 90–120, and .120 g), and comparison was made
between the first and fourth quartiles and the second and third quartiles
in terms of improvement in perioperative FEV1, RV/TLC ratio, and DLCO
at a median of 8 months (6–12 months).
Results: A statistically significant peri-operative improvement in FEV1
and RV/TLC ratio was seen in the quartiles closest to the median but not
in the first and fourth quartiles. There was no statistically proven
improvement in DLCO in our study.
Conclusion: Inadequate or overzealous resection has a detrimental effect
on outcome of lung volume reduction surgery.
P055 THE ABILITY OF SUBJECTS WITH CHEST INJURIES TO
PROVIDE BREATH SAMPLES USING LION SL 400
BREATH ALCOHOL TESTING DEVICE: A STUDY USING
POST-THORACIC SURGERY MODELS TO MIMIC CHEST
INJURIES
S. Rathinam, D. Luke, P. Nanjaiah, M. S. Kalkat, R. S. Steyn. Heart of
England NHS Foundation Trust, Birmingham Heartlands Hospital,
Birmingham, UK
Objectives: Police in the UK are using roadside alcohol testing
from1967, which is now mandatory, if stopped with a suspicion of
drink driving. Drivers are initially tested for alcohol impairment at the
roadside with a screening device. Various investigators have addressed
the impact of co-morbid respiratory illnesses and the minimum lung
function requirements to activate various breath tests at various stages.1–3
We postulated that subjects with significant chest trauma may not have
any difficulty in providing an adequate breathalyser sample.
Aim: The study was aimed to investigate if chest injury patients can
activate the Alcometer using the thoracic surgical patients as the chest
trauma model.
Methods: A prospective self controlled study of twenty patients under-
going thoracic surgical procedures in Birmingham Heartlands Hospital
was performed between August 2005 to Dec 2005 with LREC and R & D
approval. A Lion Alcometer SL400 was used which is a microprocessor
controlled, multifiltering infrared spectrometer similar to the ones used by
the UK police. The device has two functions firstly as a spirometer in
measuring the forced expiratory volume and peak flow to actually
trigger the device and micro filtering infrared spectrometer, which
analyses the sample of breath for evidence of alcohol. We tested the first
parameter testing the patient’s ability to activate the device without
alcohol (dry activation). The ability of the subjects to activate the device
preoperatively and postoperatively was analysed.
Results: Twenty patients who underwent thoracotomy for various
procedures were recruited. The mean age was 69.3 years (37–83
years) with 17 males in the study. The mean pre-op was FEV1 the mean
pre-op PEFR were 1.96 l (range 1.16–2.46 l) and 2265 l/min (range
126–429 l/min) respectively. The mean postoperative FEV1 was 1.09 l
(range 0.34–2.2 l) and post-op PEFR was 165 l/min (range 36–492 l/
min). Twelve patients had thoracic epidural for pain relief, with the rest
having intrathecal morphine followed by morphine infusion. All the
patients were able to activate the device preoperatively with varying
FEV1s. Only two patients were able to activate the device post-
operatively (10%). The two patients who activated the device were male
patients who underwent decortications.
Conclusions: Patients following thoracotomies cannot generate the
breath to activate the Lion Alcometer SL400. We hypothesise this will
be case with patients with chest injuries.
1. Briggs JE, Patel H, Butterfield K, et al. The effects of chronic
obstructive airways disease on the ability to drive and to use a
roadside alcometer. Respir Med 1990;84:43–6.
2. Gomm PJ, Osselton MD, Broster CG, et al. Study into the ability of
patients with impaired lung function to use breath alcohol testing
devices. Med Sci Law 1991;31:221–5.
3. Honeybourne D, Moore AJ, Butterfield AK, et al. A study to
investigate the ability of subjects with chronic lung disease to provide
evidential breath samples using the Lion Intoxilyser 6000 UK breath
alcohol device. Respir Med 2000;94:684–8.
Inflammation and cell responses in
asthma
P056 PRO AND ANTI-APOPTOTIC ACTIONS OF
RESPIRATORY SYNCYTIAL VIRUS ON PRODUCTIVELY
INFECTED DENDRITIC CELLS
L. Hobson, C. M. Coleman, K. Plant, M. L. Everard. Academic Unit of Child
Health, University of Sheffield, UK
Introduction: Respiratory syncytial virus (RSV) causes annual epidemics
of respiratory disease affecting the whole community. Individuals are re-
infected throughout life. This re-infection does not appear to be due to
antigenic shift or multiple subtypes of the virus. An alternative
explanation is that the virus is able to interfere with the development
of effective memory responses. Dendritic cells (DCs) are present on
mucosal surfaces and prime naı¨ve T-cells and stimulate both the primary
and secondary immune response. Due to their location and function DCs
are vulnerable targets of viral intervention. The aim of this study was to
investigate the interaction between human monocyte-derived DCs
(MoDCs) and RSV.
Methods: Monocytes were isolated from human buffy coat by magnetic
negative selection seeded at a density of 16106 cells/ml cultured in
serum free X-Vivo 20 media supplemented with GM-CSF and IL-4. On
day 6–8 of culture MoDCs were challenged with 16104–16106 pfu/ml
purified GPF expressing RSV (rg-RSV). Productive infection of MoDCs
was determined using fluorescent microscopy to monitor plaque
formation of HeLa cells cultured with infected MoDCs and/or super-
natant. Viral replication and viability of MoDCs was monitored by
fluorescent microscopy and flow cytometry.
Results: The results of this study demonstrate that RSV infects MoDCs in a
dose dependent manner. The virus is able to replicate within the MoDCs
and be released productively to infect other cells. In addition, MoDCs
infected with low titres of RSV showed prolonged survival and delayed
onset of apoptosis compared to unchallenged control cells. However, at
high viral titres both apoptosis and necrosis of infected cells was
significantly higher than unchallenged control cells. These effects on cell
viablilty were detected as early as 4 hours post infection.
Discussion: These data suggest that RSV can act in several ways. The
virus delays MoDC apoptosis to allow optimal viral replication.
However, this effect is dependent on viral load, suggesting that once a
threshold level of virus is reach within the infected cells they will rapidly
die by apoptosis or necrosis and release virus. In addition, RSV induced
cell death may stop presentation of viral antigens to T-cells and therefore
prevent the initiation of an appropriate immune response.
These data were previously presented at the ATS.
Abstract P054
Mass range 30–60 g 60–120 g .120 g
Change in %pred FEV1 5.25 (p = 0.289) 7.37 (p = 0.002) 5.22 (p = 0.175)
Change in %pred RV/TLC 28.42 (p = 0.491) 214 (p = 0.008) 225 (p = 0.107)
Change in %pred DLCO 0.75 (p = 0.787) 1.11 (p = 0.821) 21.6 (p = 0.959)
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P057 ITRACONAZOLE-MEDIATED INHIBITION OF CALCIUM
ENTRY INTO CHEMOATTRACTANT-ACTIVATED
HUMAN NEUTROPHILS IS DUE TO INTERFERENCE
WITH PRODUCTION OF LEUKOTRIENE B4
R. Anderson, G. R. Tintinger, H. C. Steel. MRC Unit for Inflammation and
Immunity, Department of Immunology, Faculty of Health Sciences, University
of Pretoria and Tshwane Academic Division of the National Health
Laboratory Service, Pretoria, South Africa
Itraconazole inhibits the influx of Ca2+ into chemoattractant-activated
neutrophils, which may be a useful secondary anti-inflammatory
property of this anti-mycotic. The current study was designed to identify
the mechanisms by which itraconazole (0.1–5 mM) antagonises Ca2+
uptake by activated human neutrophils, focusing primarily on the effects
of this agent on 59-lipoxygenase (5-LO) and phospholipase A2 (PLA2)
activities in cells activated with either the chemoattractant platelet-
activating factor (PAF, 200 nM) or the Ca2+ ionophore, A23187
(1 mM). The activities of 5-LO and PLA2 in activated neutrophils were
measured according to the magnitudes of generation of leukotriene B4
(LTB4) and arachidonic acid (AA) using immunoassay and radiometric
procedures respectively, while cytosolic Ca2+ concentrations were
determined by a spectrofluorimetric procedure using the Ca2+-sensitive
dye, fura-2/AM. Activation of neutrophils with PAF was accompanied
by a sustained elevation in cytosolic Ca2+ which was associated with
increased generation of arachidonic acid and LTB4, all of which were
attenuated by itraconazole (mean reductions of 68%, 63% and 93%
respectively, all with a p value of ,0.05 by comparison with the drug-
free control system). However, only LTB4 production was inhibited by
the anti-mycotic in cells activated with A23187, compatible with a
selective affect of this agent on 5-LO. These anti-inflammatory effects of
itraconazole on PAF-activated neutrophils were mimicked by LY255283
(1 mM), MK 886 (0.5 mM), and pyrollidine-1 (2.5 mM), an antagonist
of LTB4 receptors and selective inhibitors of 5-LO and cytosolic PLA2
respectively. Taken together these observations suggest that itracona-
zole functions primarily as an inhibitor of 5-LO and that the inhibitory
effects of this agent on Ca2+ influx and PLA2 activity in chemoattractant-
activated neutrophils are consequent to decreased production of LTB4.
This may be a useful secondary activity of itraconazole in the treatment
and prophylaxis of allergic bronchopulmonary aspergillosis and
chronic granulomatous disease respectively.
P058 PATTERN OF AIRWAY INFLAMMATION IN ACUTE
SEVERE ASTHMA
A. V. Kamath1, W. R. Monteiro2, S. Mildenhall1, C. F. Ramsay1,
O. P. Twentyman1, A. M. Wilson1, I. D. Pavord2, B. D. W. Harrison
(retired). 1Norfolk and Norwich University Hospital, Norwich, UK; 2Institute
for Lung Health, Glenfield Hospital, Leicester, UK
Introduction: Sputum cell count as a measure of airway inflammation
has been used to guide treatment response in patients with asthma.
There are very few studies looking at airway inflammation in acute
severe asthma. We investigated the pattern of airway inflammation in
patients with acute severe asthma.
Methods: Patients admitted to Norfolk and Norwich University Hospital
between October 2004 and February 2006 with acute severe asthma
were invited to participate. Patients’ demographics, history, medical
treatment, and spirometry were documented. Sputum cell counts and
peripheral blood counts were analysed. Patients were classified as
eosinophilic (>3% sputum eosinophils) or non-eosinophilic (,3% sputum
eosinophils). Patients were classified as atopic if RASTwas positive to one
or more aeroallergens. Blood eosinophilia was defined as .0.46109/l.
The characteristics of sputum eosinophilic and non-eosinophilic groups
were compared using the Student’s t test, x2 test, and Mann-Whitney U
test with p,0.05 being considered statistically significant.
Results: Ninety two patients consented to the study and 69 (46F)
successfully produced sputum samples and were analysed in the study.
Conclusion: (1) Patients with eosinophilic airway inflammation were
younger than those with non-eosinophilic airway inflammation. (2)
Peripheral blood eosinophilia only occurred in patients with eosinophilic
airway inflammation. (3) Flu-like symptoms, atopic status, and smoking
history did not differ significantly between patients with eosinophilic and
non-eosinophilic airway inflammation.
P059 PORTABLE EXHALED NITRIC OXIDE MEASUREMENT:
COMPARISON WITH THE GOLD-STANDARD
TECHNIQUE
A. Nair, D. Menzies, B. J. Lipworth. Asthma & Allergy Research Group,
Ninewells Hospital & Medical School, University of Dundee, Dundee, UK
Background: Measurement of fractional exhaled nitric oxide (FENO) can
assist in the diagnosis of asthma, and may also act as a useful surrogate
inflammatory marker on which to base treatment decisions in asthma
management algorithms. Until recently this technique was confined to
research facilities and secondary care institutions. A portable nitric oxide
analyser (NIOX MINO) has been developed, but few data exist
comparing this with established larger laboratory based analysers
(NIOX).
Methods: 101 asthmatic patients and 50 healthy volunteers had
simultaneous FENO measurements undertaken using a NIOX and MINO.
Results: In both asthmatics (fig) and healthy volunteers there was a good
correlation between the measurements obtained using each device
(r = 0.94 and r = 0.96 respectively). Altman-Bland plots confirmed the
agreement between the devices.
Conclusion: FENO obtained using a portable device correlate well with
those obtained using an established laboratory analyser. This may
facilitate measurement of asthmatic airway inflammation in primary
care.
Abstract P058
Eosinophilic Non-eosinophilic
n 36 (21F) 33 (25F)
Mean age (SD) 42.8 (15.9) 51.9 (17.1) p = 0.02*
Flu-like symptoms (n) 18 17 x2 = 0.01 (NS)
Median pack years (range) 4.5 (0–52) 7.5 (0–36) p = 0.27
Atopic (n) 21 16 x2 = 0.67 (NS)
Blood eosinophilia (n) 13 0
NS, not significant; F, female patients.
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Abstract P059 Correlation between log FENO MINO versus NIOX in
asthmatics.
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P060 T CELL RECRUITMENT TO THE HUMAN ASTHMATIC
AIRWAYS IS DEPENDENT ON CC CHEMOKINE
RECEPTOR 4
P. Vijayanand1, K. Durkin1, G. Seumois1, G. Hartmann2, D. Hall2,
G. Angco1, P. S. Friedmann1, R. Djukanovic1. 1University of Southampton,
UK; 2GSK, UK Inflammatory Cell Biology Group, Division of Infection,
Inflammation and Repair, University of Southampton, Southampton General
Hospital, Southampton, UK
Airway inflammation and remodelling in response to chronic exposure
to environmental airborne allergens are pathological hallmarks of
asthma.1 Activated Th2 type T cells, whose numbers are increased in
asthmatic airways, play an important role in perpetuating these chronic
inflammatory changes.2 The central mechanisms governing the accumu-
lation of these T cells in human asthmatics airways are not fully
elucidated. Work to date has identified increased T cell chemotactic
activity in the asthmatic airways.3 While many chemokines and their
receptors are likely to be involved in this process, we have addressed the
critical question of specificity of the chemotactic activity. We have shown
that in asthmatic subjects the proportion of CCR4 expressing blood T
cells is increased in relation to disease severity. These T cells are also
seen in significantly greater numbers in the subjects’ airways, obtained
by dispersion of bronchial tissue and DTE (dithioerythritol) treatment of
sputum, compared to the blood suggesting selective recruitment to the
airways. We have shown that when human asthmatic subject’s bronchial
biopsies are challenged with allergen (Dermatophagoides pteronyssi-
nus) ex vivo for 24 hours, the supernatant generated increased
chemotactic activity to corresponding subject’s memory CD45RO+ T
cells as demonstrated by using 96 well chemotaxis plates and
subsequent 4 colour FACS analysis of migrated cells. This increased T
cell chemotaxis is significantly reduced by a specific CC chemokine
receptor 4 antagonist (figs 1–4). Detailed phenotypic analysis of
migrated memory T cells showed that this effect was seen for both Th2
and Th1 type T cells as shown by expression of CCR4 and CXCR3
respectively. Overall these finding indicate that T cell recruitment to the
human asthmatic airways is strongly CCR4 dependent.
1. Kay AB. N Engl J Med 2001;344:30.
2. Robinson DS, et al. N Engl J Med 1992;326:298.
3. Hidi R, et al. J Immunol 2000;164:412.
P061 BRONCHOALVEOLAR LAVAGE AND FIBROBLAST
ACTIVITY IN ASTHMA
P. N. Sanders, M. G. Buckley, L. C. K. Lau, P. H. Howarth. Inflammation,
Infection and Repair (IIR) Department, Southampton General Hospital, UK
Introduction: Asthma is associated with chronic structural airway
changes associated with alterations in the extracellular matrix composi-
tion. Airway fibroblasts are integral to such changes and increased
numbers of transformed fibroblasts are evident within the airway wall in
asthma. We have investigated the net and contributory mitogenic activity
within bronchoalveolar lavage (BAL) recovered from asthmatics and
healthy airways, using primary cultured airway fibroblasts from both
asthmatics and non-asthmatics.
Methods: Primary cultures of fibroblasts were grown from endobronchial
biopsies taken from healthy and asthmatic volunteers. BAL fluid from
healthy or asthmatic donors was used to challenge the fibroblasts over
24 hours. Broad spectrum and specific inhibitors were pre-incubated
with the fibroblasts before addition of stimuli. Fibroblasts mitogenesis
was assessed using the [3H]-thymidine incorporation assay.
Results: Bronchoalveolar lavage from asthmatics (n = 8) exerted
significantly greater mitogenic activity than BAL from healthy control
subjects (n = 8) on both asthmatic and non-asthmatic primary airway
fibroblasts (p(0.05). The non-asthmatic fibroblasts demonstrated
greater mitogenic activity, independent of the stimuli, than the asthmatic
airway fibroblasts (p(0.0001). When healthy and asthmatic fibroblasts
were pre-incubated with 100 ng/ml Pertussis toxin (G-protein coupled
receptor inhibitor) before challenge with healthy or asthmatic BAL, there
was a significant inhibition of fibroblast thymidine incorporation
(p(0.028). Thymidine incorporation was also significantly inhibited
after pre-incubation with wortmannin (phosphatidylinositol-3-kinase
(PI3-K) inhibitor) (p(0.026), SU5402 (basic fibroblast growth factor
(bFGF) inhibitor) (p(0.028), AG1478 (epidermal growth factor [EGF]
inhibitor) (p(0.028), and PD123-319 (angiotensin II inhibitor)
(p(0.028). Intracellular MAPK inhibitors U0126 (MEK 1/2),
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Abstract P060 Figure 4 Mean chemotactic indices + SEM in the above
groups.
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Abstract P060 Figure 1 Show the peak chemotactic indices of memory T
cells to allergen challenged human bronchial biopsies with and without a
specific CC-chemokine receptor antagonist in 8 mild asthmatics.
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Abstract P060 Figure 2 Nine moderate asthmatics.
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Abstract P060 Figure 3 Six healthy volunteers.
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SB203580 (p38) and JNKI1 (JNK) have also been used, and they show
that U0126 inhibits fibroblast thymidine incorporation, however this is
preliminary data and no significance can be attributed.
Discussion: The use of pertussis toxin has identified the involvement of G-
protein coupled receptors in BAL induced mitogenic responses.
Subsequent use of more specific inhibitors against bFGF, EGF,
angiotensin II, MEK 1/2, JNK, p38 PI3-K indicated the relevance of
both MEK 1/2 and PI3-K mediated pathways and the individual factors
bFGF, EGF and angiotensin II to the BAL-induced fibroblast mitogenic
response in asthma. The individual factors in BAL and their relative
contribution are still being evaluated.
P062 ST2 GENE KNOCKOUT ATTENUATES ALLERGIC
AIRWAY INFLAMMATION
P. Kewin1,2, D. Xu1, B. Choo-Kang1, N. Pitman1,2, M. Patel1,
G. Megarrell1,2, N. C. Thomson1,2, F-Y. Liew1. 1Division of Immunology,
Infection & Inflammation, University of Glasow, UK; 2Department of
Respiratory Medicine, Western Infirmary, Glasgow, UK
Introduction: Asthma is a common allergic airways disease, in which T
helper type 2 (Th2) cells play a central role, and mast cells and
eosinophils are important effector cells. The membrane receptor ST2L is
found on Th2 cells (Xu D et al, J Exp Med 1998) and on mast cells, and is
important in both Th2 differentiation and effector responses. Interleukin
(IL)-33 binds to ST2L and results in production of Th2 cytokines in vivo
(Schmitz J et al, Immunity 2005). Therefore, we hypothesised that ST2
gene knockout (ST2-/-) would result in attenuation of allergic airways
disease through reduced Th2 cytokine production.
Methods: Wildtype (ST2+/+) and ST2-/- BALB/c mice were sensitised
with ovalbumin (OVA) and alum intraperitoneally on day 1. Allergic
airways disease was induced by intranasal challenge with OVA on days
9, 10, and 11, and mice culled 24 hours later. Bronchoalveolar fluid
(BALF) cell counts were performed on cytospins. Cytokines from BALF
and draining lymph node (DLN) cells restimulated with OVA were
measured by enzyme-linked immunosorbant assay (ELISA). Lungs were
fixed in formalin before processing and H&E staining.
Results: ST2-/- mice had significantly reduced total BALF cell and
eosinophil counts compared to WT mice (fig A). There was also reduced
eosinophil accumulation around the airways (fig B, C). Both BALF and
DLN cytokine production (IL-4, -5, -13, and IFNc) were similar in the two
groups, with only BALF IL-5 showing a significant reduction (WT
126 pg/ml (SEM 17.3), ST2KO 62 pg/ml (SEM 37), p = 0.01).
Conclusion: ST2-/- attenuates allergic airways disease, as measured by
airways eosinophilia, but this cannot be wholly explained by reduced
Th2 cytokine production.
P063 THE CHEMOKINE RECEPTORS CCR8 AND CRTH2 ARE
PREFERENTIALLY EXPRESSED ON PERIPHERAL BLOOD
TH2 LYMPHOCYTES IN ASTHMA AND NORMAL
SUBJECTS
K. Mutalithas, C. Guillen, B. Hargadon, A. J. Wardlaw. Institute for Lung
Health, Department of Respiratory Medicine, University Hospitals of Leicester
NHS Trust. Department of Infection, Immunity and Inflammation, University of
Leicester, UK
Cytokines secreted by TH2 cells could account for most of the
pathophysiology seen in the asthmatic airway. Chemokines and their
receptors could play key roles in the recruitment of TH2 cells into the
asthmatic lung. CCR3, CCR4, CCR8, and CRTh2 are receptors shown to
be associated with TH2 cells. Recently CCR3 and CCR4 were shown to be
preferentially expressed on TH2 cells in human asthmatics. CRTh2 a
chemokine receptor homologue and CCR8 have been shown in both in
vitro and animal studies to be expressed preferentially on TH2 cells. We
have used flow cytometry to study the possible involvement of CRTh2 and
CCR8 and their association with CCR3 and CCR4 in TH2 cell recruitment
to the lung in asthmatics. We have found that 3.1% (SEM 0.4) and 4.1%
(SEM 0.4) of the CD3+ T cells to be CCR8+ in normal and asthma subjects
respectively. CRTh2 expression was seen in 1.2% (SEM 0.4) and 2.7%
(SEM 0.7) of the CD3+ T cells in normal and asthma subjects
respectively. The percentages of IL-4 and IFN-c secreting CD3+ T cells
following stimulation with phorbol-myristate-acetate and calcium iono-
phore were 1.1 (SEM 0.1) and 8.1 (SEM 1.5) respectively. There were
significantly more (p,0.01) IL-4 secreting CD3+ T cells also expressing
CCR8 (29%; SEM 4.3) or CRTh2 (26%; SEM 4.5) than there were IFN-c
secreting cells also expressing CCR8 (4.7%; SEM 1.7) or CRTh2 (2.4;
SEM 0.5). Approximately 50% of IL-4 producing CD3+ T cells were
identifiable using CCR8 and CRTh2. All CCR8+ cells were CCR4+ and
CCR32. Majority of CRTh2+ cells were also CCR4+ (,70%). Both CCR8
and CRTh2 appear significantly enriched on TH2 cells and could play a
role in the selective recruitment of these cells to the asthmatic lung.
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Abstract P062 ST2-/- mice have attenuated airway inflammation. OVA-
specific airways inflammation was induced as described in ST2+/+ and
ST2-/- mice. Total cell numbers in the BALF were counted, and the
number of eosinophils determined by differential counts on cytospins.
5 mm lung sections were stained with H&E and examined by light
microscopy using a x20 objective lens. (A) BALF total cell counts and
eosinophil counts are reduced in ST2-/- mice. (B) ST2+/+ mice have a
florid airway inflammatory response. (C) ST2-/- mice have much
reduced airway inflammation.
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Obstructive sleep apnoea
P064 THE UNDERSTANDING AND COMPREHENSIBILITY OF
PICTOGRAMS USED IN A NEW SCREENING TOOL FOR
SLEEPINESS AND OBSTRUCTIVE SLEEP APNOEA
SYNDROME
R. Ghiassi, K. Murphy, A. R. C. Cummin, M. R. Partridge. The West London
Sleep Centre and Imperial College London, NHLI division, Charing Cross
Hospital, London, UK
Background: The diagnosis of sleepiness is key to the assessment of
those with obstructive sleep apnoea syndrome (OSAS). We have
previously translated the Epworth Sleepiness Score (ESS) into pictograms
and found good agreement between the traditional ESS and the pictorial
ESS if words were included, but without words the agreement was less
good. We found no significant difference in overall scores when we
pictorially depicted question eight as a driver or a passenger.1 This led us
to question whether all the eight questions in the ESS were useful in
evaluating sleepiness and whether we could reduce the number of
questions and add some pictorial screening questions to devise a new
tool for assessing OSAS.
Methods: With the aid of a medical artist we developed pictorial
representations of four of the original ESS questions: (1) sitting and
reading, (2) watching TV, (3) sitting quietly after lunch, and (4) as a
passenger in a car and four new pictograms to depict body size, neck
size, witnessed apnoea, and blood pressure. Using established methods
of testing for comprehensibility of pictograms, we measured the
Guessability and Translucency of these new pictograms in two groups
attending our outpatient department: those attending for assessment or
treatment of OSAS and those attending for non-sleep related respiratory
disorders (controls).2 Translucency scores were ranked from 1 to 7, with
a score of 1 representing no relationship and 7 a very strong relationship
between pictogram and words.
Results: A total of 64 patients have been studied so far, 33 in the sleep
group and 30 in the control (non-sleep) group. Comprehensibility of
each of the images has been reasonable amongst both groups of
patients and in translucency testing a mean score of 5 or more was
recorded for all images other than witnessed apnoea (mean 4.64).
Witnessed apnoea is a difficult image to portray pictorially and it was
only marginally better understood by those with OSAS compared to
controls.
Conclusion: With the exception of one image we believe we now have a
reasonable tool for use with those with potentially reduced literacy and
the new scale is now to be evaluated against other methods of assessing
sleepiness and used for screening.
1. Ghiassi R, Murphy K, Partridge MR, et al. Driving and the Epworth
Sleepiness Scale. Am J Respir Crit Care Med 2004;169:687.
2. Houts P, Witmer J, Egeth H, et al. Pat Educ Counsel 2001;43:231–
242.
Acknowledgments: Ramesh Ghiassi is supported by a Leading
Practice through Research Grant from the Health Foundation.
P065 PREVALENCE AND CLINICAL CHARCTERISTICS OF
OBESITY HYPOVENTILATION SYNDROME
PRESENTING TO A UK SLEEP CLINIC
J. Bright, M. Sharman, P. M. Turkington. Salford Royal NHS Trust, Hope
Hospital, Stott Lane, Salford M6 8HD, UK
Background: The size of the nation is increasing, 21% of both men and
women in England have a body mass index .30 kg/m2.1 With our
increasing obesity will come an epidemic of health related problems
including sleep disordered breathing.
Aims: To determine the prevalence of obesity hypoventilation syndrome
(OHVS) and which clinical or physiological characteristics distinguish it
from obstructive sleep apnoea (OSA), in patients presenting to a general
sleep clinic with snoring and or daytime hypersomnolence.
Methods: Retrospective review of Salford Royal Hospital’s sleep clinic
oximetry and polysomography (embelletta) studies June 04–July 06.
OSA defined as Apnoea Hyponoea Index (respiratory disturbance
index, RDI .5). OHVS defined as daytime hypercapnia or diagnostic
oximetry trace (oxygen saturation ,88% for .5 consecutive minutes).
Results: 368 completed studies (151 oximetry, 217 polysomography)
performed of which 159 were normal, 150 confirmed OSA, 34 OHVS
(22 high CO2 and 12 characteristic oximetry trace) and 25 revealed
alveolar hypoventilation other causes (neurological, copd).
Conclusion: OHVS was diagnosed in 16.3% in all positive sleep studies
perform in our clinic (9.2% of all studies performed). They can be
identified by their physical parameters but not by their snoring or
somnolence indices. Provision for planning of future non-invasive
ventilatory and sleep services will need to estimate the evolving trends.
1. Health survey for England 2000 (Department of Health)
P066 A DISTRICT GENERAL HOSPITAL SLEEP SERVICE BASED
ON HOME OXIMETRY 1998–2006
H. Marshall, M. Stobart, L. Papps, A. Warley. Salisbury District Hospital,
Salisbury, Wilts SP2 8BJ, UK
In 1998 a dedicated investigation and treatment service for patients with
sleep-related breathing disorders was commissioned for residents of
Dorset (pop. 701 000) with its own funding stream. Patients undergo
initial assessment by Respiratory Specialist Nurse (band 6) which
includes history, Epworth score and examination. Patients undergo
overnight oximetry in their own home and return to the consultant clinic.
If a trial of CPAP is deemed necessary this is provided at the first
consultant visit. Patients given a trial of CPAP are seen again within
6 weeks. At the 6 week assessment the decision is made as to whether to
continue with the CPAP treatment or not. Those who have become
established on CPAP successfully are then followed up at 2 yearly
intervals with compliance check, machine service, mask change, etc.
Humidification and full face masks are available to those who do not
tolerate nasal CPAP over the first 6 weeks. Telephone support is
available at all times for new and established patients. Those found to
have non-respiratory sleep disorders are followed up in a separate clinic
if necessary.
Between 1998 and May 2006, 2035 patients have been seen in the
clinic. 1142 (56%) have had a trial of CPAP of whom 682 (34%) have
remained longterm users (CPAP usage greater than 4 hours per night).
56 patients established on CPAP prior to the inception of this service and
subsequently followed up have been excluded from the analysis.
Mean compliance of those established on CPAP is 5.6 hours per night.
The dropout rate after 2 years is 4.5% and the mean reduction in Epworth
score is 5. Trend analysis suggests that this fall is maintained in later years.
The cost of the service is made up of 1 consultant PA, 1 full time
respiratory nurse specialist (37.5 hours per week), A&C support
(25 hours per week), equipment including CPAP machines, replacement
masks as necessary, computing and oximetry. Budget for the first year
was £56,000 and for 2005–06 £110,000. The total cost of the service
over 7.5 years is £750,000.
Using this model it has been possible to screen over 2000 patients for
sleep related breathing disorders and establish 682 on nasal CPAP at an
approximate cost of £375 per patient.
P067 LONG TERM CHANGES IN QUALITY OF LIFE AND
SLEEPINESS IN SNORERS AND SLEEP APNOEA
PATIENTS
H. A. Hutchings1, K. Lewis1,2, P. Ebden3, E. N. Evans3. 1School of Medicine,
University of Wales Swansea, UK; 2Prince Philip Hospital, Llanelli, UK;
3Swansea NHS Trust, UK
Background: Current guidelines recommend treatment for sleep apnoea
hypopnoea syndrome (SAHS) only if the respiratory disturbance index
(RDI) is .10 with excessive daytime sleepiness.1 Many heavy snorers
may progress to SAHS and a few may have worse daytime sleepiness or
quality of life, despite a lower RDI. We looked at long-term symptoms in
both SAHS and snoring patients.
Methods: A prospective, longitudinal cross sectional study within a sleep
disorders breathing clinic of a UK district general hospital. 102
consecutive attenders with daytime somnolence and snoring were
Abstract P065
OSA OHVS p Value
BMI kg/m2 36.3 44.1 ,0.001
Neck circumference cm 44.2 47.5 ,0.001
Epworth score _/24 12.4 12.6 NS
Snore time (minutes) 21.9 22.2 NS
RDI (events per hour) 26.8 34.7 NS
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investigated at baseline with overnight limited sleep studies and
completed the Epworth Sleepiness Scale (ESS) and SF36. In accordance
with local policy at the time, those with and ESS .10 and an apnoea
hypopnoea index (AHI) .5 were started on continuous positive airways
Pressure (CPAP) as first line treatment. Those with an AHI ,5 were
referred to ENT and/or advised to lose weight. Groups were similar in
terms of age and gender (p.0.05) but the SAHS group had a higher
mean body mass index (BMI) (p,0.01). All subjects were mailed the ESS
and SF-36 after a mean period of 7.9 (SD 0.7) years.
Results: Two patients from each group died. 46 from the 98 (47%) living
subjects responded to the follow up questionnaire. Of these, 25 were
diagnosed at baseline as snorers (AHI ,5) and 21 were diagnosed with
SAHS (AHI .5). The SAHS group reported a significant improvement in
ESS at follow up (p,0.01, effect size 0.76) with a trend towards
improvement in 4/8 of the SF36 dimensions (NS). 13/21 SAHS patients
reported using CPAP for .4 hours per night. Snorers showed a
deterioration in mean (SD) ESS from a normal (9.3 (4.9)) to an
abnormal level (10.5 (6.1)) of sleepiness (NS) and deteriorations in 7/8
of the SF36 quality of life dimensions (p,0.05, effect sizes from 0.47 to
0.84).
Conclusions: On an intention to treat basis, subjective levels of daytime
sleepiness and maintenance of quality of life improved in SAHS patients
over a prolonged period despite only moderate compliance with CPAP
and often having mild disease. Snoring patients reported significant
deterioration in quality of life and a trend towards worsening daytime
sleepiness. Snoring patients may need to be offered treatment and/or
follow up visits to ensure that there is no progression of their condition.
Further studies are warranted to prospectively study snoring patients to
determine their long term outcome.
1. Scottish Intercollegiate Guidelines Network/BTS Guideline. June
2003.
P068 VERY HIGH PREVALENCE OF SLEEP APNOEA
SYMPTOMS IN PATIENTS WHO HAVE UNDERGONE
ELECTIVE CARDIOVERSION FOR ATRIAL FIBRILLATION
D. C. Swamydass1, L. Davies1, S. E. Thomas1, G. M. Rees1, F. Hadadin1,
K. E. Lewis1,2. 1Carmarthenshire NHS Trust, UK; 2School of Medicine,
University of Wales Swansea, UK
Introduction: Recurrent hypoxia from undiagnosed sleep apnoea
syndrome (SAS) may be an independent cause of relapsed atrial
fibrillation (AF) following cardioversion (DC). We used the Berlin Sleep
Questionnaire to estimate the prevalence of SAS in patients who had
who had relapsed back into AF following successful DC, against those
who remained in sinus rhythm (SR).
Methods: Cross sectional, observational study with LREC approval. The
questionnaire was mailed to a random sample of 143 (still living)
patients who had undergone electrical DC for AF between 2000 and
2005. None had known SAS. Possible confounders on AF were noted.
Failed DC was defined as being back in AF at 3 months (cardiology)
review or the need for repeat DC up to the end of 2005.
Results: 49% (n = 70) responded. Responders were similar (p = NS) to
non-responders in baseline characteristics (see below). 54% (38/70) of
all responders had a Berlin Score of ‘‘medium to high risk’’ for SAHS.
The table compares Berlin scores in the sub-groups of responders who
were otherwise also matched for confounders for AF (age, gender,
smoking status, weight, blood pressure at DC, duration of AF, presence
of valvular heart disease, left atrial size, DC energy required (joules),
and initial DC success rates).
Conclusions: The risk of SAS, as estimated using the Berlin Sleep Qnr, is
similar in those whose AF relapsed to those who remained in SR.
However, we were surprised by the background potential of undiag-
nosed SAS in these patients undergoing elective DC. At least 27% (38/
143) scored ‘‘Medium to High risk’’ and so fulfilled the Berlin Sleep Qnr
criteria for sleep studies. A prospective study, objectively screening
people for SAS prior to DC would clarify this.
P069 INVESTIGATING TIME WITH SIGNIFICANT
NOCTURNAL DESATURATION AGAINST SLEEP
APNOEA MARKERS POSSIBLY PREDICTING SLEEP
RELATED PULMONARY HYPERTENSION
B. N. Chandrappa, R. Abdulqawi, K. S. Srinivasan, H. Moudgil. Respiratory
Medical Unit, Princess Royal Hospital, Telford, Shropshire TF1 6TF, UK
Background: Although thought to correlate with the magnitude of gas
exchange abnormalities, pulmonary hypertension (PH) associated with
hypoventilation syndromes was initially considered rare in the absence
of daytime hypoxaemia; additionally, it had been suggested that the
severity of nocturnal events assessed as the apnoea/hypopnoea index
(AHI) do not appear to be the determining factor with more in favour of
the severity of obesity and possibly coexistent respiratory disease. A
recent study (Eur Soc Cardiol 2006), however, has again shown that
severe obstructive sleep apnoea (OSA) is independently associated with
pulmonary hypertension in direct relationship with disease severity and
presence of diastolic dysfunction and importantly that continuous positive
airway pressure therapy (CPAP) reduces the pulmonary systolic pressure
levels.
Aims: We aimed to study if there are any correlation of time with
significant nocturnal desaturation against sleep apnoea markers and its
potential value as a predictor for developing significant pulmonary
hypertension.
Methods and Results: We have therefore investigated patients newly
diagnosed with any grade of sleep apnoea with the aim of identifying
the prevalence, severity, and distribution of associated nocturnal
hypoxia (as a potential surrogate marker for developing pulmonary
hypertension). Mean (SD, range) age for the 156 successive patients
diagnosed on overnight polysomnography was 52.1 (12.6, 19–81)
years. Of these, 28.7% had mild disease (AHI 5 to 14), 43.3% had
moderate disease (AHI 15 to 29), and 27.4% had severe disease (AHI
30 and above). Arbitrarily taking a threshold at oxygen saturation of
,90% for .10% of the time, 105 (66.9%) remained above this and 51
(32.5%) below; these two groups then differed statistically (both
p,0.001) considering age (49.6 v 57.2 years) and AHI (20.8 v 33.8)
but not with Epworth score or BMI. Regression analysis similarly showed
a poorly fitted model.
Conclusions: (1) Highlight the distribution of sleep apnoea patients with
the potential if left untreated of developing significant pulmonary
hypertension and (2) recognise that the magnitude of the amount of
hypoxia correlates poorly with Epworth scores.
Diagnostic methods in tuberculosis
P070 INCORRECT DIAGNOSES OF TUBERCULOSIS USING
LIQUID CULTURE MEDIUM: LESSONS TO BE LEARNT
H. J. Roberts1, J. Kirkcaldy1, J. T. Macfarlane1, F. Donald2. 1Respiratory
Medicine, 2Microbiology Department, Nottingham University Hospitals
Introduction: A positive culture of Mycobacterium tuberculosis (Mtb) is
normally taken as evidence of active disease. Liquid culture medium has
revolutionised the diagnosis by providing rapid culture results (median in
our laboratory nine days, range 3–16 days). However, the high
sensitivity of the test may occasionally result in adverse clinical
consequences.
Background: When setting up cultures for mycobacterium on 25
October 2005, a vial of antibiotic/growth supplement became
contaminated with a splash of fluid containing Mtb. Subsequently, 11
patient samples, acquired between September and October 2005,
became falsely culture positive, with a genotype identical to the
contaminating species. We have looked at the clinical effects.
Methods: Eleven sets of notes were reviewed. Patient age, sex,
consultant, date and type of sample, smear result, and date of culture
report were recorded. Information regarding subsequent TB treatment
included reason for treatment, duration of therapy and reported side
effects. Information given to the patient, documentation, HIV testing, and
contact tracing were also recorded. Complaint and communication
issues were noted.
Results: Eleven patients (aged 21 to 78 years; 6 male). Five tests were
requested by respiratory consultants, two by infectious diseases, one by
thoracic surgery and three by other departments. Four sputum samples,
two BAL fluid, one spinal abscess fluid, two pleural fluid and two soft
tissue biopsy samples were affected. All smears were negative. Five
patients were treated for TB with standard therapy, six were not. One
patient developed significant treatment side effects. One patient
subsequently died of undiagnosed pulmonary embolus. One patient
Abstract P068
High risk
SAHS
Medium risk
SAHS Low risk SAHS
Failed DC (n = 49) 17% 37% 47%
Successful DC (n = 21) 20% 34% 47%
p Value (x2) 0.76 0.58 0.99
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had an HIV test after the false positive TB result. Two patients had contact
tracing performed (one extensive due to a large family). Of the five
treated for TB, three were treated on the basis of the contaminated result
only, the other two also had a high clinical suspicion for TB. When the
result was found to be a contaminant, three patients had their
unnecessary treatment stopped, after 8 days, 20 days, and 21 days.
In all five patients treated, events were recorded in the notes, but
discussion was recorded in only two. Of the six patients in the untreated
group, four were not treated because TB was clinically unlikely and in
two the positive result appeared not to have been noticed by the
clinician, having been filed unsigned or not recorded in notes. Four
patients were told of the contaminated result, two were not. There are no
recorded complaints from any of the 11 patients.
Conclusion: Contamination of antibiotic/growth medium had significant
clinical impact. The laboratory has now changed the processing method.
Clinicians should be aware that the high sensitivity of liquid culture may
occasionally cause confusion and results should be interpreted by a
clinician experienced in tuberculosis.
P071 THE USE OF T-SPOT-TB TO ESTIMATE TB REACTIVITY
RATES AMONG HEALTHCARE WORKERS ATTENDING
THE BTS WINTER CONFERENCE 2005
C. Dempsey, K. Burn, I. Durrant. Oxford Immunotec Ltd, Abingdon, UK
Introduction: T-SPOT TB is a diagnostic assay which enumerates T cells
specific for antigens secreted by Mycobacterium tuberculosis but not by
Mycobacterium bovis bacille Calmette-Guerin (BCG) strain or the
majority of non-tuberculous Mycobacteria. The test is intended as an
aid to the diagnosis of both active and latent forms of tuberculosis (TB)
and is recommended for use in the detection of latent TB infection within
the most recent NICE Guidelines. It has been extensively validated and is
establishing widespread use in diverse clinical settings such as
preventative TB screening amongst immunocompromised patient groups,
contact tracing and occupation health related TB screening.
Methods: At the BTS Winter meeting 2005 a survey of healthcare
professionals was undertaken to estimate the latent TB infection rate
amongst this cohort using the T-SPOT TB assay. A brief medical history
was taken from a total of 44 consenting volunteers attending the
meeting, including age (range 21–78 years), gender (50:50 male:fe-
male), country of birth, ethnicity, BCG status, history of previous skin
testing, previous diagnosis of active TB, and estimated years of exposure
to TB infected patients. An 8 ml blood sample was drawn and sent for
analysis by T-SPOT.TB.
Of the 6/44 (13.6%) that tested positive for latent TB, all 6 had a
previous positive skin test and 5/6 (83.3%) recorded extensive
occupational exposure to active TB cases. Within the full cohort 36/44
had both a T-SPOT TB result and recorded a skin test result.
Results: None (0/36) of the samples were T-SPOT TB positive but skin
test negative; none of the cohort reported any current immunosuppres-
sive therapy or condition. Of the 14/36 (38.9%) of samples that were T-
SPOT TB negative but skin test positive, 12/14 (86.0%) reported as
being BCG vaccinated, 1/14 (7.1%) reported as receiving 6 skin tests.
Conclusions: T-SPOT TB, in comparison to the skin test, offers the
potential to more accurately detect latent TB infection in healthcare
workers particularly in a setting of BCG vaccination, placement of
repeated skin tests and exposure to TB patients.
P072 WHICH PATIENTS WITH TUBERCULOSIS ACCEPT AN
HIV TEST?
A. S. Collett, R. Sanefuji, E. Togun, A. Nundloll, M. Ogedengbe,
R. D. Barker. Department of Respiratory Medicine, Kings College Hospital,
London, SE5 9RS, UK
Background: Colleagues from north London, UK observed that many
tuberculosis (TB) patients were not being offered an HIV test.
Furthermore, they observed a particular problem for patients diagnosed
in out-patient clinics compared with those diagnosed on the wards.(Dart,
et al. Thorax 2006) Here we report results of HIV test offering and
acceptance at a south London hospital.
Methods: All patients diagnosed with TB at Kings College Hospital after
2001 and before 2006 were eligible for inclusion. Patients were
identified from our database that included fields for whether an HIV test
had been offered, whether it had been accepted and the result. The place
of diagnosis and ethnic group was also recorded. HIV tests are offered
with supportive counseling on the ward and by trained TB nurses in
clinic. TB nurses undertake regular reviews of who has been offered an
HIV test, an activity supported by computer generated lists.
Results: Of 422 TB patients, 395 (93.6%) were offered a test, 294
(69.7%) accepted and 85 (20.1%) of all TB patients tested HIV positive.
Conclusions: Our methods result in more than 90% of patients being
offered an HIV test. Fewer patients accept a test, but test acceptance
appears to reflect the underlying epidemiology of HIV infection. Clinician
pressure may be a significant factor in the acceptance of HIV tests by TB
patients.
P073 THE CLINICAL SPECTRUM OF ADULT TUBERCULOSIS:
A UK PROSPECTIVE STUDY
R. A. M. Breen, O. Leonard, F. M. Perrin, I. Cropley, M. C. I. Lipman.
Department of Thoracic and HIV Medicine, Royal Free Hospital, London, UK
Background: Clinicians may not consider a diagnosis of tuberculosis (TB)
unless a patient has systemic symptoms such as fever, sweats, and
Abstract P071
T-SPOT +ve T-SPOT 2ve
TST +ve 6 14 55.5%
TST 2ve 0 16 44.5%
16.7% 83.3%
Abstract P072 HIV testing for patients with tuberculosis aged .15 and (65 years at
Kings College Hospital diagnosed between 2002 and 2005
Offered test Accepted test HIV positive
Place of diagnosis
Outpatients 242/262 (92%) 170/262 (65%) 36/167 (22%)
Inpatients 151/159 (95%) 122/159 (77%) 48/121 (40%)
p = 0.2* p = 0.007 p = 0.001
Ethnic group
White 45/55 (82%) 35/55 (64%) 6/35 (18%)
South Asian 31/33 (94%) 15/33 (46%) 0/14 (0%)
Black Caribbean 40/42 (95%) 31/42 (74%) 7/30 (23%)
Black African 228/236 (97%) 183/236 (78%) 63/181 (35%)
p = 0.001 p = 0.001 p = 0.01
Age categories (years)
.15 to (25 76/82 (93%) 53/82 (65%) 6/53 (11%)
.25 to (45 245/258 (95%) 189/258 (73%) 68/187 (36%)
.45 to (65 72/81 (89%) 50/81 (62%) 10/48 (21%)
p = 0.155 p = 0.085 p = 0.001
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weight loss; together with abnormal inflammatory blood markers. We
sought to investigate whether this wisdom remained true in our ethnically
diverse, metropolitan population.
Methods: Baseline demographic data and symptoms were documented
for all individuals enrolled in a prospective study of paradoxical
reactions. Baseline blood tests were obtained including C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR), and lactate
dehydrogenase (LDH).
Results: Symptoms were recorded for 156 individuals diagnosed with
active TB, of whom 50% were female; 28% HIV infected; 59% had
pulmonary TB; 54% were of black-African ethnicity, 21% Asian, and
19% Caucasian. They had a median age of 33 years (range 18–79).
130/156 (83%) were TB culture positive. Pre-diagnosis, no fever was
reported in 67/156 (43%); no sweats in 66/156 (42%); and no weight
loss in 72/156 (46%). All three were not present in 48/156 (31%). To
exclude the possibility that those without symptoms were largely TB
culture negative and therefore incorrectly diagnosed, we reviewed the
culture positive cases (n = 130), as shown in the table. Of these subjects,
17% had a normal baseline CRP, 25% a normal ESR and 64% a normal
range LDH. Commonly noted abnormalities were low albumin in 42%,
anaemia in 54%, hyponatraemia in 30% and lymphopenia in 22%. No
difference in total lymphocyte count was seen according to HIV status.
Conclusions: All forms of active TB frequently present without ‘‘typical’’
systemic symptoms or abnormal blood inflammatory markers. This
finding has implications for the prompt diagnosis of TB; as well as the
prevention of ongoing transmission of infection through early treatment.
P074 DIAGNOSTIC PATHWAYS IN CERVICAL
TUBERCULOUS LYMPHADENITIS (CERVICAL
TUBERCULOUS)
I. D. Samson, R. J. Gorrigan, J. Moore-Gillon, V. L. C. White. Respiratory
Medicine, Barts & The London NHS Trust, London EC1A 7BE, UK
Introduction: We examined the pathways by which the diagnosis of
cervical TB was established in this hospital which serves a population
with very high rates of TB (.60/100 000).
Methods: In 3 years (2003–05) 74 adults (>18 years) were treated for the
condition. The largest ethnic group was Bangladeshi (43%) followed by
Somali (21%). 40 were female and 34 male; mean age was 33.7 years
(range 18–71 years). 89% were born outside the UK. Numerous specialities
were involved in performing diagnostic procedures: most (60%) were done
in the ENT department, but other specialists involved included radiologists,
maxillofacial and general surgeons, and general physicians.
Results: Fifteen patients had a node biopsy as their first investigation (9
excisional, 6 ultrasound-guided core biopsies). Only 10/15 had
microbiological samples sent, of which 9/10 were culture positive. All
15 were examined histologically, which was suggestive of TB in 13/15.
Two samples with negative histology grew TB on culture. 59 patients had
fine needle aspiration (FNA) as their first investigation, 32 of which were
ultrasound guided. 41/59 were sent for TB culture (69%) and 25 of these
41 (61%) grew TB. 53/59 were examined cytologically. Granulomas
suggestive of TB were seen in 26/53, of which 9 were also culture
positive. No useful diagnostic information was obtained from 15 of the
FNAs. Eight of these patients went on to biopsy, as well as 3 who had
cytology suggestive of TB and one who later grew TB from the FNA. Of
these 12 who had biopsy as a second line investigation, 6/11 sent for
microbiology grew TB and 9/11 examined had suggestive histology.
The 3 biopsies with negative or no histology grew TB on culture.
Discussion: Our investigation is of patients treated for TB, not of all those
presenting with cervical lymphadenopathy, and must be interpreted with
that reservation in mind. However, it does demonstrate an unsystematic
approach to the investigation of nodes eventually treated for TB, with
different clinical teams involved and no clear protocol for investigation.
There were variations in the diagnostic investigation performed, and
samples were often not sent for microbiological analysis despite a heavy
local workload and experience of TB. The situation appears similarly
unsatisfactory elsewhere in the UK.1 Recent NICE guidelines give no
helpful advice, and we believe the BTS should consider investigating this
matter and producing recommendations for the investigation of
suspected cervical TB.
1. Tsikoudas A. J Otorhinolaryngol Relat Spec 2003;65:261–5.
P075 DIRECT PCR EXAMINATION FOR MYCOBACTERIUM
TUBERCULOSIS IN RESPIRATORY SAMPLES CAN BE
COST EFFECTIVE
R. Bhutani1, R. P. D. Cooke2, P. Morrell2, P. D. O. Davies1. Departments of
Respiratory Medicine1 and Medical Microbiology2, University Hospital
Aintree, Liverpool, UK
Introduction: Identification of M tuberculosis (MTB) by direct polymerase
chain reaction (PCR) from respiratory samples is not routinely
recommended.1 However, in view of the low specificity of tuberculin
skin tests (TSTs) and the high cost of interferon-gamma (IFN-y) blood
assays, direct PCR may have an important role in areas of high
prevalence of environmental mycobacterial infection (EMI).
Aim: To compare the cost of direct PCR with the cost of unnecessary TB
contact procedures in patients found to have EMI on culture.
Methods: All direct PCRs performed on smear-positive patients between
2004 and 2006 were reviewed and compared with culture results. Unit
costs for PCR, chest x ray, TST, and IFN-y were estimated at £50, £11,
£10, and £30 respectively. The costing model assumed at least four
contacts per EMI index case2 and a TST specificity of 50%.
Results: Smear-positive sputa from 131 patients underwent direct PCR
testing and were further evaluated. 89 patients grew MTB and 42 (32%)
had EMI. Sensitivity, specificity, positive and negative predictive values for
direct PCR versus MTB culture were 99%, 95%, 98%, and 98% respectively.
Total cost of all PCRs performed amounted to £6550. The cost of contact
procedures for PCR-negative/MTB culture-negative index cases was
estimated at £7760 (excluding health visitor and medical staff time).
Conclusions: Direct PCR testing of smear-positive patients is cost-effective
if there is a high prevalence of EMI.
1. Roy Coll Phys, 2006.
2. Eur Resp J 2000;16:976–9.
Clinical aspects of COPD
P076 THE PATIENT AT THE CENTRE OF THEIR CARE: AN IT
BASED PACKAGE FOR CHRONIC OBSTRUCTIVE
PULMONARY DISEASE IN PRIMARY CARE
R. C. M. Jones, B. S. Shackell, J. Comyn, X. Wang. Respiratory Research
Unit, Peninsula Medical School, Plymouth, UK
Background: New guidelines for chronic obstructive pulmonary disease
(COPD) encourage early accurate diagnosis using spirometry and
effective strategies at all stages of the disease. Despite financial
incentives, primary care is often over-burdened and many practices
find it difficult to provide COPD services.
Methods: An electronic assessment and management package devised
for visiting nurses in Plymouth and North Devon, UK was used in 14
practices in Plymouth and 2 in North Devon. COPD disease registers
were checked for coding errors and patients able to attend the surgery
were invited. Clinical and spirometry data were entered by the nurse,
patients then completed the Clinical COPD questionnaire, the MRC
dyspnoea scale and the Lung Information Needs Questionnaire on the
computer. The software package collated and interpreted the data,
producing reports for both patients and GPs, including recommenda-
tions for management as per NICE guidelines. Individual information
Abstract P073
Site of TB No fevers No sweats No weight loss No fevers/sweats/weight loss
Pulmonary (n = 82) 27 (33%) 30 (37%) 30 (37%) 17 (21%)
Lymph node (n = 31) 19 (61%) 18 (58%) 19 (61%) 12 (39%)
Other (n = 12) 5 (42%) 7 (58%) 6 (50%) 5 (42%)
Miliary (n = 5) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Total (n = 130) 51 (39%) 55 (38%) 55 (38%) 34 (26%)
Poster presentations ii81
www.thoraxjnl.com
 on 1 August 2008 thorax.bmj.comDownloaded from 
needs were addressed by the nurse who provided British Lung
Foundation leaflets, advice and action plans.
Results: Of 631 patients invited, 584 were seen. COPD was confirmed in
375/534 (70%) who underwent spirometry. COPD severity grading was
188/375 (50%) mild, 152/375 (41%) moderate, and 35/375 (9%)
severe. Treatment according to NICE guidelines was assessed in 237
patients, 51 (21%) were on the correct drug treatment, and these tended
to have mild disease. Eight patients had undergone pulmonary
rehabilitation, but it was recommended in 102 patients. Oxygen
assessment criteria were met by only 7/375 (2%). Multiple regression
analysis showed main determinants of health status (total CCQ score)
were MRC dyspnoea scale (p,0.001), frequency of exacerbation
(p,0.001), lung function (p,0.001), and smoking status (p,0.001).
The system proved popular with patients and primary care staff,
especially the reports.
Conclusion: There is room for improvement in primary care diagnosis
and treatment. IT based systems have considerable potential to help
patients and support healthcare professionals. The data collected
provide insights into treatment and patient centred outcomes and may
provide useful markers for demonstrating quality of care.
P077 ‘‘VOLUME RESPONSE’’ TO BRONCHODILATORS IN
CHRONIC OBSTRUCTIVE PULMONARY DISEASE IS
RELATED BOTH TO FLOW LIMITATION AND
EMPHYSEMA PHENOTYPE
P. P. Walker1, P. Pompilio2, N. Duffy1, R. L. Dellaca2, P. M. A. Calverley1.
1Department of Medicine, University of Liverpool, Liverpool, UK; 2Biomedical
Engineering Department, Politecnico di Milano University, Milan, Italy
Introduction: Chronic obstructive pulmonary disease (COPD) is a
heterogeneous condition with diagnosis and treatment determined
primarily by clinical features and spirometry. However, different clinical,
physiological, radiological, pathological, and inflammatory phenotypes
exist and may allow individualised management and targeting of
therapy. We hypothesised that both tidal flow limitation (TFL) and degree
of emphysema are likely to represent overlapping phenotypes and will
both influence response to bronchodilators.
Methods: We studied 31 subjects with moderate to severe COPD (FEV1:
1.29 (0.64)l, 47 (20)% predicted; FEV1/FVC: 0.52 (0.12)). Subjects
completed lung function testing and assessment of TFL, using the forced
oscillation technique, before and after 5 mg salbutamol. Emphysema
phenotype (EP) was graded on a 0–15 scale based on DLCO, visual high
resolution CT emphysema score and proportion of lung parenchyma at
,2910Hu on HRCT. The 9 flow limited (FL) subjects had marginally
higher emphysema scores than 22 non-FL (NFL) subjects: FL 8.2 (0.5) v
NFL 7.3 (0.5); NS.
Results: FL subjects were more obstructed and hyperinflated than NFL
subjects: FEV1 0.92 v 1.43 l; p,0.01, FEV1/FVC 0.43 v 0.55; p,0.01,
RV 4.8 v 4.03 l; p = 0.13. After the bronchodilator each group showed a
similar, small improvement in FEV1 but FL subjects showed a greater
volume response: DFVC 0.67 v 0.3 l; p = 0.01, DSVC 0.52 v 0.15 l;
p,0.04, DRV 20.48 v 20.2 l; NS. Subjects were split into two groups
about the median emphysema score. Those with more emphysema (EP
score 9.2 v 5.9) had worse lung function: FEV1 0.96 v 1.62L; p = 0.002,
FEV1/FVC 0.44 v 0.56; 0.004, IC 1.75 v 2.1 l; p = 0.13, RV 4.57 v
3.87 l; p = 0.13. Higher emphysema score was also associated with
volume, not flow response to salbutamol: DFEV1/FVC 20.03 v 0.01;
p,0.01, DFVC 0.48 v 0.27 l; p = 0.07, DSVC 0.3 v 0.13 l; p = 0.13,
DRV 20.43 v +0.04; p,0.01.
Conclusions: Bronchodilator responsiveness, in particular ‘‘volume
response’’ is influenced both by flow limitation and extent of
emphysema, which appear to be overlapping physiological COPD
phenotypes. In patients with more severe airflow obstruction, resting flow
limitation and more extensive emphysema it is important that change in
FEV1 is not used to gauge response to bronchodilator therapy.
P078 RELATION BETWEEN LUNG FUNCTION AND FRUIT
CONSUMPTION IN SMOKING AND NON-SMOKING
MEN IN NORTHERN IRELAND
K. M. McClean1, C. R. Cardwell1, F. Kee2, I. S. Young1,2, J. S. Elborn1,3.
1Queens University, N Ireland; 2Royal Victoria Hospital, N Ireland; 3Belfast
City Hospital, N Ireland
Background: Fruit consumption may have a protective effect on lung
function. We tested the hypothesis that individuals with higher fruit
consumption would have a better percent predicted FEV1 (FEV1%). We
were also interested in the interaction with smoking history.
Methods: 10 600 French and Northern Irish men aged 50 to 59 years
were recruited mainly at their place of work from 1991 to 1994 as part
of the Prospective Epidemiological Study of Myocardial Infarction
(PRIME). This involved a food frequency questionnaire and physical
measurements including lung function by spirometry. We present a cross
sectional analysis of the 1779 Northern Irish men for whom a valid
spirometry trace and food frequency questionnaire had been obtained at
baseline.
Results: The men had a mean age of 55 years and 32% had never
smoked. The mean fruit consumption per day was one piece. The table
shows that there was a significant increase in FEV1% with fruit
consumption in the smokers of on average 3.66 per unit of fruit
consumed but in the former and never-smokers this increase in FEV1%
was only 0.9.and 0.03 per unit of fruit consumed, respectively. This
difference in association between the three groups was significant
(p = 0.04). After adjustment for confounders (including education, BMI,
alcohol intake, waist-hip ratio, age, physical activity, vitamin supplement
use, cholesterol, height, and social status) made little difference to these
findings.
Conclusions: There is a positive association between fruit consumption
and lung function in smoking middle-aged men in Northern Ireland. Fruit
consumption has more benefit with respect to lung function in smokers
than non-smokers in this population.
P079 LUNG FUNCTION IN MID-LIFE IS A BETTER PREDICTOR
OF ARTERIAL STIFFNESS THAN LATER LUNG
FUNCTION: RESULTS FROM THE CAERPHILLY
PROSPECTIVE STUDY
C. E. Bolton1, Y. Ben-Shlomo2, D. J. Shale1, M. Munnery3, J. E. Gallacher4,
R. Sabit1, S. Ebrahim2, I. B. Wilkinson5, J. R. Cockcroft3. 1Respiratory
Medicine, Cardiff University, Llandough Hospital, Penarth, S Wales;
2Department of Social Medicine, Bristol University, Bristol; 3Wales Heart
Research Institute, UHW, Cardiff University; 4Department of Epidemiology,
Cardiff University, Cardiff; 5Clinical Pharmacology Unit, Cambridge
University, Cambridge, UK
Background: Low FEV1 and increased arterial stiffness have been shown
to predict increased cardiovascular mortality over and above smoking
status. We have examined whether poor lung function increases arterial
stiffness in the Caerphilly Prospective Study (CaPS).
Methods: 2959 men (aged 49–67 years) were recruited between 1979
and 1988 (phases I and II). Between 2003–05, they were re-examined
(phase V) to obtain measures of arterial stiffness (median follow up
period 18.6 years; n = 825). FEV1 and FVC data were available at
baseline (n = 2767) and phase V (n = 1099). Arterial stiffness, was
measured using applanation tonometry (SphygmoCor) to estimate aortic
pulse wave velocity (APWV).
Results: At baseline, mean (SD) FEV1 was 2.77 (0.73) litres, FEV1%
predicted 84.4 (20.2)%, with 462 (17%) exhibiting airways obstruction.
At phase V, FEV1 was 2.25 (0.64) litres, FEV1 % predicted 82.7
(21.4)%, 583 (53%) subjects had airways obstruction. APWV was 11.5
(2.8) m/sec. Both FEV1 and FVC were inversely related to APWV,
though FVC was a stronger predictor. For a one standard deviation
Abstract P078 Average increase in FEV1% per piece of fruit consumed daily by smoking
status
Smoking status n
Unadjusted Adjusted
Increase (95% CI) p Value Increase (95% CI) p Value
Never 571 0.03 (21.50, 1.50) 0.97 20.69 (22.16, 0.78) 0.36
Former 628 0.90 (20.75, 2.60) 0.28 1.23 (20.47, 2.93) 0.15
Current 580 3.66 ( 1.55, 5.70) 0.001 2.60 ( 0.51, 4.79) 0.02
Test for interaction p = 0.025 p = 0.03
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decrease in FEV1 and FVC, APWV increased by 0.44 (95% CI 0.21 to
0.66, p,0.0001) m/sec and 0.55 (95% CI 0.34 to 0.77, p,0.0001)
m/sec respectively adjusted for age, height, heart rate and mean arterial
pressure. This was stronger than the association of APWV with serum
lipids. Lung function at baseline was a stronger predictor than at follow-
up. Neither FEV1/FVC ratio nor the rate of decline in FEV1 was
associated with APWV. Subjects with GOLD III/IV had an increase in
APWV of 1.29 (95% CI 0.48 to 2.10, p = 0.002) m/sec.
Conclusions: Arterial stiffness was more strongly related to lung function
measured over two decades earlier than current lung function. The
development of lung function and arterial elasticity may share a common
mechanism in early life. Alternatively, the determinants of lung function
may have an adverse effect on arterial stiffness, which then tracks across
the life course. This is one potential mechanism that may link COPD with
cardiovascular disease
P080 CARDIOVASCULAR AND BONE DISEASE IN PATIENTS
WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
R. Sabit1, C. E. Bolton1, P. H. Edwards1, R. J. Pettit2, W. D. Evans2,
C. M. McEniery3, I. B. Wilkinson3, J. R. Cockcroft4, D. J. Shale1. 1Section of
Respiratory Medicine, Cardiff Univeristy, Llandough Hospital, Penarth, Vale
of Glamorgan; 2Department of Medical Physics, University Hospital of
Wales, Cardiff; 3Department of Clinical Pharmacology, Univeristy of
Camridge, Cambridge; 4Department of Cardiology, Cardiff University,
Univeristy Hospital of Wales, Cardiff, UK
Background: Osteoporosis is associated with an increased risk of
cardiovascular disease, both of which pertain to chronic obstructive
pulmonary disease (COPD). We hypothesised that increased arterial
stiffness, an indicator of cardiovascular risk, and osteoporosis would be
associated in COPD.
Methods: Seventy five clinically stable patients and 42 age and sex
matched healthy smokers (HS), both free of cardiovascular disease,
underwent spirometry; dual energy x-ray absorptiometry; venous
sampling for IL-6, TNFa soluble receptors (sr) I&II; and determination
of augmentation index (AIx) and aortic pulse wave velocity (APWV)
(Sphygmocor) as measures of arterial stiffness. Arterialised capillary
pO2 was determined in patients.
Results: Patients had a mean (SD) FEV1 56.7 (21.1) % predicted
compared with 107.6 (15.9) % predicted in the HS. The AIx, APWV and
inflammatory mediators were greater in patients compared with HS.
Bone mineral density at the lumbar spine and hip were less in patients
than HS, p,0.01 with osteoporosis more common in the patients.
APWV was related to age (r = 0.63, p,0.0001), Log10 IL-6(r = 0.31,
p,0.01), Log10 TNFa srI (r = 0.27, p,0.05) and inversely with FEV1
(r =20.43, p,0.01) and pO2 (r =20.34, p,0.01) in the patient group.
Patients with osteoporosis of the hip had a greater APWV (13.1 (1.8) m/
s) than those without (11.2 (2.7) m/s), p,0.05.
Conclusions: Increased arterial stiffness was related to airways
obstruction, the presence of osteoporosis, systemic inflammation and
hypoxaemia, and may explain the excess risk of cardiovascular disease
in COPD. The association of increased arterial stiffness and osteoporosis
suggests premature aging occurs in COPD.
Supported by GlaxoSmithKline.
P081 BONE THINNING: PREVALENT IN COPD BUT EARLY
DETECTION ALLOWS TREATMENT OPPORTUNITY
BEFORE VERTEBRAL FRACTURE OCCURS
C. E. Bolton1, R. J. Pettit2, M. D. Stone3, E. V. McCloskey4, A. A. Ionescu1,
P. H. Edwards1, W. D. Evans2, D. J. Shale1. 1Respiratory Medicine,
Llandough Hospital, Cardiff University; 2Medical Physics, University Hospital
Wales, Cardiff; 3Bone Research Unit, Cardiff University; 4Metabolic Unit,
University of Sheffield, UK
Introduction: Bone thinning (osteopenia and osteoporosis) predisposes
to vertebral and long bone fractures. We have previously reported a
high prevalence of bone thinning in COPD patients (GOLD 1-IV),
compared to healthy subjects (HS).1 We explored the prevalence of
vertebral fractures in COPD patients.
Methods: We performed instant vertebral morphometric assessment
(IVA) in patients with a spectrum of severity of airways obstruction
(n = 43), aged 67.5 (9.4) years, 26 male. None were or had been on
oral maintenance corticosteroids. IVA incorporates lateral thoracic and
lumbar views at the same time as the DEXA assessment of bone mineral
density (BMD) (Hologic Discovery) to examine presence of vertebral
fractures and grade severity. We also studied 24 gender matched HS:
62.7 (6.9) years. From the BMD, a gender specific T score is calculated.
Results: Osteoporosis (T score ,22.5) was present in 30% patients (8%
HS) and osteopenia (22.5, T score,21) in 41% patients (23% HS),
p = 0.004. The presence of vertebral fractures was similar in both
groups, p = 0.91. Vertebral fractures were present in 8 (19%) patients
(severity of fracture—6 mild, 1 moderate, 1 severe) 5 male; 6 of whom
had a FEV1 ,50% predicted. In 2 patients there was .1 vertebral
fracture. In HS, there were 4 (17%) with vertebral fractures (all mild
severity fracture, all male). The upper thoracic vertebrae (above T4) were
not clearly visible. Using logistic regression with presence of vertebral
fracture being the dependent; age, BMD lumbar spine, gender and
FEV1% predicted were inputted as variables. Only FEV1% predicted was
a significant variable, p = 0.023.
Discussion: This study reinforces the need to identify osteoporosis in
patients with COPD, where prevalence is increased as there is a
therapeutic opportunity before vertebral fracture occurs.
1. Bolton CE, et al. AJ RCCM 2004.
Supported by British Lung Foundation and GSK.
P082 OUTDOOR ACTIVITY AND DEPRESSION IN CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
J. K. Quint, R. Baghai-Ravary, G. C. Donaldson, J. A. Wedzicha. Royal Free
and University College Medical School, London, UK
Background: Loss of independence in chronic obstructive pulmonary
disease (COPD) is associated with increased disease severity, reduced
quality of life, and increased anxiety (Okubadejo et al. Eur Respir J
1997;10:1572–5). We have studied the relationship between the
amount of time spent outdoors and depression in patients with COPD.
Methods: We studied 96 patients (57 male) with COPD from May to July
2006; mean age 70.3 years (SD 8.4), FEV1 1.21 l (0.61), FEV1 %
predicted 47.4% (20.2), BMI 26.2 kg/m2 (6.3) and smoking history
47.7 pack years (30.1). All patients completed a Center for
Epidemiologic Studies Depression scale (CED-20) when clinically stable.
Over the study period 43 patients completed a St. George’s Respiratory
Questionnaire (SGRQ) and 55 patients returned diary cards on which
they recorded the hours spent outdoors each day. SGRQ scores,
average hours outside and lung function were related to the CED-20.
Results: We found a relationship between higher Total scores on the
SGRQ (that is, lower quality of life) and increased depression (r = 0.46;
p = 0.002). Higher Activity and Impact domains of the SGRQ were
associated with higher CED-20 scores (r = 0.44; p = 0.004 and r = 0.43;
p = 0.004, respectively). However, there was no statistically significant
relationship between the Symptom scores on the SGRQ and depression
(r = 0.24; p = 0.12). CED-20 scores correlated inversely with the amount
of time spent outside indicating greater depression in the more
housebound patients (r =20.28; p = 0.04). There was no relationship
between FEV1 or FEV1 % predicted and depression (r = 0.01; p = 0.93,
and r = 0.14; p = 0.18 respectively).
Conclusions: This study suggests that higher CED-20 scores in COPD are
related to reduced outdoor activity and health related quality of life. We
did not find a direct relationship between depression and FEV1. These
findings suggest the importance of identifying depressive symptoms in
COPD patients, in particular when undergoing exercise training, so that
optimal benefits can be achieved on outdoor activities.
P083 EDUCATION FOR PATIENTS WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE IS VARIABLE
AND POORLY TARGETED: SELF-MANAGEMENT AND
EXERCISE ARE NEGLECTED
R. C. M. Jones1, Xu. Wang1, S. A. Harding1, M. E. Hyland2. 1Peninsula
Medical School, Plymouth, UK; 2University of Plymouth, UK
Background: To manage their disease, patients with chronic obstructive
pulmonary disease (COPD) may need to modify their behaviour as
Abstract P080
HS (n = 42) Patients (n = 75)
AIx 25.9¡6.2 30.1¡8.2*
APWV (m/s) 8.95¡1.7 11.4¡2.7**
IL-6 (pg/ml) 1.29¡1.58 2.11¡1.84**
*p,0.01, **p,0.0001.
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smoking, exercise, medication and self management can all impact on
outcomes. We examined the information needs of patients in Devon
recruited in primary care using the Lung Information Needs
Questionnaire (LINQ). There are six domains (disease knowledge,
medicines knowledge, self-management, smoking, exercise, and diet).
Methods: An electronic assessment and management package was
devised for use by visiting nurses in 16 practices in Devon, UK. In a
comprehensive assessment, data collected included spirometry, clinical
data and questionnaires: LINQ, Clinical COPD questionnaire, MRC
dyspnoea scale.
Results: Data were obtained from 375 patients with confirmed COPD
and LINQ was completed by 340. The domain score disease knowledge
was correlated with disease severity—those with more severe disease
had been given more information: Pearson coefficients with FEV1%
expected were 0.22, p,0.001; MRC dyspnoea scale 20.20, p = 0.001;
total CCQ score 20.26, p,0.001.
In some areas information needs were well met—in current smokers
93% had been advised to stop smoking and 80% had been given
practical help such as nicotine therapy. Only 7% were confused about
their medication and 93% tried to take their medication exactly as
prescribed. However, written action plans were given to 56/335 (17%),
and were provided less often to those most at need, only 2/25 (8%) with
A&E attendances and 4/25 (16%) of those admitted in the last year.
Only 5/24 (21%) with hospital admissions knew when to call an
ambulance. For exercise, 29% had information needs adequately met,
but for the most breathless (MRC grade 4 and 5) the figure was only
20%. For diet, those with low BMI (,20) are at greatest risk, of these
55% had been told nothing about diet.
Conclusions: Education for patients with COPD is important to the
patients and may affect outcomes. In this study, it appears that smoking
and medicines information needs are well met, but self-management and
exercise are poorly focused on those with greatest need.
P084 RANDOMISED CONTROLLED TRIAL OF NURSE-LED
BREATHLESSNESS INTERVENTION TO IMPROVE THE
MANAGEMENT OF BREATHLESSNESS IN PATIENTS
WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
AT A DISTRICT GENERAL HOSPITAL
L. Pearce, V. MacLeod, A. Baker, A. Grant1, N. Dotesio-Eyes, M. Sydor,
C. Laroche. Department of Respiratory Medicine, West Suffolk Hosptial, Bury
St Edmunds, Suffolk, UK; 1Research & Development Unit, Papworth Hospital,
Cambridge, UK
Introduction: We report a single centre, prospective, randomised control
trial, involving 51 patients with confirmed chronic obstructive pulmonary
disease (COPD), in whom therapy had been optimised and breath-
lessness remained a predominate symptom. Patients were assigned to
receive either four 30-minute consecutive weekly sessions in the clinic,
with interventions consisting of strategies to manage breathing control,
psychosocial support and relaxation techniques, or routine care in a
COPD nurse specialist clinic.
Measurements: Primary outcomes were dyspnoea, emotional func-
tion, fatigue, and mastery, as measured by the self-reported
Chronic Respiratory Questionnaire (CRQ-SR). FEV1, functional
status, exercise capacity by shuttle walk, Borg scores, and oxygen
saturation, at baseline, 1 and 6 month post intervention were also
measured.
Results: Borg scores on exertion decreased within both groups at one
month., whereas paradoxically, Borg scores at rest increased within both
groups. Other results are shown in the table.
Conclusion: The breathlessness intervention was associated with a small
improvement in dyspnoea and fatigue (CRQ-SR) at 1 month, and in
dyspnoea at 6 months, compared to conventional treatment, but the
results were not statistically significant. There was no change in FEV1 or
shuttle walk distance. The breathlessness intervention was popular with
patients and warrants a larger multicentered, better powered study, to
assess its benefits.
P085 ICATS CHRONIC OBSTRUCTIVE PULMONARY
DISEASE REFERRAL TRIAGE AND CLINIC OUTCOMES
AUDIT
S. Gaduzo, K. Fern, D. O’Hara, S. Parry, J. Bootes, S. Mathewson, S. Gupta,
M. Lambert. Stockport PCT ICATS, Kingsgate House, Stockport, UK
At last year’s winter BTS meeting we presented an audit of the first three
months of the Stockport COPD ICATS (Tier 2) service. We now present
an audit of the activity of the Stockport COPD Tier 2/ICATS clinic in the
first year of its existence. The multidisciplinary team consists of a GPwSI,
Specialist nurses, physiotherapist, pharmacist and respiratory physiol-
ogist. The clinic runs once a week in the PCT’s recently opened ICATS
centre.
All GP referral letters to the Respiratory service are triaged by the
team. If Choose and Book is used by the GP, the default position is for an
ICATS triage. The team decides to either continue with a secondary care
referral or send an appointment for the ICATS clinic. (Criteria for ICATS
include Known COPD, age .40, current or ex-smoker, diagnostic
uncertainty)
Between April 2005 and April 2006 392 letters were triaged. 118
(36%) were felt to be suitable for ICATS review, 211 (64%) continued to
secondary care. 90 patients were seen in the ICATS clinic (the remaining
28 are yet to be seen or have failed to attend their first appointment and
have been sent a second). Of the 90 patients seen: 52 (58%) were seen
once, assessed, and returned to their GP’s care with a treatment plan
and reference to national and local guidelines. 26 (29%) were seen
between 2 and 3 times, pending results of simple investigations etc
before being discharged to their GP’s care as above. Seven (8%) were
referred on to secondary care respiratory physicians; (2 with
?bronchiectasis, 2 with haemoptysis, 1 with rapid weight loss, 1 with
Alpha-1 Anti-trypsin deficiency, 1 with abnormal CXR). Five (6%) were
referred to non-respiratory secondary care; (3 to cardiology with aortic
valve disease, unstable angina, heart failure; 2 to ENT with post-nasal
drip).
Thus, 87% of the patients triaged to ICATS were managed successfully
by the multidisciplinary team in the ICATS setting.
Abstract P084
Baseline mean (SD) Change mean (SD) 1 month Change mean (SD) 6 month
Contr (n = 26) Treat (n = 25) Contr (n = 22) Treat (n 22) p Value Contr (n 25) Treat (n 24) p Value
CRQ Dy 2.33 (0.85) 2.15 (1.01) 0.68 (1.04) 0.88 (1.24) 0.56 0.22 (1.06) 0.55 (1.16) 0.30
CRQ Em 4.02 (1.03) 3.79 (1.49) 0.70 (1.29) 0.73 (1.00) 0.92 0.02 (1.11) 0.20 (1.00) 0.55
CRQFa 3.33 (1.15) 3.27 (1.07) 0.26 (0.99) 0.49 (1.16) 0.49 20.15 (1.15) 0.03 (1.03) 0.56
CRQ Ma 3.75 (1.18) 3.95 (1.53) 0.83 (1.24) 0.77 (1.18) 0.88 0.29 (1.21) 0.36 (1.09) 0.82
FEV1 l 1.05 (0.54) 1.23 (0.60) 0.11 (0.27) 20.09 (0.23) 0.02 0.01 (1.21) 20.01 (1.09) 0.81
SWT (m) 167.50 (131.03) 202.80 (128.24) 31.43 (71.52) 29.47 (46.48) 0.92 8.95 (67.98) 25.00 (45.85) 0.44
Abstract P083
Domain Adequately met score = 0–1 Fully met score = 0
Disease knowledge 103/340 (30%) 26/340 (8%)
Medicines 284/339 (84%) 155/337 (46%)
Self-management 26/337 (8%) 100/337 (3%)
Smoking 317/339 (94%) 228/339 (67%)
Exercise 99/340 (29%) 41/340 (12%)
Diet 153/339 (45%) 20/339 (6%)
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P086 VARIATION OF MOODS IN CHRONIC OBSTRUCTIVE
PULMONARY DISEASE AND EFFECTS OF LONG TERM
ANTIDEPRESSANTS TREATMENT ON MOODS
S. A. Husain4, A. K. Kavidasan2, S. Sarfaraz1, R. L. Cannings-John3,
N. A. Jarad1, A. B. Millar2. Bristol Royal Infirmary1, Southmead Hospital2,
Bristol, University of Cardiff3 Cardiff, Maidstone Hospital, Kent4, UK
Background: Anxiety and depression has a significant impact on
hospital admissions in a number of elderly chronic obstructive airways
disease (COPD) patients. We are currently conducting the SOMIC study
to assess variation of moods in COPD patients from stable state and the
time of hospital admission with exacerbations. We are also trying to
review the effects of long term antidepressants on moods in COPD.
Methods: Hospital Anxiety and Depression Scoring methods (HADS)
was used to assess level of anxiety and depression in 79 COPD patients
above 60 years of age during hospital admission with an exacerbation,
initially within 3 days of admission repeated again at the time of
discharge and then in a stable state. Scores of 8–10 were considered
moderately anxious or depressed above that value to have severe form
of mood changes. Score variations from 0–21. We specifically looked at
a small group of patients who were already taking antidepressant
treatment for a longer time period before entering the study. The aim of
the exercise was to review any useful impact of the treatment on moods
in these patients. As long term compliance with antidepressants for
COPD patients has noted to be not very good and difficult as reported
from previously published trials.
Results: A total of 79 COPD patients’ moods were assessed. They had a
mean age of 72 years (SD 7.3, range 60–93 years) and 54 male
patients (68%). 71(90%) patients had a strong smoking history. Mean
depression scores at admissions were noted to be: 7.7 (4.0), 7.1 (4.3),
7.5 (4.7) Mean anxiety was 8.6 (4.3), 6.9 (4.9), 6.4 (4.5) Among these
patients, five patients (7%) were on long term antidepressant treatment
and their individual Depression scoring on HADS scale were: 11, 7, 13,
10, 12 respectively with a mean HAD score of 10.6 and their mean time
on antidepressant treatment was around 13 months. The above HAD
score values suggests that severe depression in COPD patient may not
show improvement with long term usage of antidepressants in severe
forms of depression.
Conclusion: There is some evidence to suggest anxiety was slightly
higher at admission but decreased at discharge and in the outpatients.
Depression on the other hand remained constant over the three time
periods. Long term antidepressants treatment in severe depression may
not improve depression levels in COPD patients. As the number of COPD
patients on long term antidepressants were low in the study so it is
difficult to draw any conclusions but certainly trials with larger numbers
of patients on long term antidepressant treatments are needed to assess
this further.
P087 DOES THE INTERNATIONAL CLASSIFICATION OF
FUNCTIONING, DISABILITY AND HEALTH PROVIDE
AN APPROPRIATE MODEL FOR IDENTIFYING
OUTCOME MEASURES IN CHRONIC OBSTRUCTIVE
PULMONARY DISEASE?
S. E. Roberts1, F. M. Schreuder2, T. Watson2, M. Stern1. 1Whittington
Hospital, London, UK; 2University of Hertfordshire, UK
Introduction: The World Health Organization’s International
Classification of Functioning, Disability and Health (ICF) provides a
common framework for health outcome measurement (Cieza A, et al. J
Rehabil Med 2004). This study aims to investigate whether the ICF
specific core sets for obstructive pulmonary diseases (ICF OPD) (Stucki A,
et al. J Rehabil Med 2004) aids in the identification of outcome measures
to assess the effect of pursed lip breathing (PLB) in stable COPD.
Method: Search of the literature identified 17 preclinical studies, 3
clinical trials, and 6 reviews relating to PLB. Grade B evidence suggests
that PLB reduces respiratory rate (RR), increases tidal volume and
improves arterial blood gases in COPD (Dechman G, Wilson CR. Phys
Ther 2004). PLB may also reduce breathlessness through reduction in
dynamic hyperinflation (DH) and/or improvement in mastery of
symptoms. These findings were applied to the ICF OPD to generate
outcome measures for a clinical study of PLB in stable COPD.
Results: Six discrete symptom areas of COPD, potentially remediable by
PLB, were identified (numbered in table). Appropriate outcome measures
were then defined: change in inspiratory capacity and RR on exercise
(1), Hospital Anxiety and Depression Scale (2), Chronic Respiratory
Disease Questionnaire (3a, 4, 5), endurance shuttle walk test (3b),
medication usage (6).
Conclusion: The ICF OPD proved a useful tool for identifying a broad
and comprehensive range of outcome measures for studying PLB in
COPD. Use of the ICF OPD at the design stage of a clinical trial may
improve the potential for identifying positive clinical benefits of an
intervention, which might otherwise be missed
P088 IMPACT OF THE FIRST NATIONAL CHRONIC
OBSTRUCTIVE PULMONARY DISEASE AUDIT ON A
BUSY DISTRICT GENERAL HOSPITAL
D. Ghosh, N. Chanarin, N. Joshi, C. Allen. Colchester General Hospital,
Colchester, UK
The Royal College of Physicians carried out a national audit of chronic
obstructive pulmonary disease (COPD) in 2003. It involved all 238 acute
NHS hospitals in the UK. It collected demographic and clinical
information about patients hospitalised with an exacerbation of COPD.
Readmission rates and 90 day mortality were also collected. The audit
provided a snap shot of COPD care in the UK and allowed NHS trusts to
compare themselves against this National standard. Our hospital, a 620
bedded busy district general hospital (DGH) contributed 39 patients to
the previous audit. The outcomes of the audit were used to support the
continuing development of our assisted discharge team. We were
disappointed that the use of NIV was relatively low and this has been
addressed through further education within the trust. We repeated the
audit to review the effectiveness of our COPD services and changes
made since the previous audit.
The audit was done using the Royal College COPD audit collection tool
as in 2003. We studied 38 consecutive admissions with COPD
exacerbations from January 2006. Patients were identified from
Abstract P087
ICF Category ICF OPD area (number)
Symptom areas of
COPD potentially
affected by PLB
Function Respiratory (b440) DH and RR (1)
Emotional (b152) Anxiety (2)
Exercise tolerance (b455) Exercise capacity (3a)
Activities Carrying out daily routine
(d230)
Breathlessness (4)
Walking (d450) Exercise capacity (3b)
Environment
(Barrier 2)
(Facilitator +)
Air quality (-) (e260) Symptom mastery (5)
Products and substances
for personal consumption
(+) (e110)
Pattern of medication
usage (6)
Abstract P088
2006 2003 National data 2003
Mean age at admission (years) 75 72 71
How many had previous admissions 13% 26% 64%
How many were readmitted (90 days) 5% 5% 27%
How many are still alive 92% 87% 84%
Seen by respiratory consultant/nurse 63% 46% 70%
Median hospital stay 6 days 7 days 6 days
Ventilatory support for pH ,7.35 100% 63% 37%
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discharge coding information. 56 possible patients were identified, 18
were excluded as their admission was not due to COPD.
We demonstrated a low readmission rate in 2003 and this was
confirmed again in the current audit. The low readmission level is
maintained in spite of a relatively elderly population of which 60% have
significant comorbidity. There also has been an improvement in mortality
and reduction in median hospital stay by 1 day. All 8 patients with
respiratory acidosis received NIV. In 2003 this figure was only 63%.
We conclude that the first National COPD audit was very helpful in
supporting and guiding development of COPD services. Repeating the
audit has helped us assessing the impact of further changes and is a very
useful tool to demonstrate the effectiveness of supported discharge teams
in COPD. In times when ineffective services are at risk of being cut it is
timely to be able to demonstrate and continue to demonstrate that a
service works.
P089 EVALUATION OF AN INNOVATION IN CHRONIC
OBSTRUCTIVE PULMONARY DISEASE CARE IN AN
INNER LONDON HOSPITAL: RESULTS OF A
QUALITATIVE STUDY
A. Clarke1, R. Sohanpal2, S. J. C. Taylor2. 1Public Health Resource Unit,
Oxford, UK; 2Queen Mary’s, University of London, UK
Introduction: Recent systematic reviews have suggested that early
discharge schemes are safe for selected patients with chronic obstructive
pulmonary disease (COPD). However there is little information on
patients’ understanding, perceptions or experiences of this new model of
care. Here we present findings from the first qualitative evaluation of a
respiratory supported early discharge scheme (REDS) for COPD patients
from patient’s and hospital staff perspective.
Aim: To explore patients’ experiences and staff’s views of a recently
introduced SED scheme at one inner London hospital and to identify
important features that could facilitate the wider implementation of
supported early discharge in COPD.
Intervention: REDS was set up with external short term funding. It
involved planned discharge of COPD patients from hospital within
3.5 days of admission with follow up at home (for example: inhaler
technique) by trained respiratory nurses visiting daily for the first 3 days
and then for a further two weeks depending on patients needs.
Methods: Qualitative study using semi-structured in-depth interviews
with a maximum diversity sample of COPD patients admitted to the
hospital with breathing problems, including those exposed and not
exposed to the REDS scheme and hospital staff about the SED service
was carried out. A grounded theory approach was used to analyse data
from the interviews. A process of open coding was used to identify
concepts, their properties and dimensions from the data. The ‘constant
comparison method’ was used to refine emerging conceptual categories
through comparison and searching for deviant cases. An interim
analysis was undertaken where subsequent interviews could be informed
by the findings of earlier ones. Nudist N6, a computer software package
was used to organise the data.
Results: Forty interviews were conducted. Many patients were suffering
from anxiety and/or depression. Most patients perceived that they did
not have a real choice to stay in hospital. Front line staff felt that the main
purpose was to keep people in their homes. Patient discharge (transport
and medication pick-up) was rarely smooth or quick. Some patients
found REDS nurse visits helpful, many felt that nurse visits did not bring
anything new or different to their care and were not sure why the nurses
were visiting. According to the staff, the SED scheme was to keep
patients in the community but there was little awareness by the GPs of
this service.
Conclusion: Partly because of a lack of clear objectives, ‘‘on the ground’’
supported early discharge is not working as well as could be hoped.
Patients do not appear to welcome or understand this new model of care
P090 AN EVALUATION OF RELATIONSHIPS BETWEEN
FATIGUE AND DEPRESSION IN PATIENTS WITH
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
A. Lewko1, J. Canavan1, M. Spencer2, R. Garrod1. 1School of Physiotherapy,
St George’s University of London; 2GlaxoSmithKline
Background: Subjective fatigue has recently been identified as a one of
the diversified symptoms in chronic obstructive pulmonary disease
(COPD). Although, little is known about potential relationships between
fatigue and depression
Methods: Eleven patients with stable COPD (7 male; age 70(54–82)yrs);
mean (SD) FEV1 0.85 (0.22) l, % predicted FEV1 34.9 (14.0) % , FEV1/
FVC 44.9 (14.9) l, completed the Multidimensional Fatigue Inventory 20
(MFI 20), five subscale questionnaire. Depression was assessed using
Hospital Anxiety and Depression Scale (HADS) (depression subscale).
Higher scores reflect higher depression and fatigue in both cases.
Relationships between depression and fatigue were tested using
Spearman’s correlation.
Results: There was a wide range of scores in MFI 20 (28–83) and HADS
depression (2–12), mean (SD) MFI 20 total score 67 (16.4) and HADS
depression 6.6 (3.6). There was a significant correlation between
depression and total MFI 20 score, and ‘‘General Fatigue’’, ‘‘Reduced
Motivation’’, and ‘‘Mental Fatigue’’ subscales of MFI 20 (table).
Conclusion: These early data suggest that in COPD patients, reduced
motivation, mental fatigue, and general fatigue are strongly associated
with higher levels of depression. Physical fatigue and reduced activity,
however, show no association supporting the idea that fatigue is a
multicomponent construct that may have varied causes.
We gratefully acknowledge the support of GlaxoSmithKline.
P091 AN OBSERVATIONAL STUDY OF PRESCRIBING FOR
CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN
PRIMARY CARE
M. Masoli, L. Dobson, D. Sinclair, M. Stone, I. Rafferty, J. Goldman. Torbay
Hospital, Torquay, UK
Introduction: In South Devon there are in excess of 15 000 GP
consultations and 1000 hospital admissions for chronic obstructive
pulmonary disease (COPD) each year. Torbay respiratory department
has attempted to rationalise COPD prescribing by establishing local
guidelines for primary care management based on the recent NICE
guidelines and by developing an accurate register of patients with COPD
in primary care. An observational study was undertaken to examine the
management of patients with COPD in primary care in the Torbay
region.
Methods: We analysed data on all patients registered with COPD from
five local GP practices who provided information for the Torbay COPD
primary care register.
Results: In five GP practices covering 34 372 patients, 661 were
diagnosed with COPD (1.9%). 53% male and mean age 70 years. 369
(56%) were treated with inhaled corticosteroids (ICS). 83% of whom
were prescribed beclomethasone (BDP), with an average dose of
876 mg/d (BDP or equivalent range 100 to 4000 mg/d). 11% of patients
were on combination ICS/long acting beta agonists (LABA). Very high
doses of ICS were predominantly related to the use of fluticasone (FP)
32/369 (9%) (avg 2000 mg/d of BDP or equiv). 337 were prescribed
salbutamol, 111 were prescribed atrovent and 159 prescribed
combivent. Only 67 (10%) were prescribed tiotropium and 178 (27%)
were prescribed a LABA. Eight (1%) were on home Oxygen and 65
(10%) were treated with oral prednisolone. 46 (7%) were prescribed
nebulisers and 35 (5%) were taking a theophylline. 15% were on no
treatment.
Conclusions: This study suggests that GPs are largely adhering to local
prescribing policy. The high number of patients (56%) on ICS is greater
than expected. Patients on FP (5%) were prescribed much higher doses
Abstract P090 Relation between depression (HADS depression) and fatigue dimensions
(MFI 20) (Spearman’s Rho)
MFI 20 Total
score
MFI 20
General
fatigue
MFI 20 Physical
fatigue
MFI 20
Reduced
activity
MFI 20 Reduced
motivation
MFI 20 Mental
fatigue
HADS 0.77** 0.67* 0.40 0.09 0.72* 0.75**
*Correlation significant at the 0.05 level.
**Correlation significant at the 0.01 level.
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which may be associated with a greater risk of systemic adverse effects
in a vulnerable patient population who are often elderly, relatively
immobile and with significant comorbidities. The risk:benefit profile for
ICS is likely to be worse in this group. Currently a lower proportion of
patients are treated with tiotropium than we would expect and this
mitigates in favour of more education in primary care. We aim to
expand the COPD database to incorporate all GP practices in the Torbay
Care Trust and include spirometric data. This will provide an accurate
and contemporary register of patients with COPD in primary care
thereby allowing assessment of outcomes on different treatment regimes.
Clinical features of COPD
exacerbations
P092 APPETITE CONTROLLING GUT HORMONE RELEASE
DURING ACUTE EXACERBATION OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
M. Nematy1, 2, M. Hickson1, A. E. Brynes1, P. J. Charles3, G. S. Frost1.
1Nutrition and Dietetic Research Group, Hammersmith Hospital, Imperial
College London W12 0HS, UK; 2Faculty of Medicine, Mashad University of
Medical Sciences, Mashad, Iran; 3Rheumatology Laboratory, Kennedy
Institute, London W6 8RF, UK
Introduction: Chronic obstructive pulmonary disease (COPD) patients
with acute exacerbation suffer from an impaired energy balance due to
a decreased dietary intake (Vermeeren et al. 1997), leading to weight
loss and increased risk of malnutrition (Ergun et al. 2003). Nutritional
support of patients during exacerbations is often difficult due to appetite
loss. Cytokines have been shown to increase during this time (Schols et
al. 1996) and may influence this appetite loss. Ghrelin and PYY are
peptides released from the gut which stimulate and inhibited appetite
respectively. The aim of this study was to investigate how these gut
hormones change during an acute exacerbation of COPD and
secondarily, to establish the relationship between gut hormones and
cytokines.
Methods: Ten patients with acute exacerbation of COPD (mean (SEM):
74.5 (2.4) yrs, BMI 24.6 (1.6) kg/m2, 4 male) underwent fasting blood
sampling on days 1, 3, 5, and 8 of hospital admission to measure
plasma concentrations of ghrelin, PYY, IL-1b, IL-6, and IL-8. Changes in
food intake, biochemical and anthropometric markers of nutritional
status were recorded. A comparison was made to 10 matched healthy
controls (75.0 (2.9) years, BMI 25.3 (1.6) kg/m2).
Results: Compared to healthy subjects, COPD patients exhibited a higher
PYY level during the stay (day 3; 30.5 (2.6) pmol/l, p,0.05, day 5;
32.9 (4.6) pmol/l, p,0.05, day 8; 28.0 (3.7) pmol/l, p = 0.06 v 20.7
(1.8) pmol/l) (see fig). There was no significant difference in ghrelin
concentrations between patients and control subjects on day 1, 3, 5, and
8. All measured cytokines were significantly higher in patients with
COPD compared to the normal range of theses cytokines, however no
correlation between either PYY or ghrelin and any cytokine was found,
but this is most likely due to a small sample size. Patients took half of their
energy requirement on day 3. Anthropometric and biochemical indices
pointed to deterioration during exacerbation (p,0.05).
Conclusions: These data suggest PYY concentrations are elevated in
COPD exacerbations but ghrelin remains unaltered. PYY inhibits
appetite and so this may explain the suppressed appetite commonly
seen in this group of patients. Cytokines, IL-1ß, IL-6, and IL-8, all
increase during acute exacerbation of COPD and may contribute to
alterations in metabolic status during inflammatory stress in this disease.
Further research is needed to establish whether increases in cytokines
are related to increased PYY.
P093 CHEST RADIOGRAPH IN ACUTE EXACERBATION OF
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
S. Sangaraju1, S. Philip2, P. Abraham2, O. Dempsey2. 1West Wales General
Hospital, Carmarthen, UK; 2Aberdeen Royal Infirmary, Aberdeen,UK
Background: The chest radiograph is an important diagnostic tool and is
performed routinely in most patients with exacerbation of chronic
obstructive pulmonary disease (COPD). This study was performed to
determine the prevalence and pattern of clinically significant abnorm-
alities on the CXR and their impact on mortality in patients with
exacerbation of COPD.
Patients and Methods: Retrospective study of 324 patients admitted with
diagnosis of exacerbation of COPD to the medical assessment unit of
Aberdeen Royal Infirmary between April 2004 and September 2005.
Patients who had concomitant diagnosis of congestive cardiac failure,
required intubation or noninvasive ventilation at admission or had
mortality within 48 hours of admission were excluded. Only the first CXR
(portable/departmental) performed at admission was considered.
Clinically significant abnormalities were defined as presence of
consolidation/patchy infiltrates, pulmonary oedema, pneumothorax
and previously undiagnosed mass lesion. Data about the patients and
reports of the CXRs were obtained from the computerized database.
Results: Mean age of patients was 66.2 years (SD 16.4); 173 (53.4%)
were males. CXR was performed at admission in 311 patients (96%).
Clinically significant abnormalities were noted in 125 patients (40.2%).
These were infective (consolidation/patchy opacities) in 90 (28%),
pulmonary oedema in 28 (9.0%) and previously undiagnosed mass
lesion in 7 patients (2.2%). All the seven patients with mass lesion were
evaluated with CT thorax and lung cancer was confirmed in 4 patients.
Pulmonary oedema was clinically not suspected in 19/28 patients
(67.8%). Chest radiograph was reported as normal in 37 patients
(11.8%). Chronic changes related to COPD were found in 149 patients
(48.0%). Mortality at 7 days was 4% (13/324) and all these deaths
occurred in patients with infective changes on the CXR (p,0.001).
Conclusions: This study reveals high yield of clinically significant
abnormalities on the CXR in patients with exacerbation of COPD. CXR
helps in diagnosing coexisting pulmonary oedema, when it is clinically
not suspected. There is significantly higher mortality in patients who have
radiological evidence of infection in this group of patients.
P094 DIFFERENCES BETWEEN SMOKERS AND EX-SMOKERS
IN SEVERITY AND MECHANISMS OF INFECTIOUS
EXACERBATIONS
S. Bourne, G. Seumois, V. Pandurangan, M. Uddin, B. Marshall, R. Djukanovic.
Southampton University Hospital, Southampton, UK
Background: Exposure to cigarette smoke can influence an array of
inflammatory and defense mechanisms in the lungs, including those to
viral and/or bacterial infections. Following a pilot study of current
smokers and ex-smokers (.1 year abstinence) which noted that current
smokers had more severe COPD exacerbations, we embarked on a
properly powered study to test the hypothesis that current smoking,
compared with ex-smoking, leads to more severe and prolonged
infectious exacerbations of COPD, with a greater degree of inflamma-
tion within the airways which is due to reduced neutrophil responses to
the infectious agents.
Methods: We have so far assessed the first 25 (9 ex-smokers) of the
planned 60 total patients to be recruited admitted to Southampton
General Hospital with acute infectious exacerbations of COPD.
Exacerbation was defined by the following symptoms for at least 2
consecutive days: 2 or more of 3 major symptoms (increase in
dyspnoea, sputum purulence or sputum volume) or any 1 major
symptom together with any 1 of the following minor symptoms:
increased nasal discharge, wheeze, sore throat, cough or fever. Other
causes of dyspnoea/admission (eg cardiac failure, inability to cope and
pneumonia) were excluded. Throughout the exacerbation FEV1, FVC,
and IC were measured by handheld spirometer from day 1 to 7.
Neutrophil activation markers were analysed in peripheral blood and
sputum.
* *
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* p<0.05
* p = 0.06
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Abstract P092 Pattern of fasting plasma PYY (mean (SEM)) during acute
exacerbation of COPD patients compared with healthy age and body
mass index matched control group.
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Results: Ex-smokers recovered more quickly than current smokers (see
table for mean (SEM) increase in spirometry from admission to day 7)
and required fewer hospital days than current smokers. Using flow
cytometry, we observed increased expression of adhesion molecule
CD11b and decreased expression of activation marker CD66b in
sputum of smokers; in blood the opposite profile was observed. This
suggests increased recruitment of neutrophils in smokers but their
reduced state of activation.
Conclusion: Current smoking is a risk factor for more severe
exacerbations, requiring longer to recover and prolonged hospitaliza-
tion. This might result from inadequate neutrophil defenses.
S Bourne was funded by the Ministry of Defense.
P095 EXACERBATION FREQUENCY AND DECLINE IN FEV1
IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
PATIENTS WITH AND WITHOUT DIABETES
J. W. Rudd, J. R. Hurst, G. C. Donaldson, J. A. Wedzicha. Academic Unit of
Respiratory Medicine, University College London, Rowland Hill Street,
London NW3 2PF, UK
Introduction: In chronic obstructive pulmonary disease (COPD), faster
FEV1 decline is also associated with higher levels of airway and systemic
inflammatory markers. Hyperglycemia can promote inflammation
leading to higher levels of TNFa, CRP, and oxidative stress. Whether
in COPD patients, the presence of diabetes hastens lung function decline
is unknown.
Methods: We examined 219 COPD patients enrolled in the London
COPD cohort. Patient characteristics were recorded at recruitment and
FEV1 measured every 3 months. The study took place over 10 years,
with the average patient recording data for 3.09 years (range 1.0–
9.73).
Results: 4.6% (10/219) of patients had a history of diabetes. The
diabetic patients were on average 19.3 kg heavier (p = 0.0015) with a
BMI of 33.0 kg/m2 (SD 4.32) and were taking a lower beclomethasone
equivalent daily dose of inhaled steroids (200 mg (IQR 0–750) vs
1000 mg (IQR 500–1600; p = 0.0197). They had a higher FEV1 at
recruitment 1.61 l compared to 1.11 l (p = 0.0016) but no significant
difference was seen in their annual exacerbation rate (1.98 (IQR 0.61–
3.19) per year compared to 2.30 (1.03–3.59) per year; p = 0.718) or
whether they smoked or not (2/10 compared with 77/205; p = 0.261).
The diabetics were more likely to have a history of ischaemic heart
disease 40% (4/10) compared with 16% (33/206) (p = 0.049).
Generalised least squares random effects models (4433 observations
on 212 patients) with adjustment for whether FEV1 was recorded at
exacerbation or not, current smoking status and its effect on decline and
FEV1 at recruitment, showed that FEV1 fell by 27.7 ml per year (95% CI
31.5 to 23.9) in non-diabetic patients (p,0.0001). In diabetics, FEV1
fell by 7.0 ml per year which was not significantly different from the non-
diabetics. (p = 0.152). For both groups, FEV1 declined faster in smokers
by 6.2 ml/year (p = 0.044). FEV1 as % predicted was also not different
between diabetics and non-diabetics (p = 0.134).
Conclusion: This study has shown that diabetic COPD patients have a
similar rate of FEV1 decline as non-diabetic COPD patients.
P096 PAYMENT BY RESULTS, THE TARIFF AND VIRTUAL
EARLY SUPPORTED DISCHARGE
S. C. Madathil, L. Stannard, D. Thomas, S. Gompertz. Selly Oak Hospital,
University Hospital Birmingham, UK
Acute admissions for chronic obstructive pulmonary disease (COPD)
exacerbations account for over 1 million bed days per annum in the UK,
with estimated direct costs of over £490 million.1 Early supported
discharge (ESD) is possible in selected patients with no adverse effects on
outcome.2 Under Payment by Results, the Department of Health’s
National Tariff for each uncomplicated COPD admission .48 hours is
£1709 and £342 (20%) for each admission,48 hours. The local tariffs,
corrected for Market Forces Factors, are £1925 and £385 respectively.
Methods: A prospective ESD feasibility study was performed as part of
the business planning process to develop this service. Two Respiratory
Specialist Nurses working 9am–5pm, Monday–Friday described a
‘‘virtual’’ ESD scheme to 100 consecutive COPD patients admitted with
an exacerbation from 1 October 2004. Standard exclusion criteria were
used to identify those requiring a conventional admission. In those
patients who were potentially agreeable to ESD, the time-point at which
hospital staff, the patient, and any relatives felt they would cope at home
with an ESD and at which all the eligibility criteria were met, was taken
as the virtual discharge date. The difference between the actual
discharge date and virtual discharge date was calculated for each of
the patients who met the criteria for ESD.
Results: Thirty admissions (30%) met the criteria for virtual ESD between
days 1 and 7 of their admission, saving 88 virtual bed days. With
current local admission rates, this equates to 752 bed days per annum
ESD would also have reduced length of stay of 8 admissions (8%) from
.48 to ,48 hours, hence saving our local Primary Care Trust at least
£105,348 per year (2006/7 tariff). Wider potential benefits would
include reduced bed occupancy and reduced admissions.
Conclusion: The Tariff and Payment by Results can be used as powerful
levers to develop business cases for new services.
1. BTS. The burden of lung disease. Second edition. British Thoracic
Society, 2006.
2. Cotton MM, et al. Thorax 2000;55:902–6.
P097 ANXIETY AND DEPRESSION IN READMISSIONS TO
HOSPITAL WITH ACUTE EXACERBATIONS OF
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
M. J. Doherty, D. Pandit. Department of Respiratory Medicine, Russells Hall
Hospital, Pensnett Road, Dudley, W Mids DY1 2HQ, UK
Readmission is common following hospitalisation due to an exacerbation
of chronic obstructive pulmonary disease (COPD). Some studies have
shown depression to be a risk factor for readmission (Amagro et al.
Respiration 2006;73:311–17) while others have not (Gudmundsson et
al. Eur Respir J 2005;26:414–19). We set out to examine if depression
and anxiety as measured by the Hospital Anxiety and Depression score
(HAD) was a risk factor for both readmission and for rapid readmission,
that is, .3 months. A significant score being anxiety or depression score
. or = 8. Data were prospectively collected on 51 random patients
admitted to our hospital with an exacerbation of COPD, any subsequent
admissions in the one to three years of follow up were noted from the
patients records and the computerised patient administration system.
Patients had a mean (SD) age of 69 (9) years, mean FEV1 of 37 (13) %
predicted and a mean HAD score of 15(7). Thirty three patients were
male and 35 of the patients had been admitted before. Thirty three of the
patients were readmitted but a significant depression score was not any
more common in these compared to those who were not readmitted, 17
out of 33 versus 7 out of 18, x2 = 0.74, p.0.2. Nor was anxiety more
common in patients who were subsequently readmitted, 17 of 33 versus
8 of 18, x2 = 0.23, p.0.5. When we looked at rapid readmission, 10
out of 15 who were rapidly readmitted were depressed versus 14 out of
36 in the group not rapidly readmitted, x2 = 3.28, p = 0.07. Looking at
anxiety, 8 of 15 were anxious versus 17 of 36 in those not rapidly
readmitted, x2 = 0.15, p.0.5. In summary we did not find a relationship
between anxiety or depression and readmission to hospital with an
exacerbation of COPD. However there was a relationship, though not
quite statistically significant between depression and rapid readmission.
Suggesting that depression plays a part in why some patients are rapidly
readmitted to hospital but is not important as far as readmissions after
three months.
P098 REDUCING CHRONIC OBSTRUCTIVE PULMONARY
DISEASE WINTER ADMISSIONS BY PRE-EMPTIVE
PATIENT REVIEW AND PROVISION OF EMERGENCY
MEDICATIONS
J. Chinegwundoh1, G. Knowles1, C. Saraiva2, N. Waring2. 1Kingston
Hospital Trust; 2Kingston Primary Care Trust, UK
Introduction: In 2005, the Kingston chronic obstructive pulmonary
disease (COPD) Working Group devised a strategy to reduce the
number of COPD admissions in the coming winter months. We
developed a model of care for all 1352 registered COPD patients in
Kingston Primary Care Trust (PCT). This consisted of an individual
Autumn review of each patient in General Practice. A personalised self
Abstract P094
Mean (l) SEM Significance p value
FEV1 Current smokers 0.057 0.027 0.003
FEV1 Ex smokers 0.370 0.083
FVC Current smokers 0.096 0.041 0.007
FVC Ex smokers 0.267 0.059
IC Current smokers 20.005 0.047 0.002
IC Ex smokers 0.333 0.075
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treatment plan was drawn up. In addition each patient was dispensed
with an emergency supply of antibiotics and steroids with clear guidance
when to start the medications and who to contact in case of an
exacerbation. This model of care was drawn up into a Service Level
Agreement and offered to GPs as an enhanced service.
Results: 1115 patients (82%) were reviewed and given emergency
medication and a personalised self treatment plan by the end of
November 2005. We looked at the number of COPD emergency
admissions of Kingston PCT patients into Kingston Hospital over the
winter months in 2005/6 and compared with the previous winter,
2004/5. There was a 25% reduction in COPD emergency admissions
when comparing the October to February periods. The data also showed
a 40% reduction in length of stay when comparing the same time
periods.
Discussion: We demonstrated a significant reduction in COPD admis-
sions and an even greater reduction in COPD bed days in Kingston
Hospital. The personalised patient review and care plan, in conjunction
with medications to treat exacerbations early, were instrumental in this
change. There were high levels of patient satisfaction and positive
reports from Practice nurses and GPs. We appreciate that external
factors, including environmental condtions, could confound the outcomes
but we have shown that this patient centred approach is feasible and can
provide significant benefits.
P099 A QUESTIONNAIRE SURVEY OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE PATIENTS WITH
READMISSIONS AND PROLONGED LENGTH OF STAY
R. Pradeep, M. Bhatattacharya. Milton Keynes General Hospital, UK
Acute exacerbations of chronic obstructive pulmonary disease (COPD)
result in patient readmission and prolonged hospital stay, contributing to
the progressive deterioration of patients, increased mortality, and the
high cost of care. In England and Wales 900 000 COPD patients are
diagnosed with COPD (Thorax 2004; 59(Suppl I):1–232) and Milton
Keynes alone has a predicted 3750–6250 COPD patients with 488
exacerbations/year.
Preliminary data from the Milton Keynes COPD readmission audit
(August 2003–August 2004) show 449 patients admitted to hospital
with 31% (143/449) being readmitted. The total length of stay was
3592 days (average stay: 8 days). In an audit of the 449 COPD
admissions 100 patients received a questionnaire focusing on quality of
life (chronic management, acute care and social circumstances), 64
replies were received and 44 patients contributed to the audit.
Median age of patients was 77 years, 59% had mobility problems and
27% continued to smoke. Over 60% of patients had been diagnosed with
COPD for more than 4 years and 36% had 5 or more exacerbations per
year. In all, 61% of patients were unable to cope with exacerbations at
home, and 60% had no access to pulmonary rehabilitation.
Over a quarter of the patients audited were not on long acting
bronchodilators and appropriate oxygen use remained an issue. Major
factors associated with readmission were number of exacerbations per
year, exercise tolerance, mobility, albumin levels and ability to cope at
home. Major factors leading to prolonged length of stay were age, living
alone, lack of independence, impaired mobility and stairs at home.
Patients with COPD need to be well supported in the community with
greater involvement of many health care professionals.
P100 THE EPIDEMIOLOGY OF SCOTTISH HOSPITAL
ADMISSIONS DUE TO CHRONIC OBSTRUCTIVE
PULMONARY DISEASE
J. Lee, J. Miller, J. Barr, A. Deans, C. Poland, M. MacDougall, W. MacNee.
ELEGI/COLT Laboratory, MRC/UoE Centre for Inflammation Research,
Univerity of Edinburgh, UK
Introduction: Exacerbations of chronic obstructive pulmonary disease
(COPD) represent a major burden to healthcare services. This study aims
to determine the extent of this burden in the Royal Infirmary of Edinburgh
(RIE) compared with the rest of Scotland.
Methods: Data on number of patients, deaths, hospital admissions and
bed days for COPD and all other conditions requiring hospital admission
were obtained from the Information Services Department Scotland for
April 2000–March 2005 for RIE and Scotland and analysed using the
two-tailed independent samples t test.
Results: 651 (60) and 8995 (616) COPD patients/year are admitted to
RIE and rest of Scotland respectively accounting for 1.3–2.0% of the
annual hospital patient burden. Compared to hospitals in the rest of
Scotland, COPD in RIE accounted for a higher percentage of admissions
(p = 0.005), readmissions (p = 0.013), and deaths (p = 0.038), but a
lower percentage of in-hospital COPD deaths (p,0.0005). There was
no significant difference observed in percentage bed days. Data from
general practice registers show that prevalence of COPD in the
community is 1.5% in Lothian and 1.8% in Scotland.
Conclusions: COPD is associated with longer-than-average hospital
admissions, readmission and high mortality compared with all other
causes of acute hospital admissions. Better characterisation of COPD
patients, particularly frequent exacerbators should aid development of
cost-effective management strategies to reduce exacerbations and
hospital admissions.
Acknowledgments: Study supported by National Institute of Health,
grant number RFA-HL-02-005.
P101 FIRST NORTHERN IRELAND CHRONIC OBSTRUCTIVE
PULMONARY DISORDER EARLY DISCHARGE SCHEME:
A ONE YEAR REVIEW
J. McLaughlin1, L. Williamson1, K. Crawford1, U. McCaffrey2, O. Bartlet2,
L. P. A. McGarvey1, T. J. Warke1. 1Respiratory Unit, Royal Victoria Hospital,
Belfast, N Ireland; 2North & West Community Trust, Belfast, N Ireland
Background: Early discharge schemes have been shown to be effective
in reducing admission lengths for chronic obstructive pulmonary disease
(COPD) patients. It is unclear whether such schemes can reduce hospital
readmissions. The Royal Victoria Hospital respiratory early discharge
scheme (REDS) commenced in June 2005. REDS patients, following
discharge, have follow up visits from the community team (nursing and
physiotherapy) for up to two weeks. Patients can then self-refer to the
community team thereafter.
Aims: (1) To evaluate the efficacy and safety of the scheme in its first year
of operation, with particular reference to length of stay (LoS). (2) To
consider if entry onto the scheme helped reduce subsequent admission
rates of COPD patients.
Methods: Data were obtained from medical records on all COPD
patients admitted between 01/06/2005 and 31/05/2006. LoS
(trimmed at 30 days) were compared between REDS and non-REDS
patients. Of the 407 admissions, case notes of 282 were available for
more detailed assessment. The following were recorded: if patients were
assessed for REDS, accepted for REDS and if not, why not. The following
data on REDS patients were obtained from the community team: adverse
events, readmissions while on REDS, self-referrals to the scheme and if
this resulted in further hospital admission.
Results: There were 407 COPD admissions. Of the 282 reviewed in
detail, 69 were not assessed for REDS. Of the 213 assessed, reasons for
exclusion from REDS included: residing outside the community team
catchment area (44), requiring NIV (14), further investigation (12),
medically fit for discharge (11), rehabilitation (10), social issues (10),
and patient refusal (6). The remainder had various comorbid reasons.
REDS patients (n = 39) had no adverse events and had a significantly
shorter LoS (median (interquartile range)) compared to non-REDS
patients (n = 368) (3 (2–4) v 7 (4–13), p,0.001). There were 7
readmissions whilst on REDS and 3 patients required GP visits. There
were 25 subsequent self-referrals to the community team with no
resultant admissions to hospital compared with 32 readmissions from 11
REDS patients who did not avail of self-referral.
Conclusion: The review of the first year of the first respiratory early
discharge scheme in Northern Ireland showed that it is safe and
effective, facilitating a reduced length of stay. Patients were keen and
willing to self-refer thereafter and this possibly prevented subsequent
hospital admissions.
P102 CHARACTERISTICS OF CHRONIC OBSTRUCTIVE
PULMONARY DISEASE PATIENTS ACCEPTED ONTO
AN EARLY DISCHARGE SCHEME
Z. Puthucheary, V. Bulbeck, J. Paul, W. Tregidgo, J. Pople, R. Stone.
Department of Respiratory Medicine, Taunton and Somerset Hospital,
Musgrove Park, Taunton, Somerset, UK
We have been collecting data prospectively on patients accepted onto
our chronic obstructive pulmonary disease (COPD) early discharge
scheme since the beginning of 2005. We ask that the team complete,
workload permitting, large datasets on every patient they accept onto the
scheme and every 10th patient they do not accept (this latter group is
much bigger and has no further contact with the team following an initial
assessment and education session). These data are allowing us to
characterise more precisely the population we accept for early discharge
and we present some of our initial findings within this abstract. We also
attempt to contrast some of the data on patients accepted for early
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discharge (209) with those from a smaller sample (40) of the group who
have not been discharged on the scheme.
Both groups consist of patients with severe disease who exacerbate
frequently. There appears to be no difference emerging between the
accepted and not-accepted groups, suggesting we are not merely
discharging the ‘‘simpler’’ patients early, or that patients remaining in
hospital have more severe exacerbations. 28-day readmission rates are
interesting. While the accepted group appears to have a lower all-cause
readmission rate, this is not true of those readmitted with further COPD
exacerbation—both groups have low readmission rates and, while this
may reflect difficulties in coding diagnoses on IHS, we note that the team
deliver an education package to all COPD cases they assess, irrespective
of acceptance onto our scheme.
P103 MANAGEMENT OF ACUTE EXACERBATION OF
CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN
THE EMERGENCY DEPARTMENT: A COMPLETED AUDIT
ON THE INTRODUCTION OF A PATHWAY
S. Huq1, J. Finnerty2. 1Royal Liverpool Hospital, UK; 2Countess of Chester
Hospital, UK
Introduction: Acute exacerbation of chronic obstructive pulmonary
disease (COPD) is a common medical emergency presenting in
Accident and Emergency (A&E) departments. This audit was designed
to identify the deficiencies in the current practice in management of these
patients in the Emergency department, and then re-audit to assess
whether the introduction of a pathway was effective in improving
practice.
Methods: The latest guideline in management of COPD (Management of
COPD in adults in primary and secondary care, National Institute of
Clinical Excellence, 2004) was taken as the standard. 72 patients
admitted through the Emergency department of the Countess of Chester
Hospital with a final discharge diagnosis of ‘‘COPD’’ were audited.
Audit parameters included: patient profile, diagnosis status (known
COPD or not), current home treatment for COPD, initial assessment—full
set of observations and arterial blood gas (ABG) measurements, oxygen
and nebuliser therapy, use of steroids and antibiotics, investigations
requested, reassessment and outcome from A&E.
The initial audit was on 34 admissions between 3/7/05 and 28/9/
05. An emergency medicine multidisciplinary pathway for acute
exacerbation of COPD was then introduced in the A&E department of
Countess of Chester in February 2006. It incorporated guidelines for
initial oxygen therapy, ABG measurements, drug therapy, criteria for
medical admission and indications for non invasive ventilation. The re-
audit was done on 38 admissions between 27/4/06 and 19/6/06.
Outcomes: Performing initial ABG measurements: 25/34 patients (74%)
in 2005 versus 35/38 patients (92%) in 2006 audit. Time interval
between arrival in A&E and ABG measurements: median 76 minutes in
2005 versus 65 minutes in 2006. Documenting initial oxygen therapy:
15/34 (44%) in 2005 versus 31/38 (82%) in 2006. Initial nebuliser
therapy: 26/34 (76%) in 2005 versus 36/38 (95%) in 2006.
Investigations: Chest radiograph, full blood count and urea and
electrolytes: 30/34 (88%) in 2005 versus 38/38 (100%) in 2006.
Prescription of steroids: 14/34 (41%) in 2005 versus 18/38 (47%) in
2006. Medical admission from A&E: 23/34 (67%) in 2005 versus 37/
38 (97%) in 2006
Conclusion: This audit identified the key areas for improvement in
managing acute exacerbation of COPD in emergency departments. The
use of a multidisciplinary pathway proved useful in improving practice in
the emergency department setting.
P104 SYMPTOMS AND EXACERBATIONS IN A CHRONIC
OBSTRUCTIVE PULMONARY DISEASE POPULATION
ASSESSED FOR EARLY DISCHARGE
Z. Puthucheary, V. Bulbeck, J. Paul, W. Tregidgo, J. Pople, R. Stone.
Department of Respiratory Medicine, Taunton and Somerset Hospital,
Musgrove Park, Taunton, Somerset, UK
We have been asking chronic obstructive pulmonary disease (COPD)
patients about their usual symptoms as an addendum to their assessment
for early discharge. We have also asked how patients have managed
their exacerbations in the last 12 months (that is, themselves using
medications at home, via their general practitioner or by coming to
hospital). We have recorded data in 209 patients and exacerbation
management in 169. Our database shows that this group of hospitalised
patients has significant disease (% predicted FEV1 34%) and exacerbates
frequently (2.84 per annum). 74% tended to receive antibiotics and
steroids for exacerbation, 19% received antibiotics alone, and 7%
steroids alone.
Thus, in this group of patients with severe disease, breathlessness and
cough were the major reported symptoms to occur regularly but sleep
disturbance and tiredness were also prominent. It is important to
Abstract P102 Table 1
Characteristic Accepted group Not accepted
Admission heart rate 88 90
Admission respiratory rate 21 22.4
Admission systolic BP 131.3 128.4
Admission saturation (%) 93 92.7
FEV1during admission (%pred) 33.5 32.5
Body mass index (kg/m2) 24.3 22.9
Usual walking distance (m) 131 125
Usual MRC dyspnoea score 3 3.07
Exacerbations per annum 2.84 2.54
Admissions in last 12 months 1.39 1.48
Oedema (%) 34.6 38.8
Known to have angina (%) 18 11
Abstract P104 Table 1 Symptoms reported: figures represent percentages of the 209
patients
Dyspnoea 100 Daily
Cough 43 Daily 28 Occasional 10 Never 19 If unwell
Sputum volume 73 Teaspoon 12 Eggcupful 6 Tbspoon 9 Minimal
Sputum colour 38 Clear 36 White 12 Yellow 14 Other
Wheeze 11 Always 25 Occasional 41 Exertion 23 Never
Tight chest 11 Always 25 Occasional 41 Exertion 23 Never
Tiredness 31 Always 25 Occasional 44 Never
Somnolence 6 Always 22 Occasional 72 Never
Headache 13 Always 25 Occasional 62 Never
Sleep quality 46 Good 54 Disturbed
Abstract P102 Table 2
Readmission data (retrospective analysis
from Trust IHS) Accepted
Not
acc
28-day readmission rates, all causes of readmission 19.1% 23.6%
28-day readmission rates, due to exacerbation 11.7% 9.8%
Abstract P104 Table 2 Patient management of
exacerbations over last year
Method of management Self GP Hospital
Number of patients 15 73 81
Number of exacerbations 35 170 302
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consider factors other than breathlessness and cough when assessing
COPD patients, therefore. Notably, only 9% of patients tended to
manage exacerbations themselves, 43% referred to their GP and 48% to
hospital. One would perhaps expect our selected to group to have a high
rate of hospital-managed exacerbations, but the data suggest there is
also room for significant improvement to occur in the amount of self-
management. We have now altered our behaviour to increase the
number of COPD self-management plans we give to our patients, in the
hope this may lead to a reduction in the number of admissions and also
allow improved management of non-dyspnoea symptoms.
Management of chronic cough
P105 COUGH FREQUENCY DISTRIBUTION IN PATIENTS
WITH CHRONIC COUGH USING AN AUTOMATED 24
HOUR AMBULATORY COUGH MONITOR
A. A. Raj1, S. Matos2, R. Walton3, S. S. Birring4, D. H. Evans2, I. D. Pavord1.
1Institute for Lung Health, Glenfield Hospital, Leicester, UK; 2Department of
Medical Physics, University Hospitals of Leicester, UK; 3Department of
Respiratory Physiology, Glenfield Hospital, Leicester, UK; 4 King’s College
Hospital, London, UK
The Leicester Cough Monitor (LCM) is a 24-hour cough monitor that
automatically detects cough sounds recorded in an ambulatory setting.
We have previously shown that automatic cough frequency measure-
ment is valid and reproducible over 6 hours in patients with chronic
cough. We now report our experience of ambulatory cough monitoring
over 24 hours. 19 patients, (mean (SEM) age 58 (3.8) years, 11(58%)
females) undergoing investigation of their unexplained dry chronic
cough at a specialist cough clinic, underwent 24 hour cough monitoring.
Each patient completed a symptom diary indicating timing of meals and
bedtime, and time of worst symptoms. Cough count per hour ranged
from 0–307. Pattern of coughing was predominantly daytime, with an
even distribution between morning, afternoon and evening. One patient
had mainly nocturnal cough, 3 had a biphasic distribution with a
morning peak and then another peak either late afternoon or evening.
Mean cough count/hour ranged from a low of 2.47 (3am) to a high of
22.42 (11pm). Mean cough counts/hour were calculated for several
time frames (see table). The postprandial period was defined as the
2 hours following the end of each meal. Night-time was time from
patient going to bed until they arose. Paired t tests were used to compare
the mean cough counts/hour among the various time frames.
There were significantly less cough counts/hour at night compared
with the daytime (mean difference 214.8, 95% CI 225.9 to 23.8;
p = 0.01); but no difference between the postprandial period and
daytime (mean difference 0.6, 95% CI 23.1 to 4.3; p = 0.7). There were
no significant differences in mean cough count/hour between mornings,
afternoons or evenings, although there was a trend for a lower morning
cough frequency compared to the afternoon. Our data suggest that
cough predominantly occurs during the daytime in patients with chronic
cough. Cough frequency is not significantly different in the post prandial
period.
P106 OESOPHAGEAL IMPEDANCE-PH MONITORING IN
GASTRO-OESOPHAGEAL REFLUX INDUCED COUGH
M. S. Menon1, C. E. Wright1, G. K. Buckton2, M. Dakkak2, A. H. Morice1.
1Department of Academic Medicine; Castle Hill Hospital; Cottingham; East
Yorkshire HU16 5JQ, UK; 2Hull Royal Infirmary, Hull, UK
Introduction: Gastro-oesophageal reflux disease is one of the common-
est causes of chronic cough. 24 hour oesophageal ph monitoring is
considered the gold standard for acid reflux disease, however this
investigation does not determine the extent of non-acid reflux which we
suggest plays a significant role in reflux induced cough
Methods: Twelve patients with a clinical diagnosis of chronic cough due
to gastro-oesophageal reflux and a negative 24 hour esophageal ph
monitoring underwent oesophageal impedance-ph monitoring using a
nine channel combined multichannel intraluminal impedance and
manometry catheter (Sandhill Scientific). Coughing bouts were identified
by an event marker. The mean number of episodes of coughing was
26.7 (21) over 24 hours. A mean total of 46.6 (30.1) reflux episodes
were detected. Of these 16.3 (11) were related to acid reflux compared
to 30.3 (33.1) episodes that were non acid reflux events. In order to
relate cough with the reflux, the reflux events occurring up to 5 minutes
prior to cough was considered significant. Of the coughs recorded, 10%
were acid related and 14.7% non-acid related events. Reflux occurred
frequently in the 60 minutes immediately post prandial. A mean of 21.6
(16.4) episodes occurred with 57.6% being non-acid events.
Discussion: This study demonstrates in patients with negative ph
monitoring, gastro-oesophageal reflux does occur. Non-acid reflux
events occur more frequently than acid reflux and may be responsible for
a significant amount of gastro-oesophageal reflux induced cough. The
use of oesophageal impedance-ph monitoring rather than the conven-
tional ph monitoring alone may increase the sensitivity of oesophageal
monitoring in the diagnosis of reflux induced cough.
This poster was presented at the American Thoracic Society meeting in
San Diego, May 2006.
P107 BRONCHOSCOPIC ABNORMALITIES IN UNEXPLAINED
CHRONIC COUGH
S. Decalmer1, M. Greaves2, M. Howe3, A. Woodcock1, J. Smith1. 1North
West Lung Research Centre, Wythenshawe Hospital, Manchester;
2Department of Radiology, Wythenshawe Hospital, Manchester, UK;
3Department of Histopathology, Wythenshawe Hospital, Manchester, UK
Background: Flexible bronchoscopy is not routinely recommended for
the investigation of chronic cough. Diagnostic protocols advocate
sequential investigations and trials of treatment for asthma-like
syndromes, post nasal drip, and gastro-oesophageal reflux disease.1
Where this strategy fails to elucidate the diagnosis, a number of further
investigations are suggested. In such selected patients flexible broncho-
scopy may be more diagnostically useful.
Methods: The NWLRC runs a specialist cough clinic seeing patients from
the North West region. We have reviewed the bronchoscopic findings in
consecutive new referrals to this clinic over an 18 month period. Patients
with unexplained cough despite investigation and treatment trials (chest
x ray, pulmonary function, methacholine challenge, ENT examination,
and empirical reflux treatment) were bronchoscoped.
Results: Between January 2005 and June 2006, 154 new referrals were
seen (47 referrals from general practitioners and 107 tertiary referrals).
73 bronchoscopies were carried out, of these 8 (11%) had a diagnosis
made based on findings from inspection and biopsy. These included
tracheopathia osteochrondroplastica (TPO) (4 cases), tracheomalacia (1
case), elongated uvula touching the vocal cords (2 cases) and
endobronchial amyloidosis (1 case). TPO patients all had early changes
with the typical appearance of nodules mainly on the tracheal cartilage
rings but not causing significant airway obstruction. CT scans showed no
other abnormalities.
Conclusions: TPO is thought to be a rare condition but 54% of sufferers
complain of cough as a symptom.2 In selected patients with chronic
cough, in whom initial investigative protocols and treatment trials have
been unsuccessful, flexible bronchoscopy is indicated and may reveal
pathology potentially contributing to cough.
1. Morice AH, Fontana GA, Sovijarvi AR, et al. The diagnosis and
management of chronic cough. Eur Respir J 2004;24:481–92.
2. Lundgren R , S t je rnberg NL. T racheobronchopath ia
osteochondroplastica. A clinical bronchoscopic and spirometric
study. Chest 1981;80:706–9.
P108 CORRELATION BETWEEN AIRWAY WALL AREA OF THE
APICAL SEGMENTAL BRONCHUS WITH DISTAL
AIRWAY WALL THICKENING IN NON-ASTHMATIC
EOSINOPHILIC BRONCHITIS
G. Cruse, S. H. Siddiqui, S. McKenna, P. Bradding, I. D. Pavord, J. Entwistle,
C. E. Brightling. Institute For Lung Health, Glenfield Hospital, Leicester, UK
Introduction: Limited CT of the apical segmental bronchus (ASB) right
upper lobe has been validated as a measure of airway wall remodeling
in asthma and chronic obstructive pulmonary disease (COPD). Airway
wall area of the ASB has been shown to correlate inversely with post
Abstract P105
Time period
Mean cough
count/hour Minimum Maximum SEM
24 hours 13.5 3.8 61 2.9
Daytime 18.6 4.2 89.1 5.4
In bed 3.8 0 9 0.8
Postprandial 20.4 5 113 26.4
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bronchodilator (BD) FEV1. To date no study has examined whether
airway wall thickening of the ASB in non-asthmatic eosinophilic
bronchitis (EB) correlates with distal airway wall thickening.
Furthermore the correlation of thickening of the ASB and distal airways
with post BD lung function has not been assessed.
Methods: Twelve patients with EB (according to the ACCP criteria) were
recruited. Patients had a mean (range) age of 57 (36–69) with disease
duration of 9 (5–18) years and post BD FEV1 of 108 (81–139)% of
predicted. All participants took a 2 week course of oral prednisolone
0.5 mg/kg followed by limited CT (120 kv, 50 mas, 1660.75 mm
collimation, pixel area 0.323 mm2) scanning of the right upper lobe to
capture the ASB. Airway wall dimensions of the ASB were measured by
ray casting using the full width half maximum method (Harvey Coxson
VA) by a blinded and unblinded observer. The mean of measurements
taken from the origin to the division point of the ASB was corrected for
body surface area (BSA). Distal airways ranging from 4–15 mm2 in the
right upper lobe, corresponding to 4–8th generation airways, were
measured using the same technique and the mean airway wall
dimensions were corrected for BSA. We have previously validated ray
casting using an airway phantom model and generated second order
polynomial equations describing the relationship of wall area and
luminal area %error according to airway size. ASB and distal airway
measurements were corrected using the polynomial equations.
Results: The mean (SEM wall area (WA), Lumen area (LA) and total area
(TA) of the ASB were 19.4 (1.3), 13.6 (2.9), and 33.0 (3.8) mm2/m2
respectively. There was a good correlation between observers of the ASB
measurement (r2 = 0.9). Both the TA and %WA of the ASB correlate well
with the TA and %WA of smaller airways in EB (r2 = 0.457, p = 0.0158
and r2 = 0.6073, p = 0.0028, respectively). These observations are
consistent with COPD with a near identical intercept and gradient
(Nakano et al. 2000, AJRCCM, 162, 1102–1108). Interestingly, there
was no significant correlation between any airways and post BD FEV1
before correction with the polynomial equations. However, there was a
significant correlation between TA of distal airways and post BD FEV1 (%
predicted) after correction (r2 = 0.3374, p = 0.0476).
Conclusion: This study demonstrates that airway wall geometry of the
ASB correlates with distal airways in EB, and that distal airway
(generations 4–8) geometry correlates significantly with post BD FEV1 in
patients with normal lung function.
P109 WHAT IS THE MINIMAL IMPORTANT DIFFERENCE FOR
THE LEICESTER COUGH QUESTIONNAIRE?
A. A. Raj1, I. D. Pavord1, S. S. Birring2. 1Institute for Lung Health, Glenfield
Hospital, Leicester, UK; 2King’s College Hospital, London, UK
The Leicester Cough Questionnaire (LCQ) is a self-completed cough
specific health status measure that has been shown to be valid,
reproducible and responsive (Birring SS, et al. Thorax 2003;58:339–
43). The purpose of this study was to determine the LCQ minimal
important difference (MID), which is the smallest change in health status
or quality of life (QOL) that is considered to be clinically meaningful. 53
patients with chronic cough (mean (SEM) age 56 (2) years, 30 (57%)
females, duration of cough 5 (1.2) years) completed the LCQ during
investigation of their cough in a specialist cough clinic and completed a
repeat LCQ and four Global Rating of Change Questionnaires (GRCQ:
overall QOL, physical, psychological, and social domains) .2 months
after the first visit. The GRCQ is a 15-point scale widely used to assess
the MID of health related questionnaires and is scored between +7 (great
deal better) to 27 (great deal worse). The MID is the mean change in
LCQ score for patients scoring GRCQ 23/22/2/3 (2 = little, 3 = some-
what better/(-)worse). The LCQ total score range is 3–21 and domain
scores (physical, psychological and social) range from 1–7. A higher
LCQ score indicates a better QOL. The MID for the total LCQ score was
1.3; it was 0.4 for domain scores (table).
In conclusion, we propose a change in LCQ total health status score of
1.3 is the minimal important difference. This data should aid
interpretation of LCQ scores and help those designing clinical trials for
patients with cough.
P110 IMPROVEMENT IN HEALTH STATUS FOLLOWING
OUTPATIENT CHEST PHYSIOTHERAPY FOR PATIENTS
WITH REFRACTORY CHRONIC COUGH
G. Watkin1, B. W. Willig1, K. Mutalithas1, I. D. Pavord1, S. S. Birring2.
1Institute for Lung Health, Glenfield Hospital, Leicester, UK; 2King’s College
Hospital, London, UK
Chronic cough is a common condition that often results in significant
physical and psychological morbidity. Troublesome cough persists in up
to 30% of patients referred to specialist cough clinics despite extensive
investigations and treatment trials. Pharmacological therapies for
refractory cough are largely ineffective and have significant side effects.
Chest physiotherapy is occasionally prescribed for patients with
refractory cough but its efficacy has not been formally evaluated. We
assessed health related quality of life (QOL) in 23 patients with stable
chronic cough (mean age (SEM) 60 (2) years, 13 (57%) females, mean
duration of cough 13 (2) years) at baseline and .2 months after
outpatient based chest physiotherapy. All patients were investigated
using a standardised diagnostic algorithm. The causes of cough were:
idiopathic chronic cough (16), cough variant asthma (2), pulmonary
fibrosis (2), rhinitis (1), gastro-oesophageal reflux (1), and eosinophilic
bronchitis (1). Health status was assessed using the Leicester Cough
Questionnaire (LCQ), which is a well validated 19-item self-administered
questionnaire for patients with chronic cough (total score range 3–21;
higher scores indicate better QOL). There was a significant improvement
in health status after chest physiotherapy (mean (SEM) LCQ total score
before 12.4 (0.9) v after physiotherapy 15.1 (0.9); mean difference 2.7
(0.7); p,0.001). The improvement in QOL was significantly greater
than the LCQ minimal clinically important difference (MCID) of 1.3.
Health status improved by more than the MCID in 16 (70%) patients. A
significant improvement was seen in all LCQ health related domains:
physical (p = 0.001), psychological (p,0.001) and social (p = 0.02). The
health status of patients with chronic cough improved with chest
physiotherapy regardless of gender, age, and duration of cough. Our
findings suggest a potential role for chest physiotherapy in the
management of patients with refractory chronic cough. Further
randomised controlled studies are required to confirm these findings.
P111 THE TREATMENT OF CHRONIC COUGH WITH
DISOFROL
R. H. Thompson, C. E. Wright, J. Jackson, V. Hunter, M. Menon,
A. H. Morice. Cardiovascular and Respiratory Studies, University of Hull,
Castle Hill Hospital, Castle Road, Cottingham, East Yorkshire HU16 5JQ, UK
Introduction: American guidelines suggest the use of antihistamines in
the treatment of chronic cough due to post nasal drip. UK experience has
been poor. We have previously reported to the society that the
recommended antihistamine (unlicensed in the European Union),
dexbrompheniramine (DEX) inhibits the capsaicin receptor, TRPV1,
one of the primary sensory receptors for cough (Sadofsky LR, et al.
Thorax 2005;60:ii108).
Aim: To determine whether Disofrol (DEX 6 mg/pseudoephedrine
120 mg combination) is beneficial in treating chronic cough irrespective
of the diagnosed causality of cough.
Method: Fifty seven patients (70% female) mean age 56 years, with
intractable chronic cough were dispensed with open label Disofrol, twice
Abstract P109 Mean change in LCQ scores (SD)
Change in LCQ QOL score
Global rating of change
Same (21/0/1) MID (23/22/2/3) Moderate (25/24/4/5) Large (27/26/6/7)
Total score 21.3 (3.1) 1.3 (3.3) 1.7 (2.3) 2.7 (4.6)
Physical 20.6 (0.9) 0.2 (0.8) 0.7 (1.0) 1.3 (1.2)
Social 20.3 (1.2) 0.2 (1.1) 0.7 (0.9) 1.3 (2.3)
Psychological 20.1 (1.1) 0.8 (1.1) 0.5 (0.8) 1.2 (2.1)
MID, minimal important difference.
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daily, for 4 weeks. The aetiology of cough included gastro-esophageal
reflux disease (47%), idiopathic (32%), cystic fibrosis (7%), asthma (5%),
and other causes (9%). Patients were asked to complete a visual
analogue scale for the severity of cough before and after treatment. The
mean cough score before and after treatment was compared using
Wilcoxon signed ranks test. Adverse events (AEs) caused by the
treatment were also recorded.
Results: 63% of patients had an improvement in cough following
treatment. Overall the mean (SD) visual analogue cough score following
treatment was significantly lower than before treatment, 4.81 (2.68) v
7.75 (1.47), p,0.001. Response to therapy was independent of
diagnosis. 44% of patients experienced AEs of varying severities. The
most common AEs included dry mouth (28%), drowsiness (28%), and
sleep disturbances (20%). 52% of patients who suffered an AE
discontinued treatment.
Conclusion: Disofrol is an efficacious treatment of intractable chronic
cough irrespective of the diagnosis. While a placebo response is
possible this patient population displays minimal response in blinded
studies. The side effect profile suggests that the tolerability could be
increased if DEX was given without the decongestant.
P112 BACLOFEN IN COUGH SECONDARY TO GASTRO-
OESOPHAGEAL REFLUX DISEASE
M. S. Menon, C. E. Wright, A. H. Morice. University of Hull, Cottingham,
East Yorkshire HU16 5JQ, UK
Introduction: Baclofen has been shown to increase lower oesophageal
sphincter tone and alter the cough sensitivity. We have examined the
response to Baclofen in patients with gastro-oesophageal reflux cough
selected from the Hull Cough Clinic.
Methods: A retrospective analysis of the response to baclofen prescribed
for gastro-oesophageal reflux cough identified using our probability
based diagnostic algorithm (Kastelik J, et al. Eur Respir J 2005;25:235–
43) was done. 29 patients (23 women) aged 40–80 years who had
previously been tried on high dose proton pump inhibitors received
baclofen for their reflux-induced cough. The maintenance dosage varied
between 10 mg/day to 40 mg/day with the majority on 15 mg/day.
Fifteen patients (51%) reported substantial benefit in symptom relief. Ten
(34%) reported no effect on their cough. One person found transient
beneficial effects. There was worsening of cough in 2 patients.
Conclusion: Baclofen is a useful therapy in cough secondary to gastro-
esophageal reflux disease. The probable mechanisms by which this
benefit is obtained are (1) decrease in the transient relaxations of the
lower esophageal sphincter and (2) alteration of the cough sensitivity.
This poster was presented at the American Thoracic Society meeting in
San Diego, USA.
P113 TREATMENT OF CHRONIC COUGH WITH MORPHINE
C. E. Wright, R. H. Thompson, A. H. Morice. The University of Hull, Hull, East
Yorkshire, UK
Introduction: Cough is the commonest complaint for which a medical
consultation is made (Schappert SM. Nat Am Med Care Survey
1993;230:1–16). At Hull Cough Clinic patients are investigated and
managed using a probability-based algorithm (Kastelik et al. Eur Respir
J 2005;25:235–43) similar to that recommended by the ERS task force
(Morice et al. Eur Respir J 2005;24:481–92) Using this algorithm we
have been able to reach a final diagnosis in 93% of patients. However
7–10% remain undiagnosed or fail to respond to treatment. In such
patients there is a case for use of non-specific drugs that provide
symptomatic control especially when treatments directed at the clinical
cause of the cough are ineffective. The ‘‘gold standard’’ non-specific
antitussives are opiates such as codeine and pholcodeine, although
evidence of efficacy has been conflicting.
Method: Hull Cough Clinic patients with intractable cough were treated
with opiates in the form of slow release morphine sulphate (MST) 5 to
10 mg bd. Of 1189 patients seen, 94 (8%), (mean cough duration 8.31
(0.93) years), (73% female) were treated with MST, of these 41% had
gastro oesophageal reflux disease, 43% no diagnosis and other causes
included asthma, bronchiectasis, and post nasal drip (16%). After
individual assessment, treatment with 5 mg MST bd was increased to
10 mg bd if symptomatic control was suboptimal. This treatment regime
resulted in 50% of patients demonstrating a significant improvement in
cough, 16% had no change and 34% were lost to follow up. 52% had
tolerable side effects and 13.8% experienced side effects resulting in
treatment withdrawal. The most prevalent adverse events were
constipation (6.4%) and drowsiness (3.2%).
Discussion: Our experience shows that where a diagnosis cannot be
determined or the established treatments are unsuccessful, morphine is
an effective and safe treatment. However it is important that patients are
assessed on an individual basis since the dosage of morphine is a patient
dependant variable which must be individualised according to patient
metabolism, age, and response to morphine.
P114 COMPUTERISED ANALYSIS OF COUGH SOUND
CHARACTERISTICS IN DIFFERENT RESPIRATORY
DISEASES
S. Matos1, S. S. Birring2, D. H. Evans1, I. D. Pavord3. 1Department of
Medical Physics, University Hospitals of Leicester, UK; 2King’s College
Hospital, London, UK; 3Institute for Lung Health, Glenfield Hospital, Leicester,
UK
The automated, computerised detection of cough from sound based
recordings could have many clinical applications. One possibility is that
the characteristics of cough sounds differ between respiratory conditions.
We have analysed data from a total of 688 individual cough sounds
manually selected from ambulatory recordings performed in ten patients
presenting with chronic cough due to cough variant asthma (n = 4),
eosinophilic bronchitis (3), and gastro-oesophageal reflux disease (3).
All selected cough sounds were listened to and segmented into three
phases according to the usual description of cough sound components:
an initial burst of sound or first cough sound, an intermediate phase and
a second cough sound. The following parameters were calculated for
each of the three phases: duration; fraction of the total energy; centre
frequency; maximum frequency; and bandwidth. Statistical analysis
showed significant differences in the cough sound parameters between
the three disease groups studied (see table). It also showed a well
defined temporal structure of cough sounds, with significant differences
in the parameters between the different phases.
Linear discriminant analysis (LDA) was also applied to these
parameters. Classifiers were trained with two thirds of the data and
used to classify the remaining sounds as CVA, EB or GORD coughs.
Groups were compared pairwise and correct classification results from
88% to 93% were obtained. The classification results were always better
when using the parameters of each phase than when using parameters
to describe the complete cough sound.
The results of this pilot study suggest that there are significant
differences in acoustic parameters of cough sounds from patients with
different respiratory conditions and that the temporal structure of cough
sounds should be considered when analysing these signals.
Computerised analysis of the temporal and spectral characteristics of
cough sounds could provide new information about the evolution of
cough in different respiratory conditions. Further work is required to
determine whether this is clinically helpful.
Abstract P114
Duration (ms) Centre frequency (Hz) Max frequency (Hz)
1 2 3 1 2 3 1 2 3
CVA 52* 225 69 359* 516 391* 1469* 1672 938
EB 57 168* 115* 234* 578 266* 1734* 1734 578*
GORD 59 217 68 516* 1172* 297* 3281* 3399* 781
Data expressed as median values.
*Statistical significance to other groups.
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Respiratory health in children
P115 DUST EXPOSURE AND RESTRICTIVE LUNG DISEASE IN
CHILDREN IN KARAKALPAKSTAN, UZBEKISTAN
P. Bennion1, R. Hubbard1, T. McKeever1, S. O’Hara1, G. Wiggs2,
J. Wegerdt1, S. Lewis1, I. Small3, J. Van der Meer3, R. Upshur3.
1University of Nottingham; 2Oxford University; 3Medecins sans Frontieres
Objective: To investigate the association between dust exposure and
restrictive lung disease in children aged 7–10 years in the autonomous
region of Karakalpakstan, Uzbekistan.
Background: Since the 1960s there has been a gradual yet dramatic
reduction in the volume and surface area of the Aral Sea. Vast areas of
salty sea bed have been exposed and the area has experienced an
increase in dust storms. Local communities believe that the dust storms
are having an impact on their health.
Methods: A cross sectional survey was conducted using a questionnaire
on children aged 7–10 years living in 18 communities in
Karakalpakstan. The children’s lung function was tested and anthropo-
metric data recorded in both the summer (May to August) and winter
(September to December). Local dust deposition rates were monitored on
a monthly basis. We used linear and logistic regression in our analyses.
Results: Dust levels in Karakalpakstan, and in particular the areas close
to the Aral Sea are high. Dust deposition levels were considerably higher
in the summer than in the winter. In the winter, when dust levels were
low, an increase in total dust exposure was associated with an increase
in FVC by 191.1 ml and there was a 20% decreased risk of having
restrictive lung disease for every increase in total dust exposure of one
standard deviation. In the summer, when dust levels were high, an
increase in total dust caused a decrease in FVC by 161.9 ml and a
doubling of the risk of having restrictive lung disease for every increase
in total dust exposure of one standard deviation.
Conclusion: In the winter, the children living in close proximity to the Aral
Sea with the highest annual levels of dust exposure have the best lung
function. The reasons for this are not clear, but may be due to their
socioeconomic status and the healthier diets of these communities which
used to be relatively affluent fishing villages. In the summer, the reverse is
true; the children living near the Aral Sea have the worst lung function and
are at an increased risk of having restrictive lung disease. These findings
suggest that the high levels of dust experienced in this area during the
summer have a short term adverse effect on children’s respiratory health.
P116 AN INTERNATIONAL COLLABORATIVE INITIATIVE TO
DEVELOP RELIABLE REFERENCE RANGES FOR
PULMONARY FUNCTION IN YOUNG CHILDREN
S. Stanojevic1,2, S. Lum1, A. Wade2, T. J. Cole2, A. Custovic3,
M. Silverman4, J. Stocks1. 1Portex Respiratory Physiology Unit, Institute of
Child Health, UK; 2Centre for Paediatric Epidemiology and Biostatistics,
Institute of Child Health, UK; 3South Manchester University Hospitals NHS
Trust, UK; 4Leicester Royal Infirmary, University of Leicester, UK
Background and Aims: Despite recent advances in preschool pulmonary
function testing (PFT),1 the lack of appropriate reference ranges limits the
application and interpretation of these tests in this age group. The
Asthma UK collaborative initiative aims to develop reference ranges
from collated lung function measurements for spirometry, interrupter
resistance and specific airway resistance in children aged 2–9 (http://
www.growinglungs.org.uk).
Methods: To date, of the 64 centres identified as potential collaborators,
31 have agreed to participate. Data collection which includes centre
specific information (equipment, protocols and population character-
istics) and individual demographic and lung function data has been
completed in 14 centres. Quality control of PFTs will be conducted in a
systematic manner to assess comparability between centres. Reference
ranges will be developed using the LMS method2 and GAMLSS3 to
model the curvilinearity, heteroscedasticity and skewness in the
distribution of lung function measurements.
Results: Preliminary results from 10 714 spirometry measurements in
young children (6140 ,7 years) indicate that collation of reference data
for lung function in this age group is feasible (fig). After adjustment for
height there are substantial nonlinear age trends in FVC and FEV1, plus
evidence of left skewness in the distribution. Data collection is ongoing.
Conclusions: The curvilinear relationship between height-adjusted FEV1
and age emphasises why currently available linear reference ranges for
school age children should not be extrapolated to younger age groups.
Application of modern statistical methods to larger datasets than hitherto
available will improve the reliability of reference ranges for preschool PFTs.
1. Stocks J. Pulmonary function tests in infants and young children.
Chapter 9, In: Chernick V, Boat TF, Wilmott RW, Bush A (eds),
Kendig’s disorders of the respiratory tract in children. Seventh
edition. Philadelphia, PA, USA: Elsevier, 2006.
2. Cole TJ, Green PJ. Stat Med 1992;11:1305–19.
3. Rigby RA, Stasinopoulos DM. Appl Statist 2005;54:507–54.
P117 PAEDIATRIC PATIENT HAND HELD ASTHMA RECORDS
S. Clayton1, S. Davies1, T. Baggaley2, J. Riley2. 1University Hospital North
Staffordshire; Staffordshire Moorlands Primary Care Trust
Asthma affects 5.2 million people (3.7 million adults and 1.1 million
children) in the UK. Despite the availability of evidence based asthma
management guidelines and pharmacological advances in treatment
many patients are failing to reach the desired standard of asthma control
(Asthma UK, 2004).1 Strategies that optimise prescribing, adherence to
treatment and educate patients how to appropriately respond to
deteriorating asthma and exacerbations by offering personal action plans
can have significant impact on asthma morbidity (British Lung Foundation
(BLF), 2004).2 Despite the wide availability of personal action plans is has
been reported that only 5% of asthma sufferers have a personalised,
written asthma action plan, in spite of evidence that self management tools
not only improve health outcomes for people with asthma but also reduce
the need for emergency consultations. Over the past 2 years we have been
working to develop a children’s asthma hand held patient record. The
record has been individualised to the child’s age and disease status and
provides guidance regarding treatment adjustment depending on
disturbance to daily activities, symptoms and lung function. It details
when to seek emergency care and provides information on diagnosis,
investigation and treatment history, prevention advice, and contact details
of family members and healthcare professionals. Free text is available for
the child/parent and carer to record events both retrospectively and
prospectively. Integral to the record is a removable credit card sized
emergency card. One hundred families have taken part in the pilot phase
and have complete two questionnaires; one related to the record and the
other the emergency card, at 3 and 6 month post record distribution. The
results so far have been extremely positive. The presentation and style of
the record scored highly, 80% liking the size and 70% liking the colour.
Fifty per cent have actively used the record, taking it to GP consultations,
hospital visits and school. The free text section has been used by the child/
parent to record days when unwell, and future appointment dates. Twenty
to thirty per cent of children report they are carrying the record with them
all the time, particularly when going on school trips. Over 80% reported
they found the record extremely useful and easy to follow. One parent
reported she had used the day-to-day section to monitor her child’s
progress and as a result the GP altered medication that resulted in her
child achieving improved asthma control. The evaluation of the emergency
asthma card is as equally positive with 100% of users reporting they liked
the size of the card and the content. Over 50% of the children were
carrying the card with them all the time. This project is now going to be
extended to a wider population.
1. Asthma UK. Where we stand, 2004.
2. British Lung Foundation. Lung Report III – Casting a shadow over the
nation’s health, 2004.
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Abstract P116 Preliminary results of collated spirometry (FEV1)
measurements in children ,10 years of age from nine centres.
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P118 POLYMICROBIAL INFECTION IN CYSTIC FIBROSIS
INFANTS AT FIRST PRESENTATION
G. J. Connett1, G. Rogers, K. Bruce2. 1Department of Paediatrics,
Southampton General Hospital; 2Department of Life Sciences, King’s
College, London, UK
Recent molecular biological based studies have identified a diverse
range of bacterial species in cystic fibrosis (CF) sputum.1 In this abstract
we report the use of Terminal Restriction Fragment Length Polymorphism
Profiling (T-RFLP) to identify the bacteria in tracheal and bronchial
lavage specimens from twin infants newly diagnosed with CF. Twin 1
presented at 6 months of age with acute intestinal obstruction and cough
and twin 2 was noted to have cough and breathlessness at the same time
of diagnosis. Fibreoptic bronchoscopy was performed prior to antibiotic
therapy for acute symptoms. Tracheal suctioning, bronchial wash, and
broncho-alveolar lavage (BAL) were obtained from twin 1 and bronchial
wash and BAL specimens from twin 2.
DNA was extracted from each of the samples and a phylogenetically
informative region of the 16S rRNA gene amplified. Amplicons were
digested with a restriction endonuclease and separated according to
length using an automated DNA sequencer to generate a profile of the
total bacterial content of each sample. Bands within this profile were then
assigned to bacterial species according to their length.
Conventional cultures on selective media for CF pathogens identified S
aureus in Twin1 and S aureus plus a non-lactose fermenting Coliforn in
twin 2. T-RFLP profiling identified a complex bacterial community
including 28 species in twin 1 and 11 in twin 2. 16S rRNA cloned
fragment lengths were consistent with the presence of Chlamydia,
Burkholderia, Bordatella, Alcaligenes Streptococci and Moraxella.
Bands indicative of well recognised CF pathogens including
Pseudomonads, S aureus, H influenzae, and S maltophilia were
detectable at low levels. Whilst differences occurred in the range of
species identified between specimens, there was common clustering of
species across all of the samples. Both infants were improved after
prolonged broad spectrum antibiotics. These findings suggest that
complex bacterial communities are readily established during acute
respiratory exacerbations in CF infants. Most species are not grown by
conventional culture and species other than those traditionally recog-
nised as CF pathogens are also present. Cluster analyses demonstrated a
similar range of species to those seen in older expectorating individuals.
However band intensities were more evenly distributed without the
predominance of any individual CF pathogen as commonly seen in older
children and adults.
1. Rogers GB, Carroll MP, Serisier DJ, et al. Characterization of
bacterial community diversity in cystic fibrosis lung infections by use
of 16s ribosomal DNA terminal restriction fragment length
polymorphism profiling. J Clin Microbiol 2004;42:5176–83.
P119 THE PAEDIATRIC ADVANCED WARNING SCORE IN
ACCIDENT AND EMERGENCY: VALIDATION OF A
PHYSIOLOGY BASED ‘‘EARLY WARNING SCORE’’
FOR PAEDIATRIC ADMISSIONS
L. Finlay1, P. Egdell1, D. Pedley2. 1Department of Paediatrics, James Cook
University Hospital, Middlesbrough, UK; 2Department of Academic
Emergency Medicine, James Cook University Hospital, Middlesbrough, UK
Introduction: The use of Early Warning Scoring Systems has become
commonplace over recent years. Evaluation of such systems has taken
place in clinical settings such as adult acute medical admissions units,
postoperative surgical wards and, more recently, Accident and
Emergency (A&E). There is, however, no early warning system validated
for use in children. We propose that the use of a Paediatric Advanced
Warning Score (PAWS) would identify children attending A&E in need
of urgent medical assessment and appropriate intervention.
Methods: We designed a PAWS chart. The chart uses physiological
parameters (respiratory rate, work of breathing, oxygen saturation,
temperature, capillary refill, heart rate, and conscious level), taking into
account age related differences between normal values, to produce a
numerical score. The more abnormal the physiological parameters
recorded, the higher the PAWS score obtained. We validated the
scoring system by performing a retrospective analysis of paediatric
patients attending A&E. We compared patients who required admission
to the Paediatric Intensive Care Unit (PICU) with a control group of
children who were admitted to the general paediatric ward. The A&E
cards were identified and the PAWS scores were calculated, based on
data recorded at presentation. We then compared the PAWS scores
between the two groups in order to see whether the PAWS chart would
be able to identify those children in need of admission to a critical care
area.
Results: The range of PAWS scores for patients admitted to PICU was 0–
17, compared with 0–6 in the patients admitted to the general paediatric
ward. Using a cut-off score of 3 or above, PAWS was able to identify
patients requiring PICU admission with a sensitivity of 72% and a
specificity of 90%.
Conclusions: A physiology based scoring system can help identify
patients with significant illness. Assessment of paediatric patients is
complicated by the range of normal parameters in different age groups.
By drawing together clinical data as a single numerical score plotted on
a colour-coded chart, abnormal physiology is more readily identified.
This may be useful in the assessment and monitoring of sick children.
P120 SYSTEMATIC REVIEW OF THE COMMON THERAPIES IN
CHRONIC NON-SPECIFIC COUGH IN CHILDHOOD
A. Gupta1, M. McKean1, A. B. Chang2. 1Paediatric respiratory Unit,
Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK; 2Department of
Respiratory Medicine, RCH, Brisbane, Queensland 4029, Australia
Introduction: Chronic non-specific cough (NSC) is a common and
troublesome paediatric problem. NSC is defined as non-productive
cough in the absence of identifiable respiratory disease or any known
aetiology. It is increasingly recognised as a separate entity albeit without
any identifiable cause. The aim of this systematic review (SR) was to
evaluate the common therapies used in children with chronic NSC.
Methodology: Two authors (AG and MM) searched MEDLINE (from
January 1951 to December 2005), CINAHL (from January 1982 to
December 2005), EMBASE (from January 1974 to December 2005),
and the Cochrane databases (2005) for the subject headings cough and
children. The search was limited to chronic, recurrent or persistent
cough. All randomised controlled trials (RCT) or SR of RCTs were
included. References were reviewed and additional relevant articles
were identified. We excluded studies where there was another apparent
cause for chronic cough.
Results: See table.
Abstract P119
PICU (n = 50) General ward (n = 50)
PAWS score .3 36 5
Median PAWS score 5 0
Abstract P120 Common therapies used for chronic NSC in children
Therapy Evidence Data limitations and considerations
Asthma type therapy
Inhaled beta2-agonists SR Non-beneficial; only 1 small RCT
Mast cell stabilisers SR No RCT; single cohort study only
Methylxanthines SR No RCT; adverse events
Anticholinergics SR No RCT
Inhaled corticosteroids SR RCT = 2; non-beneficial; high placebo effect; adverse events
Gastro-oesophageal reflux
treatment
SR RCT = 3; data inconclusive
Anti-microbials No RCT SR in chronic ‘wet’cough—some benefit
Others No RCT No data
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Discussion: There is a clear lack of adequate RCTs in the management of
children with chronic NSC. This SR does not support the empirical
treatment approach in children with chronic NSC (as opposed to specific
cough). This clearly differentiates the management of chronic cough in
children to that in adults whereby empirical treatment is widely
advocated and used. In those with chronic wet cough, antibiotics have
shown to be of some benefit and the use of inhaled corticosteroids in
limited situations may be justified. However evaluation of response to
treatment which is not necessarily attributable to the medication itself, is
important in the clinical context.
P121 TISSUE PLASMINOGEN ACTIVATOR FOR EMPYEMA IN
CHILDREN
J. McCormick1, S. Maroo1, A. Devenny1. Respiratory Unit, Royal Hospital for
Sick Children, Yorkhill NHS Trust, Glasgow G3 8SJ, UK
Background: BTS guidelines for the management of pleural infection in
children were published in 2005 (BTS Guidelines for the Management of
Pleural Infection in Children. Thorax 2005;60(Supplement)). Published
data on experience using tissue plasminogen activator (tPA) as a
fibrinolytic therapy in childhood empyema is limited.
Aim: To report outcomes using tPA for empyema in children from a
tertiary referral paediatric hospital.
Methods: Observational study of all cases of parapneumonic effusion
and empyema requiring chest drain insertion and tPA in our centre from
January 2005–June 2006.
Results: Thirty children (15 male) were prescribed tPA following chest
drain insertion. Median age at presentation was 5.8 years (interquartile
range (IQR) 3.5–9.8 years). Initial median (IQR) haematological and
biochemical results; CRP 241.5 mg/l (154.3–321.5), WBC 20.16109/l
(16.2–31.6), Hb 11.5 g/dl (9.9–12.4), Na+ 135 mmol/l (133–135).
Length of stay in our centre was 9 days (IQR 7–12), but total length of
stay including days of hospital admission prior to transfer was 12 days
(IQR 10.0–15.8). Each patient received a median of 5 chest radiographs
(IQR 4–7) and a chest ultrasound. Antibiotics were administered for a
median of 21 days (IQR 16–22) with a median of 11.5 days of
intravenous antibiotics. 43.3% of initial drain insertions took place out of
hours (5pm or later or at weekends). 27 pigtail and 3 large-bore drains
were used (median drain size 10Fr (IQR 10–12)). tPA was administered
within 4 hours of chest drain placement. The median tPA dose
administered was a single 2 mg dose followed by a bolus of 20 ml
0.9% saline and clamping of the drain for one hour. Eight patients
(26.7%) received a microbiological diagnosis from either blood or
pleural fluid culture (Streptococcus pneumoniae in 7 patients,
Haemophilus influenzae in 1 patient). The drain was removed after a
median of 5.5 days (IQR 4–7.8). No tPA complications were recorded
and there were no deaths. Three patients (10.0%) required a secondary
thoracic procedure (debridement of empyema rind by thoracotomy), 2
required 24-hour admissions to PICU postoperatively, and 1 required
HDU care.
Discussion: tPA is a useful, well tolerated adjunct to chest drainage for
empyema in childhood with 90% of our patients recovering without
requiring a further thoracic procedure.
P122 AN AUDIT OF ORGANISMS ISOLATED FROM
TRACHEAL SECRETIONS IN CHILDREN WITH
TRACHEOSTOMIES ON LONG TERM VENTILATION
B. J. Shields1, C. Young2, A. M. Devenny1, J. Y. Paton1, C. Lucas3.
1Departments of Respiratory Paediatrics and Microbiology, Royal Hospital
for Sick Children, Glasgow, UK; 2University of Dundee, UK; 3Departments of
Respiratory Paediatrics and Microbiology, Royal Hospital for Sick Children,
Glasgow, UK
Background: Children on invasive long term ventilatory (LTV) support
can have respiratory exacerbations, defined as increased oxygen or
ventilatory requirements, which can result in hospital admissions and
inpatient morbidity.
Aims: Identification of all micro-organisms found in tracheal secretions in
all children on invasive LTV attending a single centre. Examination of the
relationship between respiratory exacerbations and positive isolates and
the role of antibiotic therapy in organism clearance. Also to assess
whether the underlying condition—that is, neuromuscular (NM), skeletal
dysplasia (SD) or chronic lung disease (CLD) affected the organisms
isolated.
Methods: Sixteen children were identified from our clinical database: 10
NM, 4 SD and 2 CLD. Microbiological cultures and case records were
examined retrospectively from Nov ‘02 to Nov ‘05 and the relation
between positive isolates and exacerbations noted.
Results: 334 potentially pathogenic organisms were isolated from 509
tracheal specimens (66%); 318 bacterial, 3 fungal and 12 viral (majority
RSV or Paraflu). The NM group had 191 (57%): 185 bacterial, 2 fungal
and 4 viral. The SD group had 72 (21.5%), of which 67 were bacterial
while the CLD group had 70 (21%), 66 of which were bacterial. 36% of
the isolates were Staphylococcus aureus, 12.5% P aeruginosa, 8.8% H
influenzae, 7.2% Moraxella catarrhalis and 6.6% MRSA. 75 exacerba-
tions occurred; 40 in the NM, 24 in the SD and 11 in the CLD groups
respectively. 60 exacerbations (80%) were associated with positive
bacterial growths—usually Staph aureus. However, only 27% of
bacterial isolates were associated with exacerbations, compared to
100% of viral isolates. Differences existed between the bacterial species
in that 50% of the H influenzae isolates were associated with
exacerbations, compared to only 20% of the Staph aureus isolates.
86% of exacerbations with positive bacterial cultures received anti-
biotics. In 70% of those children the same organism was isolated again
after treatment.
Conclusions: The commonest organisms isolated were Staph aureus and
P aeruginosa. Bacterial cultures are often positive at the time of
exacerbations but this may reflect continuing bacterial airway colonisa-
tion rather than infection. In this small sample, the underlying disorder
did not appear to affect the organisms isolated. The place of routine
antibiotics in the management of exacerbations needs re-evaluation.
P123 OUTCOME OF WHEEZY INFANTS WITH ATOPIC
BACKGROUND AT EARLY SCHOOL AGE: 5 YEAR
FOLLOW UP TRIAL
A. Adams, C. Olden, P. Seddon. The Royal Alexandra Hospital for Sick
Children, Dyke Road, Brighton BN1 3JN, UK
Wheezing in infancy is common, and although the majority of wheezy
infants do not develop persisting asthma, it is important to identify
subgroups who are likely to do so to allow targeted intervention.
We followed up, at primary school age, a group of infants with
wheezing and atopic tendency who had taken part in an intervention
study (Chavasse et al. Arch Dis Child 2001;85:143–8). We assessed
their current wheezing and atopic status using items from the ISAAC
questionnaire. We measured lung function—spirometry and interrupter
resistance (Rint), exhaled nitric oxide, and bronchial reactivity using
histamine challenge. We also compared lung function at follow up with
lung function parameters measured in infancy.
Questionnaires were returned on 26 children, mean age 8 years. 19
children had been given a diagnosis of asthma at some stage, and 12
had wheezed in the last 12 months: 14 currently had a bronchodilator
inhaler and 9 were on inhaled steroid treatment. 11 had suffered from
eczema at some stage, and this was still active in 10. Six children were
reported as having hayfever.
13 children attended for testing. Mean (SD) per cent predicted for
FEV1 was 98.4% (12.4) and Rint 106.5% (32.7). Mean exhaled nitric
oxide was 13.6 (13.9) ppb. Mean (SD) PC20Histamine was 1.63 mg/ml
(2.15). One child, who was not currently on asthma treatment, had
marked airway obstruction (FEV1 66% predicted) and PC20 0.25 mg/
ml: lung function was normal after 6 weeks of low dose inhaled steroid.
Interrupter resistance at follow up correlated strongly with total
respiratory system resistance in infancy (r = 0.71).
Wheezy infants with atopic tendency (personal history or first degree
family history) are very likely to continue to have reactive airways and
respiratory symptoms at school age.
P124 TWIN PEAKS: THE CHANGING EPIDEMIOLOGY OF
COMPLICATED PNEUMONIA AND EMPYEMA IN
CHILDREN
D. A. Spencer, S. M. Iqbal, J. R. L. Hamilton, A. Hasan. Regional
Cardiothoracic Unit, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK
The increase in paediatric empyema in the UK and elsewhere over the
last 12 years has been well documented, but the rate of increase has
now accelerated.1 This process is increasingly associated with a more
severe pneumonic process involving lung necrosis and subsequent
cavitatory lung disease.2 Over the last 11 years 281 children (median
age 5.2 years M:F 1.6:1, 47.5% of patients ,5 years) have been
referred to this centre with a presumptive diagnosis of empyema. 49
(17%) patients had either solitary pneumonia or a small additional fluid
collection managed conservatively. The remaining 232 (83%) were
managed surgically. The number of patients requiring surgical manage-
ment has nearly doubled to 50/year over the last 12 months, increasing
the rate from 5.6 to 9.7/100 000 children per year. In addition, the
length of the usual winter season is lengthening with the emergence of a
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second semi-distinct spring peak over the last three years (fig). The
increase in empyema cases has been associated with emergence of S
pneumoniae serotype 1 as the dominant serotpye, but this does not fully
explain the increased incidence of cavitatory disease. It is not yet clear
whether these problems represent an increase in the effective virulence of
the organism, increased susceptibility of the host or changes in the
environment.
The Health Protection Agency has agreed to introduce enhanced
national paediatric empyema surveillance for England and Wales from
the autumn of 2006 and a similar programme will be introduced in
Scotland and Northern Ireland. All pleural fluid specimens will be subject
to a pneumococcal PCR, with positive specimens being serotyped using
the bioplex system. Clinical data will be submitted online using an
anonymised audit tool, with data being collected from every paediatric
centre within the UK. This programme will allow for more much effective
monitoring of this rapidly changing problem.
1. Spencer DA, Iqbal SM, Hasan A, et al. BMJ 2006;332:1333.
2. Ramphul N, et al. Pediatr Pulmonol 2006;41:750–3.
P125 RESPIRATORY MUSCLE PRESSURE MEASUREMENT IN
CHILDREN WITH CYSTIC FIBROSIS
D. S. Urquhart1, E. Scrase1, I. Narang1, H. Montgomery2, A. Jaffe1, on
behalf of the Xtreme Everest Research Group, University. College London.
1Portex Respiratory Medicine Unit, Institute of Child Health, London WC1N
1EH; 2Department of Cardiovascular Genetics, University College, London,
UK
Background: Skeletal muscle wasting is reported in cystic fibrosis (CF).
However, data relating to respiratory muscle strength in CF adults are
conflicting, with reports of decreased, normal or supranormal respira-
tory muscle strength, while data relating to respiratory muscle
performance in CF children are sparse.
Aims: To assess and compare non-invasive measures of respiratory
muscle pressure in children with CF.
Methods: Measures of respiratory muscle pressure were made using a
hand-held respiratory pressure meter (RPM01 MicroMedical, UK). Sniff
inspiratory pressure (SnIP), as well as mouth inspiratory (MIP) and
expiratory (MEP) pressures were measured in seated subjects. SnIP and
MIP were measured from FRC, and MEP from TLC. Nose-clips were worn
for MIP/MEP. Respiratory muscle pressures were converted to standard
deviation scores (SDS) using reference data.1 Spirometry was also
performed in all subjects and measures converted to SDS using reference
data.2
Results: Forty subjects were studied (20 male) with a mean (SD) age of
12.6 (2.4) years. FEV1 SDS ranged from 25 to +2, with a mean (SD) of
22.1 (1.7) SDS. Mean (+/22 SD) for respiratory muscle pressure SDS
were as shown in the table.
Limits of agreement for SnIP and MIP in CF were assessed by Bland-
Altman plot. (fig) Mean (10.1) and SD (24.5) of differences are similar to
those reported in healthy children.1, 3 No correlation between FEV1 SDS
and SnIP SDS (r2 =20.001), MIP SDS (r2 = 0.01), or MEP SDS
(r2 =20.01) was noted.
Discussion: Respiratory muscle pressures in children with CF are similar
to those in healthy children, as are limits of agreement for SnIP and MIP,
despite a mean FEV1 of 22.1 SDS. Preserved respiratory muscle
function in CF is suggested. This may reflect a specific training effect due
to increased work of breathing in CF.
1. Stefanutti D, Fitting JW. Am J Respir Crit Care Med 1999.
2. Rosenthal M, et al. Thorax 1993.
3. Rafferty G, et al. Pediatr Pulmonol 2000.
Mechanisms of respiratory
infection
P126 ETHICAL PLANNING FOR AN INFLUENZA PANDEMIC
H. L. Barr, J. T. Macfarlane, W. S. Lim. Nottingham University Hospitals NHS
Trust, City Hospital Campus, UK
Introduction: Pandemic influenza guidelines have recently been devel-
oped. However, there is little research into how ethically acceptable
these plans will be to society.
Methods: Two hypothetical ethical scenarios that could arise in a
pandemic were developed. The first scenario considers the attitude of
NHS staff towards professional and ethical responsibilities of health care
workers when faced with high personal risk at work. The second
scenario considers the problem of resource allocation—which patient (A,
B, or C) should get the last Intensive Care Unit (ICU) bed? (‘‘A’’—25 year
old student with severe primary viral pneumonia and multi-organ failure,
with an estimated mortality of 80%; ‘‘B’’—67 year old patient with an
influenza exacerbation of COPD with an estimated mortality of 30% and
a long term survival of 3 years; ‘‘C’’—51 year old non-European Union
private patient who developed postoperative pneumonia following a
coronary artery bypass operation with an estimated mortality of 40%).
The postal survey was distributed to 1018 staff at City Hospital Campus,
including doctors, nurses, students, and other ward staff.
Results: 403 (40%) of surveys were returned: 183 doctors, 133 nurses,
53 medical students and 34 other staff responded. Scenario 1: 84% of
staff felt is was unprofessional for a doctor or nurse to leave work in a
pandemic. 76% felt it was unethical for them to leave. 79% of responders
would stay and work during a pandemic and 17% felt there should be a
legal framework to force NHS employees to work during a pandemic.
Having children at home did not significantly alter response rates.
Scenario 2, see table. When given the choice of patient A or B only,
doctors were more likely than nurses to chose patient A (89% v 67%,
p,0.001).
Discussion: The General Medical Council states: ‘‘you must not refuse to
treat a patient because you may be putting your self at risk … you should
take reasonable steps to protect yourself.’’ In accordance with this, most
staff surveyed felt they should (professionally) and would (voluntarily)
work during a pandemic despite high personal risk. A quarter felt it was
ethical to leave work while 17% felt there should be legal powers to
enforce working. An even wider difference of opinion regarding
resource allocation was noted. These ethical issues will arise multiple
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Abstract P125 Bland and Altman plot of SnIP versus MIP in CF
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times during a pandemic. They therefore deserve attention as an integral
part of pandemic planning.
P127 MANAGEMENT OF COMMUNITY ACQUIRED
PNEUMONIA: ARE WE FOLLOWING THE BTS 2004
CAP GUIDELINES UPDATE?
R. Nadama, D. Smith. Frenchay Hospital, Frenchay Park Road, Bristol BS16
1LE, UK
Introduction: Community acquired pneumonia (CAP) is associated with
significant morbidity, mortality, and use of health service resources. BTS
2004 update CAP guidelines CURB-65 score (6-point score, one point
for each of confusion, urea .7 mmol/l, respiratory rate >30/min, low
systolic (,90 mmHg) or diastolic ( 60 mmHg) blood pressure, age
>65 years) is valuable in defining severity and identifying patients that
may be suitable for home or outpatient management. Certain features on
discharge are associated with adverse clinical outcomes. The 2004
guidelines1 state that patients should be reviewed within 24 hours of
planned discharge home and those suitable for discharge should not
have more than one of the following characteristics present. These
clinical ‘‘instabilities’’ include temperature .37.8 C˚, heart rate .100/
min, respiratory rate .24/min, systolic blood pressure ,90 mmHg,
oxygen saturation,90%, inability to maintain oral intake and abnormal
mental status. The aim of this audit was to assess whether the BTS
guidelines are followed with regards severity assessment and discharge
planning.
Method: All patients admitted between 11/10/2004 to 22/12/2004
under the emergency adult medical take to Frenchay Hospital Bristol
which serves a population of about 200 000. Data were prospectively
collected and included demographic variables, clinical features, and
clinical and laboratory parameters. All patients who fulfilled BTS
definition of CAP were included
Results: Thirty one admissions were diagnosed with CAP with 64% were
above the age of 65. Average length of hospital stay was 11.67 days.
58% were admitted to a respiratory ward. 32% had no form of
respiratory specialist input, 1 patient was admitted to intensive care. The
CURB 65 score was not recorded on all admissions; it was not
computable on the admission clerking in 35.4%. 35.4% were suitable to
be considered for home treatment. 16% were suitable to be considered
for short inpatient stay (SIPS) treatment or hospital supervised outpatient
treatment. The mortality rate was 19%. Microbiological test requested
did not correlate with severity of CAP. Discharge planning: no patients
had more than 1 instability within 24 hours of discharge, though these
were identified from the observation charts, medical, and nursing notes.
Conclusion: Improvements are required in severity assessments for CAP
and the documentation of the CURB 65 score in the admission notes—
this requires educating the junior doctors. 35.4% were suitable for home
treatment and 16% for SIPS or hospital supervised outpatient treatment
which would have saved unnecessary hospital bed days occupancy.
Admitting the patients to respiratory wards or involving the respiratory
teams in their care will improve management.
1. Macfarlane J, et al. BTS guidelines for the management of CAP in
adults 2004 update. Available at http://www.brit-thoracic.org.uk/
c2/uploads/MACAPrevisedApr04.pdf (accessed September 2006).
P128 POSITIVE MICROBIOLOGY IS MORE FREQUENT IN
PATIENTS WITH SEVERE COMMUNITY ACQUIRED
PNEUMONIA
J. Chalmers, A. Singanayagam, A. Hill. Department of Respiratory Medicine,
Royal Infirmary of Edinburgh, Edinburgh, UK
Introduction: British Thoracic Society guidelines recommend initial
microbiology investigations such as sputum and blood cultures in all
patients with severe community acquired pneumonia (CAP) and in
patients with non-severe CAP who have not received prior antibiotic
therapy. The aim of the study was to investigate if the likelihood of either
a positive sputum or blood culture was linked to the severity of CAP.
Methods: We studied 84 adult patients admitted to the Royal Infirmary of
Edinburgh with CAP between December 2005 and June 2006 that had
sputum and/or blood cultures within 48 hours of admission and had not
received prior antibiotic therapy (within 7 days). The severity of
pneumonia was assessed using both the CURB score (new mental
confusion, urea.7 mmol/l, respiratory rate>30/minute, systolic blood
pressure ,90 mmHg, and/or diastolic blood pressure (60 mmHg)
and C reactive protein (CRP, recently identified as an independent
marker of severity of CAP). The Mann-Whitney U test was used to
analyse data and a p value less than 0.05 (two- tailed) was considered
as statistically significant.
Results: There were 74 and 52 patients that had sputum and blood
cultures sent respectively. Positive microbiology is more frequent in
patients with severe CAP (table).
Conclusion: Positive microbiology is more likely in patients with severe
CAP.
P129 AN AUDIT OF THE USE OF NEBULISED 7%
HYPERTONIC SALINE TO TREAT PATIENTS WITH
BRONCHIECTASIS OR MUCUS HYPERSECRETION
C. Allen, F. Kellett, C. Prys-Picard, R. Niven. North West Lung Research
Centre, Manchester, UK
Introduction: The short term benefit of mucus clearance with nebulised
7% hypertonic saline (HS) in bronchiectasis (BTS) has been recently
demonstrated.1 We aimed to determine whether initial improvements
were sustained with prolonged treatment and whether this was limited to
patients with CT confirmed BTS or extended to include patients with
mucus hypersecretion (MH) only.
Methods: A retrospective audit of case notes of patients treated with
hypertonic saline over a period of eight years was performed. Patients
were classified as having either BTS (from CT findings) or MH (defined
from clinical presentation and absence of CT evidence of BTS). Lung
function data were collected at baseline, prior to initiating therapy, at
3 months after starting therapy and at the most recent point whilst still
receiving treatment. Subjects who did not tolerate HS therapy and
received it for less than four months were excluded.
Results: 169 suitable patients were identified of whom case note records
were available for 125. Eight patients did not tolerate HS therapy and
were excluded from subsequent analysis. 70 of the remaining 117
patients (59.8%) had BTS on CT. 24/117 (20.5%) subjects had non-BTS
MH. There were inadequate or absent records to classify 23/117
(19.7%). The mean duration of treatment and follow up was
20.7 months. In the BTS group the mean (95% CI) FEV1 rose by 7.8%
from 1.91 l (1.73–2.09) to 2.06 l (1.85–2.27) at 3 months and by 14%
from baseline to 2.18 l (1.95–2.42) at the most recent assessment. In the
MH group the mean FEV1 rose by 37% from 1.62 l (1.30–1.99) to
Abstract P126 Number of responses: ‘‘who should get the
last ICU bed: A, B, or C?’’
Answer n (%)
A 218 (54)
B 48 (12)
C 135 (33)
Unsure 2 (1)
Abstract P128 Median (IQR) CURB and CRP levels in patients with positive and negative
sputum and blood cultures (comparisons are made between patients with positive and
negative cultures. *p,0.05 and **p,0.01)
Cultures
Number CURB median (IQR) CRP (mg/l) median (IQR)
+ve 2ve +ve 2ve +ve 2ve
Sputum culture 23 51 1.5 * (1–2) 1 (0–1) 148* (62–261) 68 (36–144)
Blood culture 10 42 3** (2–3) 2 (1–2) 344** (256–447) 98 (36–216)
Total cultures 33 93 2* (1–2) 1 (1–2) 196** (100–323) 88 (36–197)
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2.22 l (1.88–2.63) at 3 months and by 39.5% from baseline to 2.26 l
(1.88–2.63) at the most recent assessment.
Discussion: Patients in the BTS group showed a gradual and progressive
improvement in lung function. Patients in the MH showed a rapid and
significant improvement in lung function after 3 months of treatment,
which did not significantly improve after this but was sustained. The
previously reported benefit of nebulised HS therapy has been shown to
be maintained with prolonged treatment and there may continue to be
additional improvement. Treatment with HS in patients with non-BTS MH
shows a rapid and large increase in FEV1 that is sustained with
prolonged treatment.
1. Kellett F, Redfern J, Niven R. Evaluation of nebulised hypertonic
saline (7%) as an adjunct to physiotherapy in patients with stable
Bronchiectasis. Respir Med 2005;99:27–31.
P130 ANAEROBIC BACTERIA IN ADULT NON-CYSTIC
FIBROSIS BRONCHIECTASIS
A. L. Sullivan, E. Sapey, P. Bharadwa, R. Carrick, R. A. Stockley. Lung
Investigation Unit, 1st Floor Nuffield House, Queen Elizabeth Hospital,
Birmingham B15 2TH, UK
Introduction: Pathogenic bacteria are believed to be important in the
disease mechanism in bronchiectasis, contributing to inflammation and
impairing the patient’s quality of life. A number of patients in our
bronchiectasis clinic have anaerobic bacterial infection, but there is very
little information about the implications of these pathogens, whether they
should be specifically targeted with antimicrobials and what the best
protocol for treatment might be.
Methods: In our bronchiectasis clinic we performed quantitative
bacterial culture routinely on all spontaneous sputum specimens over a
6 month period for aerobic and anaerobic bacteria to assess the
incidence and potential patterns of colonisation. We performed a
smaller cross sectional study in which sputum results were analysed with
clinical information concerning the nature and severity of the disease,
current antibiotic usage and measures of inflammation in sputum and
blood.
Results: In total, 94 patients provided 161 sputum specimens. 71
specimens from 53 patients grew anaerobic organisms. Sputum
purulence did not predict the presence of anaerobes. B melaninogenicus
and Gram negative rods comprised the majority of anaerobic isolates.
43 patients provided more than one sample. Of these, 18 patients were
always negative, 8 always positive, and 17 had variable results. The
mean anaerobic bacterial load (although high) was lower than the mean
aerobic bacterial load (1.3E+07 and 1.8E+09 cfu/ml respectively,
p,0.001). There was a negative association with the presence of
pseudomonas species (p,0.05). 52 patients were recruited into the
cross sectional study. Patients with anaerobes had fewer lobes affected
on CT scan (p,0.01), higher TLCO % predicted (p,0.01) and lower
sputum neutrophil count (p,0.05). Patients colonised with pseudomonas
species had worse TLCO % predicted, dyspnoea score and higher
systemic and sputum inflammation than those without. Examination of
sputum quality by squamous cell contamination suggested that oral
contamination did not influence the results.
Conclusions: (1) Anaerobic bacteria are present in many patients with
bronchiectasis but they are not associated with worse disease. (2) The
presence of pseudomonas appears to reduce the likelihood of isolation
of anaerobic bacteria. (3) The importance of anaerobic infection in
bronchiectasis may relate mostly to b-lactamase production which may
reduce the efficacy of b-lactam antibiotics against aerobic co-pathogens
in vivo. Several patients regularly cultured anaerobes at high bacterial
load and without coexisting aerobic infection, suggesting they require
treatment in their own right. Better information is required to guide
management in these cases. Spontaneous sputum would be satisfactory
for use in a clinical trial to investigate this issue, provided appropriate
care was taken in sample collection, selection, and handling.
P131 IS SPUTUM LOAD A USEFUL OUTCOME MEASURE FOR
CLINICAL TRIALS IN BRONCHIECTASIS?
F. Moran1, J. S. Elborn2, K. Moffitt2, A. Piper3, J. M. Bradley1,2. 1University
of Ulster, N Ireland; 2Belfast City Hospital, N Ireland; 3University of Sydney,
Australia
Introduction: Controversy surrounds the use of sputum load as an
outcome measure in clinical trials examining the efficacy of airways
clearance methods. Contamination with saliva, swallowing of secretions
and reluctance to expectorate have been cited as limitations. Dry weight
of sputum overcomes some of these issues and may more accurately
reflect treatment related changes in tracheobronchial secretions. Dry
weight is however more difficult to determine as it requires an oven and
can take up to 24 hours to complete. The aim of this study was to
determine the relationship between wet and dry weight sputum and its
sensitivity to change.
Methods: Twenty patients (11 M) with moderate to severe bronchiectasis
(admission FEV1% predicted 37.75 (10.93)) requiring hospitalisation
and intravenous antibiotics for an acute exacerbation were recruited.
Sputum was collected during physiotherapy airways clearance sessions
on the first and final day of admission. Expectorated sputum was
collected in preweighed cups which were reweighed immediately after
collection on Sartorius scales with 0.01% accuracy. The samples were
then incubated in an oven at 65 C˚ and routinely weighed until weight
loss had stabilised.
Analysis: SPSS version 11.5. Pearson’s r and paired t test.
Results: There was a strong correlation in wet to dry weight (g) sputum
first day (r = 0.951; p = 0.01) and final day (r = 0.973; p = 0.01); dry
weight to water content (g) first day (r = 0.945; p = 0.01); final day
(r = 0.96; p = 0.01). There was no significant difference in the
percentage dry/wet weight between first day and final day (mean
(95%CI)) 1.95 (22.79 to 6.69) (p = 0.399). There was no significant
change from first day to final day in FEV1% predicted 22.45 (25.95 to
1.05) (p = 0.160). There was a significant change from first day to final
day in inflammatory markers: WCC(6109/l) 1.65 (0.46 to 2.84)
(p = 0.009) and CRP(mmol/l) 26.14(1.40 to 50.87) (p = 0.039). Two
patients were unproductive on the final day. There was no significant
change between first and final day: wet weight sputum (g) 1.35 (23.95
to 6.65) (p = 0.599); dry weight (g) 0.07 (20.23 to 0.38) (p = 0.625); or
water content (g) 0.63 (24.88 to 6.14) (p = 0.812) (n = 18) in the
airways clearance session. However, there was a significant decrease in
24 hour wet weight sputum (g) between first and final day 8.73 (0.41 to
17.05) (p = 0.004).
Conclusion: During an acute exacerbation there was a strong correlation
between wet and dry weight sputum. There is no significant difference in
sputum weight expectorated between first and final day airways
clearance sessions. In contract there was a significant change in 24
hour sputum weight. Sputum weight maybe a useful outcome measure
for clinical trials in bronchiectasis. Dry weight has no advantage over
wet weight.
P132 LYMPHOPENIA AND ITS RELATION TO FUNGAL
INFECTION, LENGHT OF STAY, AND MORTALITY IN
THE CRITICALLY ILL PATIENTS
S. Devenny1, M. Ghrew2. 1Medical Student, Manchester University, UK;
2Hope Hospital, Salford, UK
Introduction: Lymphopenia is a well known complication of critical
illnesses especially severe sepsis and multi-organ failure. It is attributed
to increased lymphocyte loss both through caspase mediated and
mitochondrial dependent apoptosis. Similar loss of lymphocytes may
occur in critically ill patients with other disorders. There is a well known
correlation between the severity of illness and incidence of lymphopenia.
We conducted a retrospective observational study to determine whether
there was any association between lymphopenia and length of stay,
mortality and incidence of fungal infection in the critically ill patient.
Method: Clinical records of 342 critically ill patients admitted to a 16
bedded adult ICU from 1 November 2005 to 30 April 2006 were
studied (fig 1). Information regarding lymphopenia duration and
severity, diagnosis of fungal infection and colonization, ICU length of
stay and 28 days mortality were recorded for each patient. Chi-square
and Mann-Whitney U tests were used to analyse the data.
Results: 210 (63%) patients had lymphopenia (,1.06109) during their
stay on ICU; 24 (12%) suffered from severe lymphopenia (,0.56109).
101 (48%) from prolonged lymphopenia (3–14 days), and 15 (7%) had
prolonged severe lymphopenia. 55 (26.2%) lymphopenic patients had
either fungal colonisation or infection whilst on ICU, this was statistically
different compared with the control group (8.1%). P value ,0.0001.
102 (49%) of the lymphopenic patients had a long stay in ICU
(>10 days). The median length of stay was 9 days for patients with
lymphopenia, 2 days for the control group, p value,0.0001. Of the
210 lymphopenic patients, 55 (26%) patients died within 28 days of ICU
admission. This was not statistically different compared with the control
group (25.8%) (fig 2).
Conclusion: This study demonstrates that lymphopenia in critically ill
patients is associated with increased incidence of fungal colonisation
and infection and increased length of stay in ICU. Whether this was a
cause effect relationship or simply was a surrogate marker of severity of
illness is not clear. There was no significant association between
lymphopenia and mortality, although, a tendency for increased mortality
was observed in the subgroup with severe lymphopenia.
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P133 NECROTISING PNEUMONIA DUE TO PANTON-
VALENTINE LEUKOCIDIN PRODUCING
STAPHYLOCOCCUS AUREUS TREATED WITH
INTRAVENOUS IMMUNOGLOBULIN
N. J. Bell, J. W. Dodd, B. D. Patel, M. S. Morgan. Royal Devon & Exeter
Hospital, Devon, UK
A 30 year old female was admitted following five days of influenza-like
illness with breathlessness, productive cough, haemoptysis, and pleuritic
chest pain despite 24 hours of oral amoxicillin. She had a 10-pack year
smoking history but no history of lung disease, risk factors for infection or
immune compromise. She was normotensive, temperature 38.2 C˚, with
tachycardia, tachypnoea, and coarse crepitations on the right side of the
chest. paO2 was 9.6 on 60% O2. Chest x ray (CXR) showed bilateral
alveolar shadowing. Renal function, electrolytes and liver function were
normal. CURB score was 1. On clinical microbiology review, these
features in a previously healthy young patient together with leucopenia
(WBC 1.9, neutrophils 1.3) and a C reactive protein of 520 and
suggested Panton-Valentine Leukocidin (PVL) associated staphylococcal
pneumonia. PVL is an extracellular toxin produced by some
Staphylococcus aureus isolates and is associated with soft tissue
infections and severe necrotising pneumonia. Initial therapy with
intravenous flucloxacillin and levofloxacin was changed to linezolid,
rifampicin, clindamycin, and imipenem. Rapid deterioration with
increased respiratory rate and hypotension led to intensive care unit
(ICU) admission, intubation, and inotropes. Microscopy of bloody
sputum and endotracheal secretions showed sheets of staphylococci and
a paucity of leucocytes—typical for PVL infection. The deterioration
continued, despite all measures, for the next 4 hours, until 2 g/kg
intravenous immunoglobulin (IVIG) was administered with what seemed
to be a dramatic effect: within 24 hours of admission to the ICU,
oxygenation began to improve and inotrope requirements fell; by day 4
she was no longer inotrope dependent. Cultures revealed S aureus, later
proven PVL positive, and treatment switched to flucloxacillin and
clindamycin. However, on day 5 a rapid deterioration in ventilation,
urine output, and blood pressure occurred, CXR consistent with abscess
formation at the right hilum. Bronchoscopy showed generalised
inflammation only. Linezolid was restarted with fusidic acid. The patient
continued to deteriorate and died on day 6. Postmortem showed
completely necrotic, haemorrhagic lungs, due to the inexorable necrosis
caused by PVL toxin already excreted by the sheets of staphylococci
present in the lung tissue before antimicrobial treatment, and not
neutralised by IVIG.
Conclusion: We believe that this was the first clinical use of IVIG in PVL
disease. The UK’s Chief Medical Officer recently highlighted a guidance
document on PVL disease issued by the Health Protection Agency. This
case underlines the importance of recognising the classical presentation
of PVL-Staphylococcus aureus pneumonia in healthy young people with
an influenza-like prodrome, tachycardia, hypotension, haemoptysis,
and leucopenia, and is a reminder that CURB scoring may underestimate
the severity of disease in young people.
P134 A 12 MONTH REVIEW OF RESPIRATORY
COMPLICATIONS OF HAEMATOLOGY INPATIENTS
S. J. Cooper, J. S. Brown. University College London Hospital
Patients with haematological problems frequently develop lung compli-
cations, the management of which is often challenging. At our teaching
hospital, we have established a consultant led service to advise on
haematology patients with respiratory complications and set protocols
for advising bronchoscopy. We present the clinical characteristics of
12 months of referrals to this service. A total of 53 referrals were
received, comprising 37 patients. The median age was 54 years of age
(range 15–77), and 54% of patients were male. The underlying disease
was leukaemia in 48%, lymphoma in 30%, and myeloma in 14%. 43% of
patients had had a bone marrow transplant, and 40% of referrals were
associated with recent significant neutropenia. The common clinical
presentations were fever (57%), dyspnoea (60%), and cough (36%). The
common radiological presentations were consolidation (30%), ground
glass shadowing (19%), pulmonary nodules (15%), pleural effusions
(13%), and ‘‘tree and bud’’ changes (6%). 28% of patients underwent a
fibre optic bronchoscopy. Positive microbiological data were obtained in
54% of episodes and from the respiratory tract in 26% (sputum 11%, BAL
11% and nasopharyngeal aspirate in 4%). Gram negative bacteria were
the dominant pathogens isolated, identified in 32% of episodes
(Pseudomonas aeruginosa and Klebsiella species 9% each, Escherichia
coli in 8%). Gram positive bacteria were identified in 9% of episodes,
viruses in 8% and fungi in 4%. The commonest diagnosis was bacterial
pneumonia (28%). Other common conditions were fluid overload (9%),
invasive filamentous fungal infections, non-specific pneumonitis, viral
bronchiolitis, bronchiolitis obliterans (6% of referrals each), bacterial
lung abscess, candidiasis, and metastatic bacterial nodules (4% each).
Mortality was high, with 34% of patients dying within the study period
including all three patients admitted due to exacerbations of bronchiolitis
obliterans. These data show that although haematology patients are
affected by a wide range of respiratory complications by far the
commonest problem encountered is bacterial pneumonia. Fluid overload
is also common. In addition, by targeting bronchoscopy to specific
presentations a microbiological diagnosis can be obtained in 40% of
patients.
P135 DOES VISUALISATION OF THE BRONCHIAL TREE ADD
VALUE WHEN INVESTIGATING POSSIBLE LUNG
INFECTION?
E. K. Sage1, A. MacDonald1, C. H. C. Twort1, M. C. I. Lipman2,
R. A. M. Breen1. 1Department of Respiratory Medicine, St Thomas’ Hospital,
London; 2Department of Thoracic Medicine, Royal Free Hospital, London, UK
Background: Fibre optic bronchoscopy (FOB) is commonly used to
investigate possible lung infection. However it is expensive, requires
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considerable staff training and equipment maintenance; and because of
its invasive nature, is often tolerated only after sedation. Sputum
induction with nebulised saline is a non-invasive and cheaper alternative
to FOB. Its diagnostic yield in possible infection is similar to FOB.
However it does not allow visualisation of the bronchial tree or ‘‘site
specific’’ sampling at areas of radiographic abnormality. We hypothe-
sised that observed abnormalities at FOB performed for diagnosis of
possible infection are in fact rare in clinical practice.
Method: Consecutive FOBs performed between 01/2005 and 06/2006
were analysed. Cases where the indication was possible lung infection
were identified. Bronchoscopic findings were obtained from a standard
report form. Laboratory results and demographic data were obtained
from the hospitals’ computer systems.
Results: Four hundred and twenty six FOBs were performed of which
113 (27%) were for possible infection. These 113 individuals had a
median age of 47 years (range 16–86). 23/113 (20%) were HIV-
infected, 20 (18%) HIV-uninfected and 70 (62%) had unknown HIV sero-
status. Specific infectious agents were demonstrated in 42/113 (37%). In
these, the final diagnoses were: 28/42 (67%) tuberculosis (TB); 6/42
(14%) pneumocystis pneumonia; 4/42 (10%) non-tuberculous myco-
bacteria; 4/42 (10%) aspergillus. Sputum was produced by 15/28
(54%) of TB cases before FOB. All had a negative smear for acid fast
bacilli (AFB) but in 13/15 (87%) TB was subsequently cultured. AFB
smear of bronchoscopic samples were positive in 6/15 (40%).
Bronchoscopic abnormalities were visualised in 12/42 (29%) of cases
diagnosed with infection. In all cases the abnormality noted was either
excessive secretions or inflamed mucosa and these findings did not add
to the diagnosis. In 15/71 (21%) of cases not diagnosed with infection,
bronchoscopic abnormalities were visualised. In 4 subjects this aided
diagnosis: 1/4 foreign body observed; 2/4 abnormal mucosa
diagnosed as sarcoidosis on biopsy; 1/4 squamous metaplasia on
biopsy. Therefore in total 4/113 (4%) had a visualised abnormality that
enhanced diagnosis.
Conclusions: From our data we conclude that in cases of suspected lung
infection visualisation of the bronchial tree by FOB rarely assisted with
final diagnosis. We suggest therefore that non-invasive sputum induction
may provide the same diagnostic information as FOB, but at a lesser cost
and with greater patient acceptability.
P136 DEVELOPMENT OF AN IN VITRO MODEL TO
INVESTIGATE THE EFFECT OF GLUCOSE ON THE
INTERACTION BETWEEN RESPIRATORY EPITHELIA
AND BACTERIAL PATHOGENS
A. L. Brennan1, D. L. Baines2, A. Woollhead2, J. Lindsay3, M. Hayes3,
B. J. Philips1, E. H. Baker1,2. 1Cardiac and Vascular Sciences; 2Basic Medical
Sciences; 3Cellular and Molecular Medicine, St George’s University of
London, London, UK
Background: Glucose concentrations are 12.5 times lower in normal
human lung liquid than in plasma (Brennan et al. Thorax 2005;60:ii93)
but are elevated in patients with hyperglycaemia or lung inflammation.
Ventilated patients on intensive care with elevated lung liquid glucose
concentrations were more likely to acquire respiratory Staphylococcus
aureus infection than those with normal lung liquid glucose (Philips et al.
Thorax 2005;60:761–4). The aim of the study was to develop an in vitro
model to investigate the effect of different glucose concentrations on the
interaction between respiratory epithelium and S aureus.
Methods: Immortalised respiratory epithelial cells (H441 cells) grown in
RPMI (10 mM glucose) were incubated for 2 hours in RPMI with 1, 2.5,
5, or 10 mM glucose, then infected with 106 CFU wild type S aureus
(strain 8325–4). Infected and uninfected monolayers were compared
after a further 24 hours for confluence using phase contrast microscopy
and cell numbers following trypsinisation and trypan blue staining. In
supernatant cytokines were measured using a luminex system (Biorad)
and S aureus numbers were determined by Miles & Misra.
Results: We report preliminary results obtained during model develop-
ment (uninfected controls n = 1, infected monolayers n = 2). After culture
in 1 and 2.5 mM, but not 5 and 10 mM glucose, infected monolayers
were less confluent than controls. Total epithelial cell count/well
appeared lower in infected monolayers (IM) than in controls (CM) at
1 mM (IM 4, CM 53) and 2.5 mM (IM 59, CM 116), but not at 5 mM
(IM 113, CM 128) or 10 mM (IM 93, CM 88). However at 10 mM
glucose 25% cells in infected monolayers were dead, compared to 1% of
cells in control monolayers. Prior to infection, cell supernatant contained
IL-8 (19 116 (4299) pg/ml) and IL-6 (71 (8) pg/ml) (n = 12). In controls
IL-8 decreased (211 212 (2721) pg/ml) and IL-6 was unchanged after
24 hr culture, irrespective of glucose concentration. In infected
monolayers IL-8 increased at 5 and 10 mM glucose (+14 661
(4090) pg/ml (n = 4), but decreased at 1 and 2.5 mM glucose
(216 727 (5349) pg/ml, n = 4) (p = 0.029). By contrast infection
increased IL-6 in supernatant more at 1 and 2.5 mM glucose (+477
(124) pg/ml) than at higher glucose concentrations (+58 (69) pg/ml)
(p = 0.029). Supernatant bacterial counts were 5.66105 prior to
incubation and: 1 mM 1.56106; 2.5 mM 4.56104; 5 mM 6.26103;
10 mM 5.76102 mM after 24 hours. At 10 mM glucose large numbers
of S aureus were seen attached to the monolayer.
Conclusions: We have demonstrated co-culture of respiratory epithelial
cells and S aureus at different glucose concentrations. Preliminary studies
indicate that the epithelial-bacterial interaction is altered at different
glucose concentrations. Further experiments are now warranted to
extend this study.
P137 ACQUISITION OF PENICILLIN RESISTANCE BY CELL
WALL DEFECTIVE BACTERIA
S. Mhannee1, P. Cook1,3, T. Fawcett2. 1University Hospital N Durham;
2Durham University; 3Newcastle University, UK
Introduction: We have previously shown that transient cell wall defective
(CWD) variants of Staphylococcus aureus, induced by passaging on a
medium with high osmolality (CWD medium) in the presence of sub-
lethal concentrations of penicillin, remain resistant to penicillin after
reverting to a cell wall competent (CWC) form. The CWC progeny are
meticillin-resistant, mecA- and beta-lactamase-negative, and have no
mutations in penicillin-binding proteins (Fuller et al. Antimcrob Agents
Chemother 2005;49:5075–80). Here we aim to determine the kinetics of
the penicillin resistance and whether it is constitutive or inducible.
Methods: S aureus ATCC 9144 cells (wild type) were grown in high
osmolality (modified brain-heart infusion) or control (Lauria-Bertani)
broth, with and without benzyl penicillin at subminimum inhibitory
concentrations (MIC). CWD bacteria were indicated by the presence of
Gram negative cells on a conventional Gram stain and sensitivity to
penicillin G was determined using E-test strips. S aureus cells (wild type)
were passaged 10 times in progressively higher penicillin concentra-
tions, causing the proportion of Gram negative (CWD) cells to increase
to 100%. The nature of resistance was tested by following growth of
CWC cells after the addition of sub-MIC levels of penicillin.
Results: In both media S aureus remained Gram-positive without
penicillin, but became Gram-negative (CWD) in benzyl penicillin at
sub-MIC concentrations. The yield of CWD cells was much greater in the
high osmolality medium. On serial passaging with increasing concen-
trations of benzyl penicillin, recovery of CWD cells was consistently
maximal in the 4th and 10th transfers but fell in the 5th and 6th transfers.
The fall in yield of CWD cells coincided with a steep increase in MIC from
0?25 mg/l to 32 mg/l. Maximum MIC obtained was (96 mg/l). CWD
cells yielded by addition of sub-MIC levels of penicillin to CWC that had
been growing without antibiotic caused a lag period and reductions in
growth rate and saturation density, suggesting that the penicillin
resistance requires gene induction and cell adaptation.
Conclusions: The presence of penicillin G in the medium was found to be
important for the formation of CWD cells which increased dramatically
in the CWD medium, which has an elevated osmolality. Penicillin
resistance is acquired in a stepwise rather than a linear fashion and
correlates with a change in the Gram staining reaction of a large
proportion of the cells in the population. In penicillin-free media CWD
cells are unstable; reverting rapidly to a CWC form that still has penicillin
resistance. In this way, we propose that low dose and intermittent
administration of penicillins may result in a stable form of meticillin-
resistant S aureus that is mecA- and beta-lactamase-negative and has no
mutations in penicillin-binding proteins.
Lung cancer: diagnostic procedures
P138 INTEROBSERVER VARIATION AND THE EFFECT OF
EXPERIENCE IN THE DIAGNOSIS OF LUNG CANCER
WITH A VIDEOBRONCHOSCOPE/
AUTOFLUORESCENCE SYSTEM
E. Cetti1, A. U. Wells1, A. G. Nicholson1, S. Singh2, P. Shah1. 1Royal
Brompton Hospital, UK; 2Chelsea & Westminster Hospital, UK
Introduction: Autofluorescence (AF) bronchoscopes have been devel-
oped to improve bronchoscopy as a tool for the diagnosis of lung cancer
and pre-invasive lesions. The benefit of an AF system separate to the new
videobronchoscopes has not been tested previously. Previous studies
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have examined the use of the white light (WL) mode followed by the AF
mode and not each mode separately (Chiyo et al Lung Cancer
2005;48:307–13). Also, the interobserver variation for the two modes
has not previously been examined. We assessed the separate use of
each mode of a new AF system (Olympus Tokyo) by multiple
bronchoscopists.
Methods: Forty two patients having a diagnostic bronchoscopy for
possible lung cancer were studied. At each procedure the endobronchial
tree was examined under both WL and AF with, prior to biopsy, the on-
screen images systematically saved to disc. Any abnormal areas seen
under either mode were then biopsied as well as 2 normal (control)
areas. The 129 saved images (WL and AF) of the biopsied areas were
placed in a random order and then shown to 10 bronchoscopists, 5
experienced and 5 inexperienced (,500 procedures). They graded the
mucosa shown in each image for abnormality. Their diagnostic
performance was assessed against the histological ‘‘gold standard’’
with sensitivity, specificity, positive predictive value (PPV), negative
predictive value (NPV) and accuracy all calculated. Interobserver
variation was assessed with weighted kappa values (k).
Results: Both bronchoscopy modes performed well with mean sensitiv-
ity/specificity being 83%/75% for WL and 87%/79% for AF. The level of
operator experience did not have a significant effect on these measures.
The experienced bronchoscopists were, however, significantly better at
the WL mode than the AF mode: specificity 79% v 66% (p = 0.043), PPV
60% v 46% (p = 0.049), accuracy 80% v 71% (p = 0.043) (two-sample t
test). This was different for the inexperienced operators: they were better
with the AF mode: NPV 95% v 91% (p = 0.042). Overall there was
substantial interobserver agreement but this was significantly better for
the WL mode than the AF mode: k 0.70 v 0.57 (p = 0.0086) for the
experienced bronchoscopists and k 0.72 v 0.64 (p = 0.015) for the
inexperienced.
Conclusion: The impressive performance of the WL mode and lack of
added benefit from AF for experienced operators probably reflects the
clarity of the images provided by the new videoscopes. The AF mode did
however improve the ability of less experienced operators to correctly
identify normal mucosa, potentially a useful role. It is reassuring that
interobserver variation was low and compares favourably with many
routinely used diagnostic tests. This model for assessing a new
bronchoscopic diagnostic technique worked well and could be used
again.
P139 UTILITY OF ENDOBRONCHIAL ULTRASOUND (EBUS):
A COMPARATIVE STUDY BETWEEN CONVENTIONAL
TRANSBRONCHIAL NODAL ASPIRATION (TBNA) AND
EBUS GUIDED TBNA
M. Munavvar, V. Gupta, V. Patel, J. Edwards, J. Mills. Lancashire Teaching
Hospitals, Preston, UK
Introduction: Treatment options for lung cancer critically depend on
tissue diagnosis and staging. Methods of sampling mediastinal lymph
nodes and masses include transbronchial nodal aspiration (TBNA), a
well established bronchoscopic technique. TBNA is relatively safe but
underused with only one third of chest physicians performing the
procedure (Munavvar M et al. Survey of the Practice of Interventional
Bronchoscopy in the UK. Thorax 2004;59(Suppl II):76). It is a ‘‘blind’’
procedure and therefore diagnostic yield varies between 15% and 83%,
a problem addressed by using real time imaging with endobronchial
ultrasound (EBUS) guided TBNA. The Olympus Optical Corporation,
Tokyo, developed a specially designed curved linear array broncho-
scope with a transducer at the tip and a prototype version has been used
with excellent results (Yasufuku K, et al. Chest 2004;126:122–8; Rintoul
RC, et al. Eur Res J 2005;25:416–21). The aim of this prospective study
was to evaluate the initial impact of EBUS on diagnosing and staging
mediastinal tumours at Lancashire Teaching Hospitals.
Methods: The equipment was purchased in April 2006, with the service
up and running in May 2006. In this study, we compared the diagnostic
yield of all EBUS guided TBNA procedures performed by a single
operator (MM) between May 2006 and July 2006 with data from
conventional TBNA of corresponding nodes. A total of 8 patients and 9
nodes were sampled using EBUS and 12 patients and nodes using blind
TBNA. Cases were selected based on CT appearances. Subcarinal
nodes were excluded from the study.
Results: Diagnostic yield improved from 46.2% with blind TBNA to
88.9% with EBUS. Six males and 6 females were sampled with blind
TBNA, age range 56–83 (mean 70.5). EBUS was used to sample 5 male
and 3 female patients, age range 45–81 (mean 66.4). No significant
complications were recorded.
Conclusions: EBUS guided TBNA is a novel way to diagnose and stage
lung cancers allowing a more rapid and accurate diagnosis as it is
carried out at the initial bronchoscopy. Difficult lesions ,1 cm in size
can be targeted, not usually accessible by conventional TBNA. Less
passes are required for cytological analysis, saving time and resources.
Mediastinoscopy can be avoided, which is more invasive, expensive,
and carries associated risks. Furthermore, some groups of nodes not
within the range of mediastinoscopy can also be sampled.
P140 EARLY EXPERIENCES OF TRANSBRONCHIAL NODE
ASPIRATION IN THE DIAGNOSIS AND STAGING OF
SUSPECTED LUNG CANCER AT WATFORD DISTRICT
GENERAL HOSPITAL
Z. Zoumot, A. Barlow, J. Singh, F. Odhiambo. Watford District General
Hospital, Vicarage Road, Hertfordshire WD18 0HB, UK
Introduction: Transbronchial fine-needle aspiration (TBNA) sensitivities
reported in the literature range between 0.50–0.76, with specificities
ranging between 0.92–1.00. The complication rate was reported as 2–
5%, including haemorrhage and pneumothorax.
Methods: 15.4% (2/13) of hospitals in our cancer network presently
offer this technique as part of their routine cancer work-up. TBNA has
been offered in our unit since October 2005. We present the results of
the first 35 patients who underwent TBNA as part of their routine
investigation for suspected lung cancer. Enlarged nodes were identified
by computerised tomography (CT) before bronchoscopy. TBNA was
attempted if the following node groups were involved on CT: right para-
tracheal, anterior carinal, sub-carinal, posterior carinal, right bronchial,
and right and left hilar. Aspiration sites were defined according to
Wang’s previously published endobronchial maps.
Results: TBNA provided a diagnosis in 89% of cases (31/35); identifying
cancer in 30 cases and excluding disease in 1 case. TBNA samples were
non-diagnostic in 11% of cases (4/35). In 7 of 18 cases when both
TBNA and standard samples (mucosal biopsies, bronchial brushings or
bronchial washings) where obtained bronchoscopically, TBNA provided
diagnostic samples when standard samples failed to. This avoided the
need for repeat invasive investigations. In 12 cases there were no
endobronchial abnormalities and no standard samples were obtained.
TBNA provided the diagnosis in all 12 cases. In total TBNA provided a
diagnosis unobtainable by conventional bronchoscopy in 54% of cases
(19/35). The diagnostic yield was higher for N2 station nodes (25/29–
86%) compared to N1 station nodes (3/5–60%). The mean short-axis
diameter of ‘‘positive’’ N2 and N1 nodes were 1.7 cm and 0.9 cm
respectively. We report 2 cases of haemorrhage (1 minor, 1 major), and
1 pneumothorax (small and treated conservatively). Total complication
rate for TBNA was 8.5% (3/35).
Conclusion: In summary in our series of patients, CT targeted TBNA from
enlarged nodes is a safe technique with a high diagnostic yield. TBNA
compliments standard biopsy techniques, in many cases is the sole
diagnostic source and offers the key benefit of confirming nodal
involvement. TBNA can be adopted safely by standard endoscopy units
without endobronchial ultrasound. Other benefits include reduced
reliance on expensive imaging and surgical procedures otherwise
required to assess nodal involvement. We recommend introduction of
selected TBNA into the routine process of investigating probable lung
cancer.
Abstract P139
R paratra L hilar R hilar Pretrach L paratra Diag yield
EBUS 4/4 POS 1/2POS 0/1POS* 1/1POS 1/1 POS 8/9 = 88.9%
Blind 3/7 POS 1/1POS 0/2POS 1/2POS 1/1 POS 6/13 = 46.2%
*Indicates a true negative result based on pathology reports and MDT discussions.
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P141 IS THERE A POTENTIAL FOR THE INCREASED USE OF
TRANSBRONCHIAL NEEDLE ASPIRATION FOR
CYTOLOGICAL DIAGNOSIS OF LUNG CANCER TO
AVOID MORE INVASIVE TESTS? A UK DISTRICT
GENERAL HOSPITAL EXPERIENCE
S. L. Tan, B. N. Chandrappa, R. Manns, H. Moudgil, K. S. Srinivasan.
Department of Respiratory Medicine, Princess Royal Hospital, Telford TF1 6TF
UK
Background: Transbronchial needle aspiration (TBNA) using flexible
bronchoscopy is a minimally invasive procedure used to obtain
histological diagnosis in patients with mediastinal lymphadenopathy.
Its diagnostic accuracy ranges from 63 to 85% (Frey, et al. Chest
2004;126:819S). Despite being a much simpler and better-tolerated
technique than mediastinoscopy, it is underutilised in the UK.
Aims: We aimed to see if TBNA would reduce the number of patients
requiring other more invasive, surgical procedures to obtain a
histological diagnosis of lung cancer and increase the number of
patients having a histological diagnosis overall.
Methods: Retrospective case note and radiological imaging review of all
patients with suspected lung cancers who were discussed at a
multidisciplinary team meeting between April to June 2006. Out of a
total number of 195 patients discussed, 40 were eligible for the study
after excluding those with positive histology from flexible bronchoscopy
and those with no mediastinal adenopathy on computed tomography
(CT) of the thorax.
Results: See table.
Conclusion: Increasing availability of TBNA in UK hospitals should help
us increase the number of patients obtaining histological diagnosis of
lung cancer and also potentially avoid more invasive and hazardous
techniques.
P142 CANCER YIELD OF PERSISTENT HAEMOPTYSIS AND
ABNORMAL CHEST X RAYS NOT INDICATIVE OF
MALIGNANCY
A. Youzguin, S. Bari, L. Sundararajan, A. F. S. A. Hasan, M. J. Walshaw,
M. J. Ledson. Liverpool Lung Cancer Unit, The Cardiothoracic Centre,
Liverpool, UK
Introduction: Although patients presenting with persistent haemoptysis
(defined as that occurring for three weeks or more) and a normal chest x
ray are known to have a low incidence of lung cancer (only 5–6%), those
with an abnormal chest x ray suggesting malignancy have a much
higher incidence (up to 71%) (Eur Resp J 2003;22(Suppl 45):8).
However, the incidence of lung cancer in those with persistent
haemoptysis and an abnormal chest x ray which is not indicative of
malignancy is unknown, but this is a group of patients who may
commonly be referred to the rapid access outpatient service of any lung
cancer unit. To investigate this further, we looked at the incidence of lung
cancer in such patients attending our large lung cancer unit.
Method: We have operated a rapid access lung cancer clinic (attracting
up to 300 patients per year) since 2000 and have kept a comprehensive
database of all referrals to date. From this, we identified those patients
who had been referred with persistent haemoptysis and an abnormal
chest x ray which did not suggest malignancy.
Results: Of 4839 patients processed, 121 (2.5%) fulfilled the above
criteria. Of these, an ultimate diagnosis of cancer was made in 53
patients (44%), of which 28 (53%) had squamous or otherwise
unspecified non-small cell carcinoma, 14 (26%) were adenocarcinoma,
6 (11%) were small cell carcinoma, 4 (8%) had a clinical diagnosis of
lung cancer, and 1 (2%) had a vocal cord squamous cell carcinoma.
Those with cancer were not more likely to be current smokers (81% v
73%, x2 = 0.96, p = NS), be older (median age 74 v 69; t = 0.099,
p = NS), or have worse spirometry (FEV1% predicted: mean 68 v 75,
t = 0.13, p = NS), but were more likely to be male (70% v 50%, x2 = 4.82,
p,0.05), and were less likely to have bilateral changes on chest x ray
(9% v 27%, x2 = 5.61, p,0.025). Only one third of the patients with lung
cancer had a normal bronchoscopy, compared with 98% of the
remainder (x2 = 55.2, p,0.001).
Conclusion: Although patients with persistent haemoptysis and a normal
chest x ray have a low risk of lung cancer, those with an abnormal chest
x ray, even if it is not suspicious of malignancy, have a high incidence of
the disease and therefore merit urgent referral to and investigation by the
lung cancer unit.
P143 HAEMOPTYSIS WITH A NORMAL CHEST
RADIOGRAPH: A 5 YEAR FOLLOW UP AFTER A
NORMAL BRONCHOSCOPY
A. K. Basran, G. Mulligan, M. Thompson, J. W. Hadfield, S. W. Crooks.
Chesterfield Royal Hospital NHS Foundation Trust, Chesterfield, Derbyshire,
UK
Introduction: Haemoptysis may be a presenting symptom of lung cancer,
even in patients with a normal/non-suspicious chest x ray. Case series
have suggested a prevalence of lung cancer between ,1% and 21% of
all patients presenting with these features. This audit set out to ascertain
the prevalence of lung cancer in our patients who presented with
haemoptysis and a normal chest x ray, and to determine whether any
who had normal investigations subsequently developed lung cancer
during a 5 year follow up, at a time when routine pre-bronchoscopy CT
scanning was not performed in our unit.
Setting: Respiratory Service in a UK District General Hospital serving a
population of 300 000.
Method: Patients presenting with haemoptysis and a normal/non-
suspicious chest radiograph from April 1998 to March 2001 were
identified using the hospital Lung Cancer Management System Database
(Unisoft). Radiographic findings were cross-checked with the hospital
radiology reporting system. Five year outcome data for lung cancer were
obtained from the hospital lung cancer multidisciplinary meeting
database. Further corroboration was obtained from our hospital general
records.
Results: Seventy three patients (median age 57 years) with haemoptysis
and a normal chest x ray underwent bronchoscopy in the 3-year period.
Fifteen were ,44 years old, 44 were aged between 45 and 69, and 14
were 70 years or more. One patient (1.4% of cohort) was diagnosed
with lung cancer (squamous cell carcinoma of the proximal right main
bronchus) as a result of the initial bronchoscopy. Over the next 5 years,
2 other patients (2.7% of cohort), whose initial investigations were
negative for lung cancer and who had been discharged from follow up,
were subsequently diagnosed with lung cancer. Case 1: 65 at first
bronchoscopy, had squamous carcinoma diagnosed 2 years later. Case
2: 70 at first bronchoscopy, had adenocarcinoma diagnosed just prior
to 5 years later.
Conclusions: Our audit findings support the practice of performing
bronchoscopy in patients with haemoptysis even should the chest x ray
not suggest lung cancer. In those whose initial bronchoscopy did not
reveal lung cancer, the incidence of subsequent lung cancer diagnoses
over the 5-year follow up period was small, and was of approximately
the same order as that expected from North Trent lung cancer incidence
data.
P144 IDENTIFYING CLINICAL AND RADIOLOGICAL
FACTORS ASSOCIATED WITH THE DEVELOPMENT OF
PNEUMOTHORAX COMPLICATING PERCUTANEOUS
CT-GUIDED LUNG BIOPSY
B. Chakrabarti1, C. McCann2, S. Amin2, A. Sailendra1, P. Jones2,
E. Thwaite2, J. E. Earis1, J. M. Curtis2, C. J. Warburton1. 1Aintree Chest
Centre, University Hospital Aintree, Liverpool, UK; 2Department of
Radiology, University Hospital Aintree, Liverpool, UK
Background: Pneumothorax (PTX) is a recognised complication of
percutaneous CT guided lung biopsy (CTLB) occurring in about 20% of
cases. This study aims to identify variables associated with the
occurrence of PTX and to estimate accuracy of predicting PTX risk
during CTLB.
Abstract P141
Total patients (n) 40
Mean age (range) 70 (51–89)
Patients with obvious parenchymal mass on CT thorax,
n (%)
31 (77.5)
Patients with mediastinal lymph nodes suitable for TBNA,
n (%)
32 (80)
Patients suitable for TBNA, but not having histological
diagnosis by any other method, n (%)
9 (28.2)
Patients suitable for TBNA, who had histological
diagnosis by more invasive methods, n (%)
8 (25)
Patients who had histological diagnosis made by CT
guided needle biopsy
10 (31.3)
Total no of patients who could have potentially had a
TNBA, avoiding other higher risk techniques and
increasing histological yield, n (%)
27 (84.5)
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Method: Patients undergoing co-axial cutting needle CTLB at University
Hospital Aintree between January 2000–03 were identified from the
radiology database. The case notes and complete imaging of 134
patients (mean age 69 years; 55% M) were available for the study. The
path taken by the cutting needle (20 G in all cases) during CTLB was
marked on each staging CT scan by an independent observer & these
scans were then reviewed independently by 2 thoracic radiologists (rad1
& 2) blinded to the clinical details and procedure related complications.
Each radiologist documented lesion and biopsy path characteristics, CT
emphysema severity score (nil-mild-mod-severe) as well as predicting
PTX risk during CTLB using a percentage Visual Analogue Scale.
Results: PTX occurred in 32 (24%; mean age 70 years) cases; 5 (16% of
this group; 3.7% total) requiring intercostal drainage. Biopsies
complicated by PTX were associated with smaller lesion size (3.29 v
4.92 cm; t test; p,0.005), greater lesion depth (mean 1.89 v 0.87 cm
rad1; 1.80 v 0.92 cm rad2; t test; p,0.005), non-adherence of lesion to
the pleural margin (x2 test; p,0.005; rad 1 & 2) and increased FEV1
(mean 2.06 v 1.73 l; t test; p,0.05). Patient age (mean 70 v 68 years; t
test; p.0.05), gender (x2 test; p.0.05), lesion location (x2 test;
p.0.05), currently smoking (x2 test; p.0.05), total pack years smoked
(mean 45 v 42 years; t test; p.0.05), emphysema score (x2 test;
p.0.05) and biopsy path crossing a major lung fissure (x2 test; p.0.05)
were not associated with increased likelihood of PTX during CTLB. In
those PTX requiring drainage, a trend to reduced FEV1 (mean 1.68 v
2.13 l; t test; p = 0.1), smaller lesion size (mean 2.3 v 3.48 cm; x2 test;
p = 0.1) and increased lesion depth (rad1: mean 3 v 1.69 cm, p = 0.09;
rad2: 2.9 v 1.59 cm, p = 0.06) was noted compared to those PTX
managed conservatively. Median risk of PTX was estimated at 22.5% by
rad 1 and 25% in rad2 in those biopsies complicated by PTX;
furthermore, in the 5 PTX requiring intervention, PTX risk was estimated
at (25% in 3 and 4 of these by rad 1 and 2.
Conclusions: During CTLB, smaller and deeper lesions with no pleural
adherence are associated with increased likelihood of PTX. Age,
emphysema score, lesion location, needle crossing a major fissure were
not associated with development of PTX. These factors may help to
inform future risk assessment though predicting PTX occurrence during
CTLB appears to be difficult.
P145 PREDICTING THE OCCURRENCE OF PULMONARY
HAEMORRHAGE COMPLICATING PERCUTANEOUS CT-
GUIDED LUNG BIOPSY: A STUDY OF CLINICAL AND
RADIOLOGICAL VARIABLES
B. Chakrabarti1, C. McCann2, S. Amin2, R. Pandey1, P. L. Jones2,
E. Thwaite2, J. E. Earis1, J. M. Curtis2, C. J. Warburton1. 1Aintree Chest
Centre, University Hospital Aintree, Liverpool, UK; 2Department of
Radiology, University Hospital Aintree, Liverpool, UK
Background: Pulmonary haemorrhage (PH) is an infrequent though
recognized complication of percutaneous CT guided lung biopsy (CTLB)
occurring in about 5% of cases. This study aims to identify factors
associated with PH and to estimate the accuracy in predicting risk of PH
during CTLB.
Method: Patients undergoing co-axial cutting needle CTLB at University
Hospital Aintree between January 2000–03 were identified from the
radiology database. The case notes and complete imaging of 134
patients (mean age 69 years; 55% M) were available for the study. The
path taken by the cutting needle (20 G in all cases) during CTLB was
marked on each staging CT scan by an independent observer & these
scans were then reviewed independently by 2 thoracic radiologists (rad1
& 2) blinded to clinical details and procedure related complications.
Each radiologist documented various lesion and biopsy path character-
istics, presence of pulmonary artery dilatation (PAD) and predicted PH
risk during CTLB using a percentage Visual Analogue Score. Blood
pressure (BP) recordings taken 10 minutes pre and post procedure were
available in 125 cases. PH was defined as haziness along the needle
track; new air space shadowing and/or haemoptysis post biopsy.
Results: PH occurred in 5 patients (3.7%) but none required transfusion
and no deaths occurred. Comparing this group with those CTLBs not
complicated by PH, a non-significant trend was noted between
increasing age (76 v 68 years; t test; p = 0.09) and cumulative pack
years smoked (70 v 43 pack years; t test; p = 0.08). No relationship was
found between PH complicating CTLB and gender, an established
diagnosis of systemic hypertension, having a presenting symptom of
haemoptysis (x2 test; p.0.05), whether currently smoking (x2 test;
p.0.05), pre-biopsy BP (mean 146 v 142 mmHg; p.0.05), location of
lesion (x2 test; p.0.05), histology subtype (x2 test; p.0.05), proximity
of a blood vessel to biopsy path (x2 test; p.0.05) and lesion depth (rad
1: mean 1.9 v 1.08 cm; rad 2: 1.2 v 1.12 cm; t test; p.0.05). Rad 1
and 2 noted the presence of PAD in 6 and 7 cases respectively yet none
of these resulted in PH. Rad 1 noted a trend towards presence of a blood
vessel abutting the lesion itself and the development of PH in CTLB (x2
test; p = 0.06) yet this was not observed by rad 2 (x2 test; p = 0.4). In the
5 biopsies complicated by PH, both rad 1 and 2 estimated PH risk at
(15%.
Conclusions: Pulmonary haemorrhage complicating CTLB was not found
to be associated with, among other factors, pulmonary artery dilatation
radiologically, lesion size and depth, a presenting symptom of
haemoptysis and diagnosis of systemic hypertension. Predicting the
occurrence of PH during CTLB appears to be difficult.
P146 PRELIMINARY EXPERIENCE USING LARGER CORE
AUTOMATED NEEDLES FOR PERCUTANEOUS CT-
GUIDED LUNG MASS BIOPSY: IS THERE ANY
IMPROVEMENT IN DIAGNOSTIC ACCURACY AND
COMPLICATION RATES?
M. Farrugia1, P. Daniell1, M. Sheaff3, B. C. Uday1, T. P. Ashok1,
T. C. O’Shaughnessy2. 1Departments of Radiology, Newham University
Hospital NHS Trust, London, UK; 2Chest Medicine, Newham University
Hospital NHS Trust, London, UK; 3Department of Pathology, Barts and the
London NHS Trust, London, UK
Objective: To assess whether using larger core (16 Gauge), automated
needles improves the diagnostic accuracy in percutaneous CT-guided
biopsies performed for suspected lung cancer. The safety profile of the
procedure using this modification was also carried out.
Materials and Methods: Data were collected retrospectively on 45
consecutive percutaneous CT-guided lung mass biopsy procedures over
a period of 18 months. There were 24 male and 21 female patients
(median age 62 years, range 58–79 years). All cases were referred for
biopsy of lesions suspected of being primary lung malignancy or
metastases. The aim of the biopsy was (1) to confirm the presence of
malignancy and (2) to identify the type of malignancy. The procedure
was performed in a standardised way, using local anaesthetic and16G
automated cutting needles without co-axial access. A single core
(16G62 cm) was obtained in 40/45 cases and 2 cores (two needle
passes) were obtained in 5/45cases.
Results: Samples considered adequate for a full histological diagnosis
were obtained in 45/45 cases. In one case inflammatory changes were
identified on two separate biopsy procedures and a histological
diagnosis of cancer was only made after the resected lobe was
examined. No deaths directly linked to the modified procedure occurred.
Major complications included clinically significant pneumothorax
requiring further hospitalisation and treatment in 2/45 cases (4%) and
significant haemoptysis in 1/45 case (2%). Minor complications such as
asymptomatic CT-detected parenchymal haemorrhages and pneu-
mothoraces occurred in 8/45cases (17%).
Conclusions: The use of 16 Gauge automated core needles for CT-
guided percutaneous biopsy has got a high diagnostic accuracy with no
increase in any of the clinically significant complications that are
associated with the procedure.
P147 OUTCOME OF PATIENTS ATTENDING RAPID ACCESS
LUNG CLINIC WHO UNDERGO CT THORAX BUT NO
BRONCHOSCOPY
M. Murthy, E. Shaw, O. Noorullah, M. Asim, R. J. Stead, M. Babores. East
Cheshire NHS Trust, Macclesfield, Cheshire, UK
Introduction: The benefits of having CT thorax before bronchoscopy
have been well established (NICE guidelines 2005), and following the
initiation of our rapid access lung clinic (RALC) our Trust adopted this
policy. Consequently, patients that would have had bronchoscopy in the
past now don’t have it if the CT Scan is not suggestive of malignancy.
Aim: To identify these patients and follow them up for a 2-year period to
see if any of these patients re-presented with lung cancer.
Method: We retrospectively audited the first 50 patients who underwent
CT Thorax but no bronchoscopy during the study period of March 2003
to June 2004. In the above patients the reasons for not undergoing
bronchoscopy were as follows: (1) metastatic disease: 5 (10%); (2)
patients’ wishes: 8 (16%); (3) pleural effusion: 6 (12%); (4) CT Scan not
suggestive of malignancy: 31 (62%). These 31 patients that did not
undergo bronchoscopy because CT did not suggest malignancy were
then analysed for further symptoms and investigations during two years
follow up.
Mean age (SD): 71 (11). Current smokers: 7 (22%), ex smokers: 14
(44%), never smoked 10 (32%). Mean pack years of smokers (SD): 24
(13)
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CXR on first appointment: normal 4 (12%), abnormal but not
suggestive of malignancy 23 (74%), and suggestive of malignancy 4
(12%).
CT scan reported as follows: normal 7 (22%), consolidation 2 (6%),
chronic changes 8 (26%), pleural disease 6 (20%), others 8 (26%).
20/31 (64%) patients were followed up for an average of 12 months.
15/20 (75%) of these did not develop any further symptoms. 10/15
patients underwent further investigations in the form of CXR and 1
patient had a follow up CT scan. All of these patients were well at the end
of the study and the final diagnoses were: bronchiectasis 2, COPD 5,
benign pleural disease 3, pneumonia 2, others 3.
5/20 (25%) did develop further symptoms. All of them underwent
further investigations in the form of CT and CXR. Final diagnoses in those
patients were as follows: benign nodules 2, mesothelioma 2, CCF 1.
11/31 (36%) were not followed up in our clinic. 2/11 (20%) patients
re-presented with further symptoms and were diagnosed as having other
malignancies thought to be unrelated to the primary presentation. 9/11
(80%) remain well.
Final outcome of 2 year follow up: deceased 8/31 (26%); causes of
death were other primary cancers and infection. None of the 31 patients
died of lung cancer.
Conclusion: In this study not performing bronchoscopies in patients with
non-malignant looking CTs did not have any adverse affect on outcome.
No lung cancers were missed.
P148 TIMING OF COMPUTED TOMOGRAPHY AND
BRONCHOSCOPY IN THE INVESTIGATION OF LUNG
CANCER IN THE PENINSULA CANCER NETWORK
S. Stevens, S. Pearse, C. Ingram, K. McDonell, H. Edmond, D. Yiannakis,
N. J. Withers. On behalf of Peninsula Cancer Network, Lescaze Offices,
Dartington TQ9 6JE, UK
NICE guidance for management of lung cancer recommends that all
patients with suspected lung cancer should undergo a CT scan of the
thorax prior to fibreoptic bronchoscopy (FOB) and/or CT-guided biopsy
to obtain tissue diagnosis.
We undertook an audit of all patients with a tissue-proven diagnosis
of lung cancer made within the five acute Trusts serving our Cancer
Network. We surveyed the number of patients undergoing CT prior to
FOB, the diagnostic yield when FOB was used as a first line investigation
and how histology was obtained.
Four out of five Trusts provided data for patients diagnosed with
tissue-proven lung cancer between January and December 2004. A total
of 450 patients were diagnosed, with diagnosis confirmed by bronchial
biopsy in 240 (53%), CT-guided biopsy in 79 (18%), surgical biopsy in
73 (16%) and by other means (for example, Lymph node FNA, liver
biopsy) in 58 (13%).
In 285 (63.3%) cases NICE guidance was adhered to with a CT
undertaken prior to definitive tests for tissue diagnosis. Of these, 123 (43%,
27.3% of total cases) had an investigation other than bronchoscopy as first
line to successfully obtain tissue. Diagnostic pick up rate on patients having a
bronchoscopy was 72.3% in those patients having the procedure before a
CT scan and 78.3% in those bronchoscoped post scan.
There was considerable inter-Trust variability in use of CT pre FOB. In
the main, use of CT first increased bronchoscopic yield. Results have
been disseminated to Trusts via the Network Site Specific Group.
P149 USE OF PHRASES CONTAINED IN PET SCAN REPORTS
TO HELP DIRECT PATIENT MANAGEMENT
S. Bari, L. Sundararajan, A. F. S. A. Hasan, J. Hughes, M. J. Ledson,
M. J. Walshaw. Liverpool Lung Cancer Unit, The Cardiothoracic Centre,
Liverpool, UK
Introduction: PET scans are being increasingly used to help stage lung
cancer. Although this is mainly as a tool before surgery or radical
oncological treatment, they can also be employed in the assessment of
lung nodules or help define the nature of small lymph nodes where CT
scans are equivocal. However, the degree of uptake of the radio-isotope
by the region of interest can be variable and may be reported as such.
This may influence the clinician in developing their subsequent
management plan. We therefore looked at the phraseology of the PET
scan report in our unit on the outcome for the patient.
Method: We audited all PET scans performed in our large lung cancer
unit between March 2005 and June 2006. We looked at the intended
management before PET (Surgery (S), Oncology (O), or Surveillance
(SUR)) and the ultimate outcome (which also included Palliative care
(PAL) and Discharge (D)), and whether PET changed lung cancer
staging. We noted the description of PET positivity, which was coded by
the reporting radiologist as intense increased uptake (IIU), highly
increased uptake (HIU), increased uptake (IU), moderate increased
uptake (MOIU), mild increased uptake (MIU), hot spot (HS), and normal
(N). We looked for any correlation between the outcome and the term
used to describe PET isotope uptake.
Results: 102 patients (mean age 69 years (range 41–95), mean FEV1
%predicted 72 (21–132), mean FVC %predicted 88 (46–145), median
PS 1 (0–3), 50 male) were investigated. The outcome is shown in table 1.
In 25 cases PET downstaged disease, upstaged it in 22, and 55 were
unchanged. Overall in 7 cases PET was unhelpful (2 missed lymph
nodes, 2 PET +ve but not cancer, 2 overestimated, and 1 underestimated
the disease). Observation of the wording of the PET report is shown in
table 2.
Conclusion: PET changed the management plan in a quarter of the
patients in this series. The phraseology of the PET report also gave the
clinician clues to help direct the management plan.
P150 DOES THE USE OF PET IN THE STAGING PROCESS FOR
NON-SMALL CELL LUNG CANCER SIGNIFICANTLY
DELAY SURGICAL TREATMENT?
N. D. Magee1, O. McNally2, J. S. Elborn1, K. McManus2, T. J. Warke2.
1Queens University Belfast, Northern Ireland; 2Royal Victoria Hospital,
Northern Ireland
Introduction: Positron Emission Tomography is a beneficial and cost-
effective adjunct in the staging of non-small cell lung cancer, particularly
in reducing the number of futile thoracotomies. It is unclear how much
delay the use of this limited resource adds to the diagnostic and staging
process, and how this impacts on eventual tumour growth and mortality.
Abstract P148
CT First
+ve FOB if FOB
first (%) +ve FOB if CT first (%)
Trust A (n = 49) 25 (51%) 15 (65%) 17 (94.4%)
Trust B (n = 127) 106 (83%) 13 (68.5%) 63 (81.8%)
Trust C (n = 145) 90 (62%) 30 (60%) 26 (72%)
Trust D (n = 129) 64 (53%) 52 (86.7%) 26 (86.7%)
TOTAL (n = 450) 285 (63%) 110 (72.3%) 105 (78.3%)
Abstract P149 Table 2
Outcome IIU HIU IU MOIU MIU HS N
D 0 0 0 2 0 0 2
O 27 2 7 0 0 1 0
S 22 4 12 0 2 2 0
SUR 4 0 2 1 1 0 9
PAL 1 0 0 0 0 0 0
Abstract P149 Table 1
Intended Rx Before PET After PET Remainder
O 25 21 1 D,1 PAL,1 SUR,1 S
S 64 40 1 D,13 O,10 SUR
SUR 13 6 2 D,1 S, 3 O, 1 Referred
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Aim: To estimate how much delay combined computed tomography and
positron emission tomography (CTPET) imaging adds when included in
the staging workup of non-small cell lung cancer and the effect this may
have on tumour size at the time of operation and mortality of surgically
operable non-small cell lung cancer patients.
Methods: Forty consecutive patients were retrospectively selected who
had a primary non-small cell lung cancer resected by one thoracic
surgeon and were referred from one health board between 2001 and
2004. CTPET has been routine in preoperative assessment at our
institution since 2002. Twenty patients did not receive a CTPET in their
staging process and 20 did receive a CTPET scan in addition to a
diagnostic CT scan. The duration between diagnosis (date of CT scan)
and treatment (surgical resection) was calculated and the two group
means compared. The growth of the tumour during the surgical workup
period was estimated by subtracting the maximum size of the tumour
reported by the pathologist after resection and the maximum size on the
CT scan. Although the methodology for these two measurements differs,
this confounder is equal for both groups. Mortality was also determined
for both groups.
Results: Mean age for both groups was 70 years old (range 45–78) and
68% of the patients were male. There was no significant difference in age
(p = 0.21) or sex (p = 0.74) between the two groups. Mean (standard
deviation) durations from diagnosis to surgery were compared (no
CTPET 83 (29) days v 112 (32) days CTPET; p = 0.005). The mean
(standard deviation) increase in tumour size was not significantly
different (no CTPET 0.30 (1.69) cm v 0.92 (0.98) cm CTPET; p = 0.2).
Overall one-year survival was 84%. One-year survival was not
significantly different between the two groups (no CTPET 79% v 82%
CTPET).
Conclusion: The mean delay added by CTPET scanning is 29 days.
There was a non-significant increase in tumour growth before resection
in the CTPET group. The addition of CTPET does not appear to impact on
early mortality.
P151 AN EXPERIENCE OF PET SCANNING IN NON-SMALL
CELL LUNG CANCER IN A TERTIARY CENTRE
N. Reed1, P. George1, J. Bennett1, J. Entwisle2, M. D. Peake1. 1Department of
Respiratory Medicine, Glenfield Hospital, Leicester, UK; 2Department of
Radiology, Glenfield Hospital, Leicester, UK
Introduction: Although the NICE guidelines on the management of lung
cancer (NICE, 2005) state the need for rapid access to 18F-de-
oxyglucose positron emission tomography (FDG-PET) in all patients with
non-small cell lung cancer (NSCLC) being considered for radical
therapy, experience in the UK has been limited by the lack of routine
availability of PET scans in most areas of the country. Having used PET
scans in the diagnosis and staging of our patients for around 4 years we
believed it important to assess the extent to which individual manage-
ment plans had been changed as a result of the PET scan findings
compared to the conventional work up pre-2002.
Aim: To evaluate the impact of FDG-PET scanning in the routine
diagnosis, staging, and management of patients with NSCLC in a
tertiary hospital set up in the UK.
Methods: Retrospective analysis of all patients who underwent PET
scanning for primary NSCLC in our department. Referral of patients for
PET was made by the lung cancer multidisciplinary team (MDT).The
findings were directly compared with the contrast-enhanced CT scan of
the thorax and abdomen. The data were extracted from the lung cancer
database, case notes, minutes of the MDT meeting, and CT and PET scan
reports.
Results: A total of 309 PET scans were performed during the period from
March 2002 to September 2005. Over the same period a total of
around 1575 new cases of lung cancer and mesothelioma were
diagnosed by the unit—therefore PET scans were used in 20% of our new
patients. The final diagnosis was primary NSCLC in 257 (83%) and
metastatic disease to the lung in 38 (12%). Seven scans were repeated in
four patients who had adjuvant chemotherapy and data were not
available for 7 patients. We specifically looked into the change in nodal
(N) and metastasis (M) status post PET compared to CT alone. Data on N
status were not available for 31 scans. In the remaining 226 patients PET
scan resulted in nodal down staging in 59 (26%) (N2/3 to N0/1 in 58
patients and N3 to N2 in 1 patient), upstaging in 19 (8.4%) (N0/1 to
N2/3 in 10 patients, N2 to N3 in 9 patients) and stayed the same in 148
(65.6%) patients. Data on M staging is available on all patients. 21 (8%)
of patients were upstaged (M0-M1), 72 (28%) were downstaged (M1-
M0) and 164 (64%) were unchanged. The downstaged group included
10 patients in whom the diagnosis was uncertain on CT, which turned
out to be benign lesions on PET. In patients with primary lung cancer,
178 scans were performed specifically to assess suitability for surgery. In
this group PET scan resulted in a change in the TNM staging in 117
(65.7%) of (downstaged n = 94, upstaged n = 23) and no change in 61
patients.
Conclusion: PET scanning has had a major impact on management
decisions in our busy MDT and many patients would have been
inappropriately treated if information based largely on CT was all that
had been available. It is essential that all hospitals who manage patients
with lung cancer have rapid access to PET scanning facilities.
P152 DO PET SCANS HELP REDUCE UNNECESSARY
SURGERY FOR LUNG CANCER?
S. Bari, A. Youzguin, F. Raza, A. McIver, M. J. Ledson, M. J. Walshaw.
Liverpool Lung Cancer Unit, The Cardiothoracic Centre, Liverpool UK
Introduction: PET scanning is being increasingly in the diagnosis and
staging of lung cancer. Recent NICE guidelines indicate that when
radical treatment (including curative surgery) is contemplated for
patients with lung cancer, PET scanning should be undertaken to look
for mediastinal and distant spread, thereby preventing unnecessary
treatment. To investigate this further, we looked at the outcome of PET
scanning on our patients with suspected or proven lung cancer where
surgery would have been the treatment of choice in the absence of PET.
Method: We looked at all patients who had PET scan for investigation of
lung cancer in our large lung cancer unit. We selected all patients where
the MDT decision was to perform a PET scan prior to referral for surgical
resection, and audited the effect of the PET scan on the ultimate treatment
plan.
Results: Sixty three patients (mean age 69.7 years (range 45–91), mean
FEV1% predicted 76 (34–132), mean FVC% predicted 90 (51–135),
median PS 1 (0–2), 31 male), fulfilled the criteria. The PET scans were
performed at a mean of 26 days (range 3–36) following the MDT
decision, and were reported a mean of 4 days later (0–8). In 21 patients
(33%) the PET scan had an impact on subsequent management. Of
these, in 2 cases (10%) they were discharged (PET scan normal), in 10
cases (48%) they were kept under surveillance (6 normal PET, 1
downstaged, 1 increased uptake but CT biopsy negative, 2 no change of
staging), in 9 cases (43%) they were referred for oncological treatment
(7 were upstaged, 2 had a poor PS). Of the remaining 42 (67%), 40 had
surgery and 2 declined. In the operated group, the PET scan upstaged
the disease in 2 cases, downstaged it in 7 cases but there was no change
in the remaining 31 cases. However, in 3 cases where the PET scan
downstaged the disease or suggested a benign lesion, surgery confirmed
malignancy (false negative), and in two cases PET suggested malignancy
but the surgical specimen was benign (false positive).
Conclusion: In this series PET scanning changed the management in one
third of cases and in some of these surgery was avoided, preventing
unnecessary risk to the patient. It was also useful in downstaging the
disease in other cases. However, it gave false results in 12.5% of the
cases who went to surgery. Larger studies are needed to assess its exact
sensitivity or specificity for patients with lung cancer.
Pathomechanisms of COPD
P153 GENDER DIFFERENCES IN THE RELATION BETWEEN
LUNG FUNCTION AND C-REACTIVE PROTEIN IN THE
ENGLISH LONGITUDINAL STUDY OF AGEING (ELSA)
M. Kumari1, G. Mein2, C. E. Bolton3, D. J. Shale3, R. Garrod2. 1UCL
Department of Epidemiology and Public Health, University College London;
2Faculty of Health and Social Care Sciences, St George’s and Kingston
Universities, London; 3Department of Respiratory Medicine, Cardiff
University, Llandough Hospital, Penarth, South Wales, UK
Background: It has recently been reported that the inflammatory
mediator C-reactive protein (CRP) is inversely related with lung function
in a middle aged non-smoking population. However, important
confounders such as social class were not considered in this analysis.
Method: We examine the relationship of CRP with forced expiratory
volume (FEV1) in a large national population (English Longitudinal Study
of Ageing, ELSA) aged 50 years and over who were resident in England,
2004. We explored the relationships in males and females separately.
Results: Data were available in 2272 males, 2572 females. The median
FEV1 was 2.77 litres males and 2.01 litres females. In analysis of
normalised data, significant Pearson correlations were observed in both
men and women (r =20.26 males and r =20.21 females, both
p,0.01). When analyses were restricted to never smokers (29% of
male, 44% of female population), unadjusted correlations remained
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significant (males r =20.18, females r =20.22, both p,0.01).
However, in males the association between CRP and FEV1 became
non significant following adjustment for age and wealth, as an index of
social position (adjusted beta 20.13, p = 0.23). In women the relation-
ship remained significant (adjusted beta, 20.22, p,0.01). The
association in females was unaffected by removal of those with overt
lung disease (n = 282 females) from the analysis or adjustment for body
mass index.
Conclusions: We conclude in a non-smoking population, that the
association of CRP with lung function is largely mediated by social
position in males but not in females. Other, as yet undefined, measures
are likely in to contribute in females but may include metabolic and
hormonal factors, physical activity as well as the gender differences in
the cytokine response to exercise, but these require further evaluation.
P154 GENE EXPRESSION PROFILING OF THE EFFECTS OF
CIGARETTE SMOKE ON MACROPHAGES
L. Kent1, L. Smyth1, C. Clayton2, T. Cook2, L. Scott2, N. Lambie2,
L. Warnock2, S. Fox2, R. Stephens2, R. Vessey3, D. Singh1. 1North West
Lung Centre, South Manchester University Hospitals Trust, Wythenshawe
Hospital, Southmoor Road, Manchester M23 9LT, UK; 2Disease and
Biomarker Transcriptomics, GlaxoSmithKline, Stevenage, Hertfordshire
SG1 2NY, UK; 3Target Discovery, GlaxoSmithKline, King of Prussia, PA
19406, USA
Aims: Cigarette smoke (CS) causes oxidative stress, and is the major
cause of chronic obstructive pulmonary disease (COPD). We have
investigated the effects of CS on macrophage gene expression.
Methods: Monocyte derived macrophages from 6 COPD patients were
incubated with CS extract (CSE) (control, 1, 10, and 25%) for 6 hours.
Cells were harvested in TRIzol, and RNA extracted for gene array
analysis (Affymetrix U133 +2.0 Human Genome Chips) and quantitative
TaqMan PCR. Array analysis was by mixed-model analysis of variance
and Dunnetts test to determine significant results when compared to
control. A twofold change with p,0.01 was considered biologically
significant compared to control. All probe sets that were found to be
significant in at least one concentration underwent functional analysis
using DAVID (see http://apps1.niaid.nih.gov/david/).
Results: Affymetrix analysis: 24 probe sets at 1%, 401 probe sets at 10%
and 778 probe sets at 25% CSE exhibited a biologically significant change.
Functional analysis: Functional analysis identified groups of genes
(>2-fold change and p,0.01 at one CSE concentration or more)
involved in cell growth (147 probe sets), cellular metabolism (137),
signal transduction (133), nucleobase metabolism (129), organogenesis
(74), cell death (43), and cell adhesion (25). Cluster analysis of these
groups is on-going.
Quantitative PCR: Quantitative PCR of 36 genes confirmed array
changes. These included a decrease in the anti-inflammatory cytokines
IL-10 and an increase in pro-inflammatory IL-8 (for example, 86%
decrease and 121% increase respectively at 10% CSE). There was also
evidence of decreased IL-1b and IL-6 expression.
Conclusions: Acute CSE exposure affects pro- and anti-inflammatory
gene expression in macrophages, as well as cell survival and metabolism
genes. Our Affymetrix data are confirmed by quantitative PCR. Ongoing
cluster analysis will identify groups of regulated genes.
P155 HISTOLOGY OF THE DIFFUSE EPITHELIAL RESPONSE
IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
PERIPHERAL LUNG SHOWS THAT MATURE TYPE II
PNEUMOCYTES ARE NOT THE MAJOR COLONISING
CELL
K. Pinnion, M. L. Foster. Department of Pathology, AstraZeneca R&D
Charnwood, Loughborough Leicestershire, UK
Introduction: Widespread colonisation of epithelial-like cells is a
common finding in COPD lung resections and in the lungs of long term
healthy smokers. These cells line alveolar surfaces and the external
laminae of airways and blood vessels. Many researchers have
speculated that these cells are proliferating type II pneumocytes but they
have not been systematically studied. We have employed a panel of
antibodies to examine the possible phenotype of these cells: surfactant A
(mature type II pneumocytes), pan-cytokeratin {5, 6, 8, 17, and 19}
(epithelial cells), cytokeratin 7 (non-differentiated adult epithelial cells),
cytokeratin 5/6 (basal epithelial cells) and p63 (basal epithelial cells).
Methods: COPD peripheral tissue from individuals undergoing lung
volume reduction surgery for emphysema was ethically acquired from
Glenfield Hospital, Leicester. Sections were evaluated using H&E
staining. Immunohistochemistry was carried out with the above panel
on formalin fixed paraffin embedded sections, using DAB chromagenic
detection.
Results: LVRS histology demonstrated a range of reactions from active
inflammation and pneumonitis to post-inflammatory remodelling.
Epithelial-like cell proliferation was noticeably associated with the latter
group. The pan-cytokeratin antibody stained all epithelial cells including
the colonising cells in the parenchyma. These cells are arranged linearly
across the alveolar surfaces with occasional aggregations in the alveolar
nodes. Surfactant A staining was seen on many of the alveolar surfaces
and within macrophages and type II cells, but not on the colonising
epithelial cells. Cytokeratin 5/6 was only seen in basal airway
epithelium, similar to the expression of p63, although p63 staining
was more widespread. There was sporadic staining of cytokeratin 7
within the airways and a subpopulation of colonising epithelial cells.
Conclusion: H&E evaluation suggests that colonising cells may have a
reparative function because of their association with the post inflamma-
tory phenotype. The negative surfactant staining of these cells strongly
suggests that they are not mature type II pneumocytes. In addition these
cells show a positive pan cytokeratin staining, not a characteristic of type
II cells. The lack of cytokeratin 5/6 staining and the inconsistent p63
staining suggest that these cells are not proliferating basal epithelial cells.
Cytokeratin 7 staining was variable suggesting considerable hetero-
geneity within this population. Further work is in progress to further
characterise phenotype of these cells.
P156 INFLAMMATORY CELL INFILTRATION INTO PROXIMAL
AIRWAY SMOOTH MUSCLE BUNDLES IN SUBJECTS
WITH AND WITHOUT CHRONIC OBSTRUCTIVE
PULMONARY DISEASE
S. K. Saha, N. Neale, A. J. Wardlaw, I. D. Pavord, C. E. Brightling. Institute
for Lung Health, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK
Background: Increased mast cell microlocalisation to the airway smooth
muscle (ASM) bundle is a feature of asthma. Several studies have
consistently reported that the mast cell is the only inflammatory cell to
infiltrate the ASM-bundle. In contrast in COPD and smokers without
COPD, infiltration of the ASM-bundle in the small airway by several
inflammatory cell types has been reported with an increase in
neutrophilic infiltration compared to controls. To date, the inflammatory
cell infiltrate within the ASM-bundle in the large airway in COPD has not
been elucidated.
Methods: Large airway samples were collected from surgical resection
specimens from 9 COPD subjects (GOLD stages 1–2), and age matched
controls with no evidence of obstructive airways disease including 9
smokers and 8 non-smokers. All samples were embedded in glycol-
methacrylate resin and using immunohistochemistry, samples were
stained for the presence of mast cells (tryptase+), lymphocytes (CD3+),
macrophages (CD68+), neutrophils (NE+) and eosinophils (MBP+) within
the submucosa and ASM.
Results: We identified numerous mast cells, CD68+ and CD3+ cells in
the ASM irrespective of subject group in the resection material (see
table). However, there was a paucity of neutrophils and eosinophils in
the ASM-bundle in all groups.
Conclusion: Infiltration of the large airway ASM by a several
inflammatory cell types was observed in resection samples from subjects
Abstract P156
COPD Smokers no COPD Never Smokers
Mast cells/mm2 4.98 (12.5) 8.51 (15.2) 7.89 (5.93)
CD68+ cells/mm2 3.91 (13.1) 7.69 (9.67) 10.6 (11.7)
CD3+ cells/mm2 3.22 (4.59) 1.19 (7.31) 1.26 (4.82)
Median (IQR) cells/mm2 ASM .
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with and without COPD. In contrast to a previous report in small airways
neutrophilic infiltration into the large airway ASM was unusual.
P157 MOLECULAR ANALYSIS OF BACTERIA IN CHRONIC
OBSTRUCTIVE PULMONARY DISEASE SPUTUM
SAMPLES
G. B. Rogers1, A. F. Stressmann1, V. Kehagia2, M. P. Carroll2, K. D. Bruce1.
1School of Health & Life Sciences, King’s College London, UK; 2Adult Cystic
Fibrosis Service, Southampton General Hospital, UK
Introduction: Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality in many countries. The lungs of COPD
patients are prone to colonisation by bacteria. Although the precise role
of the bacteria in the progression of the disease is not fully understood,
there is a clear need to better characterise these microbes. Previous
analyses of bacteria in COPD sputum has relied on methodologies that
require in vitro cultivation prior to analysis. For many reasons this limits
the species that can be detected. This study tests the hypothesis that there
is a diverse bacterial community of present in sputum sampled from
COPD patients. To test this hypothesis, this study used culture
independent and hence non-selective methodologies.
Methods: Sputum samples were collected from 20 COPD patients.
Phylogenetically-informative sequences were amplified from DNA
extracted directly from bacteria in these sputa. These sequences were
analysed by Terminal Restriction Fragment Length Polymorphism (T-
RFLP) analysis1 to generate a profile of the total bacterial community
present and, in four instances, by sequencing clones from prepared
libraries.
Results: A total of 66 clones were sequenced. Species from 10 different
bacterial genera—Acinetobacter, Bacillus, Haemophilus, Moraxella,
Ochrobactrum, Pseudomonas, Rhodococcus, Sphingomonas,
Stenotrophomonas, and Neisseria—were identified. The number of
individual species detected in the T-RFLP profiles generated from the 20
sputum samples ranged from 2 to 19, with a mean value of 7.9 (SD 5.8).
A total of 106 separate species were detected in the sample set. The
species with the most intense band typically represented 62.7% (17.1) of
the total lane signal, with the second and third ranked species typically
representing 18.0% (12.0) and 10.5% (6.1) respectively. The species
with the dominant band was derived from a recognised COPD pathogen
in only two samples, where P aeruginosa was identified. The other
species dominant in samples represented a range of organisms, both
Gram-negative and Gram-positive, opportunistic pathogens and species
common to natural environments.
Conclusions: The lower respiratory tract in COPD patients is therefore
colonised by a relatively complex bacterial community. This community
includes both species traditionally associated with COPD respiratory
infections and previously unreported species. The impact of this
community on respiratory health is as yet undetermined.
1. Rogers GB, Carroll MP, Serisier DJ, et al. Characterization of
bacterial community diversity in cystic fibrosis lung infections by use
of 16s ribosomal DNA terminal restriction fragment length
polymorphism profiling. J Clin Microbiol 2004;42:5176–83.
P158 RELATIONSHIP BETWEEN EXHALED NITRIC OXIDE
AND EOSINOPHILIC AIRWAY INFLAMMATION IN
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
R. Siva, M. Shelley, B. Hargadon, S. McKenna, W. Monteiro, D. Parker,
I. D. Pavord. Institute for Lung Health, Glenfield Hospital, UK
Introduction: Identification of eosinophilic airway inflammation is impor-
tant in chronic obstructive pulmonary disease (COPD) as it is associated with
a response to short term corticosteroid therapy, and with a reduction of
exacerbations with long term therapy. A raised forced expiratory nitric
oxide (FeNO), is an attractive biomarker of eosinophilic airway inflamma-
tion, since it is easy to measure and delivers immediate results where
available. We set out to determine whether there is a relationship between
eosinophilic airway inflammation and FeNO in COPD.
Method: We analysed data from 79 subjects (54 male: 25 female) with
COPD as diagnosed under BTS guidelines: mean (SD) age 68 (7.6), post
bronchodilator % predicted FEV1 38.2 (15.3). 59 subjects were ex-
smokers and 20 subjects were currents smokers, mean (SD) pack years
for all subjects 49 (28.8). Measurement of exhaled nitric oxide and
sputum induction were carried out according to standard protocols.
Results: Overall there was no correlation between levels of exhaled nitric
oxide and sputum eosinophil counts (r = 0.174, p = 0.125). The relation-
ship was closer in current smokers than in ex-smokers.
Conclusions: Exhaled nitric oxide is not a marker of eosinophilic airway
inflammation in COPD.
P159 BRONCHOALVEOLAR LAVAGE OF SMOKERS HAVE
INCREASED LYMPHOCYTE CHEMOKINE RECEPTOR
EXPRESSION
C. Starkey, L. J. C. Smyth, J. Vestbo, D. Singh. North West Lung Centre,
South Manchester University Hospitals Trust, Southmoor Road, Manchester
M23 9LT, UK
Background: Progression of chronic obstructive pulmonary disease
(COPD) in cigarette smokers is associated with increased lymphocyte
numbers in the lungs. Lymphocyte chemotaxis to the lung in COPD is
poorly understood. Aims: to identify lymphocyte chemokine receptors
with increased expression in lungs of COPD patients by (a) comparing
BAL v blood; (b) COPD BAL v healthy smokers (HS) BAL.
Methods: BAL and blood CD4 and CD8 lymphocytes from COPD
patients and HS were characterised by FACS analysis of chemokine
receptors: CCR5, CXCR3 (Th1 cells) CCR3, CCR4, and CCR8 (Th2 cells)
Results: See table. COPD patients and HS had numerically greater
CCR3, CCR8 and CCR5 expression in BAL CD8 cells compared to blood.
These differences were all statistically significant (p,0.05) in the COPD
group, but only for CCR5 in HS. This suggests that CCR3 and CCR8
expressing CD8 cells are selectively recruited in COPD. BAL and blood
CD8 CXCR3 and CCR4 expression were similar in both groups. BAL
CD8 CCR3 and CCR5 expression were significantly increased in COPD
patients and HS compared to healthy ex smokers (HEX).
Conclusions: (1) CCR3, CCR8, and CCR5 can be termed ‘‘lung
homing’’. (2) CCR3 and CCR8: evidence COPD specific. (3) Smoking
increases CCR3 and CCR5. We provide evidence that lung CXR
expression may change due to oxidative stress or inflammatory
mechanisms in smokers.
P160 GRANULOCYTE TRAFFICKING IN CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
P. Ruparelia1, K. Szczepura2, D. Bilton1, A. M. Peters2, E. R. Chilvers1.
1Department of Medicine, University of Cambridge, Addenbrooke’s and
Papworth Hospitals, Cambridge, UK; 2Department of Radiology, University
of Cambridge, Cambridge, UK
Introduction: Chronic obstructive pulmonary disease (COPD) is an
inflammatory condition of the airways characterised by intense
neutrophilia. We have used sub-imaging doses of 111 indium (111In)
labelled granulocytes and high sensitivity whole body counting to assess
neutrophil (PMN) trafficking and loss in patients with COPD.
Methods: Participants were transfused with autologous 111In-labelled
PMNs (0.2 mSv) isolated using discontinuous plasma Percoll gradients
and subsequently underwent whole body counting over a 10 day period.
A single slit collimator was placed on the lower detector in order to
obtain a longitudinal profile of PMN distribution. 111In profile and
whole body retention data were obtained at 45 minutes, day 1, 2, 4, 7,
and 10 in 7 ex smoking (XS)-COPD patients (mean FEV1 0.9 l) and 9
currently smoking (CS)-COPD patients (mean FEV1 1.0 l), 10 bronch-
iectasis patients, 12 healthy non-smokers, and 5 healthy smokers. Daily
sputum samples were counted for 111In.
Results: Mean 111In PMN retention (SD) at day 7 were: non-smokers
94.5% (1.9), healthy smokers 93.5% (4.4), XS-COPD 94.2% (1.5),
bronchiectasis 89.4% (8) but with a significant loss in the current smoker
subgroup of COPD patients of 92.1% +/2 3 (p,0.05 compared to
healthy non-smokers). The peak 111In signal in the sputum occurred at
day 2 in both patient groups. At the initial scan (45 minutes) PMNs
predominantly localised to the liver/spleen region in all patients.
Thereafter cells additionally distributed to pelvic and thoracic areas.
Thoracic SPECT using imaging doses of 99mTc-labelled PMNs (3 mSv) in
2 controls and 2 COPD subjects demonstrated 18.4% and 18.7% (values
expressed as % of total thoracic activity) respectively of the 99mTc-PMN
Abstract P159 Median chemokine receptor expression (%)
on CD8 cells
CCR3 CCR8 CCR5 CXCR3
HS BAL 18 18 40 49
Blood 1 1 3 36
COPD BAL 21 18 46 42
Blood 8 8 10 27
BAL CD8 numbers were raised in COPD compared to HS (medians/ml
6102: 25.8 v 6.6 p = 0.05); CD4 numbers were similar in both groups.
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uptake over the lung at 4 hours post injection with the remaining signal
in the rib and vertebral body bone marrow (BM) compartment. Patlak
analysis demonstrated quantifiable uptake within the lung and bone
marrow over 4 hours.
Conclusion: Low dose autologous 111In neutrophil retention affords a
measure of neutrophil loss through the airways, which appears to be
more intense in CS-COPD and may be a useful method for monitoring
granulocyte flux in CS COPD. This technique also permits accurate
monitoring of PMN trafficking to the liver/spleen and BM compartments.
Lung uptake is quantifiable using thoracic SPECT and Patlak analysis
with less than 20% of the signal being within the lungs at 4 hours.
Funded by a non-commercial grant from AstraZeneca UK.
Data from this study have previously been submitted to ATS 2006 and
COPD 5.
P161 CIRCULATING MATRIX METALLOPROTEINASES IN
CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND
BONE DISEASE
C. E. Bolton1, L. S. Nixon1, R. J. Pettit2, W. D. Evans2, M. D. Stone3,
D. J. Shale1. 1Respiratory Medicine, Cardiff University, Llandough Hospital,
Penarth, S Wales; 2Medical Physics, University Hospital Wales, Cardiff, S
Wales; 3Bone Research Unit, Cardiff University, Llandough Hospital, Penarth,
S Wales, UK
Background: The role of circulating matrix metalloproteinases (MMP) in
COPD is not fully defined. Within the airway compartment, MMP-1 and
29 have been implicated in COPD. Meanwhile, circulating MMP-9 are
elevated in patients with osteoporosis. We have previously reported that
patients with COPD have a high prevalence of bone thinning
(osteoporosis and osteopenia) across a spectrum of severity of COPD
and hence explored MMP-9 in patients with COPD with respect to
presence of osteoporosis.
Method: Patients with confirmed COPD (n = 70) and healthy subjects
(HS) (n = 39) underwent dual x ray absorptiometry to determine bone
mineral density (BMD) and hence presence of osteoporosis. Circulating
MMP-9 (ng/ml) was measured together with inflammatory mediators.
Results: Patients had a median (range) age of 66 (39–82) years; 32
patients had a FEV1.50% pred, 38 with FEV1,50% pred. There were
more patients (n = 19, 27%) with osteoporosis compared to HS (n = 5,
13%), x2, p = 0.002. Patients had greater geometric mean (SD) MMP-9:
38.48 (2.24) compared to HS 20.12 (1.99)ng/ml, p,0.001. Among
the patients, MMP-9 was greater in those with osteoporosis: 51.29
(2.33) compared to those with no osteoporosis: 32.3 (2.12), p,0.01.
There was no difference in MMP-9 between those with FEV1, or .50%
predicted, although log10 MMP-9 was related to FEV1 (r = 0.424,
p,0.001). HS had a lower MMP-9 compared to patients – in either
group: with or without osteoporosis, p,0.01. Log10 MMP-9 was related
to BMD lumbar (r =20.361, p,0.001), BMD hip (r =20.287,
p,0.01), in the whole population and also in patients: BMD lumbar
(r =20.364, p,0.01), BMD hip (r =20.234, p = 0.05). There was no
such relation in HS. IL-6, TNF-a sr I and II were greater in patients (all
p,0.01). In the whole population, log10 MMP-9 was related to log10 IL-
6 (r = 0.305, p = 0.001) and similarly with TNF-a sr I and II.
Conclusions: Circulating MMP-9 is elevated in patients with COPD.
Osteoporosis is prevalent in COPD patients and such patients have
greater MMP-9 levels. BMD is related to MMP-9. The link of matrix
metalloproteinase with both COPD and osteoporosis suggests similar
pathophysiology.
Support received from GSK.
P162 COMPARISON OF METHODS FOR MULTIPLE FLOW
RATE MODELLING OF EXHALED NITRIC OXIDE IN
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
K. Roy1, Z. Borrill1, C. Starkey1, A. Hazel2, J. Vestbo1, D. Singh1.
1Wythenshawe Hospital, Manchester, UK; 2Manchetser University, UK
Modelling exhaled nitric oxide (FeNO) at multiple flow rates estimates
NO airway wall concentration (CawNO), airway wall diffusing capacity
(DawNO), alveolar concentration (CalvNO) and maximal flux (J’awNO).
Different mathematical modelling methods are described; there is no
gold standard method or standardisation of the number of flow rates.
For three different published methods, we (1) investigated the effect of
the number of flow rates on model parameters and (2) compared the
degree of error between modelled and actual data. FeNO was
measured using Niox analyser (Aerocrine) at 10, 30, 50, 100, and
200 ml/s in 50 chronic obstructive pulmonary disease (COPD) patients
and data applied to three different methods based on (i) complete non
linear fitting of data or (ii) linear fitting to calculate CalvNO followed by
non linear fitting (mixed methods). Parameters estimated from 5 and 4
flows were compared by repeated measures ANOVA. FeNO was
significantly reduced (p,0.05) at all flow rates in COPD smokers
compared to ex-smokers. Using 5 flows, all three methods showed
reduced CawNO in smokers, while two methods also showed reduced
JawNO (p,0.05). There was no difference for CalvNO or DawNO. Table
shows comparison of 5 and 4 flow rate data as ratio (95% confidence
interval) except for DawNO (median difference). Only mixed method 2
was relatively independent of the number of flows. The median error
between modelled and actual data derived using the least squares fitting
technique was significantly lower for the non-linear method (1.96)
compared to mixed methods (3.31 and 3.62). CawNO is reduced in
COPD smokers, but these results can be dependent on the number of
flow rates used. Complete non-linear modelling gives the most accurate
fit to the actual data.
P163 BRONCHOALVEOLAR LAVAGE OF SMOKERS HAVE
INCREASED CD4 REGULATORY LYMPHOCYTES
L. J. C. Smyth, C. Starkey, J. Vestbo, D. Singh. North West Lung Centre,
South Manchester University Hospitals Trust, Southmoor Road, Manchester
M23 9LT, UK
Background: The progression of chronic obstructive pulmonary disease
(COPD) is associated with increased lymphocyte numbers in the lungs.
CD8 cells are well documented but fewer data exist about CD4 cells.
CD4 cells are capable of effector and immunoregulatory functions. We
have assessed the phenotype of bronchalveolar lavage (BAL) lympho-
cytes compared to those of peripheral lymphocytes in COPD patients
and a control group of healthy smokers (HS).
Methods: BAL and blood samples were obtained from HS (n = 19 mean
age: 59.7, mean FEV1 2.67 l, mean pack year history: 34.4 years) and
COPD patients (n = 26 mean age: 65.9, mean FEV1 1.71 l, mean pack
year history: 51.1 years). Cell surface markers for regulation (CD25,
CTLA4, neuropilin and C27), activation (CD69), memory (CD45RO),
and T cell integrin (CD103) were triple immunoflorescence labeled and
assessed by flow cytometry.
Results: There was no difference in BAL CD4 numbers in COPD and HS
(medians/ml 6102: 15.2 v 12.9). BAL CD4 cells displayed increased
activation and memory status compared to PBMC in both COPD and HS.
BAL CD4/CD25bright expression was increased compared to PBMCs in
Abstract P162
5 v 4 highest flows 5 v 4 lowest flows
Non-linear CawNO 2.02 (1.45 to 2.83)* 0.70 (0.61 to 0.81)*
CalvNO 1.99 (1.43 to 2.75)* 0.86 (0.79 to 0.92)*
DawNO 19.55* 21.24*
J’awNO 0.72 (0.58 to 0.90)* 1.10 (1.06 to 1.14)*
Mixed 1 CawNO 1.68 (1.34 to 2.11)* 0.56 (0.38 to 0.83)*
CalvNO  0.76 (0.61 to 0.94)*
DawNO 24.24* 21.01*
J’awNO 0.91 (0.76 to 1.08) NS 1.12 (1.03 to 1.23)*
Mixed 2 CawNO 0.92 (0.72 to 1.18) NS 1.12 (0.89 to 1.41) NS
CalvNO  0.68 (0.53 to 0.88)*
DawNO 0.650 NS 0.38 NS
J’awNO 1.27 (0.96 to 1.68) NS 0.97 (0.86 to 1.09) NS
*p,0.001; NS, not significant.
CalvNO is calculated using 200 and 100 ml/s, hence is the same whether using the 5 or the 4 highest flow rates.
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both groups, indicative of increased regulatory cell numbers. BAL CD4
cells also expressed increased regulatory markers CTLA4 and neuropilin
(BAL 13.5%, blood 0%). BAL CD4CD25bright cells expressed less CD27
compared to PBMCs, suggestive of reduced regulatory ability. There
were no significant differences for BAL markers between COPD and HS.
Conclusions: We have demonstrated that a subpopulation of BAL CD4
cells from COPD patients and HS display a regulatory phenotype. There
was no difference between COPD and HS, indicating that smokers with
and without airflow obstruction have lung T regulatory cells. The reduced
BAL CD4 coexpression of CD27 suggests reduced regulatory function.
This is a potential mechanism of disease progession; reduced T
regulatory function in smokers may allow the progression of inflamma-
tion.
P164 CONCEPTUAL AND PROPORTIONAL
CLASSIFICATIONS OF CHRONIC OBSTRUCTIVE
PULMONARY DISEASE PHENOTYPES
R. Beasley, S. Marsh, J. Travers, A. Hansell, M. Williams, S. Aldington,
M. Weatherall. Medical Research Institute of New Zealand, Wellington, New
Zealand
Background: Chronic obstructive pulmonary disease (COPD) encom-
passes a group of disorders characterised by incompletely reversible
airflow obstruction, with overlapping subsets of different phenotypes
including chronic bronchitis, emphysema and asthma. Attempts to
quantify the proportion of COPD subjects with these phenotypes have
been limited.
Methods: A cohort derived from a population-based survey of adults
aged 25–75 years undertook questionnaires, lung function tests and CT
scans. The proportion of subjects in each of 15 distinct phenotypes was
determined, based on combinations of chronic bronchitis, emphysema,
and asthma, with and without airflow obstruction.
Results: A total of 713 subjects completed the investigative modules of
whom 112 (15.7%) had COPD (defined as a post bronchodilator FEV1/
FVC of ,0.7). The relative proportions of the phenotypic subgroups of
subjects with and without COPD are shown in the proportional figure.
Asthma with incompletely reversible airflow obstruction was the
predominant COPD phenotype with only a small proportion of subjects
with COPD having the classical phenotype of chronic bronchitis with
emphysema but no asthma. One quarter of subjects with an FEV1/
FVC,0.7 did not meet criteria for chronic bronchitis, emphysema or
asthma and may represent a group with predominant small airways
disease.
Conclusion: This study has provided novel ways of conceptualising the
COPD phenotypes and can be used as a basis for further research into
the pathogenesis and treatment of this heterogeneous disorder.
P165 COMPARISON OF REGIONAL VENTILATORY AND
PERFUSION DEFECTS IN SEVERE CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
N. A. Marks1, W. E. Svensson2, S. West1, J. Burton1, A. M. Al-Nahhas2,
P. W. Ind1. 1Respiratory Medicine, NHLI, Imperial College, London, UK;
2Nuclear Medicine, Hammersmith Hospital, London, UK
Introduction: Patchy defects of ventilation (V) and perfusion (Q) are well
recognised on lung scintigraphy in chronic obstructive pulmonary
disease (COPD). However, we have not found any systematic analysis.
We aimed to compare V and Q defects in a pilot study in patients with
severe COPD. We have slightly modified Barter’s classification (Barter SJ
et al. Am Rev Respir Dis 1985;132:148–51) for grading defects in
81mkrypton scans of smokers.
Methods: We studied 8 patients with severe smoking related COPD, 4
during hospitalisation for an exacerbation. Anterior and posterior scans
were performed seated, to improve image acquisition. 81mKrypton was
used for V and 99mTechnetium macroaggregated albumin for Q scans.
All scans were analysed blind by 2 observers, graded normal (0) or
abnormal: minor changes (1) moderate-diffuse (2) or severe (3) and
largely matched or unmatched. Discrepancies (none of .1 grade) were
resolved by a third opinion, also blinded (WES, Consultant in Nuclear
Medicine).
Results: Six of the 8 COPD patients were male, mean age was 61.4 (SD
9) years, mean height was 168 (SD 11) cm, and mean weight was 64
(SD 7) kg. Mean FEV1 was 1.0 (SD 0.5) l (mean 34% pred), mean PEF
was 177 (SD 77) l/min, (mean 36% pred), mean kCO was 0.76 (SD
0.3) mmol/min/kPa/l (mean 49% pred). Mean V scan grade was 1.8
(range 0–3) and mean Q grade was 2.0 (range 1–3). V defects were
more marked than Q defects in 5 patients and most were regionally
matched. There was a trend towards a correlation between grades of V
and Q (r = 0.7, p = 0.05) and V grade tended to be higher in patients
with lower FEV1 (r = 0.57, p.0.1).
Despite problems of differential attenuation, body habitus and
Technetium injection upright this technique provides semiquantitative
information on regional ventilation and perfusion in COPD, with low
radiation dose, relatively cheaply. A larger group of patients with a
greater range of severity, including more with a non-emphysema
phenotype, should be investigated.
A similar version of this abstract will be presented at ERS in September
2006.
P166 ETHNIC DIFFERENCES IN SPIROMETRY IN PATIENTS
WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
C. S. Beardsmore1,2, M. Morgan2,3, D. D. Vara2,3, J. R. Thompson4.
1University of Leicester Department of Infection, Immunity and Inflammation;
2Institute for Lung Health, Leicester; 3Glenfield General Hospital, UHL NHS
Trust, 4University of Leicester Department of Health Sciences, Leicester, UK
Aim: This retrospective study aimed to discover whether lung function in
patients with chronic obstructive pulmonary disease (COPD) differed
according to ethnicity. It was based in Leicester where the largest
minority group comprises people whose ethnic origins are in south Asia.
Methods: The database from the Respiratory Physiology Unit contained
all measurements of lung function between 1990 and 2005. Data were
filtered to exclude all patients of non-white or non-Asian origin.
Diagnosis was not routinely entered into the database so we excluded
patients under 40 years, those in whom the post-bronchodilator FEV1/
FVC exceeded 70%, and those with significant response to bronchodi-
lator (increase in FEV1.200 ml). Since there are recognised differences
in FEV1 and FVC between different ethnic groups, subsequent analysis
Abstract P163 Mean CD4 surface marker expression (%)
CD25bright CTLA4 CD27 CD103 CD45 RO CD69
CD4 BAL HS 28.8 0.95 3 26.9 96 40.4
COPD 23.1 4.4 5.0 39.7 95 50.0
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was restricted to FEV1/FVC. Where patients had made repeated visits,
only data from the first visit were included. Mean values of FEV1/FVC
were compared by regression analysis, taking account of age, gender,
ethnicity, and smoking history (non-smokers compared with ever-
smokers).
Results: The filtering strategy yielded 8747 patients including 407 (5%)
Asians. Each subgroup included at least 90 patients apart from Asian
female ever-smokers (n = 6). Respiratory function was better in
nonsmokers (p,0.001) and in females (p,0.001) (table). FEV1/FVC
was 1.31% higher in Asians than whites (p = 0.033).
Discussion: This retrospective study has shown a difference in FEV1/FVC
between patients of Asian and white ethnicity, which is approximately
half the size of the gender effect. Although this was a retrospective study
that employed a filtering strategy rather than having a contemporaneous
recorded diagnosis, the observation is important because the burden of
COPD justifies the need to identify patient groups with different
respiratory function, as the first step in identifying factors related to
outcome of disease which may be open to modification.
P166A HIGH SENSITIVITY C REACTIVE PROTEIN LEVELS
CORRELATE WITH PULMONARY INFLAMMATION AND
FEV1 IN STABLE CHRONIC OBSTRUCTIVE
PULMONARY DISEASE
E. Sapey, D. Bayley, S. Gompertz, R. A. Stockley. Lung Investigation Unit,
Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TT, UK
Introduction: C reactive protein (CRP) levels are frequently raised in
chronic obstructive pulmonary disease (COPD) and correlate with
impaired functional capacity and psychological distress (Broekhuizen
et al. Thorax 2006;61:17). In severe COPD, CRP has been shown to
relate with pulmonary inflammation, however, the relation between high
sensitivity C reactive protein (HSCRP) and markers of pulmonary
inflammation has not been clarified in patients with a broad range of
disease severity.
Methods: Sixty nine patients with well characterised COPD (GOLD
stages 1–4) and chronic sputum production were studied. Interleukin-1
beta (IL-1b), tumour necrosis factor alpha (TNFa), interleukin 8 (CXCL8),
leukotriene B4 (LTB4), and myeloperoxidase (MPO) were measured in
sputum supernatant. High sensitivity CRP (CRP) was measured in plasma.
Results: The median CRP was 94nM (IQR 50–128) with 52 patients
(75%) having HSCRP levels which would be considered to be raised
(.40 nM). CRP correlated negatively with FEV1 (p = 0.02) and positively
with sputum concentrations of CXCL8 (p = 0.007), LTB4 (p = 0.01), TNFa
(p = 0.03) and IL1b (p = 0.03). Patients with raised CRP had a lower
FEV1 (p = 0.01) and higher concentrations of CXCL8 (p = 0.04) and
MPO (p = 0.02) compared with those in the normal range.
Conclusion: A raised CRP concentration in plasma is associated with
worsening lung function and a higher pulmonary burden of inflamma-
tion in COPD. This suggests an overspill of inflammation from lung to
plasma rather than higher systemic inflammation drives the lung disease.
Oxygen assessment and provision
P167 THE OUTCOME OF A REVIEW OF OXYGEN ORDERS
FOLLOWING PATIENTS’ ATTENDANCE AT AN
OXYGEN CLINIC
J. Creasey, D. Mukherjee, B. Yung, J. Samuel, A. Elsheikh, S. Lincoln.
Basildon University Hospitals NHS Foundation Trust, Essex, UK
Background: The provision of domiciliary oxygen therapy underwent
radical changes in England and Wales in February 2006. The Royal
College of Physicians1 and The British Thoracic Society2 provided
recommendations and guidance that patients with domiciliary oxygen
should be followed up to ensure optimised management.
Aim: To review the outcome of assessment of patients attending the
newly established oxygen clinic in a 652 – bedded District General
Hospital.
Method: Copies of the home oxygen order forms (HOOF) recording the
orders of oxygen therapy for patients discharged from the hospital were
sent to the oxygen service clinical lead. The clinical lead provided the
discharged patients with a follow up appointment in the oxygen clinic at
6 weeks after discharge. Other patients seen in the respiratory
outpatient department were referred to the oxygen clinic as necessary.
The outcome of the patients who had attended the weekly oxygen clinic
between 13 March to 12 June 2006 was recorded and reviewed.
Results: Thirty patients (19 female) were reviewed during this period. The
mean age of the patients was 71 years (range 56–85). The primary
diagnosis was chronic obstructive pulmonary disease (24), chronic
asthma (1), bronchiectasis (1), pulmonary embolism (1), heart failure
(2), lung cancer (1). Seven patients had more than one diagnostic
category. The patients had a mean FEV1 of 0.97 l (range 0.35–1.88),
mean FVC 1.89 l, (range 1.11–3.17); SpO2 92% (range 82–97%);
mean PaO2 9.26 kPa (range 6.46–11.26), PaCO2 5.25 kPa (range
4.21–6.76) with patients breathing room air. 20 patients (66%) had
alterations made to their oxygen therapy. Of these six patients had
oxygen therapy withdrawn (concentrator = 3), ambulatory oxygen (3).
One patient refused withdrawal of her portable oxygen supply.
Conclusions: A significant number of patients discharged from hospital
with some form of oxygen therapy had different oxygen therapy
requirements by 6 weeks following their hospital discharge. The results
of this review provide evidence in support of the BTS guidelines’
recommendation that follow up arrangements are required for patients
discharged home on oxygen therapy.
1. Domiciliary Oxygen Therapy Services. Clinical Guidelines and
Advice for Prescribers. A report of the Royal College of Physicians,
1999.
2. The Clinical Components for the Oxygen Service in England and
Wales. BTS, January 2006.
P168 EARLY EXPERIENCE OF A PHYSIOTHERAPY LED
AMBULATORY OXYGEN CLINIC
M. K. MacLeod, G. E. Rosie, G. L. Christie, O. J. Dempsey. Aberdeen Royal
Infirmary, Aberdeen, UK
Background: In March 2006 we developed the first Scottish physiother-
apy led Ambulatory Oxygen Service, running in parallel with our
Interstitial Lung Disease (ILD) clinic, in Aberdeen Royal Infimary. A
protocol was developed based on the BTS 2004 guidelines.1 Patients
underwent a structured assessment including baseline oximetry, 6-
minute walk test (6MWT), with oximetry monitoring and measurement of
Borg score (perception of breathlessness/fatigue). Patients (and their
carers) views on ambulatory oxygen therapy and their anticipated use of
this, were sought.
Results: Twenty six patients (16 male) were referred in the first 4 months,
median age 68 (range 19–83) of whom 1 still smoked, 16 were ex-
smokers, and 9 were life long non-smokers. Of these patients, 20 had
ILD (of whom 13 had idiopathic pulmonary fibrosis), 4 had chronic
obstructive pulmonary disease, and 2 had cystic fibrosis. 19/26 patients
had no oxygen at home prior to assessment, but were reporting effort
related dyspnoea with the potential for exercise desaturation (,90%)
during their 6MWT. 18/26 patients were prescribed ambulatory oxygen
following their assessment, but only 6/18 of had full correction of their
hypoxia on exercise, principally because of limited availability of
portable high flow oxygen (CD) cylinders in Scotland. Of the remaining
8 patients who were not prescribed oxygen, 4 patients declined
ambulatory oxygen, despite their assessment suggesting potential
benefit, and 4 were found not to require it. Since starting our clinic,
4/18 patients have subsequently been reviewed, and found to be using
their ambulatory oxygen appropriately. 5/18 patients completed their
baseline tests outwith the clinic, but of the remaining 13 patients, 6/13
demonstrated varying degrees of improvement in all 3 outcome
measures (walking distance, oximetry, and Borg scores) with ambulatory
oxygen and 7/13 showed improvement in 2 out of 3 outcome measures.
Conclusions: Our preliminary data suggest that patients with chronic
lung disease, the majority of whom had ILD do derive subjective and
objective benefit from ambulatory oxygen, although it is unfortunate that
high flow ambulatory oxygen cylinders are currently difficult to source.
Furthermore, we have found that physiotherapists are ideally placed to
coordinate such a service. A more rigorous evaluation of the benefits of
ambulatory oxygen, including impact on health related quality of life, is
needed.
Abstract P166 Mean FEV1/FVC (%) according to
subgroup
Asian White
Male Smokers 52.3 51.0
Non-smokers 57.6 56.9
Female Smokers 56.7 53.5
Non-smokers 61.5 58.4
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1. BTS. Clinical Component for the home oxygen service in England and
Wales 2004.
P169 HIGH FLOW OXYGEN AS A RISK FACTOR FOR DEATH
IN PATIENTS ADMITTED TO HOSPITAL WITH ACUTE
EXACERBATIONS OF CHRONIC OBSTRUCTIVE
PULMONARY DISEASE
R. D. Barker1, L. Smith1, J. Fenton1, C. Jones1, M. Johnson1, P. Cullinan2.
1Department of Respiratory Medicine, Kings College Hospital, London SE5
9RS; 2National Heart & Lung Institute, Imperial College, 1b Manresa Road,
London SW3 6LR, UK
Background: There is concern about an association between the
administration of high flow oxygen (HFO) and death, in hospitalised
patients with acute exacerbations of COPD (AECOPD). So far the
epidemiological evidence is relatively weak.(Durrington, et al. Q J Med
2005, Denniston, et al. Clin Med 2002, Murphy, et al. Emerg Med J
2001) There have been no attempts to evaluate whether any putative
association is confounded by poor lung function. We evaluated the
relation between HFO and in-hospital death, in a cohort of more than
1000 admissions with AECOPD.
Methods: Consecutive patients with AECOPD, admitted to Kings College
Hospital between September 2003 and July 2006, were identified by
specialist COPD nurses. The first blood gas taken in hospital was
recorded and the inspired O2 recorded. HFO was defined as FiO2.28%
or .2 l/min O2 via nasal speculae. Lung function was measured in
stable state in our lung function laboratory and categorised according to
GOLD criteria. Death was recorded in our COPD database and cross
checked with the hospital computerised administrative system. Each
patient’s last admission to hospital with AECOPD was used for analysis.
Results: Six hundred and eight patients contributed at least one
admission to the dataset. Eighty nine (14.6%) of these ended in death.
339 (56%) were men, median age 72 years (5th–95th centile, 50, 87),
321 of 464 (69.2%) had an FEV1% predicted of less than 50%, 97 of
503 (19.3%) received HFO. In univariate analyses, risk factors for death
in hospital included; HFO (odds ratio OR 2.40, 95% CI 1.38, 4.15),
Gold Class (FEV1,30% compared with FEV1 50–80% OR 12.09, CI
2.82, 51.71) and age (years) (OR 1.05, CI 1.03, 1.08). The effects of
HFO and Gold Class were independent of age. However, HFO was not
significantly associated with death when Gold Class was included in the
regression model. This may be because the risk of death associated with
HFO was smaller in those whose lung function had been done (n = 391,
OR 1.88, CI 0.88, 3.69) than in those in whom the lung function had not
been done (n = 112, OR 3.24, CI 1.28, 8.21).
Conclusions: These data support the contention that high flow oxygen is
associated with a doubling of the risk of death in AECOPD. Whether the
effect is independent of other risk factors for death remains in doubt.
Large numbers of patients recruited prospectively, or a randomised trial,
may be required to properly adjust for potential confounding variables.
P170 ASSESSMENT FOR LONG TERM OXYGEN THERAPY AT
A DISTRICT GENERAL HOSPITAL: DOES OVERNIGHT
PACO2 PROVIDE ADDITIONAL INFORMATION?
H. Marshall1, T. Daniels2, N. Siddique3, M. Townsend4, D. Laws4. 1Salisbury
District Hospital, UK; 2Southampton General Hospital, UK; 3Dorset County
Hospital, UK; 4Royal Bournemouth Hosptial, UK
Introduction: Long term oxygen therapy (LTOT) is of proven survival
benefit in chronically hypoxic patients with chronic obstructive pulmon-
ary disease (COPD). Current guidelines for assessing patients for LTOT
do not make recommendations on whether overnight studies are
required based on findings that daytime hypoxia is closely correlated
to overnight hypoxia (Stradling et al 1983). Due to concerns over the
development of hypercapnia the current practice for LTOT assessment at
our hospital is to perform arterial blood gas analysis after 1 hour of
LTOT (1 hour ABG), and again after overnight LTOT (overnight ABG) as
an inpatient.
Aims: We wished to assess whether overnight ABG identified patients
that had significant rises in PaCO2 that were not identified at the 1 hour
ABG.
Method: We retrospectively analysed 150 LTOT studies conducted at our
DGH between 1998 and 2005. Of these, 64 met all the criteria for LTOT
and had complete data for baseline, 1 hour, and overnight ABGs.
Results: Patient characteristics n = 64 (male = 41), mean age 71 (range
53–88) current smokers n = 6, mean FEV1 0.62 l (range 0.15–1.89 l),
BMI 25.5 (range 14.8–44.8). Results showed good correlation between
resting PaCO2 and one hour PaCO2 (r = 0.90); between resting PaCO2
and overnight PaCO2 (r = 0.79); and between 1 hour PaCO2 and
overnight PaCO2 (r = 0.89). Although mean PaCO2 rose by 0.43 kPa,
mean pH was well maintained. Five patients who had a normal pH at
1 hour developed acidosis overnight, mean pH 7.33 (7.31–7.33).
Discussion: These results show a strong correlation between PaCO2 at
baseline, 1 hour and overnight. However there was a small group of
patients who only developed acidosis after overnight oxygen. Further
research may identify the subgroups that are more at risk of nocturnal
hypercapnia (possibly the obese patients or those with daytime
hypercapnia). We believe that questions about the role of overnight
studies remain unanswered.
P171 TOO MUCH OF A GOOD THING? OXYGEN ALERT
CARDS ARE HELPFUL FOR CHRONIC OBSTRUCTIVE
PULMONARY DISEASE PATIENTS AT RISK OF OXYGEN
TOXICITY
C. Tooley1, D. Ellis1, D. Greggs2, J. Scott2. 1James Paget Healthcare NHS
Trust; 2East of England Ambulance Service
Introduction: It is well established that optimal oxygen therapy needs to
be provided for patients with COPD while they are being transferred to
hospital, or assessed in A&E. (Murphy et al 2001, Durrington et al
2005). The objective is to give appropriate oxygen to support their needs
while avoiding the risk of CO2 retention and respiratory acidosis.
Method: Working with ith the ambulance service we have designed a set
of criteria to identify patients at risk of oxygen toxicity. These patients are
issued with an oxygen alert card. This information is recorded on the
ambulance service database. From January to June 2006, 16 patients
were issued with a card. Patient notes were audited for: hospital
admissions, method of transport, journey time, written verification that
the card was used and oxygen concentration administered during the
journey.
Results: Of the 16 patients issued an oxygen alert card 10 (62.5%) were
readmitted during this period. 5 patients (31%) had one admission, 3
patients (18%) had two admissions, 2 patients (13%) had three
admissions. Six patients (38%) were not readmitted during this period.
Therefore we audited 17 admissions. Sixteen patients (94%) arrived at
hospital using the ambulance service, either as a 999 call or following
assessment by the GP who requested admission. Journey time included
time spent by the paramedic at the patients home. The mean journey
time was 42 minutes (range 31–63 minutes). Eight patients (47%) had a
record of use of the oxygen alert card in the ambulance report form. One
patient (6%) presented himself to A&E where 28% oxygen was
administered. Eight patients (47%) had no formal verification of use of
the oxygen alert card in their notes. In 15 of the 17 admissions the
patient was given controlled oxygen. In only two cases was an
inappropriately high concentration of oxygen used.
Discussion: The audit of flow rates administered was encouraging. We
feel this demonstrates success of this system. It may be a reflection of the
liaison with the ambulance service and the education delivered by the
respiratory nurse specialist when launching the oxygen alert card. We
believe these results demonstrate the importance of registering the
issuing of the card on the ambulance service data base. The ambulance
Abstract P170
ABGs Baseline mean (range) 1 hour Overnight
pH 7.42 (7.30–7.49) 7.40 (7.29–7.47) 7.40 (7.26–7.53)
pCO2 5.85 (2.95–8.81) 6.14 (3.35–9.11) 6.28 (3.55–8.79)
pO2 6.99 (5.14–7.98) 9.76 (6.90–15.61) 9.22 (6.45–13.89)
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journey time appears long, but we felt it important to include the time
spent in the home when the patient was already receiving oxygen. The
results suggest that there has been an increased awareness of the
importance of delivering controlled oxygen to patients at risk of oxygen
toxicity and that use of an oxygen alert card is an effective method of
identifying these patients.
P172 COMPARISON OF NON-INVASIVE MEASUREMENT OF
PCO2 AND O2 SATURATION WITH ARTERIAL BLOOD
GAS MEASUREMENT DURING ASSESSMENT FOR
LONG TERM OXYGEN THERAPY
H. Lamb, C. Hall, J. Calvert, J. Harvey, N. Maskell. Southmead Hospital,
Bristol BS10 5NB, UK
Background: Arterial blood gas (ABG) sampling is an essential part of
patient assessment for long term oxygen therapy (LTOT). It is an invasive
& potentially painful procedure. The TOSCA device (Transcutaneous
Oxygen Saturation & Carbon Dioxide Analysis Monitor, Linde AG)
allows non-invasive monitoring of pCO2 and SpO2 through a single
sensor applied to the ear lobe.
Aim: To determine the accuracy of pCO2 and SpO2 measurements using
transcutaneous monitoring compared with ABG (Rapidlab 348) and to
assess whether LTOT could be safely prescribed using TOSCA
measurements alone following an initial baseline arterial blood gas
measurement.
Method: Consecutive patients presenting to our oxygen assessment clinic
had concurrent ABG & TOSCA monitoring. Comparison was made of
pCO2 and SpO2 on room air and after administration of 2 litres O2 via
nasal prongs for 60 minutes. Values obtained using the two methods
were compared by the method of Bland & Altman using STATA 9
(StataCorp, Texas).
Results: 159 measurements were made in 102 subjects (52% male,
mean age 73 years) with the following mean ABG values at baseline:
pO2: 8.05KpA (95% CI 7.80–8.31), CO2 5.81KpA (95% CI 5.6–6.02)
and SpO2 90.5% (95% CI 89.6–91.4). TOSCA values for SpO2 were on
average 0.97% (95% CI 21.3% to 20.64%) below those measured by
ABG. The reference range for the difference in the reading was (mean
+/22SD) 25.2% to +3.2%. The variance of the difference in
measurements made using the 2 devices increased significantly for
patients with lower oxygen saturations (Pitman test p,0.0001). TOSCA
values for CO2 were on average 0.26 KpA (95% CI 20.35 to 20.18)
below those measured by ABG (Reference range: 21.3KpA to
+0.8KpA) with stable variance across the range of measurement.
Finally the ability of TOSCA to accurately reflect changes in CO2 was
measured (n = 35). The change in CO2 obtained using the TOSCA
device was 0.14KpA (95% CI 20.34 to 0.05) below that measured
directly by ABG (reference range: 21.272 to +0.98KpA).
Conclusion: The TOSCA device underestimates pCO2 and SpO2
compared to ABG but mean differences are not big enough to be of
clinical significance. In addition precision of the SpO2 measurement
decreased with increasing patient hypoxia as is usual with pulse
oximetry. Variability of TOSCA measurements is high but all patients
undergoing LTOT assessment who had a rise in pCO2 of up to 1KpA
were correctly identified using this non-invasive measurement.
TOSCA Equipment was loaned by Linde AG.
P173 REVIEW OF A FLIGHT ASSESSMENT SERVICE
M. Singh, J. Shakespeare, S. Gompertz. Selly Oak Hospital, University
Hospital Birmingham, UK
Background: Air travel is increasingly common, with a single UK airline
carrying over 33 million passengers annually and over 1 billion people
traveling by air worldwide each year. Longer flights are associated with
increased risks of oxygen desaturation, especially in patients with
chronic lung disease.
Aims and Objectives: To review the flight assessment service provided
by the Lung Investigation Unit (LIU) at our Trust against BTS guidelines
(Managing passengers with respiratory disease planning air travel
2002, revised 2004).
Patients and Methods: 124 patients (66 males; mean age 63 (SD 10)
years) underwent flight assessment (current cost £209 per test at our unit)
over a period of approximately 5 years (January 2001–February 2006).
Data were collected from the LIU’s electronic database.
Results: The single largest recorded disease category for which flight
assessments were performed was COPD (38%). 104 of the 124 patients
had baseline pulse oximetry; 25 had resting saturations .95%, 9 had
saturations ,92% and 70 had values of 92–95%. Sixty five of the 70
patients with intermediate saturations (92–95%) had hypoxic challenge
testing (HCT) with 15% inspired oxygen. Fifty five of these had a positive
test, indicating significant desaturation and the need for supplemental in-
flight oxygen. All 25 of the patients with baseline saturations .95% had
HCTs (contrary to the guidelines), as did 3 of those with saturations
,92% (all patients with baseline saturations ,92% will require in-flight
oxygen). Surprisingly, 11/25 (44%) of HCTs in those with baseline
saturations .95% were positive. Overall 66 of 124 patients fulfilled the
criteria for in-flight oxygen.
Conclusion: Flight assessments are expensive tests and screening
oximetry is not being used according to BTS guidelines; all patients
with saturations .95% at baseline had hypoxic challenge tests
performed. However, a significant proportion of these patients (44%)
would appear likely to desaturate while flying.
P174 IS THE HOME OXYGEN ORDER FORM FIT FOR
PURPOSE?
C. L. Shoults, S. Abeysiri, A. C. Davidson, N. T. Bateman. Guy’s and St
Thomas’ NHS Foundation Trust, London SE1 7EH, UK
Introduction: Since February 2006 hospital doctors or suitably trained
nurses have been able to prescribe home oxygen for patients using the
home oxygen order form (HOOF). The HOOF specifies the daily usage
of oxygen and the requirement for ambulatory oxygen. It was designed
to be simple to complete and assumes appropriate assessment has taken
place. In a pilot study in December 2005 we found evidence of
inadequate assessment resulting in inappropriate and incomplete
recommendations for home oxygen. The HOOF demands no informa-
tion on blood oxygen levels or respiratory function. We decided to
assess whether the introduction of the HOOF had improved the quality of
prescribing of oxygen.
Method: The notes of all patients for whom a HOOF was submitted from
the Trust in May 2006 were audited. For each patient, the recommenda-
tions on the HOOF were compared with the diagnosis, spirometry, blood
gas results and mobility in the hospital notes to assess the appropriate-
ness of the request for home oxygen. We looked for measurement of
hypoxia (PaO2 £7.3kPa) and its correction with oxygen (at the HOOF
flow rate) to a PaO2
38kPa as defined in the guidelines. The hours of
oxygen were compared with the guidelines for each diagnosis.
Results: See table. Only 7 (50%) of the 14 patients for LTOT had a
measurement of the PaO2 achieved on the oxygen prescribed on the
HOOF. In only 6 (42%) of 14 requests for LTOT did both the flow rate
reflect the measured blood gases and the hours requested match the
guidelines for the diagnosis.
Discussion: Despite an average of 45 minutes of respiratory nurse
specialist’s advice before each HOOF was submitted there was still
failure to assess patients appropriately or prescribe the correct oxygen.
(see C Eames et al submitted BTS winter meeting, 2006)
Conclusion: Inclusion of assessment data on the HOOF is crucial to
ensure accurate prescribing of oxygen. Introduction of the HOOF in its
Abstract P174 Twenty five HOOFs were completed for 22 patients.
Category n PaO2 £7.3kPa on air
PaO2
38kPa on O2 as
HOOF
Hours of O2
appropriate
Palliative 6 N/A N/A N/A
LTOT 13 8 (1) 7 (1) 8 (1)
LTOT + ambulatory 1 1 0 1
Ambulatory only 2 1 (1) 0 (1) (1)
( ) data unavailable.
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current state has not improved this. In the absence of formal
reassessment (which is not funded in our district) the HOOF is not fit
for purpose.
P175 REGIONAL DIFFERENCES IN AMBULATORY OXYGEN
PROVISION IN THE UK
J. Lenney, A. G. Robson, J. A. Innes. Respiratory Function Service, Royal
Infirmary of Edinburgh and Western General Hospital, Edinburgh, UK
In January 2004 the Scottish Executive produced new guidelines for the
provision of domiciliary and portable oxygen therapy (Scottish Executive
NHS HDL (2004) 01). Similar guidelines for England and Wales have
since been produced by the Department of Health (DOH). Both include
the provision of ambulatory oxygen for patients on long term oxygen
therapy (LTOT) who are able to leave the house. Patients who are not on
LTOT but are seen to benefit clinically may also be prescribed
ambulatory oxygen following an appropriate physiological assessment.
However, the assessment criteria recommended by the Scottish Executive
differ from the subsequent recommendations for England and Wales of
the British Thoracic Society (BTS) (Clinical Component for the Home
Oxygen Service in England and Wales, January 2006, BTS website).
We followed a simple protocol for the assessment of patients’
response to ambulatory oxygen using a treadmill exercise test. This is
a single blind, controlled trial, with the patient receiving either oxygen or
air (2 litres/minute) via a nasal cannulae. After the patient has been
breathing the test gas for 5 minutes the oxygen saturation (SaO2) and
breathlessness score (BS) using the Borg scale are recorded. Patients are
then asked to stand on the treadmill before the treadmill is started and
the patient exercised for a maximum of 15 minutes. The pace of the
treadmill is set at 1.0 or 1.5 mph depending on fitness. SaO2 and BS are
recorded every minute until the patient stops or SaO2 falls below 80%.
The patient is then rested for 30 minutes before the assessment is
repeated with the second test gas. According to the Scottish guidelines a
10% increase in walking distance and/or a 10% reduction in BS are
considered to be positive indicators for the provision of ambulatory
oxygen. In contrast, the BTS guidelines define desaturation and specify
that ambulatory oxygen should only be prescribed if exercise desatura-
tion is corrected and there is an improvement in exercise capacity and/
or breathlessness.
To date, 37 patients (24 males) have been assessed and 21 have
demonstrated an improvement in exercise capacity whilst receiving
ambulatory oxygen. Under the Scottish guidelines a further 7 patients
would have qualified for ambulatory oxygen on BS alone. In contrast,
using the BTS guidelines only 17 patients would have qualified for
ambulatory oxygen. There is little correlation between BS, SaO2 and
exercise capacity—for example, one patient walked further on air and
perceived less breathlessness despite having better SaO2 on oxygen.
Hence, the reliance of the Scottish guidelines on small improvements in
walking distance and BS can result in inappropriate provision of
ambulatory oxygen in patients without reversible hypoxia.
P176 DO WE NEED TO ADMIT PATIENTS OVERNIGHT FOR
LONG TERM OXYGEN THERAPY ASSESSMENT?
R. Khashkhusha, I. Sutcliffe. Dewsbury & District General Hospital, UK
Background: There are no clear guidelines on how patients should be
assessed for long term oxygen therapy (LTOT), particularly for the risk of
CO2 retention. Dewsbury & District General Hospital is one of the few
hospitals in UK where all patients for LTOT assessment are admitted
overnight to assess the risk of hypercapnia. Assessment is done as per an
algorithm.
Method: We performed a retrospective study of 35 patients who
had LTOT assessment at Dewsbury and District General Hospital
between May 2003 and June 2005. We reviewed the blood gases,
which were performed three weeks apart at the clinic (on air) and during
admission (on air, on 2 l of Oxygen, on 4 l of Oxygen and early
morning).
Results: 17/35 was prescribed LTOT according to the national criteria.
The blood gases of 12 patients had improved when re-assessed after
three weeks and therefore no further evaluation for LTOT was carried
out. 6/23 patients assessed developed a significant increase in PCo2
(.1 Kpa) on oxygen therapy. Out of these 4 patients developed a
significant increase in PCo2 (.1 Kpa) on 2 l of oxygen after two hours,
1 patient developed a significant increase in PCo2 (.1 Kpa) on 4 l
of oxygen after two hours and 1 patient developed a significant
increase in PCo2 (.1 Kpa) on 2 l of oxygen on the morning arterial
blood gases.
Conclusion: 6/23 (26.1%) developed significant CO2 retention and was
not prescribed LTOT. It is of interest to note that one patient developed
significant hypercapnia after overnight oxygen therapy, which is not
usually routinely tested in most hospitals prescribing LTOT. We
recommend an overnight inpatient LTOT evaluation. A study with larger
patient groups/regional data is needed.
P177 OXYGEN ASSESSMENT IN BLAENAU GWENT
D. A. Wales1, C. Wood2, N. Janes1, L. Ryan1, S. Dempsey1. 1Nevill Hall
Hospital, Brecon Road, Abergavenny Monmouthshire NP7 7EG, UK;
2Blaenau Gwent Local Health Board, Station Hill, Abertillery, Blaenau
Gwent NP13 1UJ, UK
Introduction: With the implementation of the new oxygen contract
formal assessment of the oxygen needs of patients is required. Many
patients who use home oxygen have never been formally assessed.
Aim: To review all patients receiving oxygen in Blaenau Gwent (BG), a
Local Health Board serving population of 71 000 and rationalise oxygen
prescribing.
Method: Patients using oxygen in the community were identified. A list of
340 patients was supplied by Contractor Pharmacy Wales/Business
services Mamhilad. The original list was refined by contacting all
GP practices in BG and also all pharmacies supplying oxygen. Most
of the oxygen being supplied was in the form of cylinders for short
burst. 205 patients on the list were registered at Nevill Hall Hospital
and the notes of these patients were reviewed to identify patients
who were know to the Chest Clinic and under regular review. These
patients were simply asked to fill in a consent form and a Home Oxygen
Order Form (HOOF) was completed. From the remaining patients high
users i.e. patients using at least 8 oxygen cylinders per week, were
identified. GP’s were asked to refer these patients to clinic urgently for a
full medical review and oxygen assessment. All other patients were
initially assessed by a nurse; some complex cases were referred on for
medical review.
Results: See table.
Conclusion: Following assessment, a large amount of inappropriate
oxygen prescription could be discontinued. For patients requiring
oxygen, an appropriate mode of administration was arranged. This
resulted in very significant financial saving. Investment is needed to
ensure all patients are assessed fully.
Abstract P177
Number of patients established on oxygen and under regular follow up 65
Number of patients assessed 239
Patients who discontinued oxygen
Number of patients who discontinued oxygen after assessment 92
Number of patients who had discontinued oxygen themselves 25
Total number of patients who discontinued oxygen 117
Breakdown of patients remaining on oxygen
Number of patients changed to concentrators only 46
Number of patients changed to concentrators and ambulatory 42
Number of patients changed to portable oxygen 1
Number of patients remaining on short burst oxygen 33
Total number of patients remaining on oxygen 122
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Non-invasive ventilation
P178 ‘‘DOOR TO MASK TIME’’ IN NON-INVASIVE
VENTILATION FOR EXACERBATIONS OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
S. Sivalingam, A. Blackburn, D. Ellis. James Paget Hospital, Gorleston, Great
Yarmouth, UK
Introduction: An optimum ‘‘target time’’ for starting non-invasive
ventilation (NIV) after hospital admission for exacerbation of chronic
obstructive pulmonary disease (COPD) (COPDE) has not been identified
though it is known that delay in starting it lead to poorer outcomes. We
felt that there were some delays in our service. We carried out a
retrospective audit to identify the causes and to describe an ideal ‘‘door
to mask time’’. Following the audit, educational needs would be
identified and acted upon before reauditing the service.
Methods: All patients commenced on NIV outside the intensive care unit
are logged by the respiratory nurse specialists (RNS). 41 consecutive
patients were identified from this list, covering a period of 11 months
(01/03/05 to 31/01/06). Of these, 31 case notes were available and
were included in the audit.
Outcome Measures: An indication to start NIV was considered if: (a) the
patient had known or suspected COPD (b) the patient had acute
hypercapnic respiratory failure with pH below 7.35 and (c) medical
treatment had been optimised (defined by the examining doctor). If
medical treatment had not been optimised, a further 2 hours was
allowed to do so before repeating arterial blood gases (ABGs). An
arbitrary time limit was set at two hours from ABGs to starting NIV. We
could identify no time limits in the literature, but this seemed reasonable,
based upon the practicalities of setting up the equipment once the RNS
had been informed of the need for it.
Results: 18/24 (75%) commenced NIV within 2 hours of ABGs. Delays
occurred in 6/24 (25%) of patients. In 7/31 cases, the time of starting NIV
was not clear from the documentation. In 22/31 (71%) of cases, NIV was
initiated in the Medical Admissions Unit (MAU) or Accident and Emergency
(A&E). Only 6/31 (19%) commenced NIV on the Respiratory Ward.
Conclusion: Unacceptable delays in starting NIV were found in 25% of
cases. Identifying A&E and MAU as the key areas where NIV is commenced
has enabled us to concentrate further educational efforts in these areas in
addition to our rolling programme on the Respiratory Wards. Simple visual
reminders about NIV in respiratory failure have been created and displayed
above the 2 main blood gas machines. These posters capture the junior
doctors’ attention and give vital information. It is accepted that starting NIV
early for acidotic COPDE reduces mortality, the need for intubation and
length of hospital stay. We feel a ‘‘target time’’ for NIV needs to be
established nationally as a major audit indicator, much like door-to-needle
time is in acute MI and thrombolysis.
1. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation
for acute exacerbations of chronic obstructive pulmonary disease on
general respiratory wards: a multicentre randomized controlled trial.
Lancet 2000;355:1931–5.
2. British Thoracic Society Standards of Care Committee. Non-invasive
ventilation in acute respiratory failure. Thorax 2002;57:192–211.
P179 PREDICTORS OF OUTCOME FOR PATIENTS ADMITTED
TO A RESPIRATORY HIGH CARE WARD
S. Twite, J. Curtis, J. Catterall. Bristol Royal Infirmary, Bristol, UK
Introduction: Respiratory high care wards are increasingly prevalent.
Unlike intensive care units little has been published on the predictors of
outcome for patients admitted into this environment. We looked at the
admissions to the respiratory high care ward at the Bristol Royal Infirmary
over one year and retrospectively analysed factors affecting the outcome.
Results: One hundred and eight patient episodes were analysed. The
mean age was 69 years (95% CI 66 to 72), and the mean APACHE II
score was 15.87 (95% CI 14.03 to 17.71). The inpatient mortality rate
was 24% (25 patients), and the six-month survival after the day of
admission was 55%. In survivors the mean length of hospital stay was
13.8 days (0–88). Of the 83 patients surviving to discharge 22% (18
patients) were readmitted within a month.
We collected data on a number of factors and related them to
inpatient mortality. These included; diagnosis; comorbidities; usual
exercise tolerance, performance state, and abode; and physiological
markers. Whole data sets were not available in all patients. The
continuous variables with a statistically significant correlation to inpatient
mortality are shown in table 1.
We also calculated odds ratios for inpatient death for a number of
absolute variables, as shown in table 2. Other results, such as usual abode
and exercise tolerance, did not significantly correlate with inpatient death.
Conclusion: Although the APACHE II score and other physiological
markers correlated with inpatient death, the correlations were weak.
Patients with pneumonia or those who were normally dependent on
others for self care appeared to be at an increased risk of death during
admission.
P180 OUTCOMES OF ACUTE NON-INVASIVE VENTILATION
THERAPY IN CHRONIC OBSTRUCTIVE PULMONARY
DISORDER PATIENTS WITH A PH LESS THAN 7.25
D. Banerjee, M. Needham, S. Jobanputra, E. Gallagher. Department of
Respiratory Medicine, Birmingham Heartlands Hospital, Heart of England
NHS Foundation Trust, Bordesley Green East, Birmingham, UK
Introduction: It has been suggested that chronic obstructive pulmonary
disease (COPD) patients presenting acutely with a pH,7.25 and
CO2.6.0 should be considered for intubation and ventilation. However,
limited critical care facilities may not allow all patients to undergo this
form of therapy. At the Birmingham Heartlands hospital 11-bedded NIV
multidisciplinary unit, we offer NIV to all patients with a pH,7.35 and
CO2.6.0, with close links to ITU if intubation becomes a necessity. We
conducted a 2-year prospective analysis of outcomes of all patients with
COPD presenting to the unit with a pH,7.25 and CO2.6.0.
Methods: Analysis of blood gases (when NIV considered and one hour
post NIV), intubation and in-hospital mortality rates in patients
presenting with an exacerbation of COPD in respiratory failure
(pH,7.25 and CO2.6.0), between 1 August 2004 and 31 July 2006.
Results: In the 2-year period, 354 patients were admitted to the NIV unit
with hypercapnic respiratory acidosis. These data do not include those
patients in pre-arrest situation and intubated immediately. 255 (72%)
were COPD, obesity 24 (7%), thoracic cage wall deformity 7 (2%),
neuromuscular 4 (1%) and others 64 (18%). Of the 255 COPD subjects,
82 admissions (72 subjects: 43 females) had a pH,7.25 and CO2.6.0.
There were 4 (4.8%) intubations (1 subsequent death) due to worsening
acidosis, and 16 (22%) in-hospital deaths. In 15 patients, NIV was
Abstract P179 Table 1 Factors that correlated significantly with inpatient mortality
Variable Correlation coefficient 95% CI p Value
Blood urea 0.42 0.22 to 0.58 0.0001
APACHE II score 0.40 0.15 to 0.60 0.025
WHO performance state 0.27 0.01 to 0.50 0.04
Age 0.23 0.04 to 0.40 0.02
Albumin 20.35 20.53 to 20.15 0.001
pH on admission ABG 20.35 20.58 to 20.06 0.018
Abstract P179 Table 2 Factors with significant odds ratio
for inpatient death
Variable OR 95% CI
Primary diagnosis acute exacerbation of
COPD
0.22 0.08–0.61
Primary diagnosis pneumonia 5.67 1.85–17.37
Dependent on others for self care 3.71 1.17–11.80
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considered as ‘‘ceiling of care’’, 12 had ‘‘end-stage’’ COPD with
multiple comorbidities, and 3 multiorgan failure. The table shows blood
gas data before and 1 hour after NIV: (mean (SD)).
Conclusions: This study demonstrates that NIV therapy in subjects with a
pH,7.25 has acceptable intubation rates with blood gas improvements,
and may avoid unnecessary intubation/ventilation. This high risk group,-
however, do have a high mortality rate due to multiple comorbidities.
P181 NON-INVASIVE VENTILATION: EVIDENCE OF
EFFICACY AS MAXIMAL THERAPY IN ACUTE
RESPIRATORY FAILURE OUTSIDE HDU/ICU
B. Lee, F. Chua, S. Gareeboo, A. Blay, D. Lai, P. Shah, G. Davies, S. Singh.
Department of Respiratory Medicine, Chelsea & Westminster Hospital,
Imperial College, London SW10 9NH, UK
Aim: To evaluate the effectiveness of ward-based non-invasive ventila-
tion (NIV) as maximal (ceiling) treatment for acute respiratory failure and
to identify factors that might influence clinical outcome.
Background: NIV has emerged as a valuable adjunct to standard
medical treatment for respiratory failure, primarily in decompensated
chronic obstructive pulmonary disease (COPD). Its use in such patients
has been proven to decrease the need for intubation and mechanical
ventilation. However, the potential of NIV as ceiling therapy in acute
respiratory failure remains unclear.
Method: Data were extracted from notes of patients commenced on NIV
outside HDU and ICU between June 2003 and June 2006 (n = 141;
76M, 65F, totalling 153 episodes). Indications for NIV use were: non-
infective COPD (n = 27); infective COPD (n = 61); left ventricular failure
(n = 8); pneumonia (n = 18); neuromuscular disorders (n = 5); OSA/
hypoventilation (n = 7) and others (n = 15). Differences in smoking
history, age, comorbidity, and duration on NIV were evaluated. NIV
success was defined as improved arterial blood gas (ABG) indices and
clinical state, or failure, if neither was achieved or patients were stepped
up to ICU or died. Clinical outcome was defined as survival to discharge
or death during hospitalisation. ABGs were obtained prior to and at set
intervals after NIV commencement.
Results: Median time to NIV set-up was 3 hours. Across the different
clinical categories, mean pH improved from 7.27 (0.12) to 7.46 (0.51),
with a corresponding decrease in PaCO2 (9.48 (3.23) kPa to 7.63
(2.96) kPa). Overall, 87/153 episodes (56.9%) of NIV application were
successful. Specifically, survival to discharge was evident in 96/153 NIV
treatment episodes (62.7%). Comparison of COPD against non-COPD
groups showed that NIV was successful in 87/121 instances (72%) in the
former but only 41% in the latter. Among the non-ceiling group, 54/65
(83%) episodes of NIV were associated with survival to discharge
without requiring step-up care. When capped as ceiling therapy, NIV
outside of the ICU setting was associated with a 41.3% survival rate (33/
80 treatment episodes).
Conclusions: In the current analysis, ward based ceiling NIV was
successful in two fifths of cases of hypercapnic respiratory failure.
Proportionately more patients with COPD benefited from NIV than
individuals with non-COPD respiratory failure. COPD patients were also
twice (51%) more likely to survive to discharge than the latter (25.8%)
when NIV was the pre-determined treatment limit. These findings were
not due to differences in baseline pH or PaCO2.
Summary: Ward based NIV is associated with survival in significant
numbers of patients with acute hypercapnic respiratory failure unsuitable
for ICU.
P182 CHRONIC OBSTRUCTIVE PULMONARY DISEASE
PATIENTS’ EXPERIENCE OF USING NON-INVASIVE
VENTILATION AT HOME: A CASE STUDY APPROACH
C. Mikelsons1, T. K. Muncey2, J. A. Wedzicha3. 1Physiotherapy Department,
Royal Free Hospital, London, UK; 2Research & Postgraduate Education,
Homerton School of Health Studies, Cambridge, UK; 3Academic Department
of Respiratory Medicine, University College London, London, UK
Chronic obstructive pulmonary disease (COPD) is known to affect
patients’ quality of life and anxiety and depression (Eakin et al. Qual of
Life Res 1993;2:181–91; Lacasse et al. J Cardiopulm Rehab
2001;21:80–6). Non-invasive ventilation (NIV) is a recognised treat-
ment for patients with COPD (COPD Guideline, Thorax 2004;59(S1):1–
232) but little research has been conducted into the patients’ experience
of using home NIV. The aims of the study were to explore COPD
patients’ experience of using NIV at home, their compliance with the use
of the machine, their recommendations for improving its use and their
rating of their quality of life and anxiety and depression. A mixed
methods multiple embedded case study design was used. Quantitative
data were collected from 26 participants with COPD using NIV at home,
using the St George’s Respiratory Questionnaire (SGRQ) and the
Hospital Anxiety and Depression Scale (HADS), to inform the study and
identify 8 participants for further study. The 8 cases were selected by
splitting the results of the SGRQ into quartiles and then identifying two
cases from each quartile using the highest and lowest scores for the
combined HADS score in each quartile. Data sources for the 8 cases
were: an interview at home, demographic data and their questionnaire
results. These three sets of data were used to triangulate the findings from
each data source. The domains of activity (mean 90.42, SD 9.12) and
anxiety (mean 8.73, SD 5.14) were rated as the highest in the SGRQ
and HADS respectively. Thematic analysis of the interviews identified five
themes (compliance, support, quality of life, anxiety and depression and
recommendations). The 8 cases demonstrated high levels of compliance
with the use of NIV but some described difficulties in the initial stages.
Participants attributed their success in using home NIV to their
perseverance with using the machine. Whilst participants commented
on the role other patients had played in helping in their use of the
machine, they did not comment on any interventions by healthcare staff.
Participants viewed the use of NIV as ‘‘life-enhancing’’ and did not
report any interference with daily activities because of its use.
Participants were concerned about the apparent lack of knowledge
about NIV of hospital staff and of their GPs, which was a source of
anxiety. Recommendations fell into three categories: advice and
education, improvements to equipment and support for its use at home.
Triangulation of the data sources demonstrated the variability between
participants in terms of presentation of the disease, scores for quality of
life and anxiety and depression and in self-reported experience,
suggesting that patients using home NIV would benefit from identifying
and self-selecting care and services appropriate to their own individual
needs.
P183 THE EFFECTS OF 1 WEEK’S WITHDRAWAL OF LONG
TERM NON-INVASIVE VENTILATION IN
HYPERCAPNIC CHRONIC OBSTRUCTIVE PULMONARY
DISEASE PATIENTS
N. Oscroft1, J. Ashwood1, T. Quinnell1, J. Shneerson1, I. Smith1.
1Respiratory Support and Sleep Centre, Papworth Hospital, Cambridge, UK
Introduction: Long term non-invasive positive pressure ventilation
(NIPPV) in chronic obstructive pulmonary disease (COPD) is not of
proven benefit (Wijkstra et al. Chest 2003; 124: 337) but increasing
numbers of patients receive this treatment (Janssens et al. Chest
Abstract P180
Pre NIV One hour post NIV
pH 7.16 (0.07) 7.26 (0.07)
CO2 (kpa) 11.8 (2.9) 9.2 (2.9)
O2 (kpa) 11.1 (5.4) 10.9 (5.5)
Abstract P183
HCO3-mmol/l PaO2 kPa PaCO2 kPa
Nocturnal O2
Saturation%
Nocturnal
PtcCO2 kPa
1st 31.3 (4.3) 7.9 (1.4) 6.9 (0.8) 94 (4) 6.3 (1.1)
7th 33.2 (3.1) 7.9 (0.9) 7.2 (0.6) 93 (3) 7.8 (1)
p Value 0.06 1.0 0.164 0.7 0.027
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2003;123:67) as recommended in current NICE guidelines (Thorax
2004;59(Suppl 1):1–232). We are examining the effects of withdrawing
NIPPV in well characterised COPD patients with chronic ventilatory
failure and report the first week’s results.
Methods: Patients were recruited prospectively. All had severe COPD and
ventilatory failure prior to commencing NIPPV (daytime PaCO2.7.5 kPa
with normal pH (7.35–7.45) or nocturnal transcutaneous carbon dioxide
(PtcCO2) over 9kPa). All had used nocturnal NIPPV for over 1 year and
were compliant with treatment, mean hours daily use 7.4 (SD 1.8). Patients
were screened 4 weeks prior to withdrawal. Clinical stability was defined as
a PCO2 within 1kPa and forced expiratory volume in 1 second (FEV1)
within 15% of screening value and the absence of new symptoms of cough,
sputum or breathlessness. Data were recorded on the first night and the 7th
night without NIPPV. There were preset criteria for restarting NIPPV. The
primary outcome measure was the effect on daytime arterial blood gases
(ABG). Secondary outcomes were FEV1, nocturnal oximetry and PtcCO2.
Results: Values presented mean (standard deviation). Eight subjects (3
female), age 63.9 (8) years, BMI 29.2 (6.3), FEV1 0.77 (0.34) were
recruited. Five were on long term oxygen therapy. None restarted NIPPV
during the week. No significant changes in FEV1, PO2 or PCO2 occurred.
There was a significant increase in nocturnal mean PtcCO2 and a rise in
ABG bicarbonate. Six out of eight showed a rise in daytime PCO2 values.
Discussion: There was no significant impact on daytime ABG if NIPPV
was withdrawn for 1 week in this well defined group of COPD patients.
However there was evidence of deterioration in nocturnal ventilation
with a rise in PtcCO2. Longer follow-up will determine if this nocturnal
hypoventilation is progressive and affects daytime respiratory status.
P184 MRSA: CROSS CONTAMINATION THROUGH USE OF
NON-INVASIVE VENTILATION?
H. F. Coles, P. Murphie, S. A. Little. Department of Respiratory Medicine,
Dumfries and Galloway Royal Infirmary, Dumfries DG1 4AP, UK
Introduction: Methicillin Resistant Staphylococcus Aureus (MRSA) is a
significant infection control issue in hospital clinical medical and nursing
practice. With increasing use of, and indications for, non-invasive
ventilation (NIV) this intervention offers further potential for cross
contamination with this organism.
Methods: As a consequence of the finding of MRSA on a routine screen
of an air filter from a non-invasive ventilator in a Medical High
Dependency Unit a prospective infection control audit was conducted.
The issue was highlighted to all relevant staff, followed by screening of
all machines after each use, together with patient filter changes every
24 hours, and air filter changes between patients.
Results: All four NIV machines used in the acute service were screened over
a 6 month period, according to an agreed infection control protocol,
resulting in 179 samples, out of which 20 swabs produced growth on
bacteriological culture. Six cultures of staphylococcus aureus were obtained
during the screening period but identification of all positive samples clarified
these as probable skin or environmental contamination with no evidence of
MRSA within filters or airflow tubing on the machines. There appeared no
issue of concern with regards to patient management or cross contamina-
tion as a consequence of any of the positive cultures.
Conclusions: We conclude that although non-invasive ventilation offers
potential for cross infection this does not appear to be a clinical problem
provided adequate implementation of a comprehensive infection control
policy. Appropriate machine decontamination and hand cleansing is
essential in combating the issues surrounding cross contamination, and
there remains scope for improvement and development within this area
of practice.
These data have been accepted for presentation at the European
Society Scientific Meeting in Munich 2006.
Investigation and management of
pleural disease
P185 A ONE YEAR RETROSPECTIVE REVIEW OF THE
RADIOLOGICAL INVESTIGATIONS OF CONFIRMED
MESOTHELIOMA PATIENTS IN A TERTIERY REFERAL
CENTRE
D. Barnes, J. Entwisle. University Hospitals of Leicester Department of
Radiology, Glenfield Hospital, Leicester, UK
Malignant pleural mesothelioma (MPM) accounts for 17 000 deaths per
year in the United Kingdom. This rate is increasing with and is estimated
to peak within the next decade with 1950–2450 deaths per annum
expected.1 Modern diagnostic techniques allow prompt diagnosis with
subsequent CT guided biopsy, thoracoscopy and management under the
relevant multidisciplinary meeting (MDT). Prompt early diagnosis allows
the patient to be considered for more radical treatment and entry into
clinical trials. Early treatment with chemotherapy in a single randomized
trial was thought to be advantageous to survival.2 The NICE guidelines
for the management of patients with lung cancer suggest referral for
unilateral pleural effusions (with no other cause) to a chest physician/
MDT.3 and there should be a coding mechanism for this process.
The initial diagnosis is often prompted by the chest x ray (CXR)
findings of a unilateral pleural effusion or thickening. We reviewed a
cohort of patients diagnosed pathologically or clinicoradiologically with
MPM from 1 May 2004 to 30 April 2005. All patients within
Leicestershire who had been reviewed by the single MDT for the area
and had been given a diagnosis of MPM were included. A review of the
patients’ investigations and radiology was performed using the MDT
minutes and radiology information system (RIS) respectively.
There were 30 patients, 26 male and 4 female with an average age of
70.9 years (median 75 years). 20 casers were diagnosed histologically
with the other 10 diagnosed on clinicoradiological grounds. 27 patients
(90%) were found to have a unilateral pleural effusion on CXR prior to
diagnosis (17 right, 10 left). 5 patients (17%) had pleural thickening on
CXR. Only 3 patients (10%) had cancer referral codes on the
radiological report. 2 suggested referral to a chest physician.
30 patients had an initial CXR. 29 patients had a CT with only 3
having a TMN staging in the report. 12 patients had a CT guided pleural
biopsy (7 positive and 5 inconclusive). 10 patients had a follow up CT.
Time taken from initial CXR showing an ‘‘unexplained pleural
effusion’’ to discussion at first MDT ranged from 0.2–27 months, with
average of 4.3 months and median of 0.8 months.
This study shows that a proportion of patients had a delay in diagnosis
which could have limited their treatment options. The ‘‘unexplained’’
unilateral pleural effusion on CXR needs to be highlighted as a potential
radiological sign of MPM and other malignant pleural disease, both to
radiologists and clinicians. A finding of unexplained unilateral effusion
should prompt specialist referral to limit time delays between initial
suspicion and diagnosis and treatment, appropriate coding of these
CXRs aids this process.
1. Benamore RE, et al. Use of imaging in the management of malignant
pleural mesothelioma Clin Radiol 2005;60:1237–47.
2. O’Brien ME, et al. A Randomised trial in malignant mesothelioma
(M) of early (E) versus delayed (D) chemotherapy in symptomatically
stable patients: the MED trial Ann Oncol 2006;17:270–5.
3. NICE. The diagnosis and treatment of lung cancer. February 2005.
National Institute for Clinical Excellence.
P186 THE END OF THE LINE FOR ABRAMS PERCUTANEOUS
PLEURAL BIOPSY? A SURVEY OF RESPIRATORY
SPECIALIST REGISTRAR EXPERIENCE IN CLOSED
PLEURAL BIOPSY
B. Green. Southampton General Hospital, UK
Closed needle percutaneous pleural biopsy has traditionally been used
to investigate exudative pleural effusion following non-diagnostic
thoracocentesis when there is clinical suspicion of tuberculosis or
malignancy. Diagnostic rates of 75% for tuberculosis and 57% for
carcinoma have been reported (Tomlinson JR. Semin Respir Med
1987;9:30–6). Chakrabarti et al (Chest 2006;129;1549–55) reported
low complication rates in all grades of medical staff performing the
procedure in a UK hospital between 1997 and 2003.
More recently, CT-guided biopsy has been demonstrated to have
diagnostic advantage over blind Abrams biopsy in cytology negative
malignant pleural effusion (Maskell NA, Gleeson FV, Davies RJO. Lancet
2003;362:173). Thoracoscopy has a diagnostic sensitivity of 95% in
malignant effusion, making it more sensitive than Abrams biopsy with
the added advantage of performing therapeutic pleurodesis at the same
procedure.
Increased use of image-guided and thoracoscopic biopsy, as well as
an increase in the use of seldinger chest tube insertion without the
opportunity for pleural biopsy while placing a surgical intercostal drain,
has led to a reduction in the number of Abrams biopsies being
performed with an inevitable effect on training.
An anonymous survey of experience in Abrams pleural biopsy was
carried out among respiratory specialist registrars in the Wessex region
of the UK (26 respondents). Over the last 2 years, on average, trainees
had performed 2.5 procedures (11.5 total over the course of their
training). 58% had received formal training; no respondents had
undergone DOPS (direct observation of procedural skills) assessment in
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the procedure. 62% of respondents felt competent in the procedure. 23%
felt confident of obtaining pleural tissue. 22% felt they performed enough
procedures to maintain competency.
Blind pleural biopsy remains of value in the investigation of exudative
effusion following negative thoracocentesis. It may have health economic
benefits in negating the need for image guided or thoracoscopic biopsy.
However the infrequent use of the procedure may lead to difficulty in
training future respiratory physicians and maintaining competency in
those currently undertaking Abrams biopsy.
P187 ARE BLIND PERCUTANEOUS PLEURAL BIOPSIES STILL
USEFUL IN THE DIAGNOSIS OF SUSPECTED
MALIGNANT PLEURAL EFFUSIONS?
R. Nadama, M. Pasteur. Norfolk and Norwich Universty Hospital (NNUH),
Norwich NR4 7UY, UK
Introduction: Thoracoscopic and CT guided pleural biopsies are now
often used as the next diagnostic step in investigations of suspected
malignant pleural effusions where a first diagnostic aspirate is cytology
negative. They both have a higher diagnostic yield and lower
complication rates compared to blind percutaneous pleural biopsy and
in the case of thoracoscopy the ability to carry out therapeutic
procedures. The Abrams’ pleural biopsy needle is most commonly used
in the UK. The yield compared with pleural fluid cytology alone is
increased by only 7–27% for malignancy. Complications of Abrams’
pleural biopsy include site pain(1–15%), pneumothorax (3–15%),
vasovagal reaction (1–5%), haemothorax (,2%), site haematoma
(,1%), transient fever (,1%) and, very rarely, death secondary to
haemorrhage. If a pneumothorax is caused, only 1% require chest
drainage. The aim of this project is too ascertain whether adequate
pleural samples are obtained, the diagnostic rate and requirement for
further diagnostic test aimed at obtaining histology and complication
rates.
Methods: All patients who underwent day case Abrams Needle Pleural
Biopsies for suspected malignant pleural effusion at a weekly ran Pleural
clinic at the Respiratory Investigation Unit of the NNUH over a year’s
period (1/08/02–31/08/03) were included. All biopsies were done by
a Respiratory Registrar or equivalent. Data which included demographic
variables, lab results, and complications post procedure and further
Diagnostic tests and Results were retrospectively collected from patients’
case notes.
Results: A total of 20 pleural biopsies were taken. Adequate pleural
samples defined as presence of pleura on biopsy sample adequate
enough to generate a histological opinion, were obtained in 19 patients
(95%). 11 malignant pleural effusions were diagnosed of which 6
(54.5%) were made on Abrams pleural biopsy samples. Diagnostic test
which confirmed other malignancies and diagnosis were CT guided
biopsies, Video assisted thoracoscopic surgical (VATS) biopsies and
lymph node biopsies. Six mesotheliomas were diagnosed 2 (30%) with
Abrams needle, the remaining were diagnosed in equal fashion by CT
and VATS biopsies. In 8 out of 20 cases it was felt further test aimed at
obtaining histology were necessary on clinical grounds. Complications:
1 patient had a pneumothorax which didn’t require chest drainage. One
patient had a vasovagal episode. There were no incidences of
haemothorax, biopsy site heamatoma or infection.
Conclusion: Blind percutaneous pleural biopsies in experienced hands in
the appropriate settings where CT guided or thoracoscopic biopsies are
not easily available should be considered as a valuable approach in the
diagnosis of suspected malignant pleural effusion.
P188 NINETY TWO PER CENT OF CURRENT RESPIRATORY
SPECIALIST REGISTRARS THINK THAT TRAINING IN
CHEST ULTRASOUND EXAMINATION FOR PLEURAL
DISEASES SHOULD BE INCLUDED IN THEIR TRAINING
CURRICULUM: RESULTS OF A NATIONAL WEB-BASED
QUESTIONNAIRE SURVEY ON THE PRACTICE OF
CHEST ULTRASOUND EXAMINATION IN THE UK
A. R. Guhan1, P. T. Walker2, G. S. Leen2, G. P. Naisby2. 1Department of
Respiratory Medicine; 2Department of Radiology. The James Cook University
Hospital, South Tees Hospitals NHS Trust, Middlesbrough, UK
Introduction: Chest ultrasound examination (CUS) has a well established
role in the management of patients with plural effusions (PPE). In the UK
CUS is mostly done in radiology departments (RD) where time and space
constraints could lead to delays in clinical decision making. Opinion is
growing favouring chest physicians (CP) performing their own CUS.1, 2
Training in chest ultrasound forms part of the curriculum of Respiratory
Medicine trainees in Europe. This is not the case in the UK, though the
Royal College of Radiologists (RCR) has recently published CUS training
guidelines for CPs. We wanted to ascertain the views of current
respiratory specialist registrars (SpRs) of all grades with regards to CUS
and training in CUS.
Methods: 512 SpRs whose email addresses were available on the British
Thoracic Society contact database were invited electronically to
participate in an on-line electronic questionnaire survey. There were
16 questions, with ‘‘drop-down-menu’’ (closed) choices, with the
responses being automatically added to a database.
Results: Of the 512 invitations sent, 31 returned undeliverable. Data
from 138 completed questionnaires (28.7% return-rate) were available
for analysis.
Of the 138 respondents, 6 (4.3%) were first year SpRs (SpR-1) while
32 (23.2%), 32 (23.2%), 27 (19.6%), 21 (15.2%) and 20 (14.5%) were
SpR-2, SpR-3, SpR-4, SpR-5, and SpR-6, respectively. At the time of
survey (January 2006), 57 (41.3%), 19 (13.8%), and 62 (44.9%) of the
respondents were working in District General Hospitals, Secondary
Referral Teaching Hospitals, and Tertiary Referral Hospitals, respectively,
with 39.2% and 25% of them working in firms seeing 5–8 PPEs and 9–12
PPEs per month, respectively. 119 (86.2%) of the respondents think that
chest physicians should be performing their own CUS and 128 (92.7%)
wanted CUS training included in the SpR curriculum. Who has had
formal training? 20 (14%) of the SpRs have received formal training in
CUS though only 13 (9.4%) had regular access to a CUS machine and a
training mentor (as of January 2006). Who has access to chest
ultrasound machines? 24 (17.4%) respondents had access to a CUS
machine though 11 (7.8% of all respondents) would appear to be
engaging in CUS with neither formal training nor a mentor. Were SpRs
aware of the RCR CUS training guidelines? 128 (93%) of the SpRs were
NOT aware.
Conclusions: The vast majority of current SpR who will be future CPs feel
that training in CUS should be part of their curriculum. Apart from
training in CUS, access to a CUS machine and a training mentor appear
to be important issues that need addressing.
1. Doelken. Chest 2003;123:332.
2. Guhan AR. Thorax Dec 2004.
P189 SURVEY OF THE PRACTICE OF CHEST ULTRASOUND
EXAMINATION (FOR PLEURAL EFFUSIONS) AMONG
CHEST PHYSICIANS IN THE UK
A. R. Guhan1, P. T. Walker2, G. S. Leen2, G. P. Naisby2. 1Department of
Respiratory Medicine; 2Department of Radiology. The James Cook University
Hospital, South Tees Hospitals NHS Trust, Middlesbrough, UK
Introduction: Chest ultrasound examination (CUS) is an important
investigation in the management of patients with pleural effusions (PPE).
In the UK, this is commonly done in the Radiology Departments (RD)
though opinion is growing favouring chest physicians (CP) performing
their own CUS.The Royal College of Radiologists (RCR) has published
guidelines on the training requirements for CPs acquiring CUS skills. The
current CUS practice among CPs in the UK is unknown. A web based
survey was conducted among all the consultant members of the British
Thoracic Society (BTS) to clarify this.
Methods: All 869 consultant members of the BTS were invited by e-mail
to participate in an online electronic questionnaire survey. There were 16
questions with ‘‘drop-down-menu’’ (closed) choices, with the responses
being automatically added to a database.
Results: Of 869 invitations sent, 129 returned wrongly addressed. Data
from 203 completed questionnaires (27.4% return-rate) were available
for analysis.
97 (48%) were consultants in District General Hospitals, while 47
(23%) and 59 (29%) were in Secondary Referral Teaching Hospitals and
Tertiary Referral Teaching Hospitals, respectively. 86 (42.4%) had 5–8
PPEs admitted to their firms per month, while 32 (16%) had 9–12 PPEs.
46 (22.7%) requested a CUS in 50% of their PPEs, while 42 (20.7%)
requested a CUS in 30% PPEs. with 5% using CUS rarely. Majority (64%)
of CUS requests were to localise loculated fluid collections. 189 (93%) of
CUS were performed by the RD. 98 (48.3%) waited on average one day
for a CUS after requesting one (range: 0 days (2%)–5 days (3.5%)).
Should CPs do their own bedside CUS? 129 (63.5%) positively
supported this view. Other responses were ‘‘Not sure’’ (22.7%) and
‘‘Perhaps’’ (13.8%). However, 185 (91%) were unaware of the RCR
training guidelines for CPs to acquire CUS skills. Should CUS training be
on the Respiratory Specialist Registrar (SpRs) curriculum? Overall, 167
(82%) consultants positively supported this view. This view was supported
by 74.6% of consultants in Tertiary Referral Hospitals and 85% of the
consultants who were in District General and Secondary Referral
Teaching Hospitals.
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Conclusions: Majority (63.5%) of the chest physicians (CPs) in the UK
prefer that they are skilled in bedside CUS in patients with pleural
effusions (PPE). 20% of them requested a CUS in a third of their PPE, with
a further 22% requesting this in 50% of their PPE; the vast majority (93%)
of this is performed in the RD. More than four fifths of CPs think that CUS
training should be included in the Respiratory SpR curriculum. Increased
awareness of the Royal College of Radiologists’ CUS training guidelines
for CPs could be a potential impetus for this to be achieved.
P190 CLINICAL CHARACTERISTICS AND OUTCOMES OF
EMPYEMA THORACIS IN 117 PATIENTS: A
COMPARATIVE ANALYSIS OF TUBERCULOUS VERSUS
NON-TUBERCULOUS AETIOLOGIES
P. Malhotra1, A. N. Aggarwal2, P. Ray3, R. Agarwal4, D. Gupta5,
S. K. Jindal6. Affiliation of all authors: Postgraduate Institute of Medical
Education and Research (PGIMER), Chandigarh, India
Background: Empyema thoracis remains a major problem in developing
countries. Clinical outcomes in tuberculous empyema are generally
believed to be worse than in non-tuberculous aetiologies because of the
presence of concomitant fibrocavitary parenchymal disease, frequent
bronchopleural fistulae and poor general condition of patients. We
performed a prospective study over a two-year period with the objective
of comparing the clinical characteristics and outcomes of patients with
tuberculous versus non-tuberculous empyema
Methods: Prospective study of all cases of non-surgical thoracic
empyema seen at a tertiary care centre in North India over a 2 year
period. A comparative analysis of clinical characteristics, treatment
modalities, and outcomes of patients with tuberculous versus non-
tuberculous empyema was carried out. Factors associated with poor
outcomes were analysed using multivariate logistic regression.
Results: One hundred and seventeen cases of empyema were seen in the
study period of which 95 had non-tuberculous and 41 had tuberculous
empyema. Malnutrition and bronchopleural fistulae (BPF) were more
common and duration of symptoms longer in the tuberculous empyema
group. Time to resolution of fever, duration of pleural drainage and
pleural thickening .2 cm were significantly greater as well. Eight
(10.5%) patients with non-tuberculous empyema and four (9.8%) with
tuberculous empyema succumbed. Presence of a BPF was significantly
associated with poor outcomes on multivariate logistic regression
analysis.
Conclusions: Tuberculous empyema remains a common cause of
thoracic empyema in India though it ranked second amongst all causes
of empyema after community acquired lung infections in this study.
Tuberculous empyema is associated with longer duration of symptoms,
greater duration of pleural drainage and more residual pleural fibrosis.
P191 THE MANAGEMENT OF SPONTANEOUS
PNEUMOTHORAX: ARE WE ADHERING TO BRITISH
THORACIC SOCIETY GUIDELINES?
N. Chaudhuri1, A. Darby1, D. Boldy2. 1Northern General Hospital, Sheffield
NHS Trust, Herries Road, Sheffield; 2Pilgrim Hospital, Boston, UK
There have been studies demonstrating the variability in the manage-
ment of spontaneous pneumothorax and to this effect guidelines have
been produced by the British Thoracic Society to clarify and standardise
the management of spontaneous pneumothorax. The aim of this study
was to assess whether current practices on the management of
spontaneous pneumothorax conformed to these guidelines at five
hospitals within the South Yorkshire region. A retrospective case note
audit of 145 cases of spontaneous pneumothorax was performed (x
primary and y secondary).
In the initial management of primary pneumothoraces simple
aspiration was performed in 37 (38%) and chest drain in 45 (46%)
cases. This finding did not comply with the BTS recommendation that
simple aspiration should be the treatment of choice in all such patients.
Only 36/98 (37%) of primary pneumothorax cases were managed
according to the BTS guidelines. The initial management of secondary
pneumothoraces however, faired better. Chest drainage was performed
in 32 (68%) cases.
We also assessed whether management differed according to hospital
type and size. 3 of the 5 hospitals are classified as district general
hospitals and 2 classified as tertiary teaching hospitals. In the tertiary
teaching hospital, 43% adhered to the BTS guidelines for the manage-
ment of primary pneumothoraces compared to 36% in the DGH, and
87% and 71% respectively for the management of secondary
pneumothoraces (p = NS).
Other differences in practice compared to BTS guidelines were delay
in cardiothoracic referral. Only 33% (10/30) of referrals were made in
the recommended 5 day period (mean 6.7 days, range 1–21 days).
Reasons for these included the use of prolonged suction (5/20),
placement of large bore tubes (4/20), delay in respiratory referral (2/
20), and unknown (8/20).
This study highlights that there is significant scope to improve the
management of this group of patients. The management of secondary
pneumothorax on the whole fares better, however there seems to be
some confusion as to the management of primary pneumothoraces. All
initial management of spontaneous pneumothorax was performed by
non-respiratory junior staff (27 (23%) by A+E, 51 (43%) by medical staff,
and 3 (3%) by cardiothoracic surgical teams). It is our duty as respiratory
physicians to provide a program of education and guideline dissemina-
tion so as to improve the management and provide a better standard of
care for these patients.
P191A WHICH ASPECT OF CHEST DRAINAGE CAUSES MOST
PAIN?
N. M. Rahman1, N. A. Maskell2, E. L. Hedley1, F. V. Gleeson1,
R. J. O. Davies1. 1Oxford Centre for Respiratory Medicine, Oxford, UK;
2Southmead Hospital Bristol, UK
Introduction: Chest tube drainage is painful. There are few data
describing whether this pain is influenced by insertion technique (blunt
dissection v guidewire), or tube size. Nor is it known whether these
differences influence pain at tube insertion, while the tube is in place, or
at tube removal.
Methods: 123 patients from 32 UK centres having chest tube drainage
for pleural infection completed a self-administered categorical pain
score (no pain, mild, moderate, severe pain) to describe how much pain
they experienced at chest tube insertion, while the chest tube was in
place, and at chest tube removal. These scores were summated to
produce a summary score which was compared in patients having blunt
dissection or guidewire insertion (primary analysis).
Results: Chest tubes inserted by blunt dissection were associated with
more pain than those inserted by guidewire (dissection n = 44, median
pain score 7, IQR 5–8, guidewire n = 79, med 5, IQR 4–7, p = 0.006,
Mann-Whitney). Average drain size was larger in the blunt dissection
group (dissect 22 French, IQR 20–26, guide 12, IQR 12–12,
p,0.0001, Mann-Whitney). However, within the insertion technique
groups, drain size was not significantly associated with pain (p.0.1
Spearman’s correlation, both groups). Pain at chest tube insertion or
removal was not significantly different between the two insertion
technique groups (x2 3df, p.0.1, both analyses). However, blunt
dissection inserted tubes were significantly more painful while in place
(x2, 3df = 13.2, p = 0.004).
Conclusions: We conclude that guidewire inserted tubes were less
painful than blunt dissection inserted tubes. This difference was most
marked while the tube is in place and appeared to be more strongly
associated with insertion technique than tube size.
Cystic fibrosis: clinical
management
P192 ECONOMIC IMPLICATIONS OF NEWBORN
SCREENING FOR CYSTIC FIBROSIS: REDUCED
THERAPY MAY OFFSET SCREENING COSTS
E. J. Sims1,2, M. Mugford3, A. Clark2, D. Aitken4, J. McCormick5, G. Mehta1,
A. Mehta1, on behalf of the UK CF Database (UKCFD) Steering Committee.
1UK Cystic Fibrosis Database, University of Dundee, Dundee, UK;
2Population Health; 3Health Economics Groups, School of Medicine, Health
Policy and Practice, University of East Anglia, Norwich, UK; 4Scottish
Newborn Screening Laboratory, Institute of Medical Genetics, Yorkhill,
Glasgow, UK; 5Respiratory Unit, Royal Hospital for Sick Children, Yorkhill
NHS Trust, Glasgow, UK
Background: Compared to clinical diagnosis (CD), newborn screening
(NBS) for cystic fibrosis (CF) associates with clinical benefit (Sims et al. J
Pediatr 2005;147:S42) and reduced treatment (Sims et al. J Pediatr
2005;147:306). However NBS may not be introduced if resource costs
are perceived to be prohibitive.
Aims: Using the UKCFD, we compared the cost of therapies received by
NBS and CD patients and tested whether any savings accrued that could
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offset the known costs of the new national NBS programme (Scotland),
when scaled to the UK.
Methods: The cohorts of 184 NBS and 950 CD patients reported above,
aged 1–9 years in 2002, were compared in a cost of illness
retrospective, ‘‘snapshot cohort’’ study using a prevalence strategy.
Costs of long term (LT; .3 months) drugs (including oral antibiotics and
corticosteroids, and inhaled and nebulised medications) and home and
hospital administered intravenous antibiotics (IV) were estimated. Costs
(£) in 2004 of adding a two step (immunoreactive trypsinogen/DNA
mutation) CF screening service to an established Scottish NBS service
were estimated, adjusted to 2002 prices and applied to the UK.
Results: LT therapy costs per NBS patient were significantly lower when
compared to a CD patient: mean (£4410 v £7326; 95% CI 24110 to
21237; p,0.01) and median (£215 v £1490; 95% CI 21169 to
2110; p,0.01)). Assuming the CD cohort had been diagnosed by NBS
and the disease progression was comparable to that of the NBS cohort,
mean (£2,197,525) or median (£610,937) drug cost savings may have
offset some or all of the estimated cost of a UK national CF NBS service
(£1,813,200; see table).
Conclusions: Considering the drugs budget alone, in the first 9 years of
life, diagnosis of CF by NBS could save 34% to 121% of the estimated
costs of adding CF screening to an established national NBS screening
service. Including indirect costs-savings, implementation of a NBS
service may have wider benefits to families and society.
P193 AN AUDIT OF THE NEW EFLOWHRAPID SYSTEM IN THE
PAPWORTH ADULT CF UNIT
H. Brown, K. Goldsmith, J. Cobain, C. S. Haworth, D. Bilton. Papworth
Hospital NHS Foundation Trust, Cambridge, UK
Introduction: The PARI GmbH eFlowHrapid is a new nebuliser that
utilises a perforated oscillating membrane. It has several potential
advantages over previous systems including being silent and offering
faster inhalation times. It is also small, light and can be operated by
battery or mains worldwide. Since July 2005 the Papworth Adult CF
Centre has been converting patients from their conventional nebulisers to
the eFlowHrapid.
Methods: In order to audit the impact of changing to the eFlowHrapid we
asked 37 adult CF patients (18/36 male, 23/36 age 16–25 years, 8/
36 age 26–35 years, 5/36 age older than 35 years) to complete two
questionnaires, the first prior to, and the second two months after,
starting the eFlowHrapid. The questionnaires were designed to assess
nebuliser usage and adherence.
Results: 36/37 patients completed both questionnaires. The results of the
first questionnaire showed that 33 patients were using established PARI
nebuliser systems at the start of the audit. 31 (86%) patients performed
two or more nebulisations per day. 8 (22%) patients reported being fully
adherent with their nebuliser therapy, whilst the remaining 28 patients
reported missing 1 to 17 nebulisations per week. 27 (75%) patients cited
a time factor as the main reason for missing nebuliser treatment.
From the second questionnaire, 36/36 (100%) patients preferred the
eFlowHrapid due to its speed, silence, and small size. The median
inhalation time was reduced by 8 minutes for bronchodilators, 7 minutes
for DNase, 14 minutes for antibiotics, and by 13 minutes for all
therapies combined through using the eFlowHrapid (Wilcoxon signed
rank test p values 0.042 for bronchodilators, ,0.001 for all others). 12/
36 (33%) patients reported being fully adherent to nebuliser therapy. 11
(31%) patients reported improved adherence, 8 (22%) reported less
adherence and 17 (47%) patients reported no change in adherence
using the eFlowHrapid. Full adherence with (a) DNase, (b) antibiotics
and (c) all prescribed nebulised therapies (that is, DNase plus antibiotics
plus bronchodilators) was not statistically significantly improved after the
introduction of the eFlowHrapid (Binomial test p values (a) 0.312, (b)
0.500, (c) 0.312 respectively). The number of nebulisers missed per
week with the eFlowHrapid ranged from 1 to 21. 18/36 (50%) patients
continued to cite a time factor, and 6/36 (17%) patients cited
forgetfulness, as the main reasons for missing their nebuliser therapy.
Conclusions: There was universal patient preference for the eFlowHrapid
system due to its speed, silence and size. Despite this only 31% of
patients reported improved adherence and 69% reported reduced or no
change in adherence after changing to the eFlowHrapid.
P194 THE EFFICACY, PREFERENCE, AND SAFETY OF A
NOVEL METHOD OF SPUTUM CLEARANCE, HYDRO
ACOUSTIC THERAPY, ON ADULT PATIENTS WITH
CYSTIC FIBROSIS
N. A. Jarad1, T. Powell1, E. C. Smith1, P. Cartwright2, J. Nedwell2,3. 1The
Adult CF Centre, Department of Respiratory Medicine, Bristol Royal Infirmary
Bristol, Bristol BS2 8HW; 2Acomed, Dorset, UK; 3Subacoustech, Hampshire,
UK
Background: Daily airway clearance is an important part of manage-
ment in cystic firbrosis (CF). Several methods are employed aiming to
induce vibration in the airways, these are not well tolerated by patients.
Aim: To investigate the efficacy, safety, and patients’ preference of a
novel system that vibrates the lungs at their resonant frequency, to aid
sputum clearance in CF. This system called Hydro Acoustic Therapy
(HAT).
Method: Eighteen adult CF patients with an FEV1,70% predicted
investigated during stable lung disease, received in a random order
three techniques, HAT, Flutter, a placebo session which involved being
sat in the bath without any sound waves. For HAT, sounds waves were
generated underwater in a special bath to create a percussion effect on
the lungs, aimed at dislodging bronchial secretions using the principal of
chest percussion. The patient received therapy at three different resonant
frequencies, each for 10 minutes. These frequencies ranged between
20–60 Hz with amplitude of up to 158 dB re1microPascal. Each therapy
session lasted for 30 minutes. Oxygen saturation and heart rate was
constantly monitored throughout each therapy session. We measured
wet and dry sputum, and lung function parameters before and after each
therapy session. At the end of the study patients completed a
questionnaire about their preference to the type of physiotherapy
received.
Results: The three methods resulted in similar production of sputum as
measured by the weight of dry and wet sputum. There was fall in FEV1
after HAT therapy of 76 ml (95% CI 27–125 ml) p,0.005. The value of
FVC, FEF25–75 did not significantly changed after HAT or other
methods. The HAT therapy was described to be pleasant or very pleasant
in 59% compared to 0% for flutter (x2 = 15.8, p,0.0001). A total 70% of
patients would prefer HAT as a physiotherapy method compared to 0%
for flutter (x2 = 20.3, p,0.0001). There were no procedure related
complications in any of the three methods.
Conclusion: HAT is a novel system for sputum clearance. In a cohort of
adult CF patients the technique was found to be safe, well tolerated and
favoured by the majority of the patients to the conventional flutter device.
Sponsored by Aco-med Ltd, Dorset, UK.
P195 GLUCOCORTICOIDS AS AN ADJUVANT TREATMENT
TO INTRAVENOUS ANTIBIOTICS FOR CYSTIC
FIBROSIS PULMONARY EXACERBATIONS: A UK
SURVEY
K. L. M. Hester1, T. Powell1, D. G. Downey1, J. S. Elborn2, N. A. Jarad1.
1Adult CF Centre, Bristol Royal Infirmary; 2Adult CF Centre, Belfast City
Hospital, UK
Background: The use of glucocorticoids during pulmonary exacerba-
tions (PX) of asthma and chronic obstructive pulmonary disease (COPD)
Abstract P192
2004 Scottish
births
2004 Scottish
costs
2002 Scottish
costs
2002 UK
births
2002 UK
costs
Refused screening 42 – – 514 –
Screened (IRT) 54,600 £143,154 £125,859 668,263 £1,641,719
DNA mutation screen 372 £157,744 £138,992 4557 £171,481
Patients diagnosed 28 £5634 £5346 343 £5286
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is well established. Their benefit during cystic fibrosis (CF) PX is less well
defined, a Cochrane Review established the need for a prospective
randomised controlled trial (RCT).1 Additionally, attitudes of CF
physicians towards glucocorticoid use have not been examined.
Objectives: To establish, among CF physicians, current practices and
attitudes regarding the use of adjuvant glucocorticoid treatment in adult
CF patients requiring intravenous (IV) antibiotics for a PX and to
determine the feasibility of a prospective RCT.
Methods: A questionnaire was sent to all adult CF physicians in the UK.
Questions addressed current usage of glucocorticoids, reasons for not
using glucocorticoids and interest in participating in a prospective RCT.
Results: Out of 42 physicians, 34 (81%) completed and returned the
questionnaire, 65% cared for more than 50 CF patients. A total of 64%
of responders used glucocorticoids with IV antibiotics in their practice
(63% occasionally, 26% regularly, 11% often). Of those who did not use
glucocorticoids, 56% stated lack of convincing literature or lack of
efficacy from personal experience and 44% cited potential side effects.
Using Fisher’s exact test there were no significant differences in
responses from physicians in large (.50 patients) or small (,50
patients) units. Most responders (88%) agreed that a large prospective
RCT is required and 75% would be willing to enter consenting patients
into a potential RCT.
Conclusions: The majority of adult CF physicians in the UK agree that a
prospective RCT of glucocorticoid use as an adjuvant to IV antibiotics is
required and would be willing to participate in entering consenting
patients. With the level of interest expressed, a prospective RCT could
feasibly be undertaken.
1. Cheng K, Ashby D, Smyth R. Oral steroids for cystic fibrosis. The
Cochrane Database of Systematic Reviews. 1999, Issue 4. Art No:
CD000407, DOI:10.1002/14651858.CD00040..
P196 BURKHOLDERIA SPECIES INFECTION AT THE
MANCHESTER ADULT CYSTIC FIBROSIS CENTRE:
CHANGING EPIDEMIOLOGY
M. France1, M. E. Dodd1, J. R. Govan2, C. J. Doherty2, A. K. Webb1,
A. M. Jones1. 1Manchester Adult Cystic Fibrosis Centre, UK; 2Medical
Microbiology, University of Edinburgh, UK
Introduction: All cases of Burkholderia species infection have been
recorded at our centre since 1983. Microbiological surveillance of
Burkholderia species has been performed at our cystic fibrosis (CF)
centre since 1991. All isolates are sent to a single reference
microbiology laboratory for strain typing. Patients with Burkholderia
species infection were cohorted into different areas of the inpatient
facility from 1991 onwards. Since 1993, patients with Burkholderia
species infection have been cohorted to a different ward and outpatient
clinics (complete cohort segregation). More recently, a policy of isolation
has been introduced with patients infected with transmissible B
cenocepacia strains being isolated when inpatients and attending
separate outpatient clinics from other Burkholderia infected patients. In
2001, retrospective typing of previously stored isolates was undertaken.
All subsequent new isolates since 2001 have been genomovar typed.
Methods: We reviewed the results of strain and genomovar typing of all
available Burkholderia isolates at our center: 1983–2006.
Results: The incidence/prevalence of infection with Burkholderia species
between 1983–90 was below 5%/9% each year. There was a rise in
incidence/prevalence of Burkholderia species between 1991 and 1994
with a peak of 16.3%/31.2% in 1992. Following the introduction of
complete cohort segregation, the incidence has fallen to below 3% for all
but one year and the prevalence has gradually reduced to 9.3% in 2005.
Currently, there is an increase in the prevalence to 10.6% for the first
time since 1994, predominantly due patients with unique infections
transferring into the unit from referring centres. The presence of unique
strains now exceeds transmissible strains for the first time since 1991.
Since full cohort segregation, within the centre, there have been 6 cases
of new infection with transmissible B cenocepacia strains and 13 with
unique strains of Burkholderia species. These included 2 cases of
superinfection with a transmissible strain in those with a unique strain
and patients who have not followed cohort segregation practices. For the
past 6 years, there has been just 1 case of new infection with a
transmissible B cenocepacia strain and 9 cases of new infection with
unique strains of Burkholderia species among established patients.
Conclusions: Infection control measures including patient segregation
have controlled spread of transmissible B cenocepacia strains, but not
the acquisition of unique strains. Unique strains of Burkholderia species
now account for the majority of new infections at the Manchester Adult
Cystic Fibrosis Centre.
P197 INFLUENZA VACCINATION IN CYSTIC FIBROSIS: ANY
ROLE?
D. Wat1, C. Gelder2, S. Hibbitts3, I. Doull1. 1University Hospital of Wales,
Cardiff; 2Llandough Hospital, Penarth; 3University of Wales College of
Medicine, Cardiff, UK
Background: The Department of Health in the UK recommends influenza
vaccination should be offered to all patients with chronic obstructive
pulmonary disease including cystic fibrosis (CF). Previous studies have
shown that influenza infections cause worsening lung functions and
disease progression in CF.1 In addition, influenza infection may facilitate
future bacterial colonisation. There is currently no evidence from
randomised studies that influenza vaccine given to patients with CF is
of benefit to them.2 During the season 2003/04, trivalent influenza
vaccine was used, the composition of which included: Influenza A
(H3N2) and (H1N1) strains and influenza B.
Aims: To determine the vaccination coverage level for the 2003–04
influenza season in a paediatric CF population in South Wales and the
factors associated with non-adherence with vaccination. Finally, to
evaluate how many patients who were vaccinated against influenza
subsequently acquired influenza infection.
Methods: The influenza vaccination status of 63 patients with CF
enrolled for the study looking at the impact of respiratory viruses in CF
was recorded. All these patients were older than 6 months of age on
enrolment. Pernasal swabs from these patients were taken whenever they
developed new upper respiratory tract symptoms and whenever they
attended outpatient clinic for routine visit from October 2003 to April
2004. Influenza A and influenza B were detected using Nucleic Acid
Sequence Based Amplification (NASBA).
Results: Of the 63 patients, 41 (65%) were vaccinated against influenza.
For the 22 patients who were not vaccinated, 5 of them forgot, 7 were
scared of needles, 1 was worried about side effects, 6 were too unwell to
be vaccinated and 3 did not feel influenza vaccination was effective.
Influenza virus was detected on 5 occasions; 3 influenza A (60%) and 2
influenza B (40%). 1 virus in the vaccinated group and 4 in the non-
vaccinated were detected during the study period (p value = 0.046, using
Fisher’s exact test).
Discussion: Majority of the studied patients was vaccinated against
influenza and the main reason for non-adherence was due to the fear of
needles. Although the recent Cochrane review2 has stated that the
evidence to support routine influenza vaccination is lacking in CF, this
study has shown that influenza vaccination may yet play a role in
preventing its subsequent acquisition
1. Collinson J, Nicholson KG, Cancio E, et al. Effects of upper
respiratory tract infections in patients with cystic fibrosis. Thorax
1996;51:1115–22.
2. Tan A, Bhalla P, Smyth R. Vaccines for preventing influenza in
people with cystic fibrosis. Cochrane Database Syst Rev
2000;(2):CD001753.
P198 ASSOCIATION BETWEEN ABNORMAL HEPATIC
ENZYMES, FATTY CHANGE IN THE LIVER, AND ACUTE
PULMONARY INFECTION IN CYSTIC FIBROSIS
A. Barton1, A. Choudhury1, P. Shanmugasundaram1, P. McAvinia4,
F. Coyle3, G. Foster2, L. Kuitert1. 1London Chest Hospital, Barts and the
London NHS Trust; 2Royal London Hospital, Barts and the London NHS Trust;
3St Bartholomew’s Hospital, Barts and the London NHS Trust; 4Whittington
Hospital NHS Trust, London, UK
Introduction: Liver disease complicating cystic fibrosis (CF) is well
recognised in children and progresses to cirrhosis. In adults with CF
abnormalities of hepatic enzymes are increasingly recognised, and
usually attributed to infective exacerbations or drug therapy (for
example, antibiotics). Liver ultrasounds (USS) have demonstrated either
no abnormality or fatty change similar to that seen in diabetes.
Aim: To determine if elevated hepatic enzymes are associated with
abnormalities on liver USS, and the impact of infective exacerbations
and antibiotic therapy.
Methods: Retrospective review of medical records of 91 patients
attending Adult CF Service at the London Chest Hospital. Data from
both inpatient and outpatient attendances were recorded. Liver USS
were performed and reported using a specific protocol (reporting
presence of fatty change, portal vein flow, and splenic size). Data were
analysed using Mann-Whitney U test with significance set at 0.05.
Results: Data were available for 91 patients (56 male), median age of
24 years (range 17–59), mean (SD) FEV1 2.4 (1.1) l, FVC 3.5 (1.3) l,
BMI 22 (3.9). Hepatitis and autoimmune serology were negative in all
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patients. 45 patients had had a liver USS; complete data were available
for 44. 33/44 (75%) had a normal USS. Of the 11 abnormal scans, 2
had cirrhosis, and 9 had fatty change (20.5%); all were pancreatic
insufficient. There was no significant difference in BMI between those
with normal and abnormal USS (20.9 v 21.7). By far the most common
abnormality in hepatic enzymes was an isolated elevation in alkaline
phosphatase (ALP). The highest value of ALP was seen more commonly
in inpatients receiving IV antibiotics for infective exacerbations (61%);
peak inpatient ALP was 160 (107) iU/l, v 125 (52) iU/l for outpatients.
Inpatients: In 34 inpatients with hepatic enzyme and USS data, 11 had a
normal ALP; 2 had fatty change on liver USS. In the remaining 23 with
an elevated ALP, 9 (39%) had fatty change on USS. There was no
statistically significant difference in peak ALP between patients with or
without fatty change on Liver USS (p = 0.19). Outpatients: In outpatients
with stable CF, 40 patients had had a liver USS and of these 20 had a
normal ALP; 3 had fatty change on USS. Of the 20 with an elevated ALP
8 (40%) had fatty change on USS. There was a trend to statistical
significance in peak ALP between those with and without fatty change
(p = 0.084).
Conclusions: Fatty change in the liver was more common than expected
and did occurr despite a normal ALP. While peak ALP was higher in
inpatients, the proportion of patients with fatty change was similar to
outpatients, suggesting the elevation was secondary to infection and/or
antibiotics. On these data ALP cannot be used to decide which CF
patients should have a liver USS.
P198A ADULT CYSTIC FIBROSIS LUNG FUNCTION,
NUTRITION, AND SURVIVAL AT THE ROYAL
BROMPTON HOSPITAL COMPARED WITH UK AND US
DATA
J. V. Welch, J. Burgess, M. Benlarbi, M. E. Hodson. Adult Cystic Fibrosis
Department, Royal Brompton Hospital, London, UK
Introduction: Europe’s first adult Cystic Fibrosis clinic was established at
the Royal Brompton Hospital (RBH) in 1965. The centre records annual
review data for each consenting patient. 1312 patients have been
included since 1965, 595 of whom attended clinic or were inpatients at
least once in 2004.
Method: The results of the RBH 2004 annual review data were
compared with the national UKCF database Annual Report 2003
(UKCF).1 Patient survival was compared to Cystic Fibrosis Foundation
Annual Report from the US.2
Results: RBH patient age distribution is higher than that for the adult
UKCF patients with 31% aged.35 years compared to 17%. The median
FEV1 % predicted for RBH is 54.0%. UKCF specify a median in the range
of 50–59%. Median RBH BMI is 21.76 compared to a UKCF median
range of 19–20.9. Furthermore RBH has a higher proportion of patients
with a BMI of 19 or over (81% compared with 77%) and therefore fewer
patients with a BMI of 18.9 and under (19% compared with 23%). The
US report a 50% median survival of 35.1 years. Survival curves for RBH
patients born 1949–88 (n = 1095) demonstrate a 54% survival at age 35
for patients born 1969–78. Any patients who were lost to follow up were
not included (n = 217). RBH accepts many referrals for transplant
assessment for patients with end stage respiratory failure. If patients who
died within 2 years of referral are excluded (n = 108), patient survival to
35 is 59%.
Conclusion: The RBH patient population includes sick and older patients,
however, FEV1% predicted is comparable to data presented by UKCF
and nutrition improved. Survival is shown to increase with every decade
and exceeds median values reported in US data.
1. UK Cystic Fibrosis Database, Annual Data Report 2003. University of
Dundee.
2. Cystic Fibrosis Foundation, Patient Registry 2004 Annual Report.
Bethesda, USA.
Molecular mechanisms of lung
disease
P199 ALKYLPURINE-DNA GLYCOSYLASE AND
ALKYLGUANINE-DNA ALKYLTRANSFERASE REPAIR
ACTIVITY IN PERIPHERAL BLOOD MONONUCLEAR
CELL NUCLEI FROM LUNG CANCER CASES AND
CANCER FREE CONTROLS
P. A. J. Crosbie1,2,3, A. Watson2, G. McGown2, M. R. Thorncroft2,
R. Agius3, A. C. Povey3, P. V. Barber1, G. P. Margison2. 1North West
Lung Centre, Wythenshawe Hospital, Manchester; 2Carcinogenesis Group,
Paterson Institute for Cancer Research, Manchester; 3Centre for Occupational
and Environmetal Health, Manchester University, UK
Introduction: DNA damage, caused by tobacco smoke carcinogens, is a
critical step for lung cancer development. APG and MGMT are DNA
repair proteins that repair N3/7-alkylpurines and O6-alkylguanines
respectively, DNA damage that is induced by alkylating agents such as
tobacco-specific nitrosamines present in cigarette smoke. Interindividual
variability in APG and MGMT activity might therefore influence lung
cancer susceptibility. To test this hypothesis we measured APG and
MGMT activity in lung cancer cases and controls.
Methods: Repair activity was determined using two [32P] based
oligonucleotide cleavage assays in PBMC nuclei collected from 51
incident lung cancer cases and 88 cancer free controls, who were
recruited from the Bronchoscopy Unit at Wythenshawe Hospital. APG
activity was detected in all samples (range 1.37–8.43 fmole/mg DNA/
hour) and MGMT in 114/119 samples (range 0.29–13.37 fmole/mg
DNA). APG and MGMT repair activities were significantly correlated
(r2 = 0.25, p = 0.0009).
Results: Repair activity of either protein was not related to age or
gender. MGMT activity was also unrelated to smoking or case status.
There was evidence that APG activity was greater in ever smokers when
compared to never smokers (3.81 (1.53) v 2.95 (1.04) fmole/mg DNA/
hour, p = 0.07), there was no difference in activity between current and
former smokers (p = 0.86). APG activity was significantly higher in cases
than controls (4.21 (1.67) v 3.47 (1.35) fmole/mg DNA/hour)
(p = 0.005). Ever smoking cases also had higher activity than ever
smoking controls (p = 0.009). The study population was subdivided
according to quartiles of APG activity in controls. The odds of lung
cancer incidence in the highest APG activity quartile was four times that
of the lowest quartile (OR 4.0, 95% CI 1.3–12.6, p = 0.02).
Conclusions: The increased expression of APG, by as yet unknown
mechanism/s, may be a factor in smoking related lung cancer induction.
Project funded by the COLT foundation and Cancer Research UK.
P200 HUMAN SQUAMOUS CELL CARCINOMA CELL LINES
CONTAIN A SELECTABLE SIDE POPULATION THAT IS
CELL CYCLE DEPENDENT AND HAS CANCER STEM
CELL-LIKE PROPERTIES
K. R. Groot1, L. Prichard1, C. Simpson2, D. Davies2, S. M. Janes1. 1Centre of
Respiratory Research, University College London, Rayne Building, 5
University Street, London WC1E 6JJ, UK; 2Flow Cytometry Laboratory,
Cancer Research UK, 44 Lincoln’s Inn Fields, London WC2A 3PX, UK
Introduction: ‘‘Side population’’ (SP) cells are present in a number of
adult tissues. These cells have a unique capacity to efflux lipophillic DNA
binding dyes such as Hoechst 33342. In bone marrow and muscle, SP
cells have been demonstrated to have stem cell characteristics; being
able to self renew and have the capacity to form differentiated cells. The
SP cell’s high efflux capacity correlates with the elevated expression of
drug-transporter proteins, including ABCG2. Hence these cells may be
intrinsically resistant to a number of cytotoxic drugs and thereby
contribute to tumour resistance and disease relapse. An SP has been
identified in neuroblastomas and it has been suggested that they are a
cancer stem cell population.
Aim: We examined a squamous cell carcinoma cell line (H357) for the
presence of an SP cell fraction and proceeded to see if it demonstrated
cancer stem cell characteristics.
Methods: H357 cells were incubated with Hoechst 33342, FACS sorted
into SP and non-SP populations and subsequently used in proliferation,
colony forming and drug resistance assays.
Results: SP cells can be repeatedly FACS sorted leading to a higher SP
fraction in subsequent sorts. We show that the SP fraction is not a strict
sub-population of cells but in fact Hoechst efflux is dependent on the cell
cycle. SP cells show a higher rate of proliferation and colony formation
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than non-SP cells. SP cells are more resistant than non-SP cells to
chemotoxic drugs such as mitotraxone. Treatment with drug transporter
inhibitors such as verapamil reduces the survival advantage of SP cells in
the presence of mitotraxone.
Conclusion: Squamous cell cancers contain an SP population that is
selectable. SP cells are more proliferative, have higher colony formation
efficiency and have greater resistance to chemotoxic drugs than non-SP
cells and hence have some properties of cancer stem-like cells.
This abtract has previously been presented at the American Society for
Cell Biology Summer Meeting: Stem Cell Niches in Boston 15–18 July
2006
P201 CORRELATION BETWEEN THE THE EXPRESSION OF
TOPOISOMERASE IIA AND THE THE INSTABILITY OF
CHROMOSOME 17 IN THE INTRAOPERATIVE
SPECIMENS IN NSCLC
A. Stamatelopoulos1,4, E. Tsiambas2, I. Dahabreh3, A. Chatzimichalis1,
A. Karameris2, D. Bouros4. 1Thoracic Surgery ‘‘Metaxa’’ Hospital Peireus;
2417 Military Veterans Hospital, Athens; 3Laboratory of Surgery Research,
University of Athens; 4Polmon Dep-University of Thrace
Introduction: Intraoperative imprints and FNAs offer a fast and accurate
method of diagnosis and also a qualitative substrate for immunocyto-
chemical and molecular studies—especially preserved samples by liquid
phase cytology methods—because of the high conservation of the
nucleus features. Aberrations of chromosome 17 are common in many
cancers including NSCLC. Topoisomerase family which includes Topo I
(20q11), Topo IIa (17q21), Topo IIb (3p24) is a class of enzymes in the
nucleus of all living cells, which affect the topological structure of DNA.
Cells die when Topoisomerase is inhibited and for this reason is a target
of chemotherapy.
Materials and Methods: Using Tissue Microarray Technology (Chemicon
TMArrayer ATA100), we created a 40 tumour TMA. 40 NSCLC (20
adenocarcinomas and 20 squamous carcinomas) and 10 normal lung
epithelia (as control group) were obtained and embedded into a single
paraffin block (core diameter: 1 mm). Immunohistochemical stain for
anti-Topoisomerase IIa (Ki S1-DACO Corp) combined with CISH for the
detection of chromosome 17 instability (Chr 17 Centromeric probe,
Zymed kit) and specific gene status (Topo IIa Amplification probe Zymed
kit) was performed in 2 and 5 mm sections and in intraoperative
imprints. Finally using a semi-automated Image Analysis System we
evaluated the nuclear features of number and optical density and the
number of signals of chromosome 17 centromeres and gene copies per
nucleus. Statistical analysis was performed by SPSS version 11.0
software.
Results: A significant proportion of NSCLC showed over expression of
the marker (18/40) and CISH application showed Topo IIa amplification
(high or low level) or deletion of one allele n 11/18 cases. Co-evaluating
chromosome 17 instability we observed that 10/18 only amplification
while the last 4/18 displayed deletion. We observed that chromosome
17 instability co-appearing with Topo IIa amplification correlates with
low differentiation and poor prognosis (p,0.001).
Conclusion: The results indicate that Topo IIa amplification or deletion is
a critical genetic event correlating with biological behavior in NSCLC
and determining chemo sensitivity. Also intraoperative imprints and
FNAs appeared to be more accurate at the evaluation of centromeric
and specific gene signals because of the nucleus integrity.
P202 IL-13 MEDIATES PROINFLAMMATORY BUT NOT
PROFIBROGENIC RESPONSES IN PRIMARY
FIBROBLASTS
S. Willams1, C. B. Boxall2, L. M. Hamilton1, J. W. Holloway3, S. T. Holgate1,
D. E. Davies1, A. L. Andrews1. 1Inflammation, Infection and Repair, School of
Medicine, University of Southampton, Southampton, UK; 2Synairgen
Research Ltd, Southampton UK; 3Human Genetics, School of Medicine,
University of Southampton, Southampton, UK
Introduction: IL-13 has been implicated as a key cytokine associated
with the asthmatic phenotype. Persistent inflammation in the airways
leads to airway remodelling which is mediated by TGFb1, a potent
regulator of extracellular matrix formation and tissue remodelling. Given
the previously reported increases in TGFb1 and IL-13 in asthma we
examined their ability to induce synergistic production of eotaxin in
primary human fibroblasts.
Methods: Primary human fibroblasts were grown from endobronchial
biopsies obtained from volunteers. Fibroblasts were treated with IL-4, IL-
13, and/or TGFb2 before aSMA and eotaxin mRNA was measured by
RT-PCR and eotaxin release by ELISA.
Results: IL-13 alone induced significant amounts of eotaxin release from
fibroblasts. A combination of IL-13 and TGFb2 produced a significant
synergistic increase in eotaxin production. TGFb2 induced TGFb1 release
and aSMA expression but not eotaxin. IL-13 failed to induce a significant
induction in aSMA mRNA.
Discussion: IL-13 was unable to induce significant profibrogenic
responses from fibroblasts however IL-13 induced significant amounts
of the eosinophil chemoattractant eotaxin which was synergistically
increased in the presence of TGFb2. Thus, it seems likely that the main
effect of IL-13 on fibroblasts is to drive a proinflammatory response
through recruitment of eosinophils. As eosinophils are a potent source of
TGFb1, this may represent an indirect method by which IL-13 contribute
to toward airway remodeling.
P203 TNFa ACCELERATES THE TGFb-INDUCED ‘‘EPITHELIAL-
MESENCHYMAL TRANSITION’’ IN LUNG EPITHELIAL
CELLS
Y. Yang, H. M. Haitchi, S. T. Holgate, D. E. Davies. Brooke Laboratories,
Division of Infection, Inflammation and Repair, School of Medicine, University
of Southampton, Southampton, UK
Background: Epithelial to mesenchymal transitions (EMT) play a critical
role in tissue morphogenesis during embryogenesis, but aberrant
induction of this process has been implicated in pathological processes
such as cancer metastasis and fibrosis (Willis BC, et al. Am J Pathol
2005;166:1321–32. Lee JM. J Cell Biol 2006;172:973–81). In chronic
lung diseases, inflammation usually accompanies fibrotic changes,
therefore we hypothesised that inflammatory mediators such as TNFa
may induce a stress response that acts in concert with TGFb to promote
an EMT. To test our hypothesis, we investigated the ability of TGFb1 to
induce an EMT in alveolar epithelial cells in the absence or presence of
TNFa.
Methods: A549 alveolar epithelial cells were treated with 2.5 or 10 ng/
ml TGFb1 and absence or presence of 1 ng/ml TNFa, or with TNFa
alone in low glucose DMEM medium with 0.1% BSA. The morphology of
the cells was recorded from day 2 to day 6. Cells were harvested at
2 days and 6 days for RNA extraction. Expression of mRNA for MUC2,
MMP9, Collagen I and a-SMA was analysed by quantitative RT-PCR.
Results: By day 2, morphological changes including loss of cell-cell
contact and cellular elongation were observed in the cells treated with
TGFb1 alone, but these were more prominent in cells treated with both
TGFb and TNFa. TNFa alone had minimal effect on the epithelial
morphology of the cells. From day 3 to day 6, the untreated cells or those
treated with TNFa alone entered into a ‘‘crisis’’ with large scale cell
death. Cell death was also observed in all cultures treated in the
presence of TGFb, however a significant number of cells survived. In all
cases, the surviving cells were fibroblast-like and increased in number
during the course of the experiment. The process of EMT induced by
TGFb was accompanied by reduced expression of the epithelial
phenotypic marker MUC2, and stimulation of ‘‘mesenchymal’’ markers
including collagen I and MM9. In contrast, a-smooth muscle actin
expression showed only a transient increase at day 2 but was not
different from control at day 6 suggesting an incomplete phenotypic
switch. TNFa augmented the effect of low doses of TGFb on MMP9 and
collagen I expression, but did not affect aSMA expression. Although
TNFa alone did not elicit a phenotypic change, it was able to induce
MMP9 expression.
Conclusion: TGFb1 signalling induces a phenotypic switch in alveolar
epithelial cells that is reminiscent of an EMT and TNFa can facilitate this
process. However, the absence of aSMA expression suggests that the
EMT is incomplete. We speculate that TGFb has induced a ‘‘repair’’
phenotype (that is, a migratory epithelial cell phenotype) rather than a
‘‘pro-fibrotic’’ (that is, myofibroblastic) phenotype.
P204 PREMATURE SENESCENCE OF AIRWAY EPITHELIAL
CELLS: A POSSIBLE ROLE IN AIRWAY REMODELLING
AFTER HUMAN LUNG TRANSPLANTATION
S. M. Parker1,3, G. Johnson1,3, C. Ward1,3, F. Black3, J. Lordan1,3,
P. A. Corris13, G. C. Saretzki2, A. J. Fisher1,3. 1Applied Immunobiology
and Transplantation Research Group; 2Institute for Aging and Health;
3Freeman Hospital, University of Newcastle upon Tyne, Newcastle upon
Tyne, UK
Introduction: Cells entering senescence lose their replicative capacity but
remain biologically active for many months with a proinflammatory
phenotype. This process is thought to contribute to the deterioration in
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tissue function seen with aging. External insults such as oxidative stress
can induce premature senescence in previously healthy cells in vitro, yet
the contribution of senescence to organ dysfunction in vivo and
specifically the lung is unclear. Therefore we investigated the expression
of the cell cycle inhibitor p16, an ‘‘in vivo’’ marker of senescence, in the
airway epithelium of lung transplant recipients.
Hypothesis: After transplant the airways are subject to numerous sources
of external injury that may drive epithelial cells to premature senescence;
the resulting lack of epithelial regenerative capacity and the proin-
flammatory mediators released by senescent cells may contribute to the
development of obliterative bronchiolitis (OB) the main cause of chronic
allograft dysfunction after lung transplantation.
Methods: Endobronchial biopsies were obtained from stable lung
transplant recipients without evidence of OB (n = 10), patients with OB
(n = 3) and from lungs explanted from OB affected patients at
retransplantation (n = 8). ‘‘Normal’’ control samples were taken from
lungs assessed for but not used in the lung transplant programme
(n = 11). Paraffin embedded sections were stained for p16 and the level
of airway epithelial staining quantified using an image analysis system.
Results are expressed as a percentage of cells in the epithelium staining
positive for p16.
Results: In ‘‘normal’’ biopsies the median level of p16 staining was 11%
(3–37) and increased with subject age supporting its use as a marker of
senescence. p16 staining was significantly increased beyond what
would be expected with normal aging in allografts: stable patients 33%
(range 18–40, p = 0.003), OB patients 38% (range 3–69, p = 0.03).
There was no significant difference between the stable and OB groups.
Conclusions: The higher levels of p16 staining suggest a greater
proportion of senescent cells in the allograft airway compared to normal
controls; this may be both a cause and a consequence of this stressful
environment. Further studies are needed to confirm the findings with
alternative senescence markers, to link airway injury to the senescent
phenotype and characterise the proinflammatory activity of senescent
cells.
P205 INVESTIGATION OF CLARA CELL 10 KDA PROTEIN
(CC10) POSITIVE SQUAMOUS EPITHELIUM IN LPS-
CHALLENGED RAT LUNG
S. J. Bolton1*, K. Pinnion1, C. Marshall2, E. Wilson1, J. Barker2, V. Oreffo1,
M. L. Foster1. 1Safety Assessment, AstraZeneca R&D Charnwood,
Leicestershire, UK; 2Discovery Bioscience, AstraZeneca R&D Charnwood,
Leicestershire, UK
Introduction: Clara cell 10 kDa protein (CC10, CCSP) is the major
secretory protein of the Clara cell and is thought to play a protective role
in the lung due to its anti-inflammatory properties. Studies have shown
levels of CC10 decrease in BALF and plasma following lung inflamma-
tion. In humans, CC10-positive cells increase with progression down the
bronchial tree but there is little information on the anatomical distribution
of CC10 in rat lung.
Methods: We have used immunohistochemistry to determine the
expression of CC10 along the tracheobronchial tree in control, saline-
treated, and LPS-treated rats (once/day, 5 days).
Results: Control rats showed sporadic staining of CC10 in central
airways and more frequent staining in bronchioles. In the transitional
airways, many of the cells showed strong staining except for squamous
cells. Following LPS challenge, there was a general reduction in staining
in the upper airways but little change within bronchioles. There was
increased staining in transitional airway squamous epithelia, which have
been further characterised by immunohistochemistry for CC10 and pan-
cytokeratins (fluorescent double staining), surfactant protein D and Ki-67
(standard light microscopy). The CC10-positive squamous cells co-stain
for pan-cytokeratin and appear to co-localise with surfactant D-positive
cells, indicating epithelial origin and function. There were Ki-67-positive
proliferative cells within the TA, but only some of which appeared to be
squamous cells.
Conclusions: These data show that diffuse inflammatory injury results in
generalised loss of the CC10 phenotype in central airways. Conversely,
there was an increase in expression in transitional airways, particularly
in metaplastic squamous epithelial cells. Following LPS-challenge, the
transitional airways showed evidence of a heterogeneous population of
cells that included both CC10 and surfactant D-positive cells and we
hypothesise that this is an attempt by the inflamed peripheral lung to
increase surfactant levels and thus restore compromised alveolar
compliance.
P206 SHOTGUN PROTEOMIC ANALYSIS OF HUMAN
INDUCED SPUTUM
B. Nicholas1, P. Skipp2, R. Mould1, S. Rennard3, D. E. Davies1,
D. O’Connor2, R. Djukanovic1. 1Division of Infection, Inflammation and
Repair, School of Medicine, Southampton General Hospital,UK; 2Centre for
Proteomic Research and School of Biological Sciences, University of
Southampton, UK; 3Nebraska Medical Centre, Pulmonary and Critical
Care Section, University of Nebraska, Omaha, Nebraska, USA
Sputum is increasingly recognised as a biologically relevant sample of
the environment of the airways when collected under controlled
conditions. As such, it has been used for the analysis of bacterial load,
tumour and inflammatory cell content, and of biomarkers of airways
diseases such as cystic fibrosis, asthma and chronic obstructive
pulmonary disease. While related biofluids such as broncho-alveolar
lavage1 fluid, nasal lavage fluid,2 and in particular saliva3 have been
well-characterised using standard 2-D gel based proteomics, sputum has
not. This is probably due to the presence of mucin glycoproteins that
compromise the separation of proteins during the IEF stage of 2-D gel
analysis, preventing good resolution.
We have used a combination of 2-D gel electrophoresis (fig 1B) and a
multidimensional mass-spectrometric technique (GeLC-MS/MS) (fig 1A)
to examine the proteome of induced sputum. 191 individual human
proteins were confidently assigned using these techniques. In addition to
expected components, several hitherto unreported proteins were
discovered, including three members of the annexin family, kallikreins
1 and 11, and peroxiredoxins 1, 2, and 5. The resultant data represent
the first detailed survey of the human induced sputum proteome and
allow a comparison of the induced sputum proteome with other
biologically related fluids such as broncho-alveolar lavage fluid and
saliva. They also provide a platform for the future identification of
biomarkers of airways disease.
1. Wu J, et al. Mol Cell Proteomics 2005;4:1251–64.
2. Ghafouri B, et al. Proteomics 2002;2:112–20.
3. Hu S, et al. Proteomics 2005;5:1714–28.
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Clinical aspects of asthma
P207 IS THE PREVALENCE OF ASTHMA DECLINING?
C. Anandan1, O. van Schayck2, A. Sheikh1. 1University of Edinburgh, UK;
2University of Nijmegen, the Netherlands
Background: Dramatic increases in the reported prevalence of asthma
over the latter half of the last century have made asthma one of the most
common chronic disorders globally. In recent years, however, there have
been a number of suggestions that the prevalence of asthma is now
declining, which, if true is important for health service planning and also
because it offers the possibility to generate and test new aetiological
hypotheses.
Objective: To examine recent trends in the international prevalence of
asthma.
Review Methods: Systematic search of Medline, Web of Science, and
Google Scholar databases for high quality reports of repeat cross-
sectional studies, cohort studies and analyses of routine healthcare
datasets.
Selection of Studies: We only included studies that presented data on
estimates of asthma prevalence using comparable approaches for at
least two time points during the period 1990–2006.
Output: Studies were categorised into two main groups: studies using the
validated ISAAC questionnaire and other epidemiological studies.
Conclusions: The large volume of data identified indicates that there are,
at present, no overall signs of a declining trend in asthma prevalence.
On the contrary, asthma prevalence is in most parts of the world still
increasing. The reductions in emergency healthcare utilisation being
reported in some economically developed countries most probably
reflect improvements in quality of care. There remain major gaps in the
literature in relation to large parts of Africa, Asia, and South America.
P208 INCREASED PREVALENCE OF INFLAMMATORY BOWEL
DISEASE IN PATIENTS WITH AIRWAYS DISEASE: 10
YEARS’ EXPERIENCE IN A TEACHING HOSPITAL
A. A. Raj1, S. S. Birring2, R. H. Green1, I. D. Pavord1. 1Institute for Lung
Health, Glenfield Hospital, Leicester, UK; 2King’s College Hospital, London,
UK
Lung disease is a recognised extra-intestinal manifestation of inflamma-
tory bowel disease (IBD). The lung pathology is predominantly airways
disease, but there are no consistent radiological, pulmonary, or airway
inflammation abnormalities. We undertook a retrospective analysis of
IBD prevalence in our respiratory clinic, to determine whether any
pattern of airways disease or inflammation was associated with IBD. We
identified 37 patients with IBD among 2192 patients with airways
disease seen over 10 years by a single respiratory consultant. IBD was
more prevalent (table) than expected in a similar sized general
population cohort, using local IBD prevalence data (Stone et al. Eur J
Gastroenterol Hepatol 2003;5:1275–80). This was true for both Crohn’s
disease (CD) and ulcerative colitis (UC) (OR 5.96, 95% CI 1.94 to 18.31
and OR 4.21 95% CI 1.71 to 10.41 respectively). Airways disease was
categorised using standard criteria. IBD was more frequent in all
patterns of airways disease except asthma; the association was
particularly strong in airways disease associated with productive cough
(table). All except 1 patient had established IBD; 24% had undergone
colectomy before the onset of respiratory symptoms. There were no
obvious radiological or pulmonary function differences between UC and
CD cases. Induced sputum results showed a trend for a higher sputum
lymphocyte count (3.7% v 0.5%, mean difference 23.25, 95% CI 29.1
to 2.6, p = 0.2), and lower blood lymphocyte count (1.6 v 2.2, mean
difference 0.5, 95% CI 20.2 to 1.3, p = 0.15) in CD compared with UC.
Sputum neutrophil count was also lower in CD (58.5% v 76.9%, mean
difference 18.4, 95% CI 212 to 48.7, p = 0.2).
Our findings support an association between airways disease and
IBD, particularly non-asthmatic airways disease with productive cough.
The pattern of airway inflammation seen may be different in CD
compared with UC.
P209 IS THERE A ROLE FOR INSPIRATORY FLOW RATE
MEASUREMENTS PRIOR TO PRESCRIBING INHALED
MEDICATIONS?
S. Lincoln, E. Karra, M. Airan, D. Mukherjee, B. Yung, J. Samuel, J. Creasey.
Basildon University Hospitals NHS Foundation Trust, Essex, UK
Background: Inhalation as a route of drug delivery has been used for
many years to administer medication to the lungs. Studies have shown
that particle size, pattern of deposition of an inhaled drug, patient’s
inhaler technique and device employed, are important determinants
upon drug delivery to the respiratory tract.1 In practice however,
whether the patient’s inspiratory flow rate (IFR) lies within the range of
optimum inspiratory flow rate (OIFR) at which an inhaler device will
work most effectively is rarely considered when inhalers are being
prescribed.2, 3
Aim: (1) To examine the suitability of prescribed inhaler device based on
comparing the patient’s IFR with the recommended OIFR for different
inhaler devices. (2) To determine if there is a role for IFR measurement
prior to prescribing patients inhalers.
Method: Over a 3 month period, an unselected random sample of
inpatients and outpatients with asthma and COPD were assessed for the
suitability of their prescribed inhalers on the basis of comparing their
measured IFRs with the recommended OIFRs for different inhalers
(Clement Clarke International (CCI), 2003). The patients’ IFRs were
measured using the CCI ‘‘in-check dial’’ inspiratory flow meter. Peak
expiratory flow rate (PEFR) and spirometry were also recorded.
Results: Seventy eight patients (51 female) were assessed. 46 patients
(mean age 77.5 years, range: 53–94 years) had COPD. These patients
had a mean FEV1 of 43% predicted normal (range: 9–87%). 32 patients
(mean age 64 years, range 23–87 years) had asthma with a mean PEFR
of 283 l/min (range 50–510 l/min). The asthma group had higher
values of IFR than those with COPD (mean values 82.5 l/min and
64.2 l/min respectively). In the asthma group, 24 patients (75%) were
prescribed at least one inappropriate inhaler based on comparing their
IFRs with the OIFRs. In the COPD group, 32 patients (69%) were
prescribed at least one inappropriate inhaler. The asthma group tends to
have IFRs higher than the upper limit of the OIFR for some devices
whereas COPD patients tend to have IFRs below the lower limit of the
OIFRs for some devices. Neither FEV1 or PEFR showed any correlation
with IFR.
Conclusions: (1) This study has shown that prescribing inhalers without
considering IFR measurement leads to a high number of inappropriate
inhalers being used. (2) The severity of disease based on FEVI and/or
PEFR could not predict the patients’ IFRs. (3) IFR measurements may have
a valuable role to play prior to prescribing inhaled medications.
1. Brocklebank D. et al, Health Technol Assess, 2001;5:26.
2. Pedersen S. et al, Arch Dis Childhood, 1990;65:308–9.
3. Timsina M. et al, Thorax, 1993;48:433.
P210 EVIDENCE-BASED ASTHMA TRAINING IMPROVES
ASTHMA MANAGEMENT SKILLS IN GENERAL
PRACTICE: A COMMUNITY-BASED SURVEY
M. Fletcher, J. Coomber, S. Walker. Education for Health, Warwick, UK
Background: The BTS/SIGN Asthma Guideline provides evidence-
based recommendations for the diagnosis and treatment of asthma.
Although easily accessible online, the guideline alone may not be
sufficient to change practice, and community-based health professionals
may benefit from an educational package linking the guideline to
practice. Here we assess the effects of accredited asthma training, based
on the guideline, on clinical practice in primary care.
Methods: 526 primary care nurses enrolled on an accredited (Education
for Health) diploma level asthma module received a postal questionnaire
at the start (baseline) and the end of course (6 months). Nurses’ self-
reported confidence in their abilities and frequency of performing key
components of the guidelines were measured on a Likert scale where
Abstract P208
Airways disease
Patients seen
in clinic
IBD
cases
OR observed/expected
(95% CI of OR)
COPD 588 9 3.87 (1.19–12.62)
Bronchiectasis 215 7 8.38 (2.43–28.89)
Chronic cough 426 8 4.76 (1.43–15.90)
Chronic bronchitis 66 4 16.07 (3.92–65.76)
Asthma 893 9 2.54 (0.78–8.26)
Total 2129 37 4.26 (1.48–11.71)
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1 = poor confidence or low frequency and 5 = high confidence or high
frequency. Enhanced practitioner role was assessed using a Likert scale
where 1 = not enhanced and 5 = greatly enhanced. Paired data were
analysed using McNemar’s test.
Results: 303 paired sets of data were suitable for analysis (58% overall
response rate). The proportion of the respondents who reported they
were ‘‘usually confident’’ or ‘‘very confident’’ in their ability to provide
appropriate asthma care and education to patients rose from 10% to
84%. There was a significant increase from baseline in frequency of
taking a structured respiratory history (‘‘most times’’/‘‘always’’ 38% to
80%; p,0.0001); using bronchodilator reversibility testing for diagnosis
(36% to 76%; p,0.001) and measurement of peak expiratory flow (65%
to 92%; p,0.0001). Frequency of checking of inhaler technique (58% to
91%; p,0.0001) and checking adherence to treatment (62% to 92%;
p,0.0001) also increased from baseline as did advice given to patients
and/or prescribers on inhaler device selection (25% to 74%;
p,0.0001). 57% respondents reported enhancement of their clinical
role and 54% reported enhancement of their professional education role
in their workplace.
Conclusion: In this study, nurses who completed a BTS/SIGN Guideline-
based accredited asthma module reported an increase in the manage-
ment skills associated with improved diagnosis and treatment of asthma.
Training a nurse within the practice can encourage knowledge sharing
among colleagues and therefore aid local dissemination of the key points
of the guidelines.
P211 THE EFFECTIVENESS OF SPEECH AND LANGUAGE
THERAPY IN VOCAL CORD DYSFUNCTION
N. J. Pargeter, A. H. Mansur. Severe and Brittle Asthma Unit, Birmingham
Heartlands Hospital, Birmingham B9 5SS, UK
Introduction: Vocal cord dysfunction (VCD) is a condition where the
vocal cords adduct during inspiration, resulting in inspiratory wheeze
and stridor. It is often associated with, and misdiagnosed as asthma. The
aetiology, symptom triggers and concomitant conditions are not well
defined. There is anecdotal evidence of the benefits of Speech and
Language Therapy (SLT) in management of VCD. A protocol was
developed to define the VCD population in terms of diagnosis, aetiology,
triggers, associated conditions, and treatment.
Method: Fifty patients (41 females, 9 males, mean age 47.1, range 20–
79) consecutively referred to the VCD clinic at Heartlands hospital, were
put through the protocol. They were assessed by SLT using nasendoscopy
and full lung function tests. Established cases of VCD received 4 therapy
sessions of SLT and treatment effectiveness was assessed by baseline and
post treatment self-rated symptoms questionnaire (scored out of 25).
Results: The diagnosis of VCD was confirmed by nasendoscopy
(‘‘paradoxical vocal cord movement’’) in 19/50 (38%). A further 23
(46%) patients had symptoms suggestive of VCD, but nasendoscopy was
not conclusive. VCD was excluded in 8 (16%) patients who were
alternatively diagnosed with globus pharyngeus. Of the 19 confirmed
VCD cases, the most commonly associated conditions were oesophageal
reflux (15, 79%) and asthma (14, 74%), though rhinitis and dysphonia
were also prevalent (10, 53%). The most commonly reported triggers
were stress (18, 95%), cough (18, 95%), exertion (16, 84%), heartburn
(15, 79%), and smoke (14, 74%). 15/19 patients completed a course of
SLT. A significant reduction in patient-reported symptoms was noted post
SLT. Wilcoxon Rank Test pre therapy mean 17.6, SD 3.8, post therapy
mean 10.0, SD 4.3, Z =23.4, p = 0.01. A similar improvement in
symptoms scores was also seen in ‘‘suggestive VCD cases’’.
Conclusion: VCD is a complex condition though there are a common
range of concomitant factors and triggers. SLT can play a role in
symptom management.
P212 SIMVASTATIN AS A POTENTIAL THERAPEUTIC ANTI-
INFLAMMATORY AGENT IN ASTHMA
D. Menzies1, A. Nair1, K. Meldrum1, D. Flemming2, B. Lipworth1. 1Asthma &
Allergy Research Group, Ninewells Hospital & Medical School, Dundee, UK;
2Department of Pathology, Ninewells Hospital & Medical School, Dundee,
UK
Rationale: Statins effectively lower cholesterol, and have also been
shown to exhibit anti-inflammatory properties. Recent preliminary in-
vitro and animal studies have suggested they may be useful for the
treatment of a number of inflammatory conditions including asthma.
Objectives: To evaluate the in vivo therapeutic potential of simvastatin as
a novel anti-inflammatory agent in asthmatics.
Methods: Any potential signal from treatment effect was optimised by
initially withdrawing all anti-inflammatory treatment for the duration of
the study. Thereafter, participants received one month of simvastatin and
one month of placebo in a randomised double blind, crossover trial, with
16 patients completing per protocol.
Measurements: Airway and systemic asthmatic inflammation and was
evaluated by measuring exhaled tidal nitric oxide (the primary outcome),
alveolar nitric oxide, induced sputum eosinophil count, airway
hyperresponsiveness to methacholine, salivary eosinophilic cationic
protein, high sensitivity CRP, and peripheral eosinophil count.
Dynamic and static lung volume measurements were made as was
estimation of cholesterol.
Results: Compared with placebo simvastatin led to a 0.86 geometric
mean fold difference (95% CI 0.7 to 1.04, p = 0.154) in exhaled nitric
oxide, and a 20.178 doubling dilution shift (95% CI 21.90 to 1.55,
p = 1.0) in methacholine hyperresponsiveness. Similarly, there were also
no significant differences in other inflammatory outcomes, lung volumes
or airway resistance between simvastatin and placebo. Treatment with
simvastatin did as expected lead to significant reduction (p,0.005) of
total and LDL cholesterol.
Conclusion: Despite theoretical in vitro potential for use of statins in
asthma, there is no evidence to suggest they have a therapeutic role in
patients.
This paper was entered into the BALR young investigator competition
at the 2006 summer meeting.
P213 THE RESPONSE TO METHOTREXATE IN REFRACTORY
ASTHMA
P. Haldar, M. A. Berry, A. J. Wardlaw, I. D. Pavord, R. H. Green. Institute For
Lung Health, Glenfield Hospital, Leicester, UK
Introduction: Methotrexate is a well established steroid sparing
immunosuppressive agent used in the management of refractory asthma.
The therapeutic response to methotrexate varies widely and little is
known about the factors predicting a favourable outcome.
Methods: We identified 41 patients with refractory asthma attending the
Glenfield Hospital refractory asthma clinic who had either a past or
current history of methotrexate treatment for asthma control. The cohort
represents 12.8% of the total number of refractory asthma patients on the
clinic database (n = 320) and 34.7% of all the patients on regular
maintenance oral corticosteroid therapy (n = 118). Sufficient data were
obtained from 35 of the patients for further analysis.
In all patients, methotrexate prescription followed a period of
treatment with maintenance oral corticosteroids for at least 6 months
that failed to achieve satisfactory symptom control and/or control of
underlying eosinophilic airway inflammation. When tolerated, metho-
trexate was prescribed at a dose of 15 mg weekly for at least 3 months
before an assessment of response was made. A positive response was
defined as a sustained fall in maintenance oral corticosteroid dose,
improvement in daily symptom control or improvement in lung function
when compared with control in these parameters for the 6 months prior
to starting therapy.
Results: Patients started on MTX were on a significantly higher dose of
maintenance prednisolone at baseline compared with the population on
maintenance oral steroid therapy not started on methotrexate (mean
17.7 mg v 9.6 mg, p = 0.03). The mean duration of therapy with
methotrexate following commencement was 12.2 months (SE 1.62). 11
of the 35 patients have remained on long term methotrexate. Side effects
(derangement in liver function tests, rash, gastrointestinal symptoms, and
constitutional symptoms) occurred in 6 patients that had methotrexate
stopped (17%). 49% (n = 17) showed a positive response to methotrex-
ate. 50% of this cohort had a positive response in all the specified criteria
and a further 25% showed improvement in symptoms together with a fall
in maintenance oral corticosteroid dose. A 52% reduction in the dose of
maintenance prednisolone was achieved in responders. Five patients
were able to withdraw oral corticosteroid therapy completely. Six of the
responders subsequently had to stop therapy due to side effects or loss of
efficacy. In those patients that developed impaired efficacy, the mean
duration of efficacy was 13.8 months with no patient showing ongoing
responsiveness to methotrexate beyond 24 months. Non-responders
(n = 18) had a mean duration of therapy of 8.5 months. There was no
significant difference between responders and non-responders in any
measured clinical or inflammatory variables.
Conclusions: Our results are consistent with previous publications and
indicate that methotrexate is a valuable steroid sparing agent in a small
minority of refractory asthma patients. However, factors predicting a
response remain unclear.
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P214 ELIGIBILITY FOR TREATMENT WITH OMALIZUMAB
AMONG PATIENTS ATTENDING THE GLENFIELD
HOSPITAL REFRACTORY ASTHMA CLINIC
B. Hargadon, P. Haldar, D. Shaw, M. A. Berry, A. J. Wardlaw, I. D. Pavord,
R. H. Green. Institute for Lung Health, Department of Respiratory Medicine,
Glenfield Hospital, Leicester, UK
There is a pressing need for novel therapeutic agents in the management
of patients with refractory asthma. The humanised monoclonal anti-IgE
antibody, Omalizumab, has recently been introduced as add-on therapy
for patients with severe atopic asthma. Omalizumab is licensed for use in
patients with a positive skin prick test or specific IgE to a perennial
aeroallergen, reduced lung function (FEV1,80% of predicted) along
with frequent symptoms or nocturnal awakenings and multiple severe
exacerbations despite regular inhaled corticosteroids plus a long acting
beta-2 agonist. In addition patients with a low (,30 iU/ml) or markedly
elevated total IgE should not be dosed with an upper limit for treatment of
700 iU/ml or lower dependant on body weight. We aimed to determine
what proportion of patients referred to our refractory asthma clinic
would be eligible for treatment with Omalizumab according to the above
criteria. We assessed 251 consecutive patients attending our refractory
asthma clinic with uncontrolled asthma symptoms and recurrent severe
asthma exacerbations. We recorded body weight (kg), spirometry as
FEV1 % of predicted, symptoms using the Juniper Asthma Control score,
total serum IgE (iU/ml) and skin prick tests to common aeroallergens.
Only 34 (13.5%) patients met all of the criteria for treatment. 148
patients had no evidence of persistent airflow obstruction (FEV1.80%).
58 patients had negative skin prick tests to all common aeroallergens, 45
patients had a total IgE ,30 (of which 16 had positive skin prick tests)
and 53 patients had a total IgE .700 iU/ml. A further nine patients had
a total IgE greater than the maximum recommended for dosing in
relation to their body weight. Although Omalizumab offers an additional
therapeutic option for patients with severe asthma, its use is likely to be
limited to a small proportion of patients. Further studies are needed to
determine its efficacy in patients with a total IgE outside the
recommended range for optimal dosing. There remains a high unmet
need for novel treatments for patients with severe asthma.
P215 ASSOCIATION BETWEEN CONTROL OF ASTHMA AND
GASTRO-OESOPHAGEAL REFLUX DISEASE SCORE
A. A. Raj, D. Shaw, M. A. Berry, P. Haldar, I. D. Pavord. Institute for Lung
Health, Glenfield Hospital, Leicester, UK
Gastro-oesophageal reflux disease (GORD) is more common in patients
with asthma compared to controls. There is evidence that the presence of
GORD is associated with more severe asthma. The mechanism for the
increased prevalence of GORD in asthma is unclear. We set out to
determine the relation between a validated GORD score (Manterola et
al. J Clin Epidemiol 2002;55:1041–5) and asthma characteristics in a
cohort of 113 patients with well characterised disease. Asthma
characteristics investigated were the modified Juniper Asthma Control
Questionnaire (JAC) consisting of the response to symptom questions
only, JAC score for daily bronchodilator use, dose of inhaled
corticosteroid, FEV1 as % predicted, induced sputum eosinophil
differential and neutrophil count, exhaled nitric oxide concentration
(FENO) and the results of a methacholine inhalation test (PC20). A
multiple independent linear regression model was used to predict the
reflux score. The model coefficients are given in the table. For the total
model r2 = 0.362, p = 0.003. Poorly controlled asthma symptoms, as
assessed by the modified JAC, are associated with a higher reflux score.
The reflux score was not related to use of inhaled corticosteroids or
bronchodilator use. Neither the pattern of airway inflammation, nor the
degree of airway hyperresponsiveness was associated with the reflux
score.
P216 SEVERE ASTHMA IS ASSOCIATED WITH TIDAL
BREATHING CLOSE TO RESIDUAL VOLUME
M. Schofield, C. Prys-Picard, N. Clayton, R. Niven. North West Lung
Research Centre, Manchester, UK
Introduction: Our hypothesis is that a proportion of patients with severe
asthma tidal breathe at a volume close to residual volume (RV); a feature
which may causes a worsening of symptoms. We aimed to confirm the
presence of this pattern of breathing in patients with severe asthma and
whether it bears any correlation to hyperinflation.
Methods: We recruited 32 subjects: 10 normal, 10 severe asthmatics
(BTS step 4 or greater), 7 mild asthmatics (BTS steps 1 or 2), and 5
patients with COPD and known hyperinflation. Using body plethysmo-
graphy to determine functional residual capacity, and using slow vital
capacity maneuvers, we were able to determine all lung volumes in the
different subject groups.
Results: Mean expiratory reserve volume (ERV) was significantly reduced
in the severe asthma group (mean ERV = 0.66 l) compared to normals
(1.55 l, p,0.001) and mild asthma (1.24 l, p = 0.009), and in the
COPD group (0.82 l) compared to normals (p = 0.004). In the COPD
group, all subjects were hyperinflated with high values of RV % predicted
(mean 207%). A subgroup of severe asthma patients had ERVs lower
than those in the COPD group, but with normal RV % predicted (fig 1).
Discussion: These results support the earlier data1 that some subjects
with severe asthma appear to tidal breathe at a volume close to RV. The
reasons for this are unknown, but our results show that hyperinflation is
not uniquely the cause. This may represent a distinct clinical phenotype
of severe asthma. Alternatively it may represent an acquired form of
dysfunctional breathing. So far no evaluated treatment for this pattern
exists, but it may revolve around techniques that aim to increase lung
volumes.
1. Prys-Picard CO, Niven R. Tidal breathing at residual volume may be
associated with severe asthma. Thorax 2005;60(Suppl II):55.
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Variable Coefficient
Standard
error p Value
Modified JAC score 1.42 0.37 0.000
FEV1 as % predicted 0.02 0.02 0.208
Bronchodilator use score 0.17 0.34 0.614
Dose of inhaled corticosteroid (mg)23.52 0.001 0.968
Log sputum eosinophil count (%) 20.21 0.46 0.646
Log sputum neutrophil count
(6106/g of sputum)
20.38 0.37 0.310
Log Pc20 (mg/ml) 0.10 0.25 0.699
Log FENO 20.38 20.57 0.689
BMI (kg/m2) 0.05 0.04 0.908
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Abstract P216 Scatter plot of ERV against residual volume. Broken
reference line lies at 130% predicted (values greater than which indicate
hyperinflation).
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P217 VALIDATION OF A MULTIDETECTOR CT SCANNER TO
MEASURE PROXIMAL AND DISTAL AIRWAY WALL
VOLUME
S. H. Siddiqui, G. Cruse, P. Haldar, S. Yacomeni, D. Mawby, P. Bradding,
I. D. Pavord, J. Entwisle, S. Hainsworth1, C. E. Brightling. Institute for Lung
Health and 1Department of Engineering, Leicester University, UK
Background: Multidetector CT has emerged as a useful tool to non-
invasively measure cross-sectional proximal airway wall dimensions in
airways disease. However we and others have found that there is a
systematic error in the measurement of distal airways. This is most likely
due to the effect of partial volume averaging of captured CT image. We
sought to validate and improve the accuracy our Siemens Sensation 16
slice MDCT scanner to measure airway wall area and volume.
Methods: A phantom model of 9 plastic tubes of varying airway wall
dimensions (Range wall area (WA) ¡2SD normal and asthmatic
airways (2.42–47 mm2)) embedded within a polystyrene block was
constructed. The polystyrene had a mean attenuation (SEM) of 2965
(2.4)HU, similar to the density of inflated lung tissue. Gold standard
measurements were made to the nearest 20 mm by imaging both faces
of each tube with a stereomicroscope and the length by Vernier callipers.
CT scanning was performed at 1660.75 mm collimation, 120 kV, and
50 mAs with a table feed of 13.5/0.5 s scanner rotation. Images were
reconstructed at 0.75 mm spacings using a B70-f very sharp aligorithm
at 139 mm field of view with a 5126512 matrix. Cross sectional
measurements were made at a face designated the leading face using
Ray Casting (Harvey Coxson VA) and the full-width half-maximum
technique by 3-blinded observers. Volumetric measurements were made
using a commercial platform (Mimics, Materialise). To minimise the error
in the measurement of smaller airways, we varied the threshold
measurement for tubes 5–8 to achieve the % width maximum of the
grey level across the tube wall that produced ,5% error in wall volume
when compared to the gold standard. A plot of threshold versus wall
volume was generated. We tested the validity of this relationship by
examining whether we were able to predict the % maximum threshold
required to produce ,5% error in wall volumes of tubes 1–4.
Results: Ray casting was highly reproducible amongst observers (ICC = 1
for wall area (WA), luminal area (LA) and %WA), and between
observers and the steromicroscope (ICC = 1 for %WA tubes 6–9, LA
&WA tubes1–9). Plots of the mean interobserver LA and WA versus %
error followed a second order polynomial relationship (LA r2 = 0.96,
WA r2 = 0.90). There was an excellent correlation between Vernier
calliper tube lengths and reconstructed CT 3D tube length (r2 = 1,
absolute mean error = 1.63%). For tubes 5–8 there was a close linear
relationship between wall volume and the % maximun wall threshold
(r2 = 0.98). This allowed us to predict the thresholds required to measure
tubes 1–4 and reduced the mean (SD)% error from 49.3 (13.9)% (50%
maximum wall threshold) to 5 (3.9)%.
Conclusions: The measurement of tubes corresponding to proximal and
distal airways (generation 3–8) by CT is reproducible and absolute
measurements can be made accurately.
P218 THE NIJMEGEN QUESTIONNAIRE DOES NOT APPEAR
TO PREDICT HYPERVENTILATION IN SUBJECTS WITH
SEVERE ASTHMA
C. Prys-Picard, R. Niven. North West Lung Research Centre, Manchester, UK
Introduction: The Nijmegen questionnaire was originally validated to
predict hyperventilation in the absence of chest disease.1 Its use has
subsequently been extended to predict hyperventilation in the presence
of chest disease despite never having been validated in this context.
Methods: Twenty seven subjects with severe asthma were recruited.
Nijmegen questionnaires were completed prior to spirometry and then
an incremental shuttle walk test with concomitant continuous end tidal
partial pressure of carbon dioxide (PETCO2) monitoring. PETCO2 values
were taken as the mean of 10 consecutive breaths at one minute prior to
starting exercise, and over the last 10 breaths before exercise tolerance
was reached. Subjects were considered to hyperventilate if a) resting
PETCO2,30 mmHg (chronic hyperventilation; CH) or b) PETCO2 fell with
exercise (acute exercise induced hyperventilation; AEIH). Multiple
stepwise logistic regression was performed to identify the 3, 4, 5, 6,
7, and 8 best predictive items within the questionnaire.
Results: 10/27 subjects (37%) were classed as hyperventilating (5 CH, 5
AEIH). The mean Nijmegen score for the whole cohort was 22 (normal
,23). There was no significant correlation between Nijmegen score and
either CH or AEIH. A receiver operator characteristic plot (fig) showed
that Nijmegen score was not significantly better than chance at
predicting hyperventilation (area under curve 0.659 sig = 0.175). At a
threshold of greater or equal to 22.5, the Nijmegen score had a
sensitivity of 70% and a specificity of 53%. Similar results were achieved
when the Nijmegen questionnaire was used to predict either CH or AEIH
alone. Using only the best predictive items from the questionnaire also
failed to improve the predictive value to an acceptable level.
Discussion: The original Nijmegen validation had a sensitivity of 91%
and specificity of 95. The questionnaire does not appear valid in the
prediction of hyperventilation in subjects with severe asthma. Our
definition of hyperventilation is open to discussion, however probably
reflects the original gold standard: a diagnosis of hyperventilation
‘‘made on the basis of the complaints pattern’’.1 A number of the items
within the questionnaire refer to symptoms that are commonly
experienced in asthma which may explain both the high mean scores
and the inability of the questionnaire to identify patients with both severe
asthma and hyperventilation.
1. van Dixhoorn J, Duivenvoorden HJ. Efficacy of Nijmegen
Questionnaire in recognition of the hyperventilation syndrome.
J Psychosom Res 1985;29:199–206.
P219 ADIPOSITY PREDICTS ASTHMA AND PULMONARY
FUNCTION IN A YOUNG ADULT POPULATION
G. A. Davies, M. B. Gravenor, D. Gopalakrishnan, P. Bikhchandani,
S. Benjamin, M. Moller, J. M. Hopkin. School of Medicine, Swansea
University, Wales, UK
Background: A concurrent rise in the prevalence of asthma and obesity
in recent decades has led to speculation on obesity as a causal factor in
asthma. To further elucidate the role of obesity, we examined measures
of central obesity (waist circumference, WC) and percentage body fat
(%BF) in addition to body mass index (BMI) with relation to asthma
prevalence and lung function in a population of young adults.
Methods: A prospective cross sectional study (n = 1614) was performed
in a population of adults aged 18–30. Validated questionnaires
provided data on doctor-diagnosed asthma and atopic disease.
Measurements included height, weight, WC, %BF and morning
spirometry.
Results: BMI, WC, and %BF were all associated with current asthma
(p,0.01). BMI was significantly associated with asthma (p,0.001) such
that a 5 unit increment in BMI reflects a 41.5% increase in asthma risk.
%BF was significantly associated with asthma (p = 0.001) such that a 5%
increase in %BF reflects a 16% increase in asthma risk (fig 1). %BF was
also significantly associated with current eczema (OR 1.03, p = 0.001).
BMI predicted frequency of symptoms over the last 3 months, such that
each unit rise in BMI equated to an 8.7% risk of having more frequent
symptoms—for example, ‘‘continuous’’ rather than ‘‘daily’’ (p,0.05).
BMI also predicted daily inhaled bronchodilator volume in a subgroup of
male smokers (p,0.05). BMI, WC, WHR, and %BF were positively
associated with FEV1, FVC, PEF across normal adiposity ranges but
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Abstract P218 ROC plot with Nijmegen score as test variable and
presence of hyperventilation as a positive result. Broken diagonal line
denotes predictive value of guessing.
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inversely associated once higher adiposity levels were reached (p,0.001).
A similar pattern was seen for BMI and %BF with % predicted FEV1 and PEF
(p,0.05). For instance, % predicted FEV1 increased with BMI until a BMI of
29, with % FEV1 declining thereafter. BMI, WC and WHR were inversely
associated with FEV1/FVC (p,0.001).
Conclusion: Adiposity indices were associated with asthma and this was
also true for %BF, a more direct measure of adiposity than BMI. In this
general population of young adults, adiposity indices showed non-linear
associations with lung function, with positive associations seen across
normal ranges of adiposity and inverse associations seen at higher
levels. Adiposity was inversely associated with FEV1/FVC, suggesting
an increasing degree of airflow obstruction in more adipose individuals.
Examining the relation between %BF and asthma phenotypes is likely to
further elucidate the role of obesity in asthma.
P220 A MECHANISM WHEREBY A PROPENSITY TO WHEEZE
MIGHT BOOST EXERCISE CAPACITY
J. E. Cotes, J. W. Reed. Institute of Molecular and Cell Biology, Medical
School, Newcastle upon Tyne, UK
Introduction: Airway hyperresponsiveness is common in elite athletes
and may reflect environmental exposures during training.1 Casual
observation suggests that wheeze is common amongst competitors at
junior events as well. Thus it might confer a competitive advantage. A
possible mechanism could be that mild wheeze encourages a slow deep
pattern of breathing as is promoted by physiotherapists. A newly
developed model shows that this breathing pattern is associated with a
reduced level of ventilation during submaximal exercise.2 We now
report the same pattern among 15 male subjects who were referred on
account of work related wheeze. Their average features were: age 45
years, post bronchodilator FEV1 77% predicted and reversibility 16%.
Measurements: Lung function was obtained by standard methods.3
Exercise was after inhalation of a bronchodilator aerosol; it was
progressive on a treadmill and standardised indices were obtained by
interpolation. Exercise ventilation (V’E,St) and CO2 output were at an O2
uptake of 45 mmol/min (1.0 l/min); breathing frequency and tidal
volume were at a ventilation of 30 l/min (fR30 and Vt30 respectively,
where fR30 = 30/Vt30). Reference variables were: for FEV1 age and
stature,3 for V’E,St the CO2 output and fR302 and for Vt30 the FVC.3
Differences were assessed by paired t test.
Results: The mean values for V’E,St and Vt30 were 26.1 l/min and
1.74 l; these exceeded the reference values of 22.5 l/min and 1.51 l
respectively (p,0.05). Compared with the reference values the depth of
breathing was increased (Vt30 difference 0.23 l p,0.05). However in 6
of the 15 subjects the difference was quite small (,0.2 l) whereas in 5
subjects it exceeded 0.4 l. These subgroups did not appear to differ with
respect initial spirometry or reversibility.
Discussion: The chosen work level was on average less than 50% of the
symptom limited maximum and the subjects felt comfortable with it, so
the slow deep breathing pattern was not a response to stress.
Comparison with other occupational disorders suggested that the
response was associated with wheeze. Here it was well developed only
in some subjects. In these men the model indicates that V’E,St would have
been reduced by up to 3 l/min, but the benefit appears to have been
obscured by V’A/Q’ inequality since the V‘E,St was on average slightly
increased. Had the airway obstruction been fully corrected (as would
seem to be necessary for a wheezy athlete to be successful) the model
predicted that the same breathing pattern would have reduced the
ventilation and associated breathlessness. Is this why a disproportionate
number of athletes have a tendency to wheeze?
1. Langdeau J-B, et al. Am J Respir Crit Care 2000;161:1479–84.
2. Cotes JE, Reed JW. Proc Physiol Soc 2006;3:C39.
3. Cotes JE, et al. Lung function: physiology, measurement and
application in medicine, Sixth edition. Blackwell Publications, 2006.
P221 ADRENAL FUNCTION OF PATIENTS WITH
BRONCHIECTASIS AND ASTHMA WHO TAKE INHALED
CORTICOSTEROIDS
J. Holme1, A. L. Sullivan2, J. Tomlinson2, P. Stewart2, R. A. Stockley1.
1University Hospital Birmingham; 2University of Birmingham, UK
Introduction: Asthmatic patients who take inhaled corticosteroids (ICS)
have been shown to have reduced basal serum and urine cortisol levels
(Donnelly. AJRCCM 1997;156:1746). However, no work has addressed
the ability to produce cortisol following a stimulus in patients who have
been taking long term ICS commonly used in the UK Bronchiectasis is
associated with increased airway inflammation and following an index
case of complete adrenal shut down due to ICS, we examined the
dynamic adrenal function in patients with bronchiectasis and asthma
who have taken ICS for more than 1 year.
Method: Twenty nine subjects underwent serum cortisol, ACTH, and
fasting glucose measurement prior to intramuscular administration of
250 mg synacthen. Serum cortisol was repeated after 30 minutes.
Subjects were diagnosed as suppressed if the 30-minute cortisol was
,550 nmol/l. Concomitant medications, symptoms and signs of adrenal
dysfunction, St George’s Respiratory Questionnaire (SGRQ) and Short-
Form 36 (SF-36) scores were compared for those who had adrenal
suppression and those who did not.
Results: See table.
Conclusion: 48% of patients with bronchiectasis and asthma who take
licensed doses of ICS long term have biochemical evidence of dynamic
adrenal suppression. Significantly more of those who are suppressed
have symptoms of being light headed on standing, nausea, and
abdominal pain.
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Abstract P219 Probability of asthma by percentage body fat (%BF).
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Suppressed Not suppressed p Value
n 15 14
Mean daily dose of ICS (BDP equiv) 1828 (SD 851.6) 1640 (SD 530.2) 0.64
On beclamethasone (n = ) 2 0 0.48
On budesonide (n = ) 1 2
On fluticasone (n = ) 11 13
Had nasal steroid over last year (n = ) 4 3 0.56
Had oral steroid over last year (n = ) 4 7 0.32
Total dose oral steroid last year (mg) 313 659 0.32
Lightheaded on standing (n = ) 8 4 0.048
Nausea 8 3 0.020
Abdominal pain 6 1 0.031
Vomiting 5 1 0.070
Postural hypotension at 1 or 3 mins 3 5 0.682
Fasting glucose 5.13 4.91 0.470
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P222 INCREASES IN TUBERCULOSIS IN THE UK-BORN IN
NORTH EAST LONDON AND THE LONDON BOROUGH
OF HACKNEY
T. Sanghera, G. H. Bothamley. NE London TB Network, Homerton University
Hospital, UK
Introduction: The proportion of tuberculosis (TB) in those born outside the
UK has steadily increased nationally and also within NE London. We
wanted to know whether the number of TB cases in the UK-born was
stable or not and the contribution of the outbreak strain to the increase
locally.
Methods: The NE London Tuberculosis Network receives notification
data from all boroughs within the sector. These were analysed according
to country of birth and whether UK-born or not for the period 1998–
2005. In one borough there appeared to be a significant increase in TB.
The importance of travel to a country where TB was common and a
number of risk factors for adherence (alcoholism, psychiatric treatment,
illegal drug use, prison experience, homelessness, and being a member
of the isoniazid-resistant outbreak) were documented.
Results: TB cases in the UK born have shown an increase since 1998, this
can only be partially explained by the introduction of a more robust
reporting method. Two hundred and four UK-born TB patients living in
Hackney were identified. A third of these (n = 67) had traveled or stayed
with relatives in a country where the incidence of TB was high. The
isoniazid-resistant outbreak contributed significantly to the observed
increases in UK-born TB. The complexity of cases increased during the
period of study, measured by the number of risk factors per adult patient.
Conclusions: TB in the UK-born has increased due to travel and the
isoniazid-resistant outbreak. These factors should be addressed
vigorously to prevent an increase in tuberculosis in the UK-born.
This study was funded by the NHS Culyer allocation and the NE
London TB Network.
P223 THE PERSISTENT LINK BETWEEN TUBERCULOSIS AND
POVERTY IN LIVERPOOL ILLUSTRATES THE INABILITY
TO IMPROVE HEALTH INEQUALITIES IN ENGLAND
K. Tocque1, K. Jones2, S. Hughes1, P. Davies3. 1North West Public Health
Observatory, Liverpool John Moores University, UK; 2Royal Liverpool
Hospital, UK; 3Cardiothoracic Centre, Broadgreen Hospital, UK
Aim: To compare health inequalities today with the recent past.
Background: A previous study showed that tuberculosis (TB) rates across
Liverpool are related to poverty.1 With a commitment to reduce health
inequalities, cities with the lowest life expectancy should show
improvement in patterns of a curable disease like tuberculosis.
Design: An ecological study of geographic patterns of TB and
respiratory disease.
Methods: TB notifications, mortality and hospital data (1996–2005)
were analysed against ward-level measures of deprivation.
Results: TB rates in 1996–2000 and 2001–05 had virtually exactly the
same correlation with deprivation as observed in 1985–91. There were
almost no TB cases in the most affluent areas; 2 per 100 000 in moderately
deprived areas; and over four times this rate in the most deprived wards.
Other respiratory diseases and mortality from conditions related to smoking
show the same geographical pattern across Liverpool and are also likely to
have not changed from historic distributions.
Conclusion: The persistent pattern of tuberculosis across the city of
Liverpool illustrates that health inequalities, inextricably linked with
poverty, have not reduced in the last 20 years. The ban on smoking in
public places may help to reduce some inequalities in respiratory
diseases, but tuberculosis control policies do not appear to be improving
its distribution across the city of Liverpool.
1. Spence DPS, Hotchkiss J, Williams CSD, et al. Tuberculosis and
poverty. BMJ 1993;307:759–61.
P224 INCIDENCE OF TUBERCULOSIS IN THE GREENWICH
BOROUGH OF LONDON FROM 1993 TO 2005: AN
OVERVIEW
A. Chapagain, R. Muza, S. Perkins1, J. R. Webb, T. C. Stokes. Queen
Elizabeth Hospital NHS Trust, London, United Kingdom; 1S E London Health
Protection Unit, London SE1 7NT, UK
Background: We experienced a rise in tuberculosis (TB) notifications in
Greenwich in 1998, of which we attempted to examine the epidemiol-
ogy.
Design: Clinical and demographic data on all patients diagnosed with
TB were obtained from the in-patient records, the microbiology
department, chest clinic/radiology records and notifications made to
the Director of Public health. Co-infection with HIV in adult patients with
TB was estimated from the chest clinic data.
Results: There were a total of 874 notifications, of which 175
notifications (20.6/100 000/year) were in the period 1993–1996,
compared to 699 (47.41/100 000/year) for 1998–2005.The notifica-
tion rate for the white population rose from 5/100 000 to 12.9/
100 000 (mean 11.93, SD 2.96). However, the rates are higher for
patients of Asian (168.7 to 329.89/100 000 mean 241.91, SD 50.89),
Black African (98.02 to 278.42/100 000 mean 174.13, SD 63.11) and
other Black (10 to 118.43/100 000, mean 55.41, SD 40.14) origins.
64.51% of all cases were culture positive for Mycobacterium tuberculosis
of which 3.2% were multi-drug resistant. In both periods the age
distribution, sex ratio, and principal sites involved were unchanged.
Abstract P222
Year
NE London UK
born TB
London Borough of Hackney residents
Adults
Adult
Travel
Risk
factors/
adult Child
Child
travel
Contact (all
patients)
Outbreak
related (all
patients)
1998 96 21 11 0.72 0 0 0 1
1999 98 13 3 0.62 1 1 0 0
2000 82 23 10 0.48 1 0 0 1
2001 87 19 8 0.63 0 0 0 4
2002 161 24 6 0.71 8 5 3 7
2003 191 27 4 1.52 5 1 2 9
2004 168 30 5 1.67 6 2 4 11
2005 186 19 7 1.74 7 4 4 4
Total (mean)1069 176 54 (0.98) 28 13 13 37
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TB cases 2001_2005
Smoking related deaths
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Three of the most deprived wards are responsible for most of the rise in
TB. The estimated HIV co-infection rose from 5.6% to 7.58%. The
principal sites of disease in each ethnic group was also determined.
Discussion: Notification rates were particularly high in certain ethnic
groups. However; the ethnic distribution seems dynamic with a dispropor-
tionate increase in TB rates in certain ethnic groups. The geographical
distribution seems uneven with the most deprived areas having higher rates.
The study could not determine whether this was due to new infection,
reactivation or infected immigrants gravitating to these areas. TB in patients
co-infected with HIV makes an increasingly important contribution. A
successful population-based TB control strategy shall need to accommodate
this geographical and ethnic variability and adapt accordingly.
An earlier part of this study was previously presented at the European
Society of Mycobacteriology annual meeting, July 2006.
P225 AN AUDIT OF PATIENTS WHO DIED WHILE ON
TREATMENT FOR TUBERCULOSIS
A. S. Collett, E. Togun, M. Ogedengbe, A. Nundloll, V. A. L. Graham,
R. D. Barker. Kings College Hospital, Camberwell, London SE5 9PJ, UK
Background: Tuberculosis (TB) notifications are increasing in the UK
particularly in London. Published mortality varies from 5% (USA) to 29%
(Afghanistan). At Kings College Hospital 5.8% of tuberculosis patients
die. We wanted to make a quantitative estimate of risk factors for death
and a qualitative look for possible preventable causes.
Methods: Outcomes are reported for all patients who started treatment
for TB between January 2000 and June 2005. Case records for all
patients who died while on treatment for TB were reviewed. Information
was retrieved from our TB clinical database, the paper notes and the
hospitals electronic patient record. We looked quantitatively at age, sex,
drug resistance, inpatient or outpatient at diagnosis, HIV status and
qualitatively at hepatitis, treatment interruption and delayed diagnosis in
hospital as risk factors for death.
Results: Thirty five (6.5%) of 611 patients died. These were subclassified
as shown in the table. In univariate analyses men were more likely to die
than women odds ratio (2.2 95% CI 1.0 to 4.9). Those who died were
older (mean 57 v 34 years p = 0.000). Mortality in the 8th decade was
35% and 40% in the 9th decade. Patients diagnosed with TB as an in-
patient were much more likely to die (OR 28.5, 95% CI 6.7 to 119.9)
than those diagnosed as out patients. Sixteen (46%) of the patients who
died had HIV tests, (compared to an overall offering rate of 93% and
testing rate of 68%). Death was not associated with being HIV positive
(OR 2.1 95% CI 0.7 to 5.8). Of the 35 patients who died, only 3 had drug
resistance. Death was not associated with drug resistance (OR 0.7 CI 0.2 to
2.5). One patient, with hepatitis C related cirrhosis, died with a severe
hepatitis. Treatment interruptions and delayed diagnosis in hospital did not
appear to be significant factors. In multivariate analyses only age and being
an in-patient at diagnosis significantly predicted death.
Conclusion: Dying, with tuberculosis as the sole cause, is quite
uncommon in our hospital. Drug resistance, drug induced hepatitis
and delayed diagnosis in hospital did not appear to contribute
significantly to mortality. Few patients diagnosed in clinic die but elderly
TB patients, with multiple comorbidities, are at high risk of dying.
P226 CHARACTERISTICS OF PATIENTS DYING WITH
TUBERCULOSIS
J. A. Fitton, I. Patel, H. J. Milburn. Department of Respiratory Medicine,
Guy’s & St Thomas’ Foundation Trust, London, UK
Patients reported to the London TB Register are classified as dying with
tuberculosis (TB) if they die within 1 year of the start of treatment. We
examined the medical records of patients from Guy’s and St Thomas’
Hospitals (GSTT) who died with TB from 2002 to 2005 in order to
describe their characteristics.
19 patients died with TB at GSTT during this period. 654 patients were
treated during the same period, giving a case mortality rate of 2.9%.
(National mortality rate 7.9% in 2002.) The characteristics of this group
are summarised in the table. Numbers in brackets represent percentages
of the whole group.
A subcategory of 13 patients (68.4) for whom TB caused or
contributed to death were further analysed; their characteristics were
broadly similar except for age (median 48 years), suggesting co-morbid
conditions caused death in older patients.
Conclusions: Patients dying with TB tended to be older and most had
pulmonary TB. No particular ethnic group predominated and most
immigrants to the UK had been in the country for many years. The
majority had co-morbidity, most frequently respiratory conditions. Risk
factors such as social deprivation, HIV infection and non-compliance
occurred in only a minority, several of whom demonstrated more than
one such risk. A sizeable minority were not managed primarily by a
chest physician although all were eventually referred.
P227 REVIEW OF ADVERSE EFFECTS AND TREATMENT
ALTERATIONS IN 100 PATIENTS TREATED WITH ANTI-
TUBERCULOSIS MEDICATION
M. Pammi1, W. S. Lim2. 1Specialist Registrar, Nottingham City Hospital;
2Consultant Respiratory Physician, Nottingham City Hospital, UK
Background: Anti-tuberculosis (anti-TB) therapy is associated with
abnormalities in liver function tests (LFTs) in 10–25% of cases and
clinical hepatitis in 3–5%.
Aim: To review the incidence of abnormal LFTs and other complications
leading to treatment alterations.
Methods: Retrospective case note review of 100 patients on anti-TB
therapy at Nottingham University Hospitals between January 2005 and
March 2006.
Results: Of 100 patients, 60% of the 86 adults were men. Standard
quadruple chemotherapy initiated in 87 and chemoprophylaxis in 13, of
which 9 (62%) were children. 26 patients developed complications. 18
had abnormal LFTs (6 drug induced hepatitis (DIH), 2 rifampicin
hypersensitivity and abnormal LFTs, 10 rise in LFTs but stable with
Abstract P225
Outcome Number (total 35)
Died - TB cause 7 (1.1%)
Died - TB contributed 12 (2.0%)
Died - TB incidental 13 (2.1%)
Died - TB influence unknown 3 (0.5%)
Abstract P226
Gender Male 13 (68.4); female 6 (31.6)
Age Range 17–86 years; median 61 years
Ethnicity Indian, Bangladeshi, Pakistani 6 (31.6); Black African 5 (26.3); White British 4
(21.1); Black Caribbean 2 (10.5); other 2 (10.5)
Time spent in UK 12 patients (63.2) were immigrants to UK. Of these, time ranged from 0.1 to 47
years, median 14 years
Previous TB? 4 patients (21.1) previously diagnosed with TB
Social factors Unemployed 3 (15.8); homeless 3 (15.8); alcoholics 3 (15.8); 4 not recorded
Other risk factors HIV-positive 4 (21.1); drug-resistant TB 1 (5.3); non-compliance 5 (26.3)
Comorbid conditions Primary conditions were respiratory 6 (31.6), cardiovascular 3 (15.8), renal 2
(10.5), GI 2 (10.5), HIV 2 (10.5), haematological malignancy 2 (10.5)
n = 17 (89.5%)
Site of TB Pulmonary 16 (84.2); extra-pulmonary 3 (15.8)
Primary doctor 11 (57.9) managed primarily by chest physician
Duration of symptoms Range 4–730 days; median 44 days
Time on treatment Range 4–450 days; median 23 days
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regular monitoring), 5 developed a rash, 1 joint pain, 1 drug fever, and
1 rifampicin hypersensitivity. Treatment alterations occurred in 18
patients; 3 were short term interruptions due to nausea/vomiting/rash
followed by successful full treatment within a week, treatment stopped in
3 (1 admitted to ITU with cavernous sinus granuloma, bilateral empyema
and transferred elsewhere, 1 diagnosed malignancy, 1 empirical
therapy for presumed tuberculosis but treatment stopped as she
developed rash and joint pain). Sequential re-introduction of therapy
occurred in 12. Of these 2 (17%) were unsuccessful: 1 treatment started
as a prerequisite for anti-TNF therapy but as unable to tolerate
rifampicin the patient deferred anti-TNF therapy and TB medication, 1
developed DIH while on chemoprophylaxis and treatment withdrawn.
Conclusion: Complications due to anti-TB therapy occurred in 26% of
patients on full treatment and 23% on chemoprophylaxis. A relatively
high incidence (6%) of hepatotoxicity noted. Overall, treatment with-
drawn in 5 (5%) of patients.
P228 PATIENTS LOST TO TREATMENT FOR TUBERCULOSIS
W. G. Roberts, T. Sanghera, G. H. Bothamley. NE London TB Network,
Homerton University Hospital, UK
Introduction: Treatment outcomes are routinely reported in England and
Wales, but there are no reporting structures to describe factors that may
contribute to a patient being lost to follow up.
Methods: The NE London TB Network receives outcome data from all
boroughs within the sector. The cases found to be lost to follow up for the
period 2003–05 were identified from the treatment outcome returns. A
review of the medical and nursing notes provided information on lifestyle
and treatment variables. These patients were compared to the overall
caseload for the same period.
Results: Lost to follow up patients (n = 54) can be placed into two groups:
those who cannot be found after becoming lost to follow up (n = 26) and
those that would regulalrly reconnect and disconnect from the TB service
after becoming lost to follow up (n = 28). The percentage of patients with
drug misuse, alcohol misuse, housing problems, prison history and
umemployment were higher in the lost to folow up group. Registration
with a GP was more common in the overall caseload.
Conclusions: Lost to follow up TB patients are more likely to have social
factors likely to affect their ability to comply with therapy, be
unemployed, and have worse access to primary care services. A
thorough needs assessment, when the patient with tuberculosis is first
identified may improve adherence.
This study was funded by the NE London TB Network.
P229 TREATMENT SUCCESS IN A COHORT OF PATIENTS
WITH TUBERCULOSIS FROM AN INNER LONDON
HOSPITAL. WHAT HAPPENED TO THE PATIENTS WHO
TRANSFERRED OUT?
A. S. Collett, J. M. Garland, E. Togun, A. Nundloll, M. Ogedengbe,
R. D. Barker. King’s College Hospital, Camberwell, London SE5 9PJ, UK
Background: The increased incidence of tuberculosis in London has
raised concerns about poor treatment outcomes as a possible cause. The
London Regional Office of the National Health Service has set a target
treatment completion rate of 90% for tuberculosis, whilst the millennium
development goals (MDG) target for successful treatment is 85%. The
MDG target is derived from a calculation that suggests that a case
detection rate of 70% and successful treatment rate of 85% will lead to a
decrease in incidence and prevalence of tuberculosis (Dye, et al. JAMA
2005). At our hospital we thought our 89.5% successful treatment
outcomes was satisfactory, but we were concerned that patients in the
‘‘transferred out’’ category might be concealing adverse outcomes. We
decided to obtain more detailed outcomes for our patients who had
transferred out and to combine them with existing data to obtain a true
measure of treatment success.
Methods: Outcomes are reported for all patients who started treatment
for TB between January 2000 and June 2005 at King’s College Hospital.
Patients were identified from our TB database, which includes clinical
notes from the medical team and the TB nurses. Outcomes for patients,
initially designated as ‘‘transferred out’’, were obtained from by
contacting their destination TB units.
Results: Outcomes were obtained for 34 of 48 patients initially
designated as transferred out. The remaining 14 had left the UK.
Conclusion: Detailed analysis of transfers out increased the lost to follow
up rate by 2.2% and increased treatment completion by 2.9%. This
analysis did not alter the relationship of our successful treatment
outcomes to MDG targets, which we met. We are still missing the London
target by a small margin.
P230 CHARACTERISTICS OF PATIENTS NON-COMPLIANT
WITH TUBERCULOSIS THERAPY IN LONDON
I. S. Patel, J. A. Fitton, H. J. Milburn. Department of Respiratory Medicine,
Guy’s & St Thomas’ Foundation Trust, London, UK
A proportion of patients with tuberculosis (TB) fail to complete the
appropriate course of treatment because of poor compliance with
medication or inconsistent attendance at hospital appointments. This
difficult group is a cause for concern as they run the risk of disease
relapse and increased drug resistance. We assessed the rates of non-
compliance at Guy’s and St Thomas’ Hospitals (GSTT) from 2002–05
and compared the characteristics of these patients with our previously
presented data from 1999–2000.
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Patients lost to follow up
TB caseload
2003–05
(n = 1645)
Patients with no
contact with TB
service after lost to
follow up (n = 26)
Patients who persistently
reconnect and disconnect
with TB services after lost to
follow up outcome (n = 28)
Total lost to
follow up
cases (n = 54)
GP registration 50% 40% 48% 59%
Drug misuse 0% 28% 15% 3%
Alcohol misuse 15% 25% 20% 5%
Mental health problems 0% 18% 9% Unavailable
Prison history 4% 18% 11% 3%
Unemployed 38% 57% 48% 25%
Directly observed therapy 25% 25% 28% 5%
Housing problems 8% 14% 11% 5%
Part of Isoniazid resistant
cohort
4% 25% 15% 2%
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Outcomes from original
data
Outcomes after detailed
analysis of ‘‘transfers out’’
Complete 501 82% (CI 79 to 85) 519 84.9% (CI 82.1 to 87.8)
Transferred
out
48 7.9% (CI 5.7 to 10) 14 2.3% (CI 1.1 to 3.5)
Death 35 5.7% (CI 3.9 to 7.6) 36 5.9% (CI 4 to 7.8)
Lost to
follow up
24 3.9% (CI 2.4 to 5.5) 37 6.1% (CI 4.2 to 7.9)
Still on
treatment
3 0.5% (CI 20.1 to 1) 3 0.5% (CI 20.1 to 1)
Treatment
success*
89.5% (CI 86.9 to 92) 87.7% (CI 85 to 90.3)
*(complete/(complete + death + lost to follow up))*100%.
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The total number of patients with TB who were lost to follow up or non-
compliant at GSTT from 2002–05 was 14/654 treated in total (2.14%).
This is an improvement from 14/169 or 8.3% in 1999–2000.
The characteristics of these patients were as follows: 8 (57%) males, 6
(43%) females; age range 17–49 (median 29) years with 79% aged
from 20–39; 9 (64%) Black African of whom 4 were Somali; 3 (21%)
White British; 2 (15%) of other ethnicity. Only 3 (21%) were refugees
with the majority having resident status in the UK. However for 8 patients
(57%) English was not the first language and was poor. Social
deprivation, and drug and alcohol dependence were a prominent
feature of these patients as 7/14 (50%) were unemployed, 6/14 (43%)
were homeless, 4/14 (28%) were alcoholics, 2/14 (14%) had a mental
illness and 1/14 (7%) was an intravenous drug user. 2/14 (14%) were
HIV positive. 8/14 (57%) patients had pulmonary TB and 4/14 (28%)
patients received directly observed therapy (DOT).
Eight patients (57%) were originally managed by non-chest physicians
or encountered delay in referral to the TB team. The median time on
treatment before default was 83 days, or 36% of the appropriate
duration of therapy for their disease and organism sensitivity. None
encountered serious side effects, which might have affected compliance.
In conclusion numbers of non-compliant TB patients at GSTT have
fallen since 1999 on a background of increasing numbers of cases.
Young black African men with poor English remain the most vulnerable
group in this context, as shown in our previous audit. Patients tend to
become non-compliant with TB therapy after completing approximately
36% of their time on treatment, which, we postulate, may correspond
with improvement in symptoms. TB teams need to address this by
improving communication and focusing on these patients at this critical
time. Delay in referral to the TB team may prevent the early establishment
of the rapport needed to facilitate this process.
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